	Introd	ucina	Pharmac
--	--------	-------	---------

September 2023
Volume 11

Editor:

Kaye Wilson & Ayeshah Khan email: enquiry@pharmac.govt.nz Telephone +64 4 460 4990 Level 9, 40 Mercer Street PO Box 10 254 Wellington 6143

Freephone Information Line 0800 66 00 50 (9am – 5pm weekdays)

Circulation

You can register to have an electronic version of the Pharmaceutical Schedule, Section H for Hospital Pharmaceuticals (link to PDF copy) emailed to your nominated email address each month by subscribing at schedule.pharmac.govt.nz/subscribe.

Production

Typeset automatically from XML and T_EX. XML version of the Schedule available from schedule.pharmac.govt.nz/pub/HML

Programmers

Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz @Pharmaceutical Management Agency



ISSN 1179-3708 pdf

This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to Pharmac and abide by the other licence terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/. Attribution to Pharmac should be in written form and not by reproduction of the Pharmac logo. While care has been taken in compiling this Schedule, Pharmac takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from. Part I General Rules 4 Part II 5 Alimentary Tract and Metabolism Blood and Blood Forming Organs 28 43 Cardiovascular System Dermatologicals 66 Genito-Urinary System 73 Hormone Preparations 77 Infections 87 Musculoskeletal System 110 Nervous System 117 143 Oncology Agents and Immunosuppressants Respiratory System and Allergies 240 249 Sensory Organs Various 256 264 Extemporaneous Compounds (ECPs) Special Foods 267 Vaccines 284

Part III

Optional Pharmaceuticals 295

Index 296

Introducing Pharmac

The Pharmaceutical Management Agency (Pharmac) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. Pharmac negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list.

Pharmac's role:

"to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided."

Pae Ora (Healthy Futures) Act 2022

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about Pharmac and the way we make funding decisions can be found on the Pharmac website at https://www.pharmac.govt.nz/about.

Glossary


Units of Measure

gramg	microgram mcg	millimole mmol
kilogram kg	milligram mg	unit u
international unitiu	millilitre ml	
Abbreviations		
applicationapp	enteric coated EC	solutionsoln
capsule cap	granules grans	suppositorysuppos
creamcrm	injectioninj	tablet tab
dispersibledisp	liquidliq	tincturetinc
effervescent eff	lotion lotn	
emulsion emul	ointmentoint	

HSS Hospital Supply Status

Guide to Section H listings

Example



General Rules for Section H of the Pharmaceutical Schedule are included in Section A.

Read the General Rules : https://www.pharmac.govt.nz/section-a.

PART II: ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Antacids and Antiflatulents			
Antacids and Reflux Barrier Agents			
LUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND Tab 200 mg with magnesium hydroxide 200 mg and simeticone Oral liq 400 mg with magnesium hydroxide 400 mg and simetico 30 mg per 5 ml	20 mg		e.g. Mylanta e.g. Mylanta Double Strength
IMETICONE Oral drops 100 mg per ml Oral drops 20 mg per 0.3 ml Oral drops 40 mg per ml			Chongar
ODIUM ALGINATE WITH MAGNESIUM ALGINATE Powder for oral soln 225 mg with magnesium alginate 87.5 mg, ODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIU Tab 500 mg with sodium bicarbonate 267 mg and calcium carbo	M CARBONATE		e.g. Gaviscon Infant
160 mg			e.g. Gaviscon Extra Strength
Oral liq 500 mg with sodium bicarbonate 267 mg and calcium ca 160 mg per 10 ml		500 ml	Acidex
ODIUM CITRATE Oral liq 8.8% (300 mmol/l) – 5% DV Jan-22 to 2024		90 ml	Biomed
Phosphate Binding Agents			
LUMINIUM HYDROXIDE Tab 600 mg			
ALCIUM CARBONATE – Restricted see terms below Oral liq 250 mg per ml (100 mg elemental per ml)		473 ml 500 ml	Calcium carbonate PAI Roxane
 Restricted (RS1698) ititation Inly when prescribed for patients unable to swallow calcium carbon appropriate 			
Antidiarrhoeals and Intestinal Anti-Inflammatory A	gents		
Antipropulsives			
IPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHA Tab 2.5 mg with atropine sulphate 25 mcg OPERAMIDE HYDROCHLORIDE Tab 2 mg		400	Nodia
Cap 2 mg – 5% DV Jan-23 to 2025		400	Diamide Relief
Rectal and Colonic Anti-Inflammatories			

BUDESONIDE - Restricted see terms on the next page

Price			Brand or
(ex man. excl.	GST)	_	Generic
\$		Per	Manufacturer

→ Restricted (RS1723)

Initiation - Crohn's disease

Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
 - 2.1 Diabetes; or
 - 2.2 Cushingoid habitus; or
 - 2.3 Osteoporosis where there is significant risk of fracture; or
 - 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initiation - Collagenous and lymphocytic colitis (microscopic colitis)

Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initiation - Gut Graft versus Host disease

Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

Initiation – non-cirrhotic autoimmune hepatitis

Re-assessment required after 6 months

All of the following:

- 1 Patient has autoimmune hepatitis*; and
- 2 Patient does not have cirrhosis; and
- 3 Any of the following:
 - 3.1 Diabetes; or
 - 3.2 Cushingoid habitus; or
 - 3.3 Osteoporosis where there is significant risk of fracture; or
 - 3.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 3.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 3.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 3.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated); or
 - 3.8 Adolescents with poor linear growth (where conventional corticosteroid use may limit further growth).

Note: Indications marked with * are unapproved indications.

Continuation - non-cirrhotic autoimmune hepatitis

Re-assessment required after 6 months

Treatment remains appropriate and the patient is benefitting from the treatment.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC free (14 applications)	26.55	15 g 21.1 g	Colifoam Colifoam
HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE			
Topical Aerosol foam, 1% with pramoxine hydrochloride 1%			
MESALAZINE			
Tab EC 400 mg	49.50	100	Asacol
Tab long-acting 500 mg	56.10	100	Pentasa
Tab 800 mg	85.50	90	Asacol
Modified release granules 1 g	118.10	100 g	Pentasa
Suppos 500 mg	22.80	20	Asacol
Suppos 1 g	50.96	28	Pentasa
Enema 1 g per 100 ml		7	Pentasa

Price Brand or (ex man. excl. GST) Generic Per Manufacturer s OLSALAZINE 100 Dipentum 100 Dipentum PREDNISOLONE SODIUM 1 Essential Prednisolone SODIUM CROMOGLICATE Cap 100 mg SULFASALAZINE 100 Salazopvrin 100 Salazopyrin EN Local Preparations for Anal and Rectal Disorders Antihaemorrhoidal Preparations CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE Oint 5 mg with hydrocortisone 5 mg per g.....15.00 30 g Proctosedyl Suppos 5 mg with hydrocortisone 5 mg per g9.90 12 Proctosedyl FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g......11.06 30 a Ultraproct Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg......7.30 12 Ultraproct Management of Anal Fissures **GLYCERYL TRINITRATE** 30 g Rectogesic **Bectal Scierosants OILY PHENOL [PHENOL OILY]** Inj 5%, 5 ml vial Antispasmodics and Other Agents Altering Gut Motility GLYCOPYRRONIUM BROMIDE Inj 200 mcg per ml, 1 ml ampoule - 5% DV Sep-23 to 2025 19.00 5 Robinul HYOSCINE BUTYLBROMIDE Tab 10 mg6.35 100 Buscopan Buscopan 5 Spazmol 1.91 1 (Buscopan Inj 20 mg, 1 ml ampoule to be delisted 1 December 2023) MEBEVERINE HYDROCHLORIDE Colofac 90 Antiulcerants Antisecretory and Cytoprotective MISOPROSTOL 120 Cytotec

ALIMENTARY TRACT AND METABOLISM

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

-		F	Price			Brand or
		(ex man.	excl. \$	GST)	Per	Generic Manufacturer
Н	2 Antagonists					
CIN	IETIDINE					
	Tab 200 mg					
	Tab 400 mg					
FA	MOTIDINE Tab 20 mg					
	Tab 40 mg					
	Inj 10 mg per ml, 2 ml vial					
	Inj 10 mg per ml, 4 ml vial					
RA	NITIDINE – Restricted see terms below					
i	Tab 150 mg					
ļ	Tab 300 mg					
Ţ	Inj 25 mg per ml, 2 ml ampoule Restricted (RS1703)					
	iation					
Eitl	ner:					
	1 For continuation use; or					
	2 Routine prevention of allergic reactions					
Ρ	roton Pump Inhibitors					
LA	NSOPRAZOLE					
	Cap 15 mg - 5% DV Dec-21 to 2024				100	Lanzol Relief
	Cap 30 mg - 5% DV Dec-21 to 2024		5.26	6	100	Lanzol Relief
ON						
<u>+</u>	Tab dispersible 10 mg Restricted (RS1027)					
	iation					
-	y for use in tube-fed patients.					
t	Tab dispersible 20 mg					
⇒	Restricted (RS1027)					
-	iation					
On	y for use in tube-fed patients.					
	Cap 10 mg Cap 20 mg				90 90	Omeprazole actavis 10 Omeprazole actavis 20
	Cap 40 mg				90 90	Omeprazole actavis 20
	Powder for oral lig				5 g	Midwest
	Inj 40 mg ampoule with diluent - 5% DV Jan-23 to 2025		37.38	3	5	Dr Reddy's Omeprazole
	Inj 40 mg vial - 5% DV Jan-23 to 2025		11.98	5	5	Omezol IV
PA	NTOPRAZOLE			_		
	Tab EC 20 mg - 5% DV Dec-23 to 2025				90	Panzop Relief
	Tab EC 40 mg - 5% DV Dec-23 to 2025 Inj 40 mg vial		2.74	ł	90	Panzop Relief
S	ite Protective Agents					
	LLOIDAL BISMUTH SUBCITRATE					
00	Tab 120 mg		14.5	1	50	Gastrodenol
SU	CRALFATE					
	Tab 1 g					
	-					

t Item restricted (see → above); t Item restricted (see → below)

	Price		Brand or
	(ex man. excl. GST	7)	Generic
	(ex man. excl. def \$	Per	Manufacturer
Bile and Liver Therapy			
L-ORNITHINE L-ASPARTATE – Restricted see terms below			
Grans for oral liquid 3 g			
➡ Restricted (RS1261)			
nitiation			
For patients with chronic hepatic encephalopathy who have not respon	ded to treatment wi	th, or are ir	ntolerant to lactulose, or
where lactulose is contraindicated.			
RIFAXIMIN – Restricted see terms below			
Tab 550 mg		56	Xifaxan
→ Restricted (RS1416)			
Initiation			
For patients with hepatic encephalopathy despite an adequate trial of n	naximum tolerated	doses of la	ctulose.
Diabetes			
Alpha Glucosidase Inhibitors			
ACARBOSE			
Tab 50 mg - 5% DV Dec-21 to 2024		90	Accarb
Tab 100 mg - 5% DV Dec-21 to 2024	15.29	90	Accarb
Hyperglycaemic Agents			
DIAZOXIDE – Restricted see terms below			
Cap 25 mg		100	Proglicem
Cap 100 mg		100	Proglicem
Oral liq 50 mg per ml	620.00	30 ml	Proglycem
→ Restricted (RS1028)			
Initiation			
For patients with confirmed hypoglycaemia caused by hyperinsulinism.			
GLUCAGON HYDROCHLORIDE			
Inj 1 mg syringe kit		1	Glucagen Hypokit
GLUCOSE [DEXTROSE]			
Tab 1.5 g			
Tab 3.1 g			
Tab 4 g			
Oral soln 15 g per 80 ml sachet		50	HypoPak Glucose
Gel 40%			,,
GLUCOSE WITH SUCROSE AND FRUCTOSE			
Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet			
Insulin - Intermediate-Acting Preparations			
INSULIN ASPART WITH INSULIN ASPART PROTAMINE			
Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per	r ml,		
3 ml prefilled pen		5	NovoMix 30 FlexPen
INSULIN ISOPHANE			
Inj insulin human 100 u per ml, 10 ml vial			
Inj insulin human 100 u per ml, 3 ml cartridge			
,			

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u pe 3 ml cartridge Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u pe		5	Humalog Mix 25
3 ml cartridge		5	Humalog Mix 50
NSULIN NEUTRAL WITH INSULIN ISOPHANE Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, vial	10 ml		
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, cartridge			
Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, cartridge Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, cartridge			
Insulin - Long-Acting Preparations			
NSULIN GLARGINE			
Inj 100 u per ml, 3 ml disposable pen		5	Lantus SoloStar
Inj 100 u per ml, 3 ml cartridge Inj 100 u per ml, 10 ml vial		5 1	Lantus Lantus
Insulin - Rapid-Acting Preparations			
NSULIN ASPART			
Inj 100 u per ml, 10 ml vial Inj 100 u per ml, 3 ml cartridge Inj 100 u per ml, 3 ml syringe	51 10	5	NovoRapid FlexPen
NSULIN GLULISINE		5	Novonapiu riekren
Inj 100 u per ml, 10 ml vial		1	Apidra
Inj 100 u per ml, 3 ml cartridge Inj 100 u per ml, 3 ml disposable pen		5 5	Apidra Apidra Solostar
NSULIN LISPRO	40.07	5	Apiula Solosiai
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Insulin - Short-Acting Preparations			
NSULIN NEUTRAL Inj human 100 u per ml, 10 ml vial Inj human 100 u per ml, 3 ml cartridge			
Oral Hypoglycaemic Agents			
GLIBENCLAMIDE Tab 5 mg – 5% DV Jan-22 to 2024		100	Daonil
GLICLAZIDE Tab 80 mg – 5% DV Feb-24 to 2026	20.10	500	Glizide
GLIPIZIDE Tab 5 mg – 5% DV Mar-22 to 2024		100	Minidiab

t Item restricted (see → above); t Item restricted (see → below)

Price Brand or (ex man. excl. GST) Generic Per Manufacturer \$ METEORMIN HYDROCHLORIDE Tab immediate-release 500 mg - 1% DV Mar-23 to 2024...... 14.74 Metformin Viatris 1,000 Tab immediate-release 850 mg - 1% DV Aug-23 to 2024 11.28 500 Metformin Mylan Metformin Viatris (Metformin Mylan Tab immediate-release 850 mg to be delisted 1 January 2024) PIOGLITAZONE 90 Vexazone 90 Vexazone 90 Vexazone VII DAGI IPTIN 60 Galvus VII DAGI IPTIN WITH METFORMIN HYDROCHI ORIDE Galvumet 60 Galvumet 60 **GLP-1** Agonists DULAGLUTIDE - Restricted see terms below Note: Not to be given in combination with a funded SGLT-2 inhibitor. l Inj 1.5 mg per 0.5 ml prefilled pen 115.23 Trulicity 4 → Restricted (RS1857) Initiation Any of the following: 1 For continuation use; or 2 Patient has previously had an initial approval for an SGLT-2 inhibitor; or 3 All of the following: 3.1 Patient has type 2 diabetes; and 3.2 Any of the following: 3.2.1 Patient is Māori or any Pacific ethnicity*; or 3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*: or 3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*: or 3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a voung adult*: or 3.2.5 Patient has diabetic kidney disease (see note b)*: and 3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months. Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes. a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina. myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia. b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause. LIRAGLUTIDE - Restricted see terms below Note: Not to be given in combination with a funded SGLT-2 inhibitor or other GLP-1 agonist. 3 Victoza → Restricted (RS1945) Initiation Any of the following: continued...

ALIMENTARY TRACT AND METABOLISM

Price		Brand or
(ex man. excl. G	GST)	Generic
 \$	Per	Manufacturer

continued...

- 1 For continuation use; or
- 2 Patient has previously received an initial Special Authority approval for either an SGLT-2 inhibitor or GLP-1 agonist; or
- 3 All of the following:
 - 3.1 Patient has type 2 diabetes; and
 - 3.2 Any of the following:
 - 3.2.1 Patient is Māori or any Pacific ethnicity*; or
 - 3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
 - 3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
 - 3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 3.2.5 Patient has diabetic kidney disease (see note b)*; and
 - 3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.
- Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.
 - a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
 - b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m² in the presence of diabetes, without alternative cause.

SGLT2 Inhibitors

→ Restricted (RS1852)

Initiation

Any of the following:

- 1 For continuation use; or
- 2 Patient has previously had an initial approval for a GLP-1 agonist; or
- 3 All of the following:
 - 3.1 Patient has type 2 diabetes; and
 - 3.2 Any of the following:
 - 3.2.1 Patient is Māori or any Pacific ethnicity*; or
 - 3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
 - 3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated cardiovascular risk assessment calculator*; or
 - 3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
 - 3.2.5 Patient has diabetic kidney disease (see note b)*; and
 - 3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.
- Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.
 - a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
 - b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m2 in the presence of diabetes, without alternative cause.

	Price (ex man. excl. GST \$	Per	Brand or Generic Manufacturer
EMPAGLIFLOZIN – Restricted see terms on the previous page			
Note: Not to be given in combination with a funded GLP-1 agonis	t.		
Tab 10 mg		30	Jardiance
t Tab 25 mg	58.56	30	Jardiance
EMPAGLIFLOZIN WITH METFORMIN HYDROCHLORIDE - Restric Note: Not to be given in combination with a funded GLP-1 agonis		previous	page
t Tab 5 mg with 1,000 mg metformin hydrochloride		60	Jardiamet
t Tab 5 mg with 500 mg metformin hydrochloride		60	Jardiamet
1 Tab 12.5 mg with 1,000 mg metformin hydrochloride		60	Jardiamet
1 Tab 12.5 mg with 500 mg metformin hydrochloride		60	Jardiamet
Digestives Including Enzymes PANCREATIC ENZYME Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,25 protease))			
Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 P U, total protease 600 Ph Eur U) – 5% DV Jun-22 to 2024 Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000		100	Creon 10000
Eur U, total protease 1,000 Ph Eur U) - 5% DV Jun-22 to 20 Modified release granules pancreatin 60.12 mg (amylase 3,600 Ph)24 94.38	100	Creon 25000
U, lipase 5,000 Ph Eur U, protease 200 Ph Eur U) Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylase, 5,000 P Eur. u/lipase and 200 Ph. Eur. u/protease) URSODEOXYCHOLIC ACID – Restricted see terms below		20 g	Creon Micro
 ↓ Cap 250 mg - 5% DV Feb-24 to 2026		100	Ursosan

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initiation – Chronic severe drug induced cholestatic liver injury

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initiation – Primary biliary cholangitis

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis.

Initiation - Pregnancy

Patient diagnosed with cholestasis of pregnancy.

Initiation – Haematological transplant

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

continued...

	Price (ex man. excl. GST \$	Per	Brand or Generic Manufacturer
continued Initiation – Total parenteral nutrition induced cholestasis Both:			
1 Paediatric patient has developed abnormal liver function as ir 2 Liver function has not improved with modifying the TPN comp	0	ch is likely	to be induced by TPN; and
Initiation – prevention of sinusoidal obstruction syndrome Limited to 6 months treatment Both:			
1 The patient is enrolled in the Children's Oncology Group AAL 2 The patient has leukaemia/lymphoma and is receiving inotuzi			

Laxatives

Bowel-Cleansing Preparations

CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium	
picosulfate 10 mg per sachet	e.g. PicoPrep
MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium	C 1
chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate	
80.62 mg per g, 70 g sachet – 5% DV Aug-22 to 01 Jan 2024	Glycoprep-O
Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium	alycopicp-o
chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate	
80.62 mg per g, 210 g sachet	e.g. Glycoprep-O
MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE, SODIUM CHLORIDE AND CIT	0 7 7 7
MAGNESIUM OXIDE AND SODIUM PICOSULFATE	
Powder for oral soln 52.9 g with ascorbic acid 6 g, potassium chloride	
740 mg, sodium chloride 2.6 g and sodium sulphate 5.6 g per	
sachet (1) and powder for oral soln citric acid 12 g with magnesium	
oxide 3.5 g and sodium picosulfate 10 mg per sachet (2)	e.g. Prepkit-O
MACROGOL 3350 WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE WITH/WITHOUT SOD	UM SULFATE, SODIUM
ASCORBATE, ASCORBIC ACID	
Powd for oral soln 100g with potassium chloride 1g, sodium chloride 2g and sodium sulfate 9g per sach(1), powd for oral soln 40g with	
potassium chloride 1.2g and sodium chloride 3.2g per sach(1) and	
powd for oral soln ascorbic acid 7.54g and sodium ascorbate	
48.11g per sach(1) – 5% DV Oct-23 to 2026	Plenvu
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE	
Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium	
bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate	
5.685 g per sachet	Klean Prep
(Klean Prep Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, s	
and sodium sulphate 5.685 g per sachet to be delisted 1 April 2024)	-
Pulk Forming Agente	
Bulk-Forming Agents	
ISPACHULA (PSVLLIUM) HUSK	

ISPAGHULA (PSYLLIUM) HUSK			
Powder for oral soln - 5% DV Feb-24 to 2026	20.00	500 g	Konsyl-D
STERCULIA WITH FRANGULA – Restricted: For continuation only → Powder for oral soln			

	Price (ex man. excl. GS` \$	Г) Per	Brand or Generic Manufacturer
Faecal Softeners			
OCUSATE SODIUM			
Tab 50 mg - 5% DV Feb-24 to 2026		100	Coloxyl
Tab 120 mg - 5% DV Feb-24 to 2026	4.98	100	Coloxyl
OCUSATE SODIUM WITH SENNOSIDES Tab 50 mg with sennosides 8 mg - 5% DV Nov-22 to 2025	3 50	200	Laxsol
		200	
Oral liquid 1 mg per ml			
Enema 133 ml			
	4 4 7	00 ml	Oslavul
Oral drops 10% - 5% DV Feb-24 to 2026	4.17	30 ml	Coloxyl
Opioid Receptor Antagonists - Peripheral			
ETHYLNALTREXONE BROMIDE - Restricted see terms below			
Inj 12 mg per 0.6 ml vial		1 7	Relistor Relistor
Restricted (RS1601)	240.00	1	Telision
itiation – Opioid induced constipation			
oth: 1 The patient is receiving palliative care; and			
2 Either:			
2.1 Oral and rectal treatments for opioid induced constip	pation are ineffective; or		
2.1 Oral and rectal treatments for opioid induced constip2.2 Oral and rectal treatments for opioid induced constip			
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives	pation are unable to be		
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives	pation are unable to be		Lax-suppositories
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g – 5% DV Feb-23 to 2025	pation are unable to be	tolerated.	Lax-suppositories Glycerol
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g – 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation	pation are unable to be	tolerated.	
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g – 5% DV Feb-23 to 2025	bation are unable to be	tolerated.	
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g – 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE	bation are unable to be 	20 500 ml	Giycerol Laevolac
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g – 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml – 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BIC, Powder for oral soln 6.563 g with potassium chloride 23.3 mg,	bation are unable to be 	20 500 ml	Giycerol Laevolac
 2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g - 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml - 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICA Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg 	bation are unable to be 	20 500 ml	Giycerol Laevolac
 2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g - 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml - 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BIC, Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg 	pation are unable to be 	20 500 ml	Giycerol Laevolac
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g − 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml − 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICA Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg bicarbonate 178.5 mg and sodium chloride 350.7 mg − 59 Feb-24 to 2026	bation are unable to be 	20 500 ml	Giycerol Laevolac
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g − 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml − 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BIC. Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg bicarbonate 178.5 mg and sodium chloride 350.7 mg − 59 Feb-24 to 2026 ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE	ation are unable to be 	20 20 500 ml IUM CHLO	Giycerol Laevolac RIDE
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g − 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml − 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICA Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg bicarbonate 178.5 mg and sodium chloride 350.7 mg − 59 Feb-24 to 2026 ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5	bation are unable to be 	20 20 500 ml IUM CHLO 30	Giycerol Laevolac RIDE Molaxole
2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g − 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml − 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BIC. Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg bicarbonate 178.5 mg and sodium chloride 350.7 mg − 59 Feb-24 to 2026 ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE	bation are unable to be 	20 20 500 ml IUM CHLO	Giycerol Laevolac RIDE
 2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g - 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml - 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BIC, Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg bicarbonate 178.5 mg and sodium chloride 350.7 mg - 59 Feb-24 to 2026. ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 DV Jun-23 to 2025. ODIUM PHOSPHATE WITH PHOSPHORIC ACID Oral liq 16.4% with phosphoric acid 25.14% 	bation are unable to be 	20 20 500 ml IUM CHLO 30 50	Giycerol Laevolac RIDE Molaxole Micolette
 2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g - 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml - 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BIC. Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg bicarbonate 178.5 mg and sodium chloride 350.7 mg - 55 Feb-24 to 2026 ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 DV Jun-23 to 2025 ODIUM PHOSPHATE WITH PHOSPHORIC ACID Oral liq 16.4% with phosphoric acid 25.14% Enema 10% with phosphoric acid 6.58% 	bation are unable to be 	20 20 500 ml IUM CHLO 30	Giycerol Laevolac RIDE Molaxole Micolette
 2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g - 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml - 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BIC, Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg bicarbonate 178.5 mg and sodium chloride 350.7 mg - 59 Feb-24 to 2026. ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 DV Jun-23 to 2025. ODIUM PHOSPHATE WITH PHOSPHORIC ACID Oral liq 16.4% with phosphoric acid 25.14% 	bation are unable to be 	20 20 500 ml IUM CHLO 30 50	Giycerol Laevolac RIDE Molaxole Micolette
 2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g - 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml - 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BIC, Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg bicarbonate 178.5 mg and sodium chloride 350.7 mg - 59 Feb-24 to 2026 ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 DV Jun-23 to 2025 ODIUM PHOSPHATE WITH PHOSPHORIC ACID Oral liq 16.4% with phosphoric acid 25.14% Enema 10% with phosphoric acid 6.58% Stimulant Laxatives 	bation are unable to be 	20 500 ml IUM CHLO 30 50 1	Giycerol Laevolac RIDE Molaxole Micolette Fleet Phosphate Enema
 2.2 Oral and rectal treatments for opioid induced constip Osmotic Laxatives LYCEROL Suppos 2.8/4.0 g - 5% DV Feb-23 to 2025 Note: DV limit applies to glycerol suppository presentation ACTULOSE Oral liq 10 g per 15 ml - 5% DV Apr-23 to 2025 IACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICA Powder for oral soln 6.563 g with potassium chloride 23.3 mg, bicarbonate 89.3 mg and sodium chloride 175.4 mg Powder for oral soln 13.125 g with potassium chloride 46.6 mg bicarbonate 178.5 mg and sodium chloride 350.7 mg - 55 Feb-24 to 2026 ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 DV Jun-23 to 2025 ODIUM PHOSPHATE WITH PHOSPHORIC ACID Oral liq 16.4% with phosphoric acid 25.14% Enema 10% with phosphoric acid 6.58% Stimulant Laxatives 	bation are unable to be 	20 20 500 ml IUM CHLO 30 50	Giycerol Laevolac RIDE Molaxole Micolette

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	l (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
SENNOSIDES					
Tab 7.5 mg					
SODIUM PICOSULFATE – Restricted see terms below					
Oral soln 7.5 mg per ml		7.40		30 ml	Dulcolax SP Drop
→ Restricted (RS1843)					
nitiation Both:					
 The patient is a child with problematic constipation despite ar 	n adaguata t	rial of	othor	oral nhai	macotheranies including
macrogol where practicable; and	auequate		Uner	orai priai	macomerapies meluding
2 The patient would otherwise require a high-volume bowel cle	ansing prep	aration	ı.		
– ···· p-···· · ··· · · · · · · · · · · ·					
Metabolic Disorder Agents					
ALGLUCOSIDASE ALFA – Restricted see terms below		40.00			Museuma
 Inj 50 mg vial	I,	142.60		1	Myozyme
nitiation					
letabolic physician					
Re-assessment required after 12 months					
Il of the following:					
1 The patient is aged up to 24 months at the time of initial appli	ication and I	has be	en dia	gnosed	with infantile Pompe disea
and				0	
2 Any of the following:					
 Diagnosis confirmed by documented deficiency of aci villus biopsies and/or cultured amniotic cells; or 	d alpha-gluc	osidas	e by p	orenatal	diagnosis using chorionic
2.2 Documented deficiency of acid alpha-glucosidase, an elevation of glucose tetrasaccharides; or	d urinary tet	rasacc	haride	e testing	indicating a diagnostic
2.3 Documented deficiency of acid alpha-glucosidase, an disease-causing mutation in the acid alpha-glucosidase				r genetic	testing indicating a
2.4 Documented urinary tetrasaccharide testing indicating molecular genetic testing indicating a disease-causing	a diagnosti	ic eleva	ation o		e tetrasaccharides, and
3 Patient has not required long-term invasive ventilation for res					zvmo ronlacomont thorar
(ERT); and	phatory land	ine prie	1 10 3		izyme replacement therap
 4 Patient does not have another life-threatening or severe dise 	ase where t	he pro	anosis	s is unlike	elv to be influenced by ER
or might be reasonably expected to compromise a response			9		.,
5 Alglucosidase alfa to be administered at doses no greater that			2 wee	eks.	
continuation					
letabolic physician					
Re-assessment required after 12 months					
Il of the following:					
1 The treatment remains appropriate for the patient and the pa					and
2 Alglucosidase alfa to be administered at doses no greater that					
3 Patient has not had severe infusion-related adverse reactions	s which were	e not p	reven	table by	appropriate pre-medicatio

- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

16

	F (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
ARGININE					
Tab 1,000 mg					
Cap 500 mg					
Powder					
Inj 500 mg per ml, 10 ml vial					
Inj 600 mg per ml, 25 ml vial					
BETAINE - Restricted see terms below					
Powder for oral soln		575.0	0	180 g	Cystadane
➡ Restricted (RS1794)				0	
Initiation					
Metabolic physician					
Re-assessment required after 12 months					
All of the following:					
1 The patient has a confirmed diagnosis of homocystinuria; and					
2 Any of the following:					
2.1 A cystathionine beta-synthase (CBS) deficiency; or					
2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR)	deficiency	; or			
2.3 A disorder of intracellular cobalamin metabolism; and					
3 An appropriate homocysteine level has not been achieved des	pite a suffi	cient	trial of	appropria	te vitamin supplementation.
Continuation					
Metabolic physician					
Re-assessment required after 12 months					
The treatment remains appropriate and the patient is benefiting from t	reatment.				
BIOTIN – Restricted see terms below					
Cap 50 mg					
Cap 100 mg					
Inj 10 mg per ml, 5 ml vial					
➡ Restricted (RS1330)					
Metabolic physician or metabolic disorders dietitian					
CARGLUMIC ACID – Restricted see terms below					
Tab disp 200 mg					
→ Restricted (RS1831)					
Initiation					
Metabolic physician	1				
For the acute in-patient treatment of organic acidaemias as an alterna	tive to hae	moniii	tration.		
COENZYME Q10 – Restricted see terms below					
Cap 120 mg					
Cap 160 mg					
➡ Restricted (RS1832) Initiation					
Metabolic physician Re-assessment required after 6 months					
The patient has a suspected inborn error of metabolism that may resp	and to coe	nzvm	ne (010	suppleme	entation
Continuation		/···~y·I	10 0(10	Suppleine	
Metabolic physician					
Re-assessment required after 24 months					
Both:					
1 The patient has a confirmed diagnosis of an inborn error of me	tabolism tł	nat re	sponds	to coenz	yme Q10 supplementation:
and					· · · · · · · · · · · · · · · · · · ·
2 The treatment remains appropriate and the patient is benefiting	n from trea	tment	t		

2 The treatment remains appropriate and the patient is benefiting from treatment.

	Price (ex man. excl. G \$	ST) Per	Brand or Generic Manufacturer
GALSULFASE - Restricted see terms below			
Inj 1 mg per ml, 5 ml vial	2,234.00	1	Naglazyme
➡ Restricted (RS1795)			
Initiation			
Metabolic physician			
Re-assessment required after 12 months			
Both:			
 The patient has been diagnosed with mucopolysaccharidosis Either: 	VI; and		
 2.1 Diagnosis confirmed by demonstration of N-acetyl-gal by either enzyme activity assay in leukocytes or skin f 2.2 Detection of two disease causing mutations and patie VI. 	ibroblasts; or		, ,
Continuation			
Metabolic physician			
Re-assessment required after 12 months			
All of the following:			
 The treatment remains appropriate for the patient and the patient has not had severe infusion-related adverse reactions 			
and/or adjustment of infusion rates; and 3 Patient has not developed another life threatening or severe	disaasa whara tha lu	ona term nro	anosis is unlikely to be
influenced by Enzyme Replacement Therapy (ERT); and		Sing term pro	
 4 Patient has not developed another medical condition that mig ERT. 	ht reasonably be ex	pected to co	ompromise a response to
HAEM ARGINATE			
Inj 25 mg per ml, 10 ml ampoule			
IDURSULFASE – Restricted see terms below			
Inj 2 mg per ml, 3 ml vial		1	Elaprase
→ Restricted (RS1546)			
Initiation			
Metabolic physician			
Limited to 24 weeks treatment			
All of the following:			
 The patient has been diagnosed with Hunter Syndrome (muc Either: 	opolysacchardosis	ll); and	
 Diagnosis confirmed by demonstration of iduronate 2- assay in cultured skin fibroblasts; or 	sulfatase deficiency	in white blo	od cells by either enzyme
2.2 Detection of a disease causing mutation in the idurona	ate 2-sulfatase gene	; and	
3 Patient is going to proceed with a haematopoietic stem cell tr idursulfase would be bridging treatment to transplant; and	ansplant (HSCT) wi	thin the next	3 months and treatment with
4 Patient has not required long-term invasive ventilation for res (ERT); and	piratory failure prior	to starting E	nzyme Replacement Therapy
5 Idursulfase to be administered for a total of 24 weeks (equiva greater than 0.5 mg/kg every week.	lent to 12 weeks pre	e- and 12 we	eeks post-HSCT) at doses no
LARONIDASE – Restricted see terms below			
 Inj 100 U per ml, 5 ml vial → Restricted (RS1607) 	1,335.16	1	Aldurazyme
Initiation			
Metabolic physician			
Limited to 24 weeks treatment			continued
All of the following:			continued

Price		Brand or
(ex man. excl. GST)	_	Generic
 \$	Per	Manufacturer

continued...

- 1 The patient has been diagnosed with Hurler Syndrome (mucopolysacchardosis I-H); and
- 2 Either:
 - 2.1 Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
 - 2.2 Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and
- 3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and
- 4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
- 5 Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week.

LEVOCARNITINE - Restricted see terms below

- ↓ Tab 500 mg
- Cap 250 mg
- Cap 500 mg
- I Oral liq 500 mg per 10 ml
- I Oral soln 1,000 mg per 10 ml
- ↓ Oral soln 1,100 mg per 15 ml
- Inj 200 mg per ml, 5 ml vial

➡ Restricted (RS1035)

Neurologist, metabolic physician or metabolic disorders dietitian

PYRIDOXAL-5-PHOSPHATE - Restricted see terms below

- → Restricted (RS1331)

Neurologist, metabolic physician or metabolic disorders dietitian

RIBOFLAVIN – **Restricted** see terms below

- Cap 100 mg

➡ Restricted (RS1833)

Initiation

Metabolic physician or neurologist

Re-assessment required after 6 months

The patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation.

Continuation

Metabolic physician or neurologist

Re-assessment required after 24 months Both:

- 1 The patient has a confirmed diagnosis of an inborn error of metabolism that responds to riboflavin supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

SAPROPTERIN DIHYDROCHLORIDE - Restricted see terms below

Tab soluble 100 mg	1,452.70	30	Kuvan
➡ Restricted (RS1796)			
Initiation			
Metabolic physician			
Re-assessment required after 1 month			
All of the following:			

continued...

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and
- 2 Treatment with sapropterin is required to support management of PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

Continuation

Metabolic physician

Re-assessment required after 12 months

All of the following:

- 1 Either:
 - 1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or
 - 1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
- 2 Any of the following:
 - 2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
 - 2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
 - 2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE

Cap 500 mg
Powder
Soln 100 mg per ml
Inj 20%, 10 ml ampoule
SODIUM PHENYLBUTYRATE – Some items restricted see terms below
Tab 500 mg
Image: Grans 483 mg per g2,016.00 174 g Pheburane
Oral liq 250 mg per ml
Inj 200 mg per ml, 10 ml ampoule
→ Restricted (RS1797)
Initiation
Metabolic physician
Re-assessment required after 12 months
For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine
transcarbamylase or argininosuccinate synthetase.
Continuation
Metabolic physician
Re-assessment required after 12 months
The treatment remains appropriate and the patient is benefiting from treatment.
TALIGLUCERASE ALFA - Restricted see terms on the next page
↓ Inj 200 unit vial

Price (ex man. excl	. GST) Per	Brand or Generic Manufacturer
9	Fei	Wallulaciulei

➡ Restricted (RS1897)

Initiation

Metabolic physician

Re-assessment required after 12 months

All of the following:

- 1 The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis; and
- 2 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by enzyme replacement therapy (ERT) or the disease might be reasonably expected to compromise a response to ERT; and
- 3 Any of the following:
 - 3.1 Patient has haematological complications of Gaucher disease; or
 - 3.2 Patient has skeletal complications of Gaucher disease; or
 - 3.3 Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease; or
 - 3.4 Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease; or
 - 3.5 Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period; and
- 4 Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).
- Note: Indication marked with * is an unapproved indication

Continuation

Metabolic physician or any relevant practitioner on the recommendation of a metabolic physician

Re-assessment required after 3 years

All of the following:

- 1 Patient has demonstrated a symptomatic improvement and has maintained improvements in the main symptom or symptoms for which therapy was started; and
- 2 Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size; and
- 3 RRadiological (MRI) signs of bone activity performed at two years since initiation of treatment, and five yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose; and
- 4 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 5 Patient is adherent with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units).

TAURINE - Restricted see terms below

- Cap 500 mg
- ↓ Cap 1,000 mg
- Powder

➡ Restricted (RS1834)

Initiation

Metabolic physician

Re-assessment required after 6 months

The patient has a suspected specific mitochondrial disorder that may respond to taurine supplementation.

Continuation

Metabolic physician

Re-assessment required after 24 months

Both:

- 1 The patient has a confirmed diagnosis of a specific mitochondrial disorder which responds to taurine supplementation; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
TRIENTINE DIHYDROCHLORIDE Cap 300 mg			
Minerals			
Calcium			
CALCIUM CARBONATE Tab 1.25 g (500 mg elemental) – 5% DV Feb-24 to 2026 Tab eff 1.25 g (500 mg elemental) Tab eff 1.75 g (1 g elemental)	7.28	250	Calci-Tab 500
Copper			
Restricted (RS1928) Initiation – Moderate to severe burns Limited to 3 months treatment Both: Patient has been hospitalised with moderate to severe burns			
 2 Treatment is recommended by a National Burns Unit speciali COPPER - Restricted see terms above Tab 2.5 mg, chelated COPPER CHLORIDE - Restricted see terms above Inj 0.4 mg per ml, 10 ml vial 	SI.		
Fluoride			
SODIUM FLUORIDE Tab 1.1 mg (0.5 mg elemental)			
lodine			
POTASSIUM IODATE Tab 253 mcg (150 mcg elemental iodine) – 5% DV Feb-24 to 2 POTASSIUM IODATE WITH IODINE Oral liq 10% with iodine 5%	026 5.99	90	NeuroTabs
Iron			
FERROUS FUMARATE Tab 200 mg (65 mg elemental) – 5% DV May-22 to 2024		100	Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID Tab 310 mg (100 mg elemental) with folic acid 350 mcg – 5% C Aug-22 to 2024		100	Ferro-F-Tabs
FERROUS GLUCONATE WITH ASCORBIC ACID Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg			
FERROUS SULFATE Tab long-acting 325 mg (105 mg elemental) – 5% DV Jan-23 to Oral liq 30 mg (6 mg elemental) per ml – 5% DV Jan-23 to 202 FERROUS SULFATE WITH ASCORBIC ACID Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 5	5 13.10	30 500 ml	Ferrograd Ferodan

t Item restricted (see → above); t Item restricted (see → below)

	Duine		Durand au
	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
IRON (AS FERRIC CARBOXYMALTOSE) – Restricted see terms be ↓ Inj 50 mg per ml, 10 ml vial		1	Ferinject
Initiation Treatment with oral iron has proven ineffective or is clinically inapprop IRON (AS SUCROSE)	riate.		
Inj 20 mg per ml, 5 ml ampoule IRON POLYMALTOSE		5	Venofer
Inj 50 mg per ml, 2 ml ampoule		5	Ferrosig
Magnesium			
 MAGNESIUM AMINO ACID CHELATE Cap 750 mg (150 mg elemental) MAGNESIUM CHLORIDE Inj 1 mmol per 1 ml, 100 ml bag MAGNESIUM HYDROXIDE Tab 311 mg (130 mg elemental) Suspension 8% MAGNESIUM OXIDE Cap 663 mg (400 mg elemental) Cap 696 mg (420 mg elemental) MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIU Cap 500 mg with magnesium aspartate 100 mg, magnesium amir chelate 100 mg and magnesium citrate 100 mg (360 mg elem magnesium) MAGNESIUM SULPHATE Inj 100 mg per ml, 40 ml bag Inj 0.4 mmol per ml, 250 ml bag Inj 2 mmol per ml, 5 ml ampoule	no acid nental	LATE AND	D MAGNESIUM CITRATE
Selenium			
 SELENIUM - Restricted see terms below Oral liq 150 mcg per 3 drops Inj 300 mcg per ml, 1 ml ampoule → Restricted (RS1929) Initiation - Moderate to severe burns Limited to 3 months treatment Both: 1 Patient has been hospitalised with moderate to severe burns; a 			eg Clinicians selenium oral drops
2 Treatment is recommended by a National Burns Unit specialist Zinc			
ZINC Oral liq 5 mg per 5 drops ZINC CHLORIDE Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ZINC SULPHATE Cap 137.4 mg (50 mg elemental)	11.00	100	Zincaps
Mouth and Throat			
Agents Used in Mouth Ulceration			
SENZYDAMINE HYDROCHLORIDE Soln 0.15% Spray 0.15% Spray 0.3% SENZYDAMINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHLO Lozenge 3 mg with cetylpyridinium chloride CARBOXYMETHYLCELLULOSE Oral spray CARMELLOSE SODIUM WITH PECTIN AND GELATINE Paste Powder CHLORHEXIDINE GLUCONATE Mouthwash 0.2% CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE Adhesive gel 8.7% with cetalkonium chloride 0.01% DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL Lozenge 1.2 mg with amylmetacresol 0.6 mg TRIAMCINOLONE ACETONIDE Paste 0.1% – 5% DV Feb-24 to 2026		5 g	Kenalog in Orabase
Oropharyngeal Anti-Infectives		Jy	Relialog in Grabase
MPHOTERICIN B	5.00	00	Freedlin
Lozenge 10 mg		20	Fungilin
Oral gel 20 mg per g – 5% DV Dec-21 to 2024		40 g	Decozol
Oral liquid 100,000 u per ml - 5% DV Feb-24 to 2026	2.22	24 ml	Nilstat
Other Oral Agents HYALURONIC ACID WITH LIDOCAINE [LIGNOCAINE] Inj 20 mg per ml SODIUM HYALURONATE [HYALURONIC ACID] - Restricted see te Inj 20 mg per ml, 1 ml syringe → Restricted (RS1175) Dtolaryngologist	rms below		
Vitamins			
Multivitamin Preparations			
ULTIVITAMIN AND MINERAL SUPPLEMENT – Restricted see terr		180	Clinicians Multivit & Mineral Boost

t Item restricted (see → above); t Item restricted (see → below)

24

	Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
➡ Restricted (RS1498)			
Initiation			
Limited to 3 months treatment			
Both:			
1 Patient was admitted to hospital with burns; and			
2 Any of the following:			
2.1 Burn size is greater than 15% of total body surface area2.2 Burn size is greater than 10% of BSA for mid-dermal or2.3 Nutritional status prior to admission or dietary intake is p	deep dermal burns		
MULTIVITAMIN RENAL - Restricted see terms below	6 4 9	30	Clinicians Renal Vit
 ► Restricted (RS1499) 	0.49	30	
Initiation			
Either:			
 The patient has chronic kidney disease and is receiving either p The patient has chronic kidney disease grade 5, defined as pat 15 ml/min/1.73m² body surface area (BSA). 			
MULTIVITAMINS			
Tab (BPC cap strength) – 5% DV Feb-23 to 2025		1,000	Mvite
 ↓ cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 n riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 r cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg → Restricted (RS1620) 	, ng,		e.g. Vitabdeck
Initiation			
Any of the following:			
 Patient has cystic fibrosis with pancreatic insufficiency; or Patient is an infant or child with liver disease or short gut syndri Patient has severe malabsorption syndrome. 	ome; or		
Powder vitamin A 3200 mcg with vitamin D 100 mcg, vitamin E 54 vitamin C 400 mg, vitamin K1 108 mcg thiamine 3.2 mg, ribofi 4.4 mg, niacin 41 mg, vitamin B6 3.6 mg, folic acid 600 mcg, v B12 9 mcg, biotin 120 mcg, pantothenic acid 24 mg, choline 1250 mg and inositol 700 mg	avin		e.g. Paediatric Seravit
→ Restricted (RS1178)			Ū
Initiation			
Patient has inborn errors of metabolism.			
Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyrido hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 5	00 mg		2 · · · · · ·
with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoul Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridov hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 5	line		e.g. Pabrinex IV
with nicotinamide 160 mg, 2 ml ampoule (1) Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyrido	Ū		e.g. Pabrinex IM
hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic aci 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10	Ł		
ampoule (1)			e.g. Pabrinex IV

	Price	-\	Brand or Generic
	(ex man. excl. GST \$	Per	Manufacturer
Vitamin A			
RETINOL Tab 10,000 iu Cap 25,000 iu Oral liq 150,000 iu per ml Oral liq 666.7 mcg per 2 drops, 10 ml Oral liq 5,000 iu per drop, 30 ml			
Vitamin B			
HYDROXOCOBALAMIN Inj 1 mg per ml, 1 ml ampoule – 5% DV Nov-22 to 2024	2.46	3	Hydroxocobalamin Panpharma
PYRIDOXINE HYDROCHLORIDE			
Tab 25 mg – 5% DV Feb-24 to 2026 Tab 50 mg		90 500	Vitamin B6 25
Inj 100 mg per ml, 2 ml vial Inj 100 mg per ml, 1 ml ampoule Inj 100 mg per ml, 30 ml vial	23.45	500	Pyridoxine multichem
THIAMINE HYDROCHLORIDE Tab 50 mg – 5% DV Apr-23 to 2025	4.65	100	Thiamine multichem
Tab 100 mg Inj 100 mg per ml, 1 ml vial Inj 100 mg per ml, 2 ml vial VITAMIN B COMPLEX		100	e.g. Benerva
Tab strong, BPC	11.25	500	Bplex
Vitamin C			
ASCORBIC ACID Tab 100 mg – 5% DV Feb-23 to 2025 Tab chewable 250 mg	12.50	500	Cvite
Vitamin D			
ALFACALCIDOL			
Cap 0.25 mcg		100	One-Alpha
Cap 1 mcg		100	One-Alpha
Oral drops 2 mcg per ml	80.00	20 ml	One-Alpha
CALCITRIOL Cap 0.25 mcg – 5% DV Dec-22 to 2025 Cap 0.5 mcg – 5% DV Dec-22 to 2025 Oral liq 1 mcg per ml Inj 1 mcg per ml, 1 ml ampoule		100 100	Calcitriol-AFT Calcitriol-AFT
COLECALCIFEROL			
Cap 1.25 mg (50,000 iu) Oral liq 188 mcg per ml (7,500 iu per ml)		12 5 ml	Vit.D3 Clinicians
(Puria Oral liq 188 mcg per ml (7,500 iu per ml) to be delisted 1 March	2024)	4.8 ml	Puria

		F (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer	
--	--	---------------	----------------------	------	-----	-------------------------------------	--

Vitamin E

ALPHA TOCOPHERYL - Restricted see terms below

- I Oral liq 156 u per ml
- ➡ Restricted (RS1632)

Initiation – Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
 - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
 - 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis

For the treatment of osteoradionecrosis.

Initiation – Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
 - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
 - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

ALPHA TOCOPHERYL ACETATE - Restricted see terms below

- I Oral liq 156 u per ml

→ Restricted (RS1176)

Initiation - Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
 - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
 - 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis

For the treatment of osteoradionecrosis.

Initiation – Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
 - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
 - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
	÷		manaraotaroi
Antianaemics			
Hypoplastic and Haemolytic			
EPOETIN ALFA – Restricted see terms below			
Inj 1,000 iu in 0.5 ml syringe	250.00	6	Binocrit
Inj 2,000 iu in 1 ml syringe		6	Binocrit
Inj 3,000 iu in 0.3 ml syringe	150.00	6	Binocrit
Inj 4,000 iu in 0.4 ml syringe	96.50	6	Binocrit
Inj 5,000 iu in 0.5 ml syringe	125.00	6	Binocrit
Inj 6,000 iu in 0.6 ml syringe	145.00	6	Binocrit
Inj 8,000 iu in 0.8 ml syringe		6	Binocrit
Inj 10,000 iu in 1 ml syringe		6	Binocrit
Inj 40,000 iu in 1 ml syringe	250.00	1	Binocrit
→ Restricted (RS1660)			
Initiation – chronic renal failure			
All of the following:			
1 Patient in chronic renal failure; and			
2 Haemoglobin is less than or equal to 100g/L; and			
3 Either:			
3.1 Both:			
3.1.1 Patient does not have diabetes mellitus; and			
3.1.2 Glomerular filtration rate is less than or equal to	30ml/min; or		
3.2 Both:			
3.2.1 Patient has diabetes mellitus; and			
3.2.2 Glomerular filtration rate is less than or equal to	45ml/min; and		
4 Patient is on haemodialysis or peritoneal dialysis.			
Initiation – myelodysplasia*			
Re-assessment required after 2 months			
All of the following:			
1 Patient has a confirmed diagnosis of myelodysplasia (MDS); a	nd		
2 Has had symptomatic anaemia with haemoglobin < 100g/L and			
3 Patient has very low, low or intermediate risk MDS based on th	ne WHO classification-	based pro	gnostic scoring system for
myelodysplastic syndrome (WPSS); and		ام	
4 Other causes of anaemia such as B12 and folate deficiency ha	ive been excluded; an	u	

- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*

Re-assessment required after 12 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with epoetin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation - all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative. Note: Indications marked with * are unapproved indications

t Item restricted (see → above); t Item restricted (see → below)

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

EPOETIN BETA - Restricted see terms below

Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- Inj 2,000 iu in 0.3 ml syringe
- Inj 3,000 iu in 0.3 ml syringe
- Inj 4,000 iu in 0.3 ml syringe
- Inj 5,000 iu in 0.3 ml syringe
- Inj 6,000 iu in 0.3 ml syringe
- Inj 10,000 iu in 0.6 ml syringe

➡ Restricted (RS1661)

Initiation - chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Either:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
- 4 Patient is on haemodialysis or peritoneal dialysis.

Initiation - myelodysplasia*

Re-assessment required after 12 months

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*

Re-assessment required after 2 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with epoetin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation - all other indications

Haematologist.

For use in patients where blood transfusion is not a viable treatment alternative. *Note: Indications marked with * are unapproved indications.

Megaloblastic

FOLIC ACID		
Tab 0.8 mg	 1,000	Folic Acid multichem
Tab 5 mg - 1% DV Mar-23 to 2024	 100	Folic Acid Mylan
		Folic Acid Viatris
Oral lig 50 mcg per ml	 25 ml	Biomed
Inj 5 mg per ml, 10 ml vial		
(Folic Acid Mylan Tab 5 mg to be delisted 1 January 2024)		

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Dries		Drand ar
	Price (ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
Antifibrinolytics, Haemostatics and Local Scleros	ants		
ALUMINIUM CHLORIDE – Restricted see terms below			
			e.g. Driclor
→ Restricted (RS1500)			
Initiation			
For use as a haemostatis agent.			
APROTININ – Restricted see terms below			
Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial → Restricted (RS1332)			
Initiation			
Cardiac anaesthetist			
Either:			
 Paediatric patient undergoing cardiopulmonary bypass proce Adult patient undergoing cardiac surgical procedure where th adverse effects of the drug. 		sive blee	ding outweighs the potential
ELTROMBOPAG – Restricted see terms below			
Tab 25 mg	1,550.00	28	Revolade
↓ Tab 50 mg	3,100.00	28	Revolade
→ Restricted (RS1648)			
Initiation – idiopathic thrombocytopenic purpura - post-splenec	tomy		
Haematologist Re-assessment required after 6 weeks			
All of the following:			
1 Patient has had a splenectomy; and			
2 Two immunosuppressive therapies have been trialled and fai	led after therapy of 3 m	onths eac	h (or 1 month for rituximab):
and			
3 Any of the following:			
3.1 Patient has a platelet count of 20,000 to 30,000 platel	ets per microlitre and ha	s eviden	ce of significant
mucocutaneous bleeding; or			•
3.2 Patient has a platelet count of less than or equal to 20	,000 platelets per micro	litre and	has evidence of active
bleeding; or			
3.3 Patient has a platelet count of less than or equal to 10		litre.	
Initiation – idiopathic thrombocytopenic purpura - preparation f	or splenectomy		
Haematologist			
Limited to 6 weeks treatment	a atamu /		
The patient requires eltrombopag treatment as preparation for splen Continuation – idiopathic thrombocytopenic purpura - post-sple			
Haematologist	enectomy		
Re-assessment required after 12 months			
The patient has obtained a response (see Note) from treatment durin	ng the initial approval or	subseau	ent renewal periods and
further treatment is required.	ig ale illusi approval el	ousooqu	ent fononal ponodo and
Note: Response to treatment is defined as a platelet count of > 30,0	000 platelets per microlit	re	
Initiation - idiopathic thrombocytopenic purpura contraindicate			
Haematologist	•		
Re-assessment required after 3 months			
All of the following:			

All of the following:

30

1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and

Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer	
 Ψ	1.01	Manalastarer	

continued...

- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant muccoutaneous bleeding.

Continuation - idiopathic thrombocytopenic purpura contraindicated to splenectomy

Haematologist

Re-assessment required after 12 months

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

Initiation - severe aplastic anaemia

Haematologist

Re-assessment required after 3 months

Both:

- 1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
- 2 Either:
 - 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Continuation - severe aplastic anaemia

Haematologist

Re-assessment required after 12 months Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

EMICIZUMAB - Restricted see terms below

1	Inj 30 mg in 1 ml vial) 1	Hemlibra
t	Inj 60 mg in 0.4 ml vial) 1	Hemlibra
t	Inj 105 mg in 0.7 ml vial) 1	Hemlibra
t	Inj 150 mg in 1 ml vial) 1	Hemlibra

⇒ Restricted (RS1780)

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

1 Patient has severe congenital haemophilia A and history of bleeding and bypassing agent usage within the last six months; and

2 Either:

2.1 Patient has had greater than or equal to 6 documented and treated spontaneous bleeds within the last 6 months if on an on-demand bypassing agent regimen; or

continued...

	Price (ex man. excl. GST)		Brand or
			Generic
	\$	Per	Manufacturer

continued...

- 2.2 Patient has had greater than or equal to 2 documented and treated spontaneous bleeds within the last 6 months if on a bypassing agent prophylaxis regimen; and
- 3 Patient has a high-titre inhibitor to Factor VIII (greater than or equal to 5 Bethesda units per ml) which has persisted for six months or more; and
- 4 There is no immediate plan for major surgery within the next 12 months; and

5 Either:

- 5.1 Patient has failed immune tolerance induction (ITI) after an initial period of 12 months; or
- 5.2 The Haemophilia Treaters Group considers the patient is not a suitable candidate for ITI; and
- 6 Treatment is to be administered at a maximum dose of 3 mg/kg weekly for 4 weeks followed by the equivalent of 1.5 mg/kg weekly.

Continuation

Haematologist

Re-assessment required after 6 months

Both:

- 1 Patient has had no more than two spontaneous and clinically significant treated bleeds after the end of the loading dose period (i.e. after the first four weeks of treatment until the end of the 24-week treatment period); and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

FERRIC SUBSULFATE

Gel 25.9% Soln 500 ml

POLIDOCANOL

Inj 0.5%, 30 ml vial

SODIUM TETRADECYL SULPHATE

Inj 3%, 2 ml ampoule

THROMBIN

Powder

TRANEXAMIC ACID

Tab 500 mg – 5% DV Jun-23 to 2025 10.45	60	Mercury Pharma
Inj 100 mg per ml, 5 ml ampoule - 5% DV Dec-21 to 2024	5	Tranexamic-AFT
Inj 100 mg per ml, 10 ml ampoule - 5% DV Dec-21 to 2024	5	Tranexamic-AFT

Anticoagulant Reversal Agents

IDARUCIZUMAB – Restricted see terms below			
Inj 50 mg per ml, 50 ml vial	4,250.00	2	Praxbind
➡ Restricted (RS1535)			

Initiation

For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures.

Blood Factors

EF	TRENONACOG ALFA [RECOMBINANT FACTOR IX] - Restricted see terms of	on the next	bage	
	Inj 250 iu vial612		1	Alprolix
t	Inj 500 iu vial	5.00	1	Alprolix
t	Inj 1,000 iu vial2,450	.00	1	Alprolix
t	Inj 2,000 iu vial	.00	1	Alprolix
t	Inj 3,000 iu vial	.00	1	Alprolix
t	Inj 4,000 iu vial	0.00	1	Alprolix

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
→ Restricted (RS1684)			
nitiation			
For patients with haemophilia B receiving prophylaxis treatment.	Access to funded treatme	ent is man	aged by the Haemophilia
Treaters Group in conjunction with the National Haemophilia Mar			
EPTACOG ALFA [RECOMBINANT FACTOR VIIA] - Restricted	see terms below		
Inj 1 mg syringe	1,178.30	1	NovoSeven RT
Inj 2 mg syringe		1	NovoSeven RT
Inj 5 mg syringe	5,891.50	1	NovoSeven RT
Inj 8 mg syringe	9,426.40	1	NovoSeven RT
→ Restricted (RS1704)			
nitiation			
For patients with haemophilia. Access to funded treatment is ma			
he National Haemophilia Management Group. Rare Clinical Circ			
use. Access to funded treatment for > 14 days predicted use is to	y named patient application	on to the	Haemophilia Treaters Grou
subject to access criteria.			
FACTOR EIGHT INHIBITOR BYPASSING FRACTION – Restrie	cted see terms below		
Inj 500 U	'	1	FEIBA NF
Inj 1,000 U		1	FEIBA NF
Inj 2,500 U	6,575.00	1	FEIBA NF
→ Restricted (RS1705)			
nitiation			
For patients with haemophilia. Preferred Brand of bypassing age			
nanaged by the Haemophilia Treaters Group in conjunction with		Manager	nent Group.
MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] - Restr			
Inj 250 iu prefilled syringe		1	Xyntha
Inj 500 iu prefilled syringe		1	Xyntha
· · · j · ; · · · · · · · · · · · · ·		1	Xyntha
Inj 2,000 iu prefilled syringe	2,300.00	1	Xyntha
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe 	2,300.00		
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe → Restricted (RS1706) 	2,300.00	1	Xyntha
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe → Restricted (RS1706) nitiation 	2,300.00 3,450.00	1 1	Xyntha Xyntha
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe → Restricted (RS1706) nitiation For patients with haemophilia. Rare Clinical Circumstances Brar 	2,300.00 3,450.00 d of short half-life recomb	1 1 inant fact	Xyntha Xyntha or VIII. Access to funded
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe Restricted (RS1706) nitiation For patients with haemophilia. Rare Clinical Circumstances Brar reatment is managed by the Haemophilia Treaters Group in conjunction 	2,300.00 3,450.00 d of short half-life recomb	1 1 inant fact	Xyntha Xyntha or VIII. Access to funded
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe Restricted (RS1706) nitiation For patients with haemophilia. Rare Clinical Circumstances Brar reatment is managed by the Haemophilia Treaters Group in conjugue subject to criteria. 	2,300.00 3,450.00 d of short half-life recomb unction with the National I	1 1 inant fact	Xyntha Xyntha or VIII. Access to funded
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe Restricted (RS1706) nitiation For patients with haemophilia. Rare Clinical Circumstances Brar reatment is managed by the Haemophilia Treaters Group in conjsubject to criteria. NONACOG GAMMA, [RECOMBINANT FACTOR IX] - Restricted 	d of short half-life recomb unction with the National I ed see terms below	1 1 inant fact Haemoph	Xyntha Xyntha or VIII. Access to funded ilia Management Group,
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe Restricted (RS1706) nitiation For patients with haemophilia. Rare Clinical Circumstances Brar reatment is managed by the Haemophilia Treaters Group in conjsubject to criteria. NONACOG GAMMA, [RECOMBINANT FACTOR IX] - Restricte Inj 500 iu vial 	d of short half-life recomb unction with the National I d see terms below 	1 1 inant fact Haemoph 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe Restricted (RS1706) nitiation For patients with haemophilia. Rare Clinical Circumstances Brar reatment is managed by the Haemophilia Treaters Group in conjsubject to criteria. NONACOG GAMMA, [RECOMBINANT FACTOR IX] - Restricte Inj 500 iu vial Inj 1,000 iu vial 	d of short half-life recomb unction with the National I ed see terms below 435.00	1 1 inant fact Haemoph 1 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe Restricted (RS1706) nitiation For patients with haemophilia. Rare Clinical Circumstances Brar reatment is managed by the Haemophilia Treaters Group in conjsubject to criteria. NONACOG GAMMA, [RECOMBINANT FACTOR IX] - Restricte Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial 	2,300.00 	1 1 Haemoph 1 1 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe Restricted (RS1706) nitiation For patients with haemophilia. Rare Clinical Circumstances Brar reatment is managed by the Haemophilia Treaters Group in conjsubject to criteria. NONACOG GAMMA, [RECOMBINANT FACTOR IX] - Restrict Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial Inj 3,000 iu vial 	2,300.00 	1 1 inant fact Haemoph 1 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 Haemoph 1 1 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 Haemoph 1 1 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS RIXUBIS
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 Haemoph 1 1 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS RIXUBIS
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 Haemoph 1 1 1 1 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS RIXUBIS S Group in conjunction with
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 inant fact Haemoph 1 1 1 1 a Treaters the next p	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS RIXUBIS S Group in conjunction with
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 Haemoph 1 1 1 1 a Treaters the next p 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS RIXUBIS Group in conjunction with hage Advate
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 Haemoph 1 1 1 1 1 the next p 1 1	Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS Group in conjunction with hage Advate Advate
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 Haemoph 1 1 1 1 1 the next p 1 1 1	Xyntha Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS Group in conjunction with Page Advate Advate Advate Advate
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 inant fact Haemoph 1 1 1 1 a Treaters the next p 1 1 1	Xyntha Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS Group in conjunction with age Advate Advate Advate Advate Advate
 Inj 2,000 iu prefilled syringe Inj 3,000 iu prefilled syringe	2,300.00 	1 1 Haemoph 1 1 1 1 1 the next p 1 1 1	Xyntha Xyntha Xyntha or VIII. Access to funded ilia Management Group, RIXUBIS RIXUBIS RIXUBIS RIXUBIS Group in conjunction with Page Advate Advate Advate Advate

Price		Brand or
(ex man. excl.		Generic
 \$	Per	Manufacturer

➡ Restricted (RS1707)

Initiation

For patients with haemophilia. Preferred Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) - Restricted see terms below

t	Inj 250 iu vial.	 1	Kogenate FS
	Inj 500 iu vial	1	Kogenate FS
t	Inj 1,000 iu vial	 1	Kogenate FS
t	Inj 2,000 iu vial	 1	Kogenate FS
t	Inj 3,000 iu vial	 1	Kogenate FS
_	Destricted (DC1700)		0

➡ Restricted (RS1708)

Initiation

For patients with haemophilia. Rare Clinical Circumstances Brand of short half-life recombinant factor VIII. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group, subject to criteria.

RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] - Restricted see terms below

t	Inj 250 iu vial	1	Adynovate
t	Inj 500 iu vial	1	Adynovate
t	Inj 1,000 iu vial	1	Adynovate
		1	Adynovate
	Destricted (DC1692)		•

➡ Restricted (RS1682)

Initiation

For patients with haemophilia A receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Vitamin K

PHYTOMENADIONE			
Inj 2 mg in 0.2 ml ampoule	.8.00	5	Konakion MM
Inj 10 mg per ml, 1 ml ampoule	.9.21	5	Konakion MM

Antithrombotics

Anticoagulants

BIVALIRUDIN - Restricted see terms below

- Inj 250 mg vial
- ➡ Restricted (RS1181)

Initiation

Either:

1 For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or

2 For use in patients undergoing endovascular procedures.

CITRATE SODIUM

Inj 4% (200 mg per 5 ml), 5 ml ampoule

Inj 46.7% (1.4 g per 3 ml), 3 ml syringe

Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule

DABIGATRAN

Cap 75 mg76.36	60	Pradaxa
Cap 110 mg76.36	60	Pradaxa
Cap 150 mg76.36	60	Pradaxa

t Item restricted (see → above); ↓ Item restricted (see → below)

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
DANAPAROID - Restricted see terms below	*	-	
Inj 750 u in 0.6 ml ampoule			
→ Restricted (RS1182)			
Initiation			
For use in heparin-induced thrombocytopaenia, heparin resistance or	heparin intolerance.		
DEFIBROTIDE – Restricted see terms below			
Inj 80 mg per ml, 2.5 ml ampoule			
→ Restricted (RS1183)			
Initiation			
Haematologist			
Patient has moderate or severe sinusoidal obstruction syndrome as a	result of chemothera	oy or regin	nen-related toxicities.
DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CIT	RATE DEXTROSE A		
Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per n	nl,		
100 ml bag			
ENOXAPARIN SODIUM			
Inj 20 mg in 0.2 ml syringe		10	Clexane
Inj 40 mg in 0.4 ml ampoule			
Inj 40 mg in 0.4 ml syringe		10	Clexane
Inj 60 mg in 0.6 ml syringe		10	Clexane
Inj 80 mg in 0.8 ml syringe		10	Clexane
Inj 100 mg in 1 ml syringe		10	Clexane
Inj 120 mg in 0.8 ml syringe Inj 150 mg in 1 ml syringe		10 10	Clexane Forte Clexane Forte
, , , , ,		10	Clexalle Fulle
FONDAPARINUX SODIUM – Restricted see terms below			
 Inj 2.5 mg in 0.5 ml syringe Inj 7.5 mg in 0.6 ml syringe 			
 ➡ Restricted (RS1184) 			
Initiation			
For use in heparin-induced thrombocytopaenia, heparin resistance or	heparin intolerance.		
HEPARIN SODIUM	-p		
Inj 5,000 iu per ml, 5 ml vial - 5% DV Jul-23 to 2025		10	Heparin Sodium
······································			Panpharma
Inj 100 iu per ml, 250 ml bag			•
Inj 1,000 iu per ml, 1 ml ampoule	245.26	50	Hospira
Inj 1,000 iu per ml, 5 ml ampoule		50	Pfizer
Inj 5,000 iu in 0.2 ml ampoule		_	
Inj 5,000 iu per ml, 1 ml ampoule	70.33	5	Hospira
HEPARINISED SALINE			
Inj 10 iu per ml, 5 ml ampoule	65.48	50	Pfizer
Inj 100 iu per ml, 2 ml ampoule			
Inj 100 iu per ml, 5 ml ampoule			
PHENINDIONE			
Tab 10 mg			
Tab 25 mg			
Tab 50 mg			
PROTAMINE SULPHATE			
Inj 10 mg per ml, 5 ml ampoule			

	Price		Brand or
	(ex man. excl. GS \$	T) Per	Generic Manufacturer
RIVAROXABAN			
Tab 10 mg - 5% DV Dec-23 to 2026		30	Xarelto
Tab 15 mg - 5% DV Dec-23 to 2026		28	Xarelto
Tab 20 mg - 5% DV Dec-23 to 2026	14.56	28	Xarelto
SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHI Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 per ml, 5,000 ml bag WARFARIN SODIUM	-		
Tab 1 mg	6 46	100	Marevan
Tab 2 mg		100	Walevan
Tab 3 mg		100	Marevan
Tab 5 mg		100	Marevan
Antiplatelets			
ASPIRIN			
Tab 100 mg		90	Ethics Aspirin EC
,	14.95	990	Ethics Aspirin EC
Suppos 300 mg CLOPIDOGREL			
Tab 75 mg - 5% DV May-23 to 2025	5.07	84	Arrow - Clopid
DIPYRIDAMOLE Tab 25 mg			
Tab long-acting 150 mg Inj 5 mg per ml, 2 ml ampoule	13.93	60	Pytazen SR
EPTIFIBATIDE – Restricted see terms below Inj 2 mg per ml, 10 ml vial		1	Eptifibatide Viatris Mylan
Inj 750 mcg per ml, 100 ml vial → Restricted (RS1759) nitiation	526.50	1	Eptifibatide Viatris
Any of the following:			
 For use in patients with acute coronary syndromes undergoing p For use in patients with definite or strongly suspected intra-coror For use in patients undergoing intra-cranial intervention. 			
LYSINE ACETYLSALICYLATE [LYSINE ASPRIN] – Restricted see te Inj 500 mg → Restricted (RS1689)	rms below		e.g. Aspegic
Initiation Both: 1 For use when an immediate antiplatelet effect is required prior to	an urgent interve	ntional neu	ro-radiology or interventiona
cardiology procedure; and 2 Administration of oral aspirin would delay the procedure.			
TICAGRELOR – Restricted see terms below ↓ Tab 90 mg – 5% DV Mar-23 to 2024 → Restricted (RS1774) nitiation	23.85	56	Ticagrelor Sandoz
Restricted to treatment of acute coronary syndromes specifically for pat	ients who have re	cently (with	in the last 60 days) been

continued...

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

continued...

diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Initiation – thrombosis prevention neurological stenting

Re-assessment required after 12 months

Both:

1 Either:

- 1.1 Patient has had a neurological stenting procedure* in the last 60 days; or
- 1.2 Patient is about to have a neurological stenting procedure performed*; and

2 Either:

- 2.1 Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor; or
- 2.2 Either:
 - 2.2.1 Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event; or
 - 2.2.2 Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent..

Continuation - thrombosis prevention neurological stenting

Re-assessment required after 12 months Both:

- 1 Patient is continuing to benefit from treatment; and
- 2 Treatment continues to be clinically appropriate.

Initiation - Percutaneous coronary intervention with stent deployment

Limited to 12 months treatment

All of the following:

- 1 Patient has undergone percutaneous coronary intervention; and
- 2 Patient has had a stent deployed in the previous 4 weeks; and
- 3 Patient is clopidogrel-allergic**.

Initiation – Stent thrombosis

Patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Initiation - Myocardial infarction

Limited to 1 week treatment

For short term use while in hospital following ST-elevated myocardial infarction.

Notes: Indications marked with * are unapproved indications.

Note: ** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

TICLOPIDINE

Tab 250 mg

Fibrinolytic Agents

ALTEPLASE

Inj 2 mg vial Inj 10 mg vial Inj 50 mg vial

TENECTEPLASE Inj 50 mg vial

Price		Brand or	
(ex man. excl. GST)		Generic	
 \$	Per	Manufacturer	

UROKINASE Inj 5,000 iu vial Inj 10,000 iu vial Inj 50,000 iu vial Inj 100,000 iu vial

Inj 250,000 iu vial

Inj 500,000 iu vial

Colony-Stimulating Factors

Drugs Used to Mobilise Stem Cells

·		
PLERIXAFOR – Restricted see terms below Inj 20 mg per ml, 1.2 ml vial	1	Mozobil
→ Restricted (RS1536)	I	MOZODII
Initiation – Autologous stem cell transplant		
Haematologist		
Limited to 3 days treatment		
All of the following:		
 Patient is to undergo stem cell transplantation; and 		
Patient has not had a previous unsuccessful mobilisation attempt with plerixafor; an	d	
3 Any of the following:		
3.1 Both:		
3.1.1 Patient is undergoing G-CSF mobilisation; and		
3.1.2 Either:		
3.1.2.1 Has a suboptimal peripheral blood CD34 count of less than or 4 days of G-CSF treatment; or	•	
3.1.2.2 Efforts to collect > 1 $\times 10^{6}$ CD34 cells/kg have failed after one	apheresis	s procedure; or
3.2 Both:		
3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation; and		
3.2.2 Any of the following:		
3.2.2.1 Both:		
3.2.2.1.1 Has rising white blood cell counts of > 5 × 10^9 /L; and		
3.2.2.1.2 Has a suboptimal peripheral blood CD34 count of less the		
3.2.2.2 Efforts to collect > 1 × 10^6 CD34 cells/kg have failed after one		
3.2.2.3 The peripheral blood CD34 cell counts are decreasing before t	0	has been received; or
3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy ha	as failed.	

Granulocyte Colony-Stimulating Factors

FILGRASTIM - Restricted see terms below Inj 300 mcg in 0.5 ml prefilled syringe - 5% DV Dec-21 to 2024	10 4	Nivestim Neupogen
Inj 480 mcg in 0.5 ml prefilled syringe − 5% DV Dec-21 to 2024	10	Nivestim
→ Restricted (RS1188) Haematologist or oncologist		
PEGFILGRASTIM – Restricted see terms on the next page		
Inj 6 mg per 0.6 ml syringe − 5% DV Jun-23 to 2025	1	Ziextenzo

e.g. Brand indicates brand example only. It is not a contracted product.

|--|

→ Restricted (RS1743)

Initiation

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 5%*).

Note: *Febrile neutropenia risk greater than or equal to 5% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

Fluids and Electrolytes

Intravenous Administration

CALCIUM CHLORIDE		
Inj 100 mg per ml, 10 ml vial		
Inj 100 mg per ml, 50 ml syringe		e.g. Baxter
CALCIUM GLUCONATE		
Inj 10%, 10 ml ampoule		e.g. Max Health
COMPOUND ELECTROLYTES		-
Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l,		
chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml		
bag	06 18	Plasma-Lyte 148
Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l,		
chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l,		
1,000 ml bag29.2	28 12	Plasma-Lyte 148
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]		
Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium,		
98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate,		
glucose 23 mmol/l (5%), 1,000 ml bag 227.0	64 12	Plasma-Lyte 148 & 5%
		Glucose
COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]		
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag	20 18	Baxter
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l,	20 10	Daxiel
bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag	92 12	Baxter
GLUCOSE [DEXTROSE]		Daxion
Inj 5%, 1,000 ml bag	30 10	Fresenius Kabi
Inj 5%, 100 ml bag		Fresenius Kabi
Inj 5%, 250 ml bag		Fresenius Kabi
Inj 5%, 50 ml bag		Baxter Glucose 5%
Inj 5%, 500 ml bag24.0	20 20	Fresenius Kabi
Inj 10%, 1,000 ml bag120.3		Baxter Glucose 10%
Inj 10%, 500 ml bag118.2		Baxter Glucose 10%
Inj 50%, 10 ml ampoule - 5% DV Feb-24 to 2026		Biomed
Inj 50%, 500 ml bag		Baxter Glucose 50%
Inj 50%, 90 ml bottle - 5% DV Feb-24 to 2026	50 1	Biomed
GLUCOSE WITH POTASSIUM CHLORIDE		

GLUCOSE WITH POTASSIUM CHLORIDE

Inj 10% glucose with 20 mmol/l potassium chloride, 500 ml bag

Price (ex man. excl. \$	GST)	Per	Brand or Generic Manufacturer
GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE			
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag			
Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag			
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, 1,000 ml bag218.52	2	12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 1,000 ml bag	4	12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, 1,000 ml bag	2	12	Baxter
GLUCOSE WITH SODIUM CHLORIDE Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag			
Inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag	4	12	Baxter
Inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag		12	Baxter
Inj 5% glucose and sodium chloride 0.9%, 1,000 ml bag 186.24	4	12	Baxter
POTASSIUM CHLORIDE Inj 75 mg (1 mmol) per ml, 10 ml ampoule Inj 225 mg (3 mmol) per ml, 20 ml ampoule			
POTASSIUM CHLORIDE WITH SODIUM CHLORIDE			
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag512.16		48	Baxter
Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag 175.20		12 12	Baxter
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag272.16 Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag829.92		12 48	Baxter Baxter
POTASSIUM DIHYDROGEN PHOSPHATE	-	10	Buildi
Inj 1 mmol per ml, 10 ml ampoule	7	10	Hospira
RINGER'S SOLUTION			
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, 1,000 ml bag			
SODIUM ACETATE			
Inj 4 mmol per ml, 20 ml ampoule			
SODIUM BICARBONATE			
Inj 8.4%, 10 ml vial	•		D'aura d
Inj 8.4%, 50 ml vial		1	Biomed Biomed
ing 0.770, 100 mil vial	0	1	Diomeu

40

	Price		Brand or
	(ex man. excl. GS \$	T) Per	Generic Manufacturer
SODIUM CHLORIDE			
Inj 0.9%, 5 ml ampoule - 5% DV Jan-23 to 2025	4.00	20	Fresenius Kabi
Inj 0.9%, 10 ml ampoule - 5% DV Jan-23 to 2025	5.25	50	Fresenius Kabi
Inj 0.9%, 3 ml syringe, non-sterile pack – 5% DV Mar-23 to 2025		30	BD PosiFlush
➡ Restricted (RS1297)			
Initiation			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, 5 ml syringe, non-sterile pack − 5% DV Mar-23 to 2025 → Restricted (RS1297)		30	BD PosiFlush
Initiation			
For use in flushing of in-situ vascular access devices only.			
 Inj 0.9%, 10 ml syringe, non-sterile pack - 5% DV Mar-23 to 202 → Restricted (RS1297) 	5 11.70	30	BD PosiFlush
Initiation			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, 20 ml ampoule - 5% DV Jan-23 to 2025	5.00	20	Fresenius Kabi
Inj 23.4% (4 mmol/ml), 20 ml ampoule		5	Biomed
Inj 0.45%, 500 ml bag		18	Baxter
Inj 3%, 1,000 ml bag		12	Baxter
Inj 0.9%, 50 ml bag		60	Baxter
	147.75	75	Baxter-Viaflo
Inj 0.9%, 100 ml bag		48	Baxter
	105.60	60	Baxter-Viaflo
Inj 0.9%, 250 ml bag		24	Baxter
Inj 0.9%, 500 ml bag	23.94	18	Baxter
Inj 0.9%, 1,000 ml bag		12	Baxter
Inj 1.8%, 500 ml bottle			
SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE	-1		
Inj 1 mmol per ml, 20 ml ampoule		5	Biomed
WATER		Ŭ	21011104
	7.60	50	Multichem
Inj 10 ml ampoule – 5% DV Sep-23 to 2025 Inj 20 ml ampoule – 5% DV Jan-23 to 2025		50 20	Fresenius Kabi
Inj 250 ml bag	5.00	20	Fresenius Rabi
Inj 500 ml bag	00.50	10	Deuter
Inj, 1,000 ml bag	20.52	12	Baxter
Oral Administration			
CALCIUM POLYSTYRENE SULPHONATE			
Powder		300 g	Calcium Resonium
COMPOUND ELECTROLYTES		Ũ	
Powder for oral soln - 5% DV Dec-22 to 2025	9.53	50	Electral
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] Soln with electrolytes (2 × 500 ml)	8.55	1,000 ml	Pedialyte - Bubblegum
PHOSPHORUS Tab eff 500 mg (16 mmol)			
POTASSIUM CHLORIDE			
Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)			
Tab long-acting 600 mg (8 mmol)		200	Span-K
Oral liq 2 mmol per ml			
· ·			

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

(e,	Price (man. ex \$		GST)	Per	Brand or Generic Manufacturer
SODIUM BICARBONATE Cap 840 mg SODIUM CHLORIDE	8	.52		100	Sodibic
Tab 600 mg Oral liq 2 mmol/ml					
SODIUM POLYSTYRENE SULPHONATE Powder	84	.65		454 g	Resonium A
Plasma Volume Expanders					
GELATINE, SUCCINYLATED Inj 4%, 500 ml bag	129	.00		10	Gelofusine

42

	Price (ex man. excl. GST \$	Per	Brand or Generic Manufacturer
Agents Affecting the Renin-Angiotensin System			
ACE Inhibitors			
CAPTOPRIL I Oral lig 5 mg per ml	94.99	95 ml	Capoten
 → Restricted (RS1263) Initiation Any of the following: For use in children under 12 years of age; or For use in tube-fed patients; or For management of rebound transient hypertension following c 	ardiac surgery.		
CILAZAPRIL – Restricted: For continuation only	0.00	00	Zerril
 ➡ Tab 0.5 mg ➡ Tab 2.5 mg 		90 90	Zapril Zapril
→ Tab 5 mg		90 90	Zapril
ENALAPRIL MALEATE		50	Zapin
Tab 5 mg - 5% DV Feb-24 to 2025	1 75	90	Acetec
Tab 10 mg - 5% DV Feb-24 to 2025		90	Acetec
Tab 20 mg - 5% DV Feb-24 to 2025		90	Acetec
LISINOPRIL			
Tab 5 mg - 5% DV Oct-22 to 2025	11.07	90	Ethics Lisinopril Teva Lisinopril
Tab 10 mg – 5% DV Oct-22 to 2025	11.67	90	Ethics Lisinopril Teva Lisinopril
Tab 20 mg - 5% DV Oct-22 to 2025	14.69	90	Ethics Lisinopril Teva Lisinopril
PERINDOPRIL			
Tab 2 mg - 5% DV Jan-22 to 2024		30	Coversyl
Tab 4 mg – 5% DV Jan-22 to 2024		30 30	Coversyl
Tab 8 mg		30	Coversyl
QUINAPRIL Tab 5 mg - 5% DV Feb-22 to 2024	5.07	90	Arrow-Quinapril 5
Tab 10 mg - 5% DV Feb-22 to 2024		90 90	Arrow-Quinapril 10
Tab 20 mg - 5% DV Feb-22 to 2024		90	Arrow-Quinapril 20
RAMIPRIL			
Cap 1.25 mg – 5% DV May-23 to 2024	6.90	90	Tryzan
Cap 2.5 mg – 5% DV May-23 to 2024		90	Tryzan
Cap 5 mg – 5% DV May-23 to 2024	6.75	90	Tryzan
Cap 10 mg – 5% DV May-23 to 2024	7.05	90	Tryzan
ACE Inhibitors with Diuretics			
QUINAPRIL WITH HYDROCHLOROTHIAZIDE - Restricted: For co	ntinuation only		
➡ Tab 10 mg with hydrochlorothiazide 12.5 mg – 5% DV Mar-22 to		30	Accuretic 10
→ Tab 20 mg with hydrochlorothiazide 12.5 mg - 5% DV Mar-22 to		30	Accuretic 20

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Angiotensin II Antagonists			
CANDESARTAN CILEXETIL Tab 4 mg - 5% DV Dec-21 to 2024		90	Candestar
Tab 8 mg - 5% DV Dec-21 to 2024		90	Candestar
Tab 16 mg – 5% DV Dec-21 to 2024		90	Candestar
Tab 32 mg - 5% DV Dec-21 to 2024		90	Candestar
LOSABTAN POTASSIUM			
Tab 12.5 mg	1 56	84	Losartan Actavis
		84	Losartan Actavis
Tab 25 mg		84 84	Losartan Actavis
Tab 50 mg		84	Losartan Actavis
Tab 100 mg		04	LUSATIAN ACIAVIS
Angiotensin II Antagonists with Diuretics			
CANDESARTAN CILEXETIL WITH HYDROCHLOROTHIAZIDE			
Tab 16 mg with hydrochlorothiazide 12.5 mg	4.10	30	APO-Candesartan HCTZ 16/12.5
Tab 32 mg with hydrochlorothiazide 12.5 mg	5.25	30	APO-Candesartan HCTZ 32/12.5
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE			
Tab 50 mg with hydrochlorothiazide 12.5 mg - 5% DV Jan-23 to	2025 4.00	30	Arrow-Losartan & Hydrochlorothiazide

Angiotensin II Antagonists with Neprilysin Inhibitors

SACUBITRIL WITH VALSARTAN - Restricted see terms below

t	Tab 24.3 mg with valsartan 25.7 mg	56	Entresto 24/26
t	Tab 48.6 mg with valsartan 51.4 mg	56	Entresto 49/51
t	Tab 97.2 mg with valsartan 102.8 mg 190.00	56	Entresto 97/103

→ Restricted (RS1738)

Initiation

Re-assessment required after 12 months All of the following:

- 1 Patient has heart failure; and
- 2 Any of the following:
 - 2.1 Patient is in NYHA/WHO functional class II; or
 - 2.2 Patient is in NYHA/WHO functional class III; or
 - 2.3 Patient is in NYHA/WHO functional class IV; and
- 3 Either:
 - 3.1 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; or
 - 3.2 An ECHO is not reasonably practical, and in the opinion of the treating practitioner the patient would benefit from treatment; and
- 4 Patient is receiving concomitant optimal standard chronic heart failure treatments.

Continuation

Re-assessment required after 12 months

The treatment remains appropriate and the patient is benefiting from treatment.

44

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Alpha-Adrenoceptor Blockers			
DOXAZOSIN			
Tab 2 mg		500	Doxazosin Clinect
Tab 4 mg	20.94	500	Doxazosin Clinect
PHENOXYBENZAMINE HYDROCHLORIDE Cap 10 mg Inj 50 mg per ml, 1 ml ampoule Inj 50 mg per ml, 2 ml ampoule			
PHENTOLAMINE MESYLATE Inj 5 mg per ml, 1 ml ampoule Inj 10 mg per ml, 1 ml ampoule			
PRAZOSIN			
Tab 1 mg		100	Arrotex-Prazosin S29
Tab 2 mg Tab 5 mg		100 100	Arrotex-Prazosin S29 Arrotex-Prazosin S29
TERAZOSIN - Restricted: For continuation only		100	Anolex-i lazosin 029
➡ Tab 1 mg			
Antiarrhythmics			
ADENOSINE Inj 3 mg per ml, 2 ml vial ↓ Inj 3 mg per ml, 10 ml vial → Restricted (RS1266) Initiation For use in cardiac catheterisation, electrophysiology and MRI.	62.73	6	Adenocor
AJMALINE - Restricted see terms below			
 Inj 5 mg per ml, 10 ml ampoule → Restricted (RS1001) Cardiologist 			
AMIODARONE HYDROCHLORIDE			
Tab 100 mg - 5% DV Dec-22 to 2025		30	Aratac
Tab 200 mg - 5% DV Dec-22 to 2025		30	Aratac
Inj 50 mg per ml, 3 ml ampoule – 5% DV Dec-22 to 2025	15.22	10	Max Health
ATROPINE SULPHATE Inj 600 mcg per ml, 1 ml ampoule - 5% DV Jan-22 to 2024		10	Martindale
DIGOXIN			
Tab 62.5 mcg – 5% DV Jan-23 to 2025		240 240	Lanoxin PG Lanoxin
Tab 250 mcg – 5% DV Jan-23 to 2025 Oral liq 50 mcg per ml Inj 250 mcg per ml, 2 ml vial		240	Lanoxin
DISOPYRAMIDE PHOSPHATE			
Cap 100 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
FLECAINIDE ACETATE			
Tab 50 mg – 5% DV Dec-23 to 2026		60	Flecainide BNM
Cap long-acting 100 mg - 5% DV Aug-23 to 2026	35.78	90	Flecainide Controlled
Cap long-acting 200 mg - 5% DV Aug-23 to 2026		90	Release Teva Flecainide Controlled
Inj 10 mg per ml, 15 ml ampoule		5	Release Teva Tambocor
IVABRADINE – Restricted see terms below Tab 5 mg			
→ Restricted (RS1566)			
Initiation Both:			
 Patient is indicated for computed tomography coronary angi Either: 	ography; and		
2.1 Patient has a heart rate of greater than 70 beats per	minute while taking a ma	aximally to	plerated dose of beta blocker:
or	č		
2.2 Patient is unable to tolerate beta blockers.			
MEXILETINE HYDROCHLORIDE			
Cap 150 mg		100	Teva
Cap 250 mg	202.00	100	Teva
PROPAFENONE HYDROCHLORIDE			
Tab 150 mg			
Antihypotensives			
Antinypotensives			
MIDODRINE – Restricted see terms below			
Tab 2.5 mg - 5% DV Aug-23 to 2024		100	Midodrine Medsurge
↓ Tab 5 mg - 5% DV Aug-23 to 2024		100	Midodrine Medsurge
→ Restricted (RS1427) Initiation			
Patient has disabling orthostatic hypotension not due to drugs.			
Beta-Adrenoceptor Blockers			
ATENOLOL			
Tab 50 mg – 5% DV Jun-23 to 2024	9.33	500	Mylan Atenolol
			Viatris
Tab 100 mg – 5% DV Jan-22 to 2024	14.20	500	Atenolol Viatris
Oral liq 5 mg per ml	10.95	300 ml	Mylan Atenolol Atenolol-AFT
(Mylan Atenolol Tab 50 mg to be delisted 1 November 2023)	49.00	300 mi	
BISOPROLOL FUMARATE			
Tab 2.5 mg	1 8/	90	Bisoprolol Mylan
ι ων 2.0 mg	1.04	30	Bisoprolol Viatris
Tab 5 mg	2.55	90	Bisoprolol Mylan
J			Bisoprolol Viatris
	1.72	30	Bosvate
Tab 10 mg	3.62	90	Bisoprolol Mylan
			Bisoprolol Viatris
(Bisoprolol Mylan Tab 2.5 mg to be delisted 1 November 2023)			

(Bisoproloi Mylan Tab 5 mg to be delisted 1 November 2023)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CARVEDILOL	φ	rei	Manulaciulei
Tab 6.25 mg	2 24	60	Carvedilol Sandoz
Tab 12.5 mg		60	Carvedilol Sandoz
Tab 25 mg		60	Carvedilol Sandoz
CELIPROLOL – Restricted: For continuation only			
→ Tab 200 mg			
ESMOLOL HYDROCHLORIDE			
Inj 10 mg per ml, 10 ml vial			
LABETALOL Tob 50 mg			
Tab 50 mg Tab 100 mg – 1% DV Sep-20 to 2024	14 50	100	Trandate
Tab 200 mg - 1% DV Sep-20 to 2024		100	Trandate
Inj 5 mg per ml, 20 ml ampoule	27.00	100	Tanuale
METOPROLOL SUCCINATE			
Tab long-acting 23.75 mg	1.45	30	Betaloc CR
Tab long-acting 23.75 mg		30	Betaloc CR
Tab long-acting 95 mg		30	Betaloc CR
Tab long-acting 190 mg		30	Betaloc CR
METOPROLOL TARTRATE			Dotaloo of t
Tab 50 mg - 1% DV Mar-22 to 2024	5.66	100	IPCA-Metoprolol
Tab 100 mg - 1% DV Mar-22 to 2024		60	IPCA-Metoprolol
Tab long-acting 200 mg.		28	Slow-Lopresor
Inj 1 mg per ml, 5 ml vial		5	Metoprolol IV Mylan
			Metoprolol IV Viatris
NADOLOL			
Tab 40 mg – 1% DV Mar-22 to 2024		100	Nadolol BNM
Tab 80 mg – 1% DV Mar-22 to 2024		100	Nadolol BNM
PROPRANOLOL			
Tab 10 mg - 1% DV Mar-22 to 2024		100	Drofate
Tab 40 mg – 1% DV Mar-22 to 2024		100	IPCA-Propranolol
Cap long-acting 160 mg		100	Cardinol LA
Oral liq 4 mg per ml Inj 1 mg per ml, 1 ml ampoule			
SOTALOL Tab 80 mg - 5% DV Jan-23 to 2025	07.50	500	Mulan
Tab 160 mg - 5% DV Jan-23 to 2025		500 100	Mylan Mylan
	14.00	100	Mylan
Calcium Channel Blockers			
Dihydropyridine Calcium Channel Blockers			
AMLODIPINE			
Tab 2.5 mg - 5% DV Feb-24 to 2026	1.45	90	Vasorex
Tab 5 mg – 5% DV Feb-24 to 2026	1.21	90	Vasorex
Tab 10 mg - 5% DV Feb-24 to 2026	1.31	90	Vasorex
FELODIPINE			
Tab long-acting 2.5 mg	1.45	30	Plendil ER
Tob long opting E mg E9/ DV lon 00 to 0004		00	

Tab long-acting 10 mg - 5% DV Jan-22 to 2024......4.32

Felo 5 ER

Felo 10 ER

90

90

	Price		Brand or	
	(ex man.	excl. GST) \$	Per	Generic Manufacturer
SRADIPINE				
Tab 2.5 mg				
Cap 2.5 mg				
IICARDIPINE HYDROCHLORIDE – Restricted see terms below				
Inj 2.5 mg per ml, 10 ml vial				
→ Restricted (RS1699)				
nitiation				
naesthetist, intensivist, cardiologist or paediatric cardiologist				
ny of the following:				
1 Patient has hypertension requiring urgent treatment with an int	ravenous a	agent; or		
2 Patient has excessive ventricular afterload; or		h		
3 Patient is awaiting or undergoing cardiac surgery using cardio	buimonary	bypass.		
lifedipine				
Tab long-acting 10 mg			56	Tensipine MR10
Tab long-acting 20 mg			100	Nyefax Retard
Tab long-acting 30 mg		.34.10 4.78	100 14	Mylan (24 hr release) Mylan Italy (24 hr
		4.70	14	release)
Tab long-acting 60 mg		52.81	100	Mylan (24 hr release)
Cap 5 mg				
Mylan (24 hr release) Tab long-acting 30 mg to be delisted 1 Februa	ry 2024)			
IMODIPINE				
Tab 30 mg - 5% DV Dec-22 to 2025	3	350.00	100	Nimotop
Inj 200 mcg per ml, 50 ml vial			1	Nimotop
Other Calcium Channel Blockers				
Tab 30 mg Cap long-acting 120 mg – 5% DV Jun-23 to 2025		65.35	500	Diltiazem CD Clinect
Cap long-acting 180 mg – 1% DV Mar-22 to 2025			30	Cardizem CD Cimect
Cap long-acting 240 mg – 1% DV Mar-22 to 2024			30	Cardizem CD
Inj 5 mg per ml, 5 ml vial				
ERHEXILINE MALEATE				
Tab 100 mg		.62.90	100	Pexsig
ERAPAMIL HYDROCHLORIDE				-
Tab 40 mg		7.01	100	Isoptin
Tab 80 mg		.11.74	100	Isoptin
Tab long-acting 120 mg			100	Isoptin SR
Tab long-acting 240 mg			30	Isoptin SR
Inj 2.5 mg per ml, 2 ml ampoule		.25.00	5	Isoptin
Centrally-Acting Agents				
Patch 2.5 mg, 100 mcg per day - 5% DV Feb-24 to 2026			4	Mylan
Patch 5 mg, 200 mcg per day – 5% DV Feb-24 to 2026			4	Mylan Mylan
Patch 7.5 mg, 300 mcg per day - 5% DV Feb-24 to 2026		17.90	4	Mylan

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or
	(ex man. excl. GST)	Generic
	\$	Per	Manufacturer
CLONIDINE HYDROCHLORIDE			
Tab 25 mcg – 5% DV Nov-22 to 2025	29.32	112	Clonidine Teva
Tab 150 mcg – 5% DV Jan-22 to 2024		100	Catapres
Inj 150 mcg per ml, 1 ml ampoule – 5% DV Jan-22 to 2024	20.68	100	Medsurge
	29.00	10	weusuige
METHYLDOPA			
Tab 250 mg	15.10	100	Methyldopa Mylan
Diuretics			
Loop Diuretics			
BUMETANIDE			
Tab 1 mg	16.36	100	Burinex
Inj 500 mcg per ml, 4 ml vial			
FUROSEMIDE [FRUSEMIDE]			
Tab 40 mg – 1% DV Mar-21 to 2024	8 00	1,000	IPCA-Frusemide
Tab 500 mg		50	Urex Forte
		30 ml	
Oral liq 10 mg per ml			Lasix
Inj 10 mg per ml, 2 ml ampoule - 5% DV Jan-23 to 2025		5	Furosemide-Baxter
Inj 10 mg per ml, 25 ml ampoule	60.65	6	Lasix
Osmotic Diuretics			
MANNITOL			
Inj 10%, 1,000 ml bag	802.56	12	Baxter
Inj 20%, 500 ml bag		18	Baxter
		10	Baxtor
Potassium Sparing Combination Diuretics			
AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE			
Tab 5 mg with furosemide 40 mg			
Tab 5 mg with hydrochlorothiazide 50 mg			
<i>,</i>			
Potassium Sparing Diuretics			
AMILORIDE HYDROCHLORIDE			
Tab 5 mg			
Oral liq 1 mg per ml	32.10	25 ml	Biomed
EPLERENONE – Restricted see terms below			
Tab 25 mg – 5% DV Jun-22 to 2024	18 50	30	Inspra
		30	
Tab 50 mg - 5% DV Jun-22 to 2024	20.00	30	Inspra
→ Restricted (RS1640)			
nitiation			
Both:			
1 Patient has heart failure with ejection fraction less than 40%; ar	nd		
2 Either:			
2.1 Patient is intolerant to optimal dosing of spironolactone;	or		
2.2 Patient has experienced a clinically significant adverse		al dosina (of spiropolactone
Z.Z. T adont has experienced a christally significant duverse t		a aboing t	

	Price		Brand or
	(ex man. excl. G		Generic
	\$	Per	Manufacturer
PIRONOLACTONE			
Tab 25 mg - 5% DV Sep-22 to 2025	3.68	100	Spiractin
Tab 100 mg - 5% DV Sep-22 to 2025	10.65	100	Spiractin
Oral liq 5 mg per ml		25 ml	Biomed
Thiazide and Related Diuretics			
ENDROFLUMETHIAZIDE [BENDROFLUAZIDE]			
Tab 2.5 mg		500	Arrow-Bendrofluazide
Tab 5 mg		500	Arrow-Bendrofluazide
HLOROTHIAZIDE			
Oral liq 50 mg per ml	27.82	25 ml	Biomed
HLORTALIDONE [CHLORTHALIDONE]			
Tab 25 mg – 5% DV Apr-23 to 2025	6.95	50	Hygroton
DAPAMIDE			
Tab 2.5 mg – 5% DV Feb-24 to 2026	16.00	90	Dapa-Tabs
ů		50	Bapa Tabo

Tab 5 mg

Vasopressin receptor antagonists

TOLVAPTAN - Restricted see terms below

t	Tab 15 mg	28	Jinarc
t	Tab 30 mg	28	Jinarc
t	Tab 45 mg + 15 mg 1,747.00	56	Jinarc
t	Tab 60 mg + 30 mg 1,747.00	56	Jinarc
t	Tab 90 mg + 30 mg 1,747.00	56	Jinarc

➡ Restricted (RS1930)

Initiation - autosomal dominant polycystic kidney disease

Renal physician or any relevant practitioner on the recommendation of a renal physician

Re-assessment required after 12 months

All of the following:

- 1 Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease; and
- 2 Patient has an estimated glomerular filtration rate (eGFR) of greater than or equal to 25 ml/min/1.73 m² at treatment initiation; and
- 3 Either:
 - 3.1 Patient's disease is rapidly progressing, with a decline in eGFR of greater than or equal to 5 mL/min/1.73 m² within one-year; or
 - 3.2 Patient's disease is rapidly progressing, with an average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m² per year over a five-year period.

Continuation - autosomal dominant polycystic kidney disease

Renal physician or any relevant practitioner on the recommendation of a renal physician

Re-assessment required after 12 months

Both:

- 1 Patient has not developed end-stage renal disease, defined as an eGFR of less than 15 mL/min/1.73 m²; and
- 2 Patient has not undergone a kidney transplant.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Lipid-Modifying Agents			
Fibrates			
BEZAFIBRATE Tab 200 mg – 5% DV Feb-22 to 2024 Tab long-acting 400 mg – 5% DV Feb-22 to 2024		90 30	Bezalip Bezalip Retard
HMG CoA Reductase Inhibitors (Statins)			
ATORVASTATIN Tab 10 mg – 5% DV Dec-21 to 2024 Tab 20 mg – 5% DV Dec-21 to 2024 Tab 40 mg – 5% DV Dec-21 to 2024 Tab 80 mg – 5% DV Dec-21 to 2024	9.24 14.92	500 500 500 500	Lorstat Lorstat Lorstat Lorstat
PRAVASTATIN Tab 10 mg Tab 20 mg Tab 40 mg (Pravastatin Mylan Tab 20 mg to be delisted 1 January 2024)		28 28	Pravastatin Mylan Pravastatin Viatris Pravastatin Mylan
ROSUVASTATIN - Restricted see terms below Image: Tab 5 mg - 5% DV Oct-24 to 2026	1.69 2.71	30 30 30 30	Rosuvastatin Viatris Rosuvastatin Viatris Rosuvastatin Viatris Rosuvastatin Viatris
Either: 1 Both: 1.1 Patient is considered to be at risk of cardiovascular dist 1.2 Patient is Māori or any Pacific ethnicity; or 2 Both: 2.1 Patient has a calculated risk of cardiovascular disease 2.2 LDL cholesterol has not reduced to less than 1.8 mmol atorvastatin and/or simvastatin. Initiation – familial hypercholesterolemia Both: 1 Patient has familial hypercholesterolemia (defined as a Dutch 2 LDL cholesterol has not reduced to less than 1.8 mmol/litre wit and/or simvastatin.	of at least 15% over 5 /litre with treatment wit Lipid Criteria score gre	h the ma	ximum tolerated dose of n or equal to 6); and
Initiation – established cardiovascular disease Both:			

- 1 Any of the following:
 - 1.1 Patient has proven coronary artery disease (CAD); or
 - 1.2 Patient has proven peripheral artery disease (PAD); or
 - 1.3 Patient has experienced an ischaemic stroke; and

2 LDL cholesterol has not reduced to less than 1.4 mmol/litre with treatment with the maximum tolerated dose of atorvastatin

continued...

	F (ex man.	Price excl. (\$	GST)	Per	Brand or Generic Manufacturer
ontinued					
and/or simvastatin.					
itiation – recurrent major cardiovascular events oth:					
 Patient has experienced a recurrent major cardiovascular coronary revascularisation, hospitalisation for unstable ar LDL cholesterol has not reduced to less than 1.0 mmol/lit 	igina) in the last	2 year	s; and	b	
and/or simvastatin.		it with t			
IMVASTATIN					
Tab 10 mg - 5% DV Feb-24 to 2026		1.23		90	Simvastatin Mylan
		1.68			Simvastatin Viatris
Tab 20 mg - 5% DV Feb-24 to 2026		2.03		90	Simvastatin Mylan
-		2.54			Simvastatin Viatris
Tab 40 mg - 5% DV Feb-24 to 2026		3.58		90	Simvastatin Mylan
-		4.11			Simvastatin Viatris
Tab 80 mg – 5% DV Feb-24 to 2026		7.12		90	Simvastatin Mylan
o b b b b b b b b b b		8.81			Simvastatin Viatris
Simvastatin Mylan Tab 10 mg to be delisted 1 February 2024)					
Simvastatin Mylan Tab 20 mg to be delisted 1 February 2024)					
Simvastatin Mylan Tab 40 mg to be delisted 1 February 2024)					
Simvastatin Mylan Tab 80 mg to be delisted 1 February 2024)					
Resins					
CHOLESTYRAMINE					
Powder for oral liq 4 g					
OLESTIPOL HYDROCHLORIDE					
Grans for oral lig 5 g					
OLESTYRAMINE					
Powder for oral suspension 4 g sachet		61 50		50	Colestyramine - Mylan
		.01.50		50	Colestyramine - Wylan
Selective Cholesterol Absorption Inhibitors					
ZETIMIBE – Restricted see terms below		4 = 6		00	
Tab 10 mg - 5% DV Dec-23 to 2026		1./6		30	Ezetimibe Sandoz
Restricted (RS1005)					
litiation					
II of the following:					
1 Patient has a calculated absolute risk of cardiovascular d	isease of at leas	st 15%	over {	5 years;	and
2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and					
3 Any of the following:					
3.1 The patient has rhabdomyolysis (defined as musc	le aches and cre	eatine k	kinase	e more t	han 10 × normal) when
treated with one statin; or					,
3.2 The patient is intolerant to both simvastatin and at	orvastatin: or				
3.3 The patient has not reduced their LDL cholesterol		mmol/	litre w	ith the i	use of the maximal tolerate
dose of atorvastatin.					
ZETIMIBE WITH SIMVASTATIN - Restricted see terms on th	e next page				
		5 15		20	Zimuho
		ว. เว		30	Zimybe
		6 15		20	Zimuha
Tab 10 mg with simvastatin 20 mg				30	Zimybe
		7.15		30 30 30	Zimybe Zimybe Zimybe

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price			Brand or
(ex ma	n. excl.	GST)	_	Generic
	\$		Per	Manufacturer

➡ Restricted (RS1006)

Initiation

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Other Lipid-Modifying Agents

ACIPIMOX

Cap 250 mg

Nitrates

GLYCERYL TRINITRATE Inj 1 mg per ml, 5 ml ampoule Inj 1 mg per ml, 10 ml ampoule Inj 1 mg per ml, 50 ml vial 5 Hospira Oral pump spray, 400 mcg per dose7.48 250 dose Nitrolingual Pump Spray Patch 25 mg, 5 mg per day 15.73 30 Nitroderm TTS 5 30 Nitroderm TTS 10 ISOSOBBIDE MONONITRATE 100 Ismo 20 Ismo 40 Retard 30 Duride 90

Other Cardiac Agents

LEVOSIMENDAN - Restricted see terms below

- Inj 2.5 mg per ml, 5 ml vial
- Inj 2.5 mg per ml, 10 ml vial

→ Restricted (RS1007)

Initiation - Heart transplant

Either:

- 1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
- 2 For the treatment of heart failure following heart transplant.

Initiation – Heart failure

Cardiologist or intensivist

For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

Sympathomimetics		
ADRENALINE		
Inj 1 in 1,000, 1 ml ampoule4.98	5	Aspen Adrenaline
12.65		DBL Adrenaline
Inj 1 in 1,000, 30 ml vial		
Inj 1 in 10,000, 10 ml ampoule	10	Aspen Adrenaline
27.00	5	Hospira
Inj 1 in 10,000, 10 ml syringe		
DOBUTAMINE		
Inj 12.5 mg per ml, 20 ml ampoule – 5% DV Dec-21 to 2024	5	Dobutamine-hameIn

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST)	Brand or Generic
	\$	Per	Manufacturer
DOPAMINE HYDROCHLORIDE			
Inj 40 mg per ml, 5 ml ampoule - 5% DV Jan-22 to 2024		10	Max Health Ltd
EPHEDRINE			
Inj 3 mg per ml, 10 ml syringe Inj 30 mg per ml, 1 ml ampoule – 5% DV Feb-24 to 2026	04.01	10	May Haalth
		10	Max Health
SOPRENALINE [ISOPROTERENOL] Inj 200 mcg per ml, 1 ml ampoule			
Inj 200 mcg per ml, 5 ml ampoule			
METARAMINOL			
Inj 0.5 mg per ml, 10 ml syringe			
Inj 0.5 mg per ml, 20 ml syringe			
Inj 0.5 mg per ml, 5 ml syringe			
Inj 1 mg per ml, 1 ml ampoule Inj 1 mg per ml, 10 ml syringe			
Inj 10 mg per ml, 1 ml ampoule – 5% DV Feb-24 to 2026		10	Torbay
VORADRENALINE			
Inj 0.06 mg per ml, 100 ml bag			
Inj 0.06 mg per ml, 50 ml syringe			
Inj 0.1 mg per ml, 100 ml bag Inj 0.1 mg per ml, 50 ml syringe			
Inj 0.12 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 50 ml syringe			
Inj 0.16 mg per ml, 50 ml syringe			
Inj 1 mg per ml, 100 ml bag	15.00		
Inj 1 mg per ml, 4 ml ampoule – 5% DV Feb-24 to 2025	45.00	10	Noradrenaline BNM
PHENYLEPHRINE HYDROCHLORIDE Inj 10 mg per ml, 1 ml ampoule	163 38	25	Neosynephrine HCL
		25	Neosynephinie HOE
Vasodilators			
ALPROSTADIL HYDROCHLORIDE			
Inj 500 mcg per ml, 1 ml ampoule		5	Prostin VR
DIAZOXIDE	,		
Inj 15 mg per ml, 20 ml ampoule			
IYDRALAZINE HYDROCHLORIDE			
I Tab 25 mg			
→ Restricted (RS1008)			
nitiation jither:			
1 For the treatment of refractory hypertension; or			
2 For the treatment of heart failure, in combination with a nitra	ate, in patients who are i	ntolerant	or have not responded to
ACE inhibitors and/or angiotensin receptor blockers.	·		
Inj 20 mg ampoule		5	Apresoline
MILRINONE			
Inj 1 mg per ml, 10 ml ampoule - 5% DV Dec-21 to 2024	71.00	10	Milrinone-Baxter
MINOXIDIL			
Tab 10 mg		100	Loniten
NICORANDIL			
Tab 10 mg		60 60	lkorel
Tab 20 mg	32.20	60	lkorel

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

54

	Price (ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
PAPAVERINE HYDROCHLORIDE Inj 30 mg per ml, 1 ml vial Inj 12 mg per ml, 10 ml ampoule	257 12	5	Hospira
PENTOXIFYLLINE [OXPENTIFYLLINE] Tab 400 mg		-	
SODIUM NITROPRUSSIDE Inj 50 mg vial			
Endothelin Receptor Antagonists			
AMBRISENTAN – Restricted see terms below			
↓ Tab 5 mg - 5% DV Dec-23 to 2026	1,550.00 200.00	30	Ambrisentan Mylan Ambrisentan Viatris
↓ Tab 10 mg - 5% DV Dec-23 to 2026		30	Ambrisentan Viatris Mylan
(Ambrisentan Mylan Tab 5 mg to be delisted 1 December 202	,		mylan
(Mylan Tab 10 mg to be delisted 1 December 2023) → Restricted (RS1981)	- /		
Initiation – PAH monotherapy			
Respiratory specialist, cardiologist, rheumatologist or any relevant	ant practitioner on the recom	mendati	on of a respiratory specialist.
cardiologist or rheumatologist	····		· · · · · · · · · · · · · · · · · · ·
Limited to 6 months treatment			
All of the following:			
 Patient has pulmonary arterial hypertension (PAH); and PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) cl PAH is in New York Heart Association/World Health Or 	nical classifications; and	tional cl	ass II, III or IV; and
4 Any of the following:			
4.1 All of the following:			
 4.1.1 PAH has been confirmed by right heart of 4.1.2 A mean pulmonary artery pressure (PAF 4.1.3 A pulmonary capillary wedge pressure (Far 4.1.4 Pulmonary vascular resistance greater th cm⁻⁵); and 4.1.5 Any of the following: 	rm) greater than 20 mmHg (ur PCWP) less than or equal to 1	5 mmHg	g; and
4.1.5.1 PAH has been demonstrated to be nitric oxide, as defined in the 2022 guidelines) †; or			0 1
4.1.5.2 Patient has not experienced an ac validated risk stratification tool**; c	or .	Ū	, o
4.1.5.3 Patient has PAH other than idiopa			
4.2 Patient is a child with PAH secondary to conger developmental lung disorders including chronic		to idiop	athic, congenital or
4.3 Patient has palliated single ventricle congenital complication of the Fontan circulation requiring			
5 Both:			
5.1 Ambrisentan is to be used as PAH monotherapy5.2 Any of the following:	/; and		
5.2.1 Patient has experienced intolerable side	effects with both sildenafil an	d hosen	an: or
	shout man bour shuthall all		

continued...

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
- 5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

Initiation – PAH dual therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 All of the following:
 - 5.1 Ambrisentan is to be used as PAH dual therapy; and
 - 5.2 Either:
 - 5.2.1 Patient has tried a PAH monotherapy (sildenafil or bosentan) for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; or
 - 5.2.2 Patient has tried PAH dual therapy including bosentan and has experienced intolerable side effects on bosentan; and
 - 5.3 Both:
 - 5.3.1 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy; and
 - 5.3.2 Patient has an absolute or relative contraindication to bosentan (eg due to current use of a combined oral contraceptive or liver disease).

Initiation – PAH triple therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

All of the following:

1 Patient has pulmonary arterial hypertension (PAH); and

Price		Brand or	
(ex man. excl. GST)		Generic	
 \$	Per	Manufacturer	

- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Ambrisentan is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Both:
 - 5.2.2.1 Patient is presenting in NYHA/WHO functional class IV; and
 - 5.2.2.2 Patient has an absolute or relative contraindication to bosentan (e.g. due to current use of a combined oral contraceptive or liver disease); or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Continuation

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Re-assessment required after 2 years

The patient is continuing to derive benefit from ambrisentan treatment according to a validated PAH risk stratification tool**. Notes: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH</u>

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

BOSENTAN - Restricted see terms below

t	Tab 62.5 mg - 5% DV Dec-21 to 2024	 60	Bosentan Dr Reddy's
t	Tab 125 mg - 5% DV Dec-21 to 2024	 60	Bosentan Dr Reddy's
⇒	Restricted (RS1982)		-

Initiation – PAH monotherapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, continued...

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer	
Ŷ	1.01	Manalaotaroi	

cardiologist or rheumatologist Limited to 6 months treatment

Linited to 6 months treat

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Bosentan is to be used as PAH monotherapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient has experienced intolerable side effects on sildenafil; or
 - 5.2.2 Patient has an absolute contraindication to sildenafil; or
 - 5.2.3 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease.

Initiation – PAH dual therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or

- 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
- 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

5 Both:

- 5.1 Bosentan is to be used as part of PAH dual therapy; and
- 5.2 Either:
 - 5.2.1 Patient has tried a PAH monotherapy (sildenafil) for at least three months and has experienced an inadequate therapeutic response to treatment according to a validated risk stratification tool**; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would likely benefit from initial dual therapy.

Initiation – PAH triple therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Bosentan is to be used as part of PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or

P	rice			Brand or
(ex man.	excl.	GST)		Generic
	\$		Per	Manufacturer

5.2.3 Both:

- 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; and
- 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Continuation

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Re-assessment required after 2 years

Patient is continuing to derive benefit from bosentan treatment according to a validated PAH risk stratification tool**.

Notes: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and</u> treatment of pulmonary hypertension PAH

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL - Restricted see terms below

t	Tab 25 mg – 5% DV Jan-22 to 20240.85	4	Vedafil
t	Tab 50 mg - 5% DV Jan-22 to 2024	4	Vedafil
l	Tab 100 mg - 5% DV Jan-22 to 2024 10.20	12	Vedafil

Inj 0.8 mg per ml, 12.5 ml vial

→ Restricted (RS1983)

Initiation - tablets Raynaud's Phenomenon

All of the following:

- 1 Patient has Raynaud's phenomenon; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

Initiation - tablets Pulmonary arterial hypertension

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH is confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) of greater than 20 mmHg; and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) that is less than or equal to 15 mmHg; and
 - 4.1.4 Pulmonary vascular resistance (PVR) of at least 2 Wood Units or at least 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 4.1.5.1 PAH is non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
- 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
- 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures.

Initiation - tablets other conditions

Any of the following:

- 1 For use in weaning patients from inhaled nitric oxide; or
- 2 For perioperative use in cardiac surgery patients; or
- 3 For use in intensive care as an alternative to nitric oxide; or
- 4 For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit.

Initiation - injection

Both:

- 1 For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible; and
- 2 Any of the following:
 - 2.1 For perioperative use following cardiac surgery; or
 - 2.2 For use in persistent pulmonary hypertension of the newborn (PPHN); or
 - 2.3 For use in congenital diaphragmatic hernia.

Notes: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH</u>

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

Prostacyclin Analogues

EPOPROSTENOL – **Restricted** see terms below

t	Inj 500 mcg vial	61 1	Veletri
t	Inj 1.5 mg vial73.	21 1	Veletri
	Besteleteral (DO1004)		

➡ Restricted (RS1984)

Initiation - PAH dual therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and

continued...

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
- 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
- 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
- 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
- 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 All of the following:
 - 5.1 Epoprostenol is to be used as part of PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
 - 5.2 Patient is presenting in NYHA/WHO functional class IV; and
 - 5.3 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool.

Initiation – PAH triple therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and

5 Both:

	Pric	e		Brand or
(e:	x man. ex	ccl. GST)	_	Generic
	\$		Per	Manufacturer

- 5.1 Epoprostenol is to be used as PAH triple therapy; and
- 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Continuation

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Re-assessment required after 2 years

Patient is continuing to derive benefit from epoprostenol treatment according to a validated PAH risk stratification tool.

Notes: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH</u>

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

ILOPROST

	Inj 50 mcg in 0.5 ml ampoule	.380.00	5	llomedin
t	Nebuliser soln 10 mcg per ml, 2 ml - 5% DV Mar-23 to 2025	.185.03	30	Vebulis

→ Restricted (RS1985)

Initiation – PAH monotherapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or

Price		Brand or	
(ex man. excl.		Generic	
\$	Per	Manufacturer	

4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and

5 Both:

- 5.1 Iloprost is to be used as PAH monotherapy; and
- 5.2 Either:
 - 5.2.1 Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan); or
 - 5.2.2 Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists.

Initiation – PAH dual therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures ; and
- 5 All of the following:
 - 5.1 Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist; and
 - 5.2 Either:
 - 5.2.1 Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil; or
 - 5.2.2 Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist; and
 - 5.3 Either:
 - 5.3.1 Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**; or
 - 5.3.2 Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy.

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

Initiation - PAH triple therapy

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Limited to 6 months treatment

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH); and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications; and
- 3 PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV; and
- 4 Any of the following:
 - 4.1 All of the following:
 - 4.1.1 PAH has been confirmed by right heart catheterisation; and
 - 4.1.2 A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair); and
 - 4.1.3 A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
 - 4.1.4 A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm^{-5}); and
 - 4.1.5 Any of the following:
 - 4.1.5.1 PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH (see note below for link to these guidelines) †; or
 - 4.1.5.2 Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**; or
 - 4.1.5.3 Patient has PAH other than idiopathic / heritable or drug-associated type; or
 - 4.2 Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including severe chronic neonatal lung disease; or
 - 4.3 Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures; and
- 5 Both:
 - 5.1 Iloprost is to be used as PAH triple therapy; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is on the lung transplant list; or
 - 5.2.2 Patient is presenting in NYHA/WHO functional class IV; or
 - 5.2.3 Both:
 - 5.2.3.1 Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**; and
 - 5.2.3.2 Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario.

Continuation

Respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist

Re-assessment required after 2 years

Patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool.

Notes: † The European Respiratory Journal Guidelines can be found here: <u>2022 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension PAH</u>

** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
HYDROGEN PEROXIDE Crm 1% Soln 3% (10 vol) MAFENIDE ACETATE – Restricted see terms below I Powder 50 g sachet Restricted (RS1299) Initiation For the treatment of burns patients. MUPIROCIN Oint 2%	8.56	10 g	Crystaderm
SODIUM FUSIDATE [FUSIDIC ACID] Crm 2% - 5% DV Dec-21 to 2024 Oint 2% - 5% DV Dec-21 to 2024		5 g 5 g	Foban Foban
SULFADIAZINE SILVER Crm 1%		50 g	Flamazine
Antifungals			
AMOROLFINE Nail soln 5% – 5% DV Feb-24 to 2026 CICLOPIROX OLAMINE Nail soln 8% → Soln 1% – Restricted: For continuation only	21.87	5 ml	MycoNail
 → Solin 1% Theshreted: For continuation only CLOTRIMAZOLE Crm 1% - 5% DV Apr-23 to 2025	1.10	20 g	Clomazol
Foaming soln 1% KETOCONAZOLE Shampoo 2% METRONIDAZOLE Gel 0.75%	3.23	100 ml	Sebizole
MICONAZOLE NITRATE Crm 2% → Lotn 2% - Restricted: For continuation only Tinc 2% NYSTATIN	0.81	15 g	Multichem
Crm 100,000 u per g Antiparasitics			
DIMETHICONE			
Lotn 4% – 5% DV Dec-22 to 2025	4.25	200 ml	healthE Dimethicone 4% Lotion

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MALATHION [MALDISON]			
Lotn 0.5%			
Shampoo 1%			
PERMETHRIN			
Crm 5%	5 75	30 g	Lyderm
Lotn 5% – 5% DV Feb-24 to 2026		30 ml	A-Scabies
(Lyderm Crm 5% to be delisted 1 February 2024)		00111	
PHENOTHRIN			
Shampoo 0.5%			
Antiacne Preparations			
ADAPALENE			
Crm 0.1%			
Gel 0.1%			
BENZOYL PEROXIDE			
Soln 5%			
ISOTRETINOIN Cap 5 mg - 5% DV Mar-22 to 2024	11.06	60	Oratane
Cap 10 mg - 5% DV Mar-22 to 2024		120	Oratane
Cap 20 mg - 5% DV Mar-22 to 2024		120	Oratane
TRETINOIN			
Crm 0.05% – 5% DV Jan-22 to 2024	15.57	50 g	ReTrieve
	10.07	00 g	nomovo
Antipruritic Preparations			
CALAMINE			
Crm, aqueous, BP – 5% DV May-22 to 2024	1.08	100 g	Calamine-AFT
	1.00	100 g	Calalline-AFT
CROTAMITON Crm 10% - 5% DV Dec-21 to 2024	2.20	20 a	Itch-Soothe
CIII 10% - 5% DV Dec-21 to 2024		20 g	IICII-SOOLIIE
Barrier Creams and Emollients			
Barrier Creams			
DIMETHICONE			
Crm 5% tube – 5% DV Dec-22 to 2025	1.47	100 g	healthE Dimethicone
		Ũ	5%
Crm 5% pump bottle - 5% DV Dec-22 to 2025	4.30	500 ml	healthE Dimethicone
Crm 10% pump bottle	1 50	500 ml	5% healthE Dimethicone
		500 111	10%
ZINC			1070
Crm			e.g. Zinc Cream (Orion-)
			Zinc Cream (PSM)
Oint			e.g. Zinc oxide (PSM)
Paste			

ZINC AND CASTOR OIL Crm	4.65 4.25	20 g 500 g 20 g	Orion Boucher Evara healthE
Oint – 5% DV Nov-23 to 2025 Note: DV limit applies to the pack sizes of greater than 30 g. Oint, BP Note: DV limit applies to the pack sizes of 30 g or less. (Boucher Oint to be delisted 1 November 2023) ZINC WITH WOOL FAT Crm zinc 15.25% with wool fat 4% Emollients AQUEOUS CREAM Crm 100 g Note: DV limit applies to the pack sizes of 100 g or less. Crm 500 g – 5% DV Jul-22 to 2024 Note: DV limit applies to the pack sizes of greater than 100 g. CETOMACROGOL Crm BP, 500 g – 5% DV May-22 to 2024 Crm BP, 100 g CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,	4.65 4.25	500 g	Boucher Evara
Oint, BP Note: DV limit applies to the pack sizes of 30 g or less. (Boucher Oint to be delisted 1 November 2023) ZINC WITH WOOL FAT Crm zinc 15.25% with wool fat 4% Emollients AQUEOUS CREAM Crm 100 g Note: DV limit applies to the pack sizes of 100 g or less. Crm 500 g – 5% DV Jul-22 to 2024 Note: DV limit applies to the pack sizes of greater than 100 g. CETOMACROGOL Crm BP, 500 g – 5% DV May-22 to 2024 Crm BP, 100 g CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,		20 g	healthE
(Boucher Oint to be delisted 1 November 2023) ZINC WITH WOOL FAT Crm zinc 15.25% with wool fat 4% Emollients AQUEOUS CREAM Crm 100 g Note: DV limit applies to the pack sizes of 100 g or less. Crm 500 g - 5% DV Jul-22 to 2024		-	
Crm zinc 15.25% with wool fat 4% Emollients AQUEOUS CREAM Crm 100 g Note: DV limit applies to the pack sizes of 100 g or less. Crm 500 g - 5% DV Jul-22 to 2024 Note: DV limit applies to the pack sizes of greater than 100 g. CETOMACROGOL Crm BP, 500 g - 5% DV May-22 to 2024 Crm BP, 100 g CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,			
AQUEOUS CREAM Crm 100 g Note: DV limit applies to the pack sizes of 100 g or less. Crm 500 g - 5% DV Jul-22 to 2024			e.g. Sudocrem
Crm 100 g Note: DV limit applies to the pack sizes of 100 g or less. Crm 500 g - 5% DV Jul-22 to 2024 Note: DV limit applies to the pack sizes of greater than 100 g. CETOMACROGOL Crm BP, 500 g - 5% DV May-22 to 2024 Crm BP, 100 g CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,			
Note: DV limit applies to the pack sizes of 100 g or less. Crm 500 g – 5% DV Jul-22 to 2024 Note: DV limit applies to the pack sizes of greater than 100 g. CETOMACROGOL Crm BP, 500 g – 5% DV May-22 to 2024 Crm BP, 100 g CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,			
Crm 500 g – 5% DV jul-22 to 2024 Note: DV limit applies to the pack sizes of greater than 100 g. CETOMACROGOL Crm BP, 500 g – 5% DV May-22 to 2024 Crm BP, 100 g CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,			
Note: DV limit applies to the pack sizes of greater than 100 g. CETOMACROGOL Crm BP, 500 g – 5% DV May-22 to 2024 Crm BP, 100 g CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,	1 73	500 g	GEM Aqueous Cream
Crm BP, 500 g – 5% DV May-22 to 2024 Crm BP, 100 g CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,		500 y	alm Aqueous cream
Crm BP, 100 g CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,			
CETOMACROGOL WITH GLYCEROL Crm 90% with glycerol 10%,	1.99	500 g	Cetomacrogol-AFT
Crm 90% with glycerol 10%,			
	1.65	100 ~	haalth
	1.00	100 g	healthE
Crm 90% with glycerol 10% – 5% DV Jul-23 to 2025	2.13	500 ml	Evara
	3.50	1,000 ml	Evara
Note: DV limit applies to the pack sizes of greater than 100 g.			
	0.00	100	In the second
Oint BP – 5% DV Feb-24 to 2026 Note: DV limit applies to pack sizes of less than 200 g.	2.30	100 g	Jaychem
Oint BP, 500 g	3.40	500 g	Emulsifying Ointment
			ADE
Note: DV limit applies to pack sizes of greater than 200 g.			
GLYCEROL WITH PARAFFIN			
Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%			e.g. QV cream
OIL IN WATER EMULSION Crm, 500 g – 5% DV Sep-22 to 2025	2 04	500 g	Fatty Cream AFT
Note: DV limit applies to the pack sizes of greater than 100 g.	2.04	500 g	
Crm, 100 g - 5% DV Aug-22 to 2024	1.59	1	healthE Fatty Cream
Note: DV limit applies to the pack sizes of 100 g or less.			
PARAFFIN			
Oint liquid paraffin 50% with white soft paraffin 50% – 5% DV May-23	4.04	100	
to 2025	1.84	100 g	White Soft Liquid Paraffin AFT
Note: DV limit applies to the pack sizes of 100 g or less.			
White soft	0 70	10 g	healthE
Note: DV limit applies to pack sizes of 30 g or less, and to both white White soft			
Yellow soft	e soft paraffi	n and yellow	soft paraffin.
Lotn liquid paraffin 85%	e soft paraffi		

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
PARAFFIN WITH WOOL FAT			
Lotn liquid paraffin 15.9% with wool fat 0.6%			e.g. AlphaKeri;BK ;DP;
			Hydroderm Lotn
Lotn liquid paraffin 91.7% with wool fat 3%			e.g. Alpha Keri Bath Oil
UREA	4.07	100	
Crm 10%	1.37	100 g	healthE Urea Cream
WOOL FAT			
Crm			
Corticosteroids			
BETAMETHASONE DIPROPIONATE			
Crm 0.05%		50 g	Diprosone
Note: DV limit applies to the pack sizes of greater than 30 g.			
Oint 0.05%		50 g	Diprosone
Note: DV limit applies to the pack sizes of greater than 30 g.			
BETAMETHASONE VALERATE	4.50	F0 -	Data Orean
Crm 0.1% – 5% DV Jan-22 to 2024 Oint 0.1% – 5% DV Jan-22 to 2024		50 g 50 g	Beta Cream Beta Ointment
Lotn 0.1% – 5% DV Mar-22 to 2024		50 g 50 ml	Betnovate
CLOBETASOL PROPIONATE	20.00		
Crm 0.05% - 5% DV Jan-23 to 2025	2 40	30 g	Dermol
Oint 0.05% - 5% DV Jan-23 to 2025		30 g	Dermol
CLOBETASONE BUTYRATE Crm 0.05%		-	
DIFLUCORTOLONE VALERATE - Restricted: For continuation only			
→ Crm 0.1%			
➡ Fatty oint 0.1%			
HYDROCORTISONE			
Crm 1%, 30 g - 5% DV Apr-23 to 2025		30 g	Ethics
Note: DV limit applies to the pack sizes of less than or equal t	•	F00 m	Naumad
Crm 1%, 500 g – 5% DV Aug-23 to 2025 Note: DV limit applies to the pack sizes of greater than 100 g.		500 g	Noumed
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN Lotn 1% with paraffin liquid 15.9% and lanolin 0.6%	10.57	250 ml	DP Lotn HC
HYDROCORTISONE BUTYRATE		200 111	DI LOUITIO
Crm 0.1%	4.85	100 g	Locoid Lipocream
Oint 0.1% - 5% DV Dec-21 to 2024		100 g	Locoid
Milky emul 0.1% - 5% DV Dec-21 to 2024	12.33	100 ml	Locoid Crelo
METHYLPREDNISOLONE ACEPONATE			
Crm 0.1% - 5% DV Feb-24 to 2026		15 g	Advantan
Oint 0.1% - 5% DV Feb-24 to 2026	4.95	15 g	Advantan
MOMETASONE FUROATE			
Crm 0.1% - 5% DV Feb-22 to 2024		15 g	Elocon Alcohol Free
Oint 0.1% - 5% DV Feb-22 to 2024	3.10	50 g	Elocon Alcohol Free Elocon
	2.90	15 g 50 g	Elocon
Lotn 0.1% - 5% DV Feb-22 to 2024		30 ml	Elocon

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
TRIAMCINOLONE ACETONIDE Crm 0.02% - 5% DV Feb-24 to 2026 Oint 0.02% - 5% DV Feb-24 to 2026		100 g 100 g	Aristocort Aristocort
Corticosteroids with Anti-Infective Agents			
BETAMETHASONE VALERATE WITH CLIOQUINOL - Restricted see ↓ Crm 0.1% with clioquiniol 3% → Restricted (RS1125) Initiation Either: 1 For the treatment of intertrigo; or 2 For continuation use.	e terms below		
BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC Crm 0.1% with sodium fusidate (fusidic acid) 2%	ACID]		
HYDROCORTISONE WITH MICONAZOLE Crm 1% with miconazole nitrate 2% – 5% DV Dec-21 to 2024 HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN	1.89	15 g	Micreme H
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	3.35	15 g	Pimafucort
TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAM Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	AICIDIN AND NYS	TATIN	
Psoriasis and Eczema Preparations			
ACITRETIN			
Cap 10 mg		60	Novatretin
Cap 25 mg BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL		60	Novatretin
Foam spray 500 mcg with calcipotriol 50 mcg per g		60 g	Enstilar
Gel 500 mcg with calcipotriol 50 mcg per g - 5% DV Dec-21 to 202		60 g	Daivobet
Oint 500 mcg with calcipotriol 50 mcg per g - 5% DV Dec-21 to 20	24 15.90	30 g	Daivobet
CALCIPOTRIOL	40.00	100 -	Deiman
Oint 50 mcg per g COAL TAR WITH SALICYLIC ACID AND SULPHUR Oint 12% with salicylic acid 2% and sulphur 4%	40.00	120 g	Daivonex
METHOXSALEN [8-METHOXYPSORALEN] Tab 10 mg Lotn 1.2%			
PIMECROLIMUS - Restricted see terms below ↓ Crm 1% - 5% DV Feb-24 to 2026	33.00	15 g	Elidel
Dermatologist, paediatrician or ophthalmologist Both:			
1 Patient has atopic dermatitis on the eyelid; and			

2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy, documented allergy to topical corticosteroids, cataracts, glaucoma, or raised intraocular pressure.

70

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
		Fei	
PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCE Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – Feb-24 to 2026 POTASSIUM PERMANGANATE	5% DV	500 ml	Pinetarsol
Tab 400 mg Crystals TACROLIMUS			
I Oint 0.1% - 5% DV Dec-23 to 2026 → Restricted (RS1859) Initiation Dermatologist or paediatrician		30 g	Zematop
 Both: 1 Patient has atopic dermatitis on the face; and 2 Patient has at least one of the following contraindications to to documented epidermal atrophy or documented allergy to topic 		periorificial	dermatiitis, rosacea,
Scalp Preparations			
BETAMETHASONE VALERATE Scalp app 0.1% - 5% DV Jan-22 to 2024	9.84	100 ml	Beta Scalp
CLOBETASOL PROPIONATE Scalp app 0.05% – 5% DV Jan-23 to 2025	6.26	30 ml	Dermol
HYDROCORTISONE BUTYRATE Scalp lotn 0.1% – 5% DV Dec-21 to 2024	6.57	100 ml	Locoid
Wart Preparations			
PODOPHYLLOTOXIN Soln 0.5%		3.5 ml	Condyline
SILVER NITRATE Sticks with applicator			
Other Skin Preparations			
DIPHEMANIL METILSULFATE Powder 2%			
IMIQUIMOD Crm 5%, 250 mg sachet	21.72	24	Perrigo
SUNSCREEN, PROPRIETARY Lotn – 5% DV Apr-23 to 2025	6.50	200 g	Marine Blue Lotion SPF 50+
Antineoplastics			
FLUOROURACIL SODIUM Crm 5% - 5% DV Dec-21 to 2024	6.95	20 g	Efudix
METHYL AMINOLEVULINATE HYDROCHLORIDE - Restricted set ↓ Crm 16% → Restricted (RS1127) Dermatologist or plastic surgeon	e terms below		

Price		Brand or	_
(ex man. excl. GST)		Generic	
 \$	Per	Manufacturer	

Wound Management Products

CALCIUM GLUCONATE Gel 2.5%

e.g. Orion

GENITO-URINARY SYSTEM

Dries		Drand ar
Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Agents		
ACETIC ACID Soln 3% Soln 5%		
ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator		
CHLORHEXIDINE GLUCONATE Crm 1% Lotn 1%		
CLOTRIMAZOLE		
Vaginal crm 1% with applicator – 5% DV Apr-23 to 2025	35 g 20 g	Clomazol Clomazol
Vaginal child 2% with applicator = 5% bv Apr-25 to 2025	20 y	Giomazoi
Vaginal crm 2% with applicator6.89	40 g	Micreme
VYSTATIN	•	
Vaginal crm 100,000 u per 5 g with applicator(s) - 5% DV Feb-24 to 2026 5.70	75 g	Nilstat
Contraceptives		
Antiandrogen Oral Contraceptives		
CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets – 5% DV Feb-24 to 2026	168	Ginet
Combined Oral Contraceptives		
THINYLOESTRADIOL WITH DESOGESTREL		
Tab 20 mcg with desogestrel 150 mcg Tab 30 mcg with desogestrel 150 mcg		
ETHINYLOESTRADIOL WITH LEVONORGESTREL		
Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets - 5% DV Aug-23 to 2025	84	Lo-Oralcon 20 ED
Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets - 5% DV		
Aug-23 to 2025	84	Oralcon 30 ED
THINYLOESTRADIOL WITH NORETHISTERONE		
Tab 35 mcg with norethisterone 1 mg Tab 35 mcg with norethisterone 1 mg and 7 inert tab	84	Brevinor 1/28
NORETHISTERONE WITH MESTRANOL Tab 1 mg with mestranol 50 mcg		

GENITO-URINARY SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Contraceptive Devices			
INTRA-UTERINE DEVICE IUD 29.1 mm length × 23.2 mm width – 5% DV Apr-23 to 2025 . IUD 33.6 mm length × 29.9 mm width – 5% DV Apr-23 to 2025 . IUD 35.5 mm length × 19.6 mm width – 5% DV Apr-23 to 2025 .	29.80	1 1 1	Choice TT380 Short Choice TT380 Standard Choice Load 375
Emergency Contraception			
LEVONORGESTREL Tab 1.5 mg - 5% DV Jun-23 to 2025	1.75	1	Levonorgestrel BNM
Progestogen-Only Contraceptives			
LEVONORGESTREL Tab 30 mcg Subdermal implant (2 × 75 mg rods) – 5% DV Dec-23 to 2026 Intra-uterine device 52 mg Intra-uterine device 13.5 mg MEDROXYPROGESTERONE ACETATE Inj 150 mg per ml, 1 ml syringe NORETHISTERONE Tab 350 mcg – 5% DV Mar-22 to 2024		84 1 1 1 1	Microlut Jadelle Mirena Jaydess Depo-Provera Noriday 28
Obstetric Preparations			
Antiprogestogens			
MIFEPRISTONE Tab 200 mg			
Oxytocics			
CARBOPROST TROMETAMOL Inj 250 mcg per ml, 1 ml ampoule DINOPROSTONE Pessaries 10 mg Vaginal gel 1 mg in 3 g Vaginal gel 2 mg in 3 g		1	Prostin E2 Prostin E2
ERGOMETRINE MALEATE Inj 500 mcg per ml, 1 ml ampoule		5	DBL Ergometrine
OXYTOCIN Inj 5 iu per ml, 1 ml ampoule – 5% DV Jun-23 to 2025 Inj 10 iu per ml, 1 ml ampoule – 5% DV Jun-23 to 2025 OXYTOCIN WITH ERGOMETRINE MALEATE Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule DV Dec-22 to 2025	4.98 5.98 – 5%	5 5 5	Oxytocin BNM Oxytocin BNM Syntometrine
Tocolytics			
PROGESTERONE Cap 100 mg - 5% DV May-23 to 2025		30	Utrogestan

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

74

Price Brand or (ex man. excl. GST) Generic Per Manufacturer \$ TERBUTALINE - Restricted see terms below Ini 500 mcg ampoule → Restricted (RS1130) Obstetrician Oestrogens OESTRIO Ovestin 15 g Ovestin 15 Urologicals 5-Alpha Reductase Inhibitors FINASTERIDE - Restricted see terms below 100 Ricit → Restricted (RS1131) Initiation Both: 1 Patient has symptomatic benign prostatic hyperplasia; and 2 Either: 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or 2.2 Symptoms are not adequately controlled with non-selective alpha blockers. Alpha-1A Adrenoceptor Blockers TAMSULOSIN HYDROCHLOBIDE - Restricted see terms below 100 Tamsulosin-Rex → Restricted (RS1132) Initiation Both: 1 Patient has symptomatic benign prostatic hyperplasia; and 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated. Urinary Alkalisers POTASSIUM CITRATE - Restricted see terms below 200 ml Biomed → Restricted (RS1133) Initiation Both: 1 The patient has recurrent calcium oxalate urolithiasis; and 2 The patient has had more than two renal calculi in the two years prior to the application. SODIUM CITRO-TARTRATE 28 Ural Urinary Antispasmodics OXYBUTYNIN Tab 5 mg5.42 100 Alchemy Oxybutynin Oral lig 5 mg per 5 ml

GENITO-URINARY SYSTEM

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

GENITO-URINARY SYSTEM

	 Price excl. GST) \$	Per	Brand or Generic Manufacturer
SOLIFENACIN SUCCINATE Tab 5 mg – 5% DV Jun-23 to 2024	 2.05	30	Solifenacin Mylan Solifenacin Viatris
Tab 10 mg - 5% DV Jun-23 to 2024	 3.72	30	Solifenacin Mylan Solifenacin Viatris
(Solifenacin Mylan Tab 5 mg to be delisted 1 December 2023)			

(Solifenacin Mylan Tab 10 mg to be delisted 1 December 2023)

76

HORMONE PREPARATIONS

Price Brand or (ex man. excl. GST) Generic \$Per Manufacturer

Anabolic Agents

OXANDROLONE

Tab 2.5 mg

→ Restricted (RS1302)

Initiation

For the treatment of burns patients.

Androgen Agonists and Antagonists

CYPROTERONE ACETATE		
Tab 50 mg – 5% DV Jan-22 to 2024 14.37	50	Siterone
Tab 100 mg – 5% DV Jan-22 to 2024 28.03	50	Siterone
TESTOSTERONE		
Patch 5 mg per day225.00	30	Androderm
TESTOSTERONE CIPIONATE		
Inj 100 mg per ml, 10 ml vial85.00	1	Depo-Testosterone
TESTOSTERONE ESTERS		
Inj testosterone decanoate 100 mg, testosterone isocarproate 60 mg, testosterone phenylpropionate 60 mg and testosterone propionate 30 mg per ml, 1 ml ampoule TESTOSTERONE UNDECANOATE		
→ Cap 40 mg - Restricted: For continuation only	60	Andriol Testocaps
Inj 250 mg per ml, 4 ml vial	1	Reandron 1000
Calcium Homeostasis		
CALCITONIN		
Inj 100 iu per ml, 1 ml ampoule121.00	5	Miacalcic
CINACALCET – Restricted see terms below		
Tab 30 mg - 5% DV Apr-22 to 2024	28	Cinacalet Devatis
Tab 60 mg – 5% DV Apr-22 to 2024	28	Cinacalet Devatis

→ Restricted (RS1931)

Initiation - parathyroid carcinoma or calciphylaxis

Nephrologist or endocrinologist

Re-assessment required after 6 months

Either:

- 1 All of the following:
 - 1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
 - 1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
 - 1.3 The patient is symptomatic; or

2 All of the following:

- 2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
- 2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
- 2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium

continued...

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

thiosulfate.

Continuation – parathyroid carcinoma or calciphylaxis

Nephrologist or endocrinologist

Both:

- 1 The patient's serum calcium level has fallen to < 3mmol/L; and
- 2 The patient has experienced clinically significant symptom improvement.
- Note: This does not include parathyroid adenomas unless these have become malignant.

Initiation - primary hyperparathyroidism

All of the following:

- 1 Patient has primary hyperparathyroidism; and
- 2 Either:
 - 2.1 Patient has hypercalcaemia of more than 3 mmol/L with or without symptoms; or
 - 2.2 Patient has hypercalcaemia of more than 2.85 mmol/L with symptoms; and
- 3 Surgery is not feasible or has failed; and
- 4 Patient has other comorbidities, severe bone pain, or calciphylaxis.

Initiation - secondary or tertiary hyperparathyroidism

Re-assessment required after 6 months

- All of the following:
 - 1 Either:
 - 1.1 Patient has tertiary hyperparathyroidism and markedly elevated parathyroid hormone (PTH) with hypercalcaemia; or
 - 1.2 Patient has symptomatic secondary hyperparathyroidism and elevated PTH; and
 - 2 Patient is on renal replacement therapy; and
 - 3 Any of the following:
 - 3.1 Residual parathyroid tissue has not been localised despite repeat unsuccessful parathyroid explorations; or
 - 3.2 Parathyroid tissue is surgically inaccessible; or
 - 3.3 Parathyroid surgery is not feasible.

Continuation – secondary or tertiary hyperparathyroidism

Re-assessment required after 12 months

Either:

78

- 1 The patient has had a kidney transplant, and following a treatment free interval of at least 12 weeks a clinically acceptable parathyroid hormone (PTH) level to support ongoing cessation of treatment has not been reached; or
- 2 The patient has not received a kidney transplant and trial of withdrawal of cinacalcet is clinically inappropriate.

ZOLEDRONIC ACID

Inj 4 mg per 5 ml, vial - 5% DV Jun-23 to 2024	 1	Zoledronic acid Mylan
		Zoledronic acid Viatris

(Zoledronic acid Mylan Inj 4 mg per 5 ml, vial to be delisted 1 November 2023)

Corticosteroids		
BETAMETHASONE		
Tab 500 mcg		
Inj 4 mg per ml, 1 ml ampoule		
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule		
DEXAMETHASONE		
Tab 0.5 mg - 5% DV Jan-22 to 2024 1.50	30	Dexmethsone
Tab 4 mg - 5% DV Jan-22 to 2024	30	Dexmethsone
Oral lig 1 mg per ml	25 ml	Biomed

t Item restricted (see \rightarrow above); **f** Item restricted (see \rightarrow below)

HORMONE PREPARATIONS

Price		Brand or	
	(ex man. excl. GST \$) Per	Generic Manufacturer
DEXAMETHASONE PHOSPHATE			
Inj 4 mg per ml, 1 ml ampoule - 5% DV Feb-23 to 2025	7.86	10	Hameln
Inj 4 mg per ml, 2 ml ampoule - 5% DV Feb-23 to 2025	13.10	10	Hameln
FLUDROCORTISONE ACETATE			
Tab 100 mcg - 5% DV Dec-22 to 2025	11.46	100	Florinef
HYDROCORTISONE			
Tab 5 mg		100	Douglas
Tab 20 mg		100	Douglas
Inj 100 mg vial – 5% DV Nov-21 to 2024		1	Solu-Cortef
METHYLPREDNISOLONE (AS SODIUM SUCCINATE)			
Tab 4 mg		100	Medrol
Tab 100 mg		20	Medrol
Inj 40 mg vial		1	Solu-Medrol Act-O-Vial
Inj 125 mg vial		1	Solu-Medrol Act-O-Vial
Inj 500 mg vial		1	Solu-Medrol Act-O-Vial
Inj 1 g vial		1	Solu-Medrol
METHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml vial		5	Depo-Medrol
PREDNISOLONE			
Oral lig 5 mg per ml – 5% DV Dec-21 to 2024	6.00	30 ml	Redipred
Enema 200 mcg per ml, 100 ml			
PREDNISONE			
Tab 1 mg	18.58	500	Prednisone Clinect
Tab 2.5 mg		500	Prednisone Clinect
Tab 5 mg		500	Prednisone Clinect
Tab 20 mg		500	Prednisone Clinect
TRIAMCINOLONE ACETONIDE			
Inj 10 mg per ml, 1 ml ampoule – 10% DV Feb-24 to 2026		5	Kenacort-A 10
Inj 40 mg per ml, 1 ml ampoule – 5% DV Feb-24 to 2026		5	Kenacort-A 40
TRIAMCINOLONE HEXACETONIDE			

Inj 20 mg per ml, 1 ml vial

Hormone Replacement Therapy

6.12	8	Estradot
7.04	8	Estradot
7.91	8	Estradot
7.91	8	Estradot
12.36	84	Progynova
12.36	84	Progynova
	6.12 7.04 7.91 7.91 12.36 12.36	

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Progestogen and Oestrogen Combined Preparat	tions		
 OESTRADIOL WITH NORETHISTERONE ACETATE Tab 1 mg with 0.5 mg norethisterone acetate Tab 2 mg with 1 mg norethisterone acetate Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg (12) and tab 1 mg oestradiol (6) OESTROGENS WITH MEDROXYPROGESTERONE ACETATE Tab 625 mcg conjugated equine with 2.5 mg medroxyprogester acetate Tab 625 mcg conjugated equine with 5 mg medroxyprogester acetate 	erone		
Progestogens			
MEDROXYPROGESTERONE ACETATE Tab 2.5 mg Tab 5 mg Tab 10 mg	17.50	30 100 30	Provera Provera Provera
Other Endocrine Agents			
CABERGOLINE - Restricted see terms below ↓ Tab 0.5 mg	4.43 17.94	2 8	Dostinex Dostinex
Any of the following: 1 Inhibition of lactation; or 2 Patient has hyperprolactinemia; or 3 Patient has acromegaly. Note: Indication marked with * is an unapproved indication. CLOMIFENE CITRATE Tab 50 mg		10	Mylan Clomiphen
GESTRINONE Cap 2.5 mg METYRAPONE Cap 250 mg			
PENTAGASTRIN Inj 250 mcg per ml, 2 ml ampoule			
Other Oestrogen Preparations			
OESTRADIOL Implant 50 mg			
OESTRIOL Tab 2 mg – 5% DV Feb-24 to 2026	7.70	30	Ovestin
Other Progestogen Preparations			
MEDROXYPROGESTERONE Tab 100 mg		100	Provera HD

sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

HORMONE PREPARATIONS

\$	Per	Manufacturer
5.49	30	Primolut N
logues		
	1 1	Synacthen Synacthen Depot
65.68 122.37	1 1	Teva Teva
221.60 	1 1	Lucrin Depot 1-month Lucrin Depot 3-month
	1 1 1	Omnitrope Omnitrope Omnitrope
	logues 	logues

continued...

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 2 All of the following:
 - 2.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and</p>
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and</p>
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - 2.5 Appropriate imaging of the pituitary gland has been obtained.

Continuation - growth hormone deficiency in children

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initiation – Turner syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Continuation – Turner syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initiation - short stature without growth hormone deficiency

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and

 Price (ex man. excl. GST) \$ Pe	Brand or Generic er Manufacturer	

- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Continuation - short stature without growth hormone deficiency

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the followina:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 Current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initiation - short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months All of the followina:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease: and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
 - 6.1 The patient has a GFR less than or equal to 30 ml/min/1.73 m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m²) in a child who may or may not be receiving dialysis; or
 - 6.2 The patient has received a renal transplant and has received $< 5mg/m^2/day$ of prednisone or equivalent for at least 6 months.

Continuation - short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of a endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months All of the followina:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred: and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

continued...

	Price		Brand or	
(e	ex man. excl.		Generic	
	\$	Per	Manufacturer	

Initiation - Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist *Re-assessment required after 12 months* All of the followino:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 The patient is aged two years or older; and
 - 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
 - 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Continuation – Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist con siders is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initiation - adults and adolescents

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Continuation - adults and adolescents

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

Any of the following:

1 All of the following:

- 1.1 The patient has been treated with somatropin for < 12 months; and
- 1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
- 1.3 Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex; and
- 1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
 - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients; or
- 3 All of the following:
 - 3.1 The patient has had a Special Authority approval for somatropin for childhood deficiency in children and no longer meets the renewal criteria under this indication; and
 - 3.2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
 - 3.3 The patient has severe growth hormone deficiency (see notes); and
 - 3.4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
 - 3.5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Thyroid and Antithyroid Preparations		
CARBIMAZOLE Tab 5 mg - 5% DV Sep-22 to 2025	100	Neo-Mercazole
IODINE		
Soln BP 50 mg per ml		

HORMONE PREPARATIONS

		Price			Brand or
	(ex man.		GST)	Per	Generic Manufacturer
LEVOTHYROXINE Tab 25 mcg Tab 50 mcg Tab 100 mcg					
LIOTHYRONINE SODIUM ↓ Tab 20 mcg → Restricted (RS1301) Initiation					
For a maximum of 14 days' treatment in patients with thyroid cancer wh Inj 20 mcg vial Inj 100 mcg vial	o are du	e to r	eceive ı	radioiodine	e therapy.
POTASSIUM IODATE Tab 170 mg					
POTASSIUM PERCHLORATE Cap 200 mg					
PROPYLTHIOURACIL – Restricted see terms below ↓ Tab 50 mg → Restricted (RS1276)		.35.0	0	100	PTU
Initiation Both:					
 The patient has hyperthyroidism; and The patient is intolerant of carbimazole or carbimazole is contrai 	ndicated				
PROTIRELIN Inj 100 mcg per ml, 2 ml ampoule					
Vasopressin Agents					
ARGIPRESSIN [VASOPRESSIN] Inj 20 u per ml, 1 ml ampoule					
DESMOPRESSIN Wafer 120 mcg		.47.0	0	30	Minirin Melt
DESMOPRESSIN ACETATE Tab 100 mcg		.25.0	0	30	Minirin
Tab 200 mcg Nasal spray 10 mcg per dose – 5% DV Feb-24 to 2026 Inj 4 mcg per ml, 1 ml ampoule Inj 15 mcg per ml, 1 ml ampoule Nasal drops 100 mcg per ml		.54.4	5	30 6 ml	Minirin Desmopressin-PH&T
TERLIPRESSIN Inj 1 mg per 8.5 ml ampoule		015.0	0	5	Cluproccip
		210.0	U	5	Glypressin

86

		rice excl. GST) \$	Per	Brand or Generic Manufacturer
Antibacterials				
Aminoglycosides				
AMIKACIN - Restricted see terms below				
 Inj 5 mg per ml, 10 ml syringe Inj 5 mg per ml, 5 ml syringe 		01 40	1	Biomed
 Inj 5 mg per ml, 5 ml syringe Inj 15 mg per ml, 5 ml syringe 		21.43	I	Diomeu
 Inj 250 mg per ml, 2 ml vial - 5% DV Dec-21 to 2024 → Restricted (RS1041) 	1	99.95	5	DBL Amikacin
Clinical microbiologist, infectious disease specialist or respiratory speci	alist			
GENTAMICIN SULPHATE				
Inj 10 mg per ml, 1 ml ampoule			5	DBL Gentamicin
Inj 40 mg per ml, 2 ml ampoule		18.38	10	Pfizer
PAROMOMYCIN – Restricted see terms below			40	11
↓ Cap 250 mg → Restricted (RS1603)	1	26.00	16	Humatin
Clinical microbiologist, infectious disease specialist or gastroenterologis	st			
STREPTOMYCIN SULPHATE – Restricted see terms below				
Inj 400 mg per ml, 2.5 ml ampoule				
 Restricted (RS1043) Clinical microbiologist, infectious disease specialist or respiratory specialist 	aliet			
TOBRAMYCIN	anst			
↓ Powder				
→ Restricted (RS1475)				
Initiation				
For addition to orthopaedic bone cement. Inj 40 mg per ml, 2 ml vial – 5% DV Jul-23 to 2024		18 50	5	Tobramycin Mylan
• III 40 III per III, 2 III viai – 5% DV 001-25 to 2024		10.50	5	Viatris
→ Restricted (RS1044)				
Clinical microbiologist, infectious disease specialist or respiratory speci	alist			
↓ Inj 100 mg per ml, 5 ml vial → Restricted (RS1044)				
Clinical microbiologist, infectious disease specialist or respiratory speci	alist			
Solution for inhalation 60 mg per ml, 5 ml - 5% DV Dec-23 to 202	6 3	95.00 5	56 dose	Tobramycin BNM
→ Restricted (RS1435)				
Initiation Patient has cystic fibrosis.				
(Tobramycin Mylan Inj 40 mg per ml, 2 ml vial to be delisted 1 January	2024)			
	2024)			
Carbapenems				
ERTAPENEM – Restricted see terms below				
↓ Inj 1 g vial → Restricted (RS1045)		70.00	1	Invanz
Clinical microbiologist or infectious disease specialist				
IMIPENEM WITH CILASTATIN – Restricted see terms on the next pa	age			
Inj 500 mg with 500 mg cilastatin vial	•	60.00	1	Imipenem+Cilastatin RBX

INFECTIONS

	Price (ex man. excl. GST		Brand or Generic
Pertricted (D01040)	\$	Per	Manufacturer
→ Restricted (RS1046) Ninical microbiological and information discourse approximation			
Clinical microbiologist or infectious disease specialist			
IEROPENEM – Restricted see terms below			
Inj 500 mg vial		10	Meropenem-AFT
Inj 1 g vial		10	Meropenem-AFT
→ Restricted (RS1047)			
Ninical microbiologist or infectious disease specialist			
Cephalosporins and Cephamycins - 1st Generation			
EFALEXIN			
Cap 250 mg - 5% DV Apr-23 to 2025	3.85	20	Cephalexin ABM
Cap 500 mg - 5% DV Apr-23 to 2025	5.85	20	Cephalexin ABM
Grans for oral liq 25 mg per ml - 5% DV Jan-23 to 2025		100 ml	Flynn
Grans for oral liq 50 mg per ml -5% DV Jan-23 to 2025		100 ml	Flynn
			,
EFAZOLIN	0.00	~	A
Inj 500 mg vial		5	AFT
lnj 1 g vial	3.49	5	AFT
Cephalosporins and Cephamycins - 2nd Generation			
EFACLOR			
Cap 250 mg - 5% DV Apr-23 to 2025		100	Ranbaxy-Cefaclor
Grans for oral lig 25 mg per ml – 5% DV Apr-23 to 2025		100 ml	Ranbaxy-Cefaclor
		100 11	nanbaxy concord
EFOXITIN			
Inj 1 g vial			
EFUROXIME			
Tab 250 mg			
Inj 750 mg vial	8 59	10	Cefuroxime-AFT
Inj 1.5 g vial		10	Cefuroxime-AFT
, .		10	
Cephalosporins and Cephamycins - 3rd Generation			
EFOTAXIME			
Inj 500 mg vial	1.90	1	Cefotaxime Sandoz
Inj 1 g vial - 5% DV Dec-23 to 2026		10	DBL Cefotaxime
EFTAZIDIME – Restricted see terms below			
Inj 1 g vial – 5% DV Dec-23 to 2026	25 90	10	Ceftazidime Kabi
י ווון ו y vial – סא שע שפט-צט נט 2020			Ceftazidime Kabi
Cattaridime AET Ini 1 a vial to be delicted 1 December 2022)	2.69	1	Cettazidime-AF I
Ceftazidime-AFT Inj 1 g vial to be delisted 1 December 2023)			
Restricted (RS1048)	:-1		
linical microbiologist, infectious disease specialist or respiratory special	IST		
EFTRIAXONE			
	0.79	1	Ceftriaxone-AFT
Inj 500 mg vial – 5% DV Apr-23 to 2025		5	Ceftriaxone-AFT
Inj 500 mg vial – 5% DV Apr-23 to 2025 Inj 1 g vial – 5% DV Apr-23 to 2025		5	Ceftriaxone-AFT
Inj 500 mg vial – 5% DV Apr-23 to 2025 Inj 1 g vial – 5% DV Apr-23 to 2025 Inj 2 g vial – 5% DV Aug-23 to 2025		0	
Inj 1 g vial – 5% DV Apr-23 to 2025 Inj 2 g vial – 5% DV Aug-23 to 2025		5	
Inj 1 g vial – 5% DV Apr-23 to 2025 Inj 2 g vial – 5% DV Aug-23 to 2025 Cephalosporins and Cephamycins - 4th Generation		3	
Inj 1 g vial – 5% DV Apr-23 to 2025 Inj 2 g vial – 5% DV Aug-23 to 2025 Cephalosporins and Cephamycins - 4th Generation EFEPIME – Restricted see terms on the next page	7.85	-	Cefepime Kabi
Inj 1 g vial – 5% DV Apr-23 to 2025 Inj 2 g vial – 5% DV Aug-23 to 2025	7.85	10 10	Cefepime Kabi Cefepime Kabi

t Item restricted (see → above); t Item restricted (see → below)

			INFECTIONS
	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Restricted (RS1049) Zinical microbiologist or infectious disease specialist			
Cephalosporins and Cephamycins - 5th Generat	ion		
CEFTAROLINE FOSAMIL - Restricted see terms below ↓ Inj 600 mg vial		10	Zinforo
2 for patients who have a contraindication or hypersensitivity	to standard current therap	oies.	
Macrolides			
 Tab 250 mg Tab 500 mg – 1% DV Dec-21 to 2024 Grans for oral liq 200 mg per 5 ml (40 mg per ml) Restricted (RS1598) nitiation – bronchiolitis obliterans syndrome, cystic fibrosis a syndrom the following: Patient has received a lung transplant, stem cell transplant bronchiolitis obliterans syndrome*; or Patient has received a lung transplant and requires prophy Patient has cystic fibrosis and has chronic infection with Ps negative organisms*; or Patient has an atypical Mycobacterium infection. Indications marked with * are unapproved indications 	and atypical Mycobacter or bone marrow transplar laxis for bronchiolitis oblite	nt and requerrans synd	uires treatment for rome*; or
nitiation – non-cystic fibrosis bronchiectasis* Respiratory specialist or paediatrician Re-assessment required after 12 months III of the following:			
 For prophylaxis of exacerbations of non-cystic fibrosis bron Patient is aged 18 and under; and Either: A Patient has had 3 or more exacerbations of their bro Patient has had 3 acute admissions to hospital for tr month period. 	onchiectasis, within a 12 n		
lote: Indications marked with * are unapproved indications. A ma brosis will be subsidised in the community. Continuation – non-cystic fibrosis bronchiectasis* Respiratory specialist or paediatrician Re-assessment required after 12 months Ill of the following:	aximum of 24 months of a	zithromyci	n treatment for non-cystic
 The patient has completed 12 months of azithromycin treat Following initial 12 months of treatment, the patient has not fibrosis bronchiectasis for a further 12 months, unless cons 	t received any further azith	nromycin ti	reatment for non-cystic

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
ontinued			
3 The patient will not receive more than a total of 24 months	s' azithromycin cumulativ	e treatment	(see note).
lote: Indications marked with * are unapproved indications. A n	naximum of 24 months o	f azithromyo	cin treatment for non-cysti
brosis will be subsidised in the community.			
nitiation – other indications			
Re-assessment required after 5 days			
or any other condition.			
Continuation – other indications			
Re-assessment required after 5 days			
for any other condition.			
CLARITHROMYCIN – Restricted see terms below	0.50		Klastal
Tab 250 mg – 1% DV Feb-22 to 2024 Tab 500 mg – 1% DV Feb-22 to 2024		14	Klacid
Tab 500 mg – 1% DV Feb-22 to 2024 Grans for oral lig 50 mg per ml		14 50 ml	Klacid Klacid
Inj 500 mg vial		1	Martindale
Restricted (RS1709)			Martindale
nitiation – Tab 250 mg and oral liquid			
ny of the following:			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug	resistance or intolerance	to standard	d pharmaceutical agents;
	resistance or intolerance	to standard	d pharmaceutical agents;
2 Mycobacterium tuberculosis infection where there is drug			
 Mycobacterium tuberculosis infection where there is drug Helicobacter pylori eradication; or 			
 Mycobacterium tuberculosis infection where there is drug Helicobacter pylori eradication; or Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg Ielicobacter pylori eradication. 			
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. hitiation – Infusion 			
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. hitiation – Infusion hy of the following: 			
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg Helicobacter pylori eradication. hitiation – Infusion my of the following: 1 Atypical mycobacterial infection; or 	ical or dental procedures	if amoxicilli	n is contra-indicated.
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg Helicobacter pylori eradication. hitiation – Infusion any of the following: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug 	ical or dental procedures	if amoxicilli	n is contra-indicated.
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. httation – Infusion ny of the following: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug 3 Community-acquired pneumonia. 	ical or dental procedures	if amoxicilli	n is contra-indicated.
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug 3 Community-acquired pneumonia. IRYTHROMYCIN (AS ETHYLSUCCINATE) 	ical or dental procedures	if amoxicilli to standard	n is contra-indicated.
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. hitiation – Infusion ny of the following: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug 3 Community-acquired pneumonia. ERYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg 	resistance or intolerance	if amoxicilli to standard 100	n is contra-indicated. d pharmaceutical agents; r E-Mycin
Mycobacterium tuberculosis infection where there is drug Helicobacter pylori eradication; or Prophylaxis of infective endocarditis associated with surgi hitiation – Tab 500 mg Helicobacter pylori eradication. hitiation – Infusion ny of the following: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug 3 Community-acquired pneumonia. ERYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml.	resistance or intolerance	if amoxicilli to standard 100 100 ml	n is contra-indicated. d pharmaceutical agents; E-Mycin E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug Community-acquired pneumonia. ERYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml 	resistance or intolerance	if amoxicilli to standard 100	n is contra-indicated. d pharmaceutical agents; r E-Mycin
Mycobacterium tuberculosis infection where there is drug Helicobacter pylori eradication; or Prophylaxis of infective endocarditis associated with surgi hitiation – Tab 500 mg lelicobacter pylori eradication. hitiation – Infusion ny of the following: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug 3 Community-acquired pneumonia. IRYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml IRYTHROMYCIN (AS LACTOBIONATE)	resistance or intolerance	if amoxicilli to standard 100 100 ml 100 ml	n is contra-indicated. d pharmaceutical agents; E-Mycin E-Mycin E-Mycin E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml RYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial – 5% DV Dec-22 to 2025 	resistance or intolerance 	if amoxicilli to standard 100 100 ml	n is contra-indicated. d pharmaceutical agents; E-Mycin E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is drug 3 Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml RYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial – 5% DV Dec-22 to 2025 RYTHROMYCIN (AS STEARATE) – Restricted: For continua 	resistance or intolerance 	if amoxicilli to standard 100 100 ml 100 ml	n is contra-indicated. d pharmaceutical agents; E-Mycin E-Mycin E-Mycin E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug Community-acquired pneumonia. ERYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml	resistance or intolerance 	if amoxicilli to standard 100 100 ml 100 ml	n is contra-indicated. d pharmaceutical agents; E-Mycin E-Mycin E-Mycin E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug Community-acquired pneumonia. ERYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml ERYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial – 5% DV Dec-22 to 2025 ERYTHROMYCIN (AS STEARATE) – Restricted: For continua Tab 250 mg Tab 500 mg 	resistance or intolerance 	if amoxicilli to standard 100 100 ml 100 ml	n is contra-indicated. d pharmaceutical agents; E-Mycin E-Mycin E-Mycin E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml SRYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial – 5% DV Dec-22 to 2025 SRYTHROMYCIN (AS STEARATE) – Restricted: For continua Tab 250 mg Tab 500 mg 	resistance or intolerance 	if amoxicilli to standard 100 100 ml 100 ml	n is contra-indicated. d pharmaceutical agents; E-Mycin E-Mycin E-Mycin E-Mycin
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug Community-acquired pneumonia. (RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml SRYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial – 5% DV Dec-22 to 2025 SRYTHROMYCIN (AS STEARATE) – Restricted: For continua Tab 250 mg Tab 500 mg (OXITHROMYCIN – Some items restricted see terms below Tab dispersible 50 mg 	resistance or intolerance 	if amoxicilli to standard 100 100 ml 100 ml 1	n is contra-indicated. d pharmaceutical agents; o E-Mycin E-Mycin E-Mycin Erythrocin IV
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug Community-acquired pneumonia. RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 5% DV Dec-22 to 2025 CRYTHROMYCIN (AS STEARATE) – Restricted: For continuation = 1ab 250 mg Tab 500 mg MOXITHROMYCIN – Some items restricted see terms below Tab dispersible 50 mg Tab 150 mg – 5% DV Aug-23 to 2026. 	resistance or intolerance 	if amoxicilli to standard 100 100 ml 100 ml 1	n is contra-indicated. d pharmaceutical agents; E-Mycin E-Mycin E-Mycin Erythrocin IV Arrow-Roxithromycin
 2 Mycobacterium tuberculosis infection where there is drug 3 Helicobacter pylori eradication; or 4 Prophylaxis of infective endocarditis associated with surginitiation – Tab 500 mg lelicobacter pylori eradication. nitiation – Infusion ny of the following: Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug Community-acquired pneumonia. (RYTHROMYCIN (AS ETHYLSUCCINATE) Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Grans for oral liq 400 mg per 5 ml SRYTHROMYCIN (AS LACTOBIONATE) Inj 1 g vial – 5% DV Dec-22 to 2025 SRYTHROMYCIN (AS STEARATE) – Restricted: For continua Tab 250 mg Tab 500 mg (OXITHROMYCIN – Some items restricted see terms below Tab dispersible 50 mg 	resistance or intolerance 	if amoxicilli to standard 100 100 ml 100 ml 1	n is contra-indicated. d pharmaceutical agents; E-Mycin E-Mycin E-Mycin Erythrocin IV

Initiation

90

Only for use in patients under 12 years of age.

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
Penicillins				
MOXICILLIN				
Cap 250 mg		.43.45	500	Alphamox
Cap 500 mg		.66.44	500	Alphamox
Grans for oral liq 125 mg per 5 ml - 5% DV Feb-24 to 2026		2.22	100 ml	Alphamox 125
Grans for oral lig 250 mg per 5 ml - 5% DV Feb-24 to 2026			100 ml	Alphamox 250
Inj 250 mg vial			10	Ibiamox
Inj 500 mg vial			10	Ibiamox
lnį 1 g vial			10	Ibiamox
MOXICILLIN WITH CLAVULANIC ACID				
Tab 500 mg with clavulanic acid 125 mg - 5% DV Feb-24 to 2026		1 50	10	Curam Duo 500/125
Grans for oral lig 25 mg with clavulanic acid 6.25 mg per ml			100 ml	Augmentin
Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml		2 20	100 ml	Curam
Inj 500 mg with clavulanic acid 100 mg vial – 5% DV Dec-21 to 20			10	Amoxiclav multicher
Inj 1,000 mg with clavulanic acid 200 mg vial – 5% DV Dec-21 to 20			10	Amoxiclav multichen
	2024	.20.30	10	
ENZATHINE BENZYLPENICILLIN				
Inj 900 mg (1.2 million units) in 2.3 ml syringe		375.97	10	Bicillin LA
ENZYLPENICILLIN SODIUM [PENICILLIN G]				
Inj 600 mg (1 million units) vial - 5% DV Feb-24 to 2026		. 16.50	10	Sandoz
LUCLOXACILLIN				
Cap 250 mg – 5% DV May-22 to 2024		15 79	250	Flucloxacillin-AFT
Cap 500 mg - 5% DV May-22 to 2024			500	Flucloxacillin-AFT
Grans for oral liq 25 mg per ml – 5% DV Jan-22 to 2024			100 ml	AFT
Grans for oral liq 50 mg per ml – 5% DV Jan-22 to 2024			100 ml	AFT
Inj 250 mg vial			10	Flucloxin
Inj 500 mg vial			10	Flucloxin
Inj 1 g vial - 5% DV Feb-24 to 2026			5	Flucil
, ,		0.00	0	
		0.04	50	
Cap 250 mg - 5% DV Jan-22 to 2024			50 50	Cilicaine VK
Cap 500 mg – 5% DV Jan-22 to 2024			50 100 ml	Cilicaine VK AFT
Grans for oral liq 125 mg per 5 ml – 5% DV Jan-23 to 2025				
Grans for oral liq 250 mg per 5 ml - 5% DV Jan-23 to 2025		4.24	100 ml	AFT
IPERACILLIN WITH TAZOBACTAM – Restricted see terms below				
Inj 4 g with tazobactam 0.5 g vial – 5% DV Feb-23 to 2025		3.59	1	PipTaz-AFT
➤ Restricted (RS1053)				
linical microbiologist, infectious disease specialist or respiratory speci-	alist			
PROCAINE PENICILLIN				
Inj 1.5 g in 3.4 ml syringe				
TCARCILLIN WITH CLAVULANIC ACID - Restricted see terms belo	w			
Inj 3 g with clavulanic acid 0.1 mg vial				
→ Restricted (RS1054)				
\rightarrow nestricieu (no 1004)	-1:-4			

Clinical microbiologist, infectious disease specialist or respiratory specialist

INFECTIONS

	Price		Brand or
	(ex man. excl. GST \$) Per	Generic Manufacturer
Quinolones			
CIPROFLOXACIN - Restricted see terms below			
I Tab 250 mg		28	Cipflox
Tab 500 mg	3.40	28	Cipflox
Tab 750 mg	5.95	28	Cipflox
Oral liq 50 mg per ml			
Oral liq 100 mg per ml			
Inj 2 mg per ml, 100 ml bag	105.00	10	Cinroflevenin Kehi
Inj 2 mg per ml, 100 ml bottle	125.00	10	Ciprofloxacin Kabi
Restricted (RS1055) Clinical microbiologist or infectious disease specialist			
MOXIFLOXACIN – Restricted see terms below Tab 400 mg	40.00	F	Avelox
 Tab 400 mg Inj 1.6 mg per ml, 250 ml bottle – 5% DV Feb-24 to 2026 		5 1	Moxifloxacin Kabi
• III 1.0 IIIg per III, 230 III bottle - 3% bv 1 eb-24 to 2020	413.40	10	Moxifloxacin Kabi
(Moxifloxacin Kabi Inj 1.6 mg per ml, 250 ml bottle to be delisted 1		10	Moxilloxuolii Rubi
→ Restricted (RS1644)	1 0010019 202 1)		
Initiation – Mycobacterium infection			
nfectious disease specialist, clinical microbiologist or respiratory s	pecialist		
Any of the following:			
1 Both:			
1.1 Active tuberculosis; and			
1.2 Any of the following:			
 1.2.1 Documented resistance to one or more first-line area with known resistance), as part of regim 1.2.3 Impaired visual acuity (considered to preclud 1.2.4 Significant pre-existing liver disease or hepat 1.2.5 Significant documented intolerance and/or sion 	e medications (tuberculo ien containing other seco le ethambutol use); or totoxicity from tuberculos	ond-line a	gents; or ations; or
2 Mycobacterium avium-intracellulare complex not respondin 3 Patient is under five years of age and has had close contac			
Initiation – Pneumonia			
Infectious disease specialist or clinical microbiologist Either:			
1 Immunocompromised patient with pneumonia that is unresp			
2 Pneumococcal pneumonia or other invasive pneumococcal	disease highly resistant	to other a	antibiotics.
nitiation – Penetrating eye injury			
Dphthalmologist			
Five days treatment for patients requiring prophylaxis following a p nitiation – Mycoplasma genitalium	enetrating eye injury.		
 All of the following: 1 Has nucleic acid amplification test (NAAT) confirmed Mycop 2 Either: 	plasma genitalium and is	sympton	natic; and
2.1 Has tried and failed to clear infection using azithrom 2.2 Has laboratory confirmed azithromycin resistance; a			
3 Treatment is only for 7 days.			

 Tab 400 mg
 100
 Arrow-Norfloxacin

t Item restricted (see → above); t Item restricted (see → below)

	(ex man.	ice excl. GST) \$	Per	Brand or Generic Manufacturer
Tetracyclines				
DEMECLOCYCLINE HYDROCHLORIDE Tab 150 mg Cap 150 mg Cap 300 mg DOXYCYCLINE				
 Tab 50 mg - Restricted: For continuation only Tab 100 mg Inj 5 mg per ml, 20 ml vial WINOCYCLINE Tab 50 mg → Cap 100 mg - Restricted: For continuation only 		64.43	500	Doxine
TETRACYCLINE Tab 250 mg Cap 500 mg TIGECYCLINE – Restricted see terms below ↓ Inj 50 mg vial → Restricted (RS1059) Clinical microbiologist or infectious disease specialist		58.20	28	Accord
Other Antibacterials				
AZTREONAM - Restricted see terms below ↓ Inj 1 g vial	30	64.92	10	Azactam
CLINDAMYCIN - Restricted see terms below Cap 150 mg		.5.30	24	Dalacin C
 ✓ Oral liq 15 mg per ml ✓ Inj 150 mg per ml, 4 ml ampoule – 5% DV Aug-23 to 2025 → Restricted (RS1061) Clinical microbiologist or infectious disease specialist 		35.10	10	Hamein
COLISTIN SULPHOMETHATE [COLESTIMETHATE] – Restricted s Inj 150 mg per ml, 1 ml vial Restricted (RS1062) Clinical microbiologist, infectious disease specialist or respiratory spe			1	Colistin-Link
DAPTOMYCIN – Restricted see terms below Inj 500 mg vial – 5% DV Jan-24 to 2025		43.52 15.36	1	Cubicin Daptomycin Dr Reddy's
(Cubicin Inj 500 mg vial to be delisted 1 January 2024) → Restricted (RS1063) Clinical microbiologist or infectious disease specialist				
FOSFOMYCIN - Restricted see terms on the next page				
Powder for oral solution, 3 g sachet				e.g. UroFos

INFECTIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
→ Restricted (RS1315)	· · · · · · · · · · · · · · · · · · ·		
Clinical microbiologist or infectious disease specialist			
LINCOMYCIN - Restricted see terms below			
Inj 300 mg per ml, 2 ml vial			
→ Restricted (RS1065)			
Clinical microbiologist or infectious disease specialist			
LINEZOLID – Restricted see terms below			
Tab 600 mg - 5% DV Dec-21 to 2024		10	Zyvox
Oral lig 20 mg per ml		150 ml	Zyvox
Inj 2 mg per ml, 300 ml bottle - 5% DV Dec-21 to 2024		10	Linezolid Kabi
→ Restricted (RS1066)			
Clinical microbiologist or infectious disease specialist			
METHENAMINE (HEXAMINE) HIPPURATE			
Tab 1 g – 5% DV Feb-23 to 2025		100	Hiprex
NITROFURANTOIN			
Tab 50 mg - 5% DV Dec-22 to 2024		100	Nifuran
Tab 100 mg - 5% DV Dec-22 to 2024		100	Nifuran
Cap modified-release 100 mg - 5% DV Dec-23 to 2026		100	Macrobid
PIVMECILLINAM – Restricted see terms below			
I Tab 200 mg			
➡ Restricted (RS1322)			
Clinical microbiologist or infectious disease specialist			
SODIUM FUSIDATE [FUSIDIC ACID] – Restricted see terms below			
Tab 250 mg	135.70	36	Fucidin
➡ Restricted (RS1064)			
Clinical microbiologist or infectious disease specialist			
SULPHADIAZINE - Restricted see terms below			
↓ Tab 500 mg			
→ Restricted (RS1067)			
Clinical microbiologist, infectious disease specialist or maternal-foetal m	edicine specialist		
TEICOPLANIN - Restricted see terms below	·		
↓ Inj 400 mg vial - 5% DV Jun-22 to 2024		1	Targocid
→ Restricted (RS1068)			
Clinical microbiologist or infectious disease specialist			
TRIMETHOPRIM			
Tab 100 mg			
Tab 300 mg – 5% DV Jan-22 to 2024		50	TMP
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE			
Tab 80 mg with sulphamethoxazole 400 mg - 5% DV Jan-22 to 20		500	Trisul
Oral lig 8 mg with sulphamethoxazole 40 mg per ml		100 ml	Deprim
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule			
VANCOMYCIN – Restricted see terms below			
Inj 500 mg vial − 5% DV Feb-24 to 2026		1	Mylan
→ Restricted (RS1069)		-	,
Clinical microbiologist or infectious disease specialist			

Clinical microbiologist or infectious disease specialist

INFE	CTIONS
------	--------

F	Price		Brand or
(ex man.	excl. GST) \$	Per	Generic Manufacturer
	,	-	

Antifungals

Imidazoles

KETOCONAZOLE ↓ Tab 200 mg → Restricted (RS1410) Oncologist

Polyene Antimycotics

AMPHOTERIC	IN B

➡ Restricted (RS1071)

Initiation

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
 - 2.1 Possible invasive fungal infection; and
 - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.
- Inj 50 mg vial

→ Restricted (RS1316)

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

NYSTATIN

Tab 500,000 u	50	Nilstat
Cap 500,000 u	50	Nilstat

Triazoles

FLUCONAZOLE – Restricted see terms below		
	28	Mylan
Cap 150 mg − 5% DV Dec-23 to 20260.45	1	Mylan
Cap 200 mg - 5% DV Dec-23 to 2026	28	Mylan
I Oral liquid 50 mg per 5 ml	35 ml	Diflucan
Inj 2 mg per ml, 50 ml vial	1	Fluconazole-Baxter
Inj 2 mg per ml, 100 ml vial	1	Fluconazole-Baxter
➡ Restricted (RS1072)		
Consultant		
ITRACONAZOLE – Restricted see terms below		
Cap 100 mg	15	Itrazole
I Oral liquid 10 mg per ml		
→ Restricted (RS1073)		
Clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist		
POSACONAZOLE – Restricted see terms on the next page		
Tab modified-release 100 mg - 5% DV Apr-23 to 2025	24	Posaconazole Juno
✔ Oral liq 40 mg per ml - 5% DV May-23 to 2025	105 ml	Devatis

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST)			Brand or
			_	Generic
	\$		Per	Manufacturer

➡ Restricted (RS1074)

Initiation

Haematologist or infectious disease specialist *Re-assessment required after 6 weeks*

Both:

- 1 Either:
 - 1.1 Patient has acute myeloid leukaemia; or
 - 1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
- 2 Patient is to be treated with high dose remission induction therapy or re-induction therapy.

Continuation

Haematologist or infectious disease specialist

Re-assessment required after 6 weeks

Both:

- 1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and
- 2 Any of the following:
 - 2.1 Patient is to be treated with high dose remission re-induction therapy; or
 - 2.2 Patient is to be treated with high dose consolidation therapy; or
 - 2.3 Patient is receiving a high risk stem cell transplant.

VORICONAZOLE - Restricted see terms below

Tab :	50 mg	56	Vttack
↓ Tab :	200 mg	56	Vttack
	der for oral suspension 40 mg per ml1,523.22	70 ml	Vfend
	00 mg vial – 5% DV Aug-23 to 2025	1	AFT

→ Restricted (RS1075)

Initiation - Proven or probable aspergillus infection

Clinical microbiologist, haematologist or infectious disease specialist Both:

- 1 Patient is immunocompromised; and
- 2 Patient has proven or probable invasive aspergillus infection.

Initiation - Possible aspergillus infection

Clinical microbiologist, haematologist or infectious disease specialist All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient has possible invasive aspergillus infection; and
- 3 A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

Initiation - Resistant candidiasis infections and other moulds

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

- 1 Patient is immunocompromised; and
- 2 Either:
 - 2.1 Patient has fluconazole resistant candidiasis; or
 - 2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and
- 3 A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

Other Antifungals

CA	SPOFUNGIN - Restricted see terms on the next page		
t	Inj 50 mg vial - 5% DV Apr-23 to 2025	 1	Alchemy Caspofungin
t	Inj 70 mg vial - 5% DV Apr-23 to 2025	 1	Alchemy Caspofungin

		Duite			Dread ar
	(ex man.	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
→ Restricted (RS1076)					
Initiation Clinical microbiologist, haematologist, infectious disease specialist, on Either:	cologist, r	espira	atory sp	ecialist o	r transplant specialist
 Proven or probable invasive fungal infection, to be prescribed u Both: 	inder an e	establi	shed p	rotocol; o	r
2.1 Possible invasive fungal infection; and2.2 A multidisciplinary team (including an infectious disease treatment to be appropriate.	physiciar	n or a	clinical	microbic	logist) considers the
FLUCYTOSINE - Restricted see terms below ↓ Tab 500 mg ↓ Cap 500 mg → Restricted (RS1279) Clinical microbiologist or infectious disease specialist TERBINAFINE					
Tab 250 mg - 5% DV Feb-24 to 2026		8.9	7	84	Deolate
Antimycobacterials					
Antileprotics					
CLOFAZIMINE - Restricted see terms below ↓ Cap 50 mg → Restricted (RS1077) Clinical microbiologist, dermatologist or infectious disease specialist DAPSONE - Restricted see terms below ↓ Tab 25 mg ↓ Tab 100 mg				100 100	Dapsone Dapsone
→ Restricted (RS1078) Clinical microbiologist, dermatologist or infectious disease specialist					
Antituberculotics					
BEDAQUILINE - Restricted see terms below Tab 100 mg		084.5 162.0		24 188	Sirturo Sirturo
 → Restricted (RS1977) Initiation – multi-drug resistant tuberculosis Limited to 6 months treatment Both: The person has multi-drug resistant tuberculosis (MDR-TB); an Manatū Hauora - Ministry of Health's Tuberculosis Clinical Netw 		aviow	ed the	individua	lessa and recommends
 Manatu Hauora - Ministry of Health's Tuberculosis Clinical Netwood bedaquiline as part of the treatment regimen. CYCLOSERINE - Restricted see terms below Cap 250 mg Restricted (RS1079) Clinical microbiologist, infectious disease specialist or respiratory specter the special see terms on the network of the special see terms of the special see terms on the network of the special see terms of the special see terms on the network of the special see terms on the network of the special see terms of the special sec terms of term	ialist	eview	ied the	Individua	i case and recommends
Tab 400 mg		49.3	4	56	Myambutol

		rice excl. GST) \$	Per	Brand or Generic Manufacturer
→ Restricted (RS1080)				
Clinical microbiologist, infectious disease specialist or respiratory specia	ılist			
ISONIAZID – Restricted see terms below				
Tab 100 mg - 5% DV Jan-22 to 2024		23.00	100	PSM
→ Restricted (RS1281)				
Clinical microbiologist, dermatologist, paediatrician, public health physic	ian or int	ernal medic	ine phys	ician
ISONIAZID WITH RIFAMPICIN – Restricted see terms below				
Tab 100 mg with rifampicin 150 mg			100	Rifinah
↓ Tab 150 mg with rifampicin 300 mg - 5% DV Jan-22 to 2024	1	79.13	100	Rifinah
➡ Restricted (RS1282)				:-:
Clinical microbiologist, dermatologist, paediatrician, public health physic	ian or int	emai medic	ine priys	ICIAN
PARA-AMINOSALICYLIC ACID – Restricted see terms below	-	~~~~	~~	-
Grans for oral liq 4 g	2	80.00	30	Paser
→ Restricted (RS1083)	P.4			
Clinical microbiologist, infectious disease specialist or respiratory specia	llist			
PROTIONAMIDE – Restricted see terms below	_			
↓ Tab 250 mg	3	05.00	100	Peteha
→ Restricted (RS1084)	P.4			
Clinical microbiologist, infectious disease specialist or respiratory specia	llist			
PYRAZINAMIDE – Restricted see terms below				
Tab 500 mg				
→ Restricted (RS1085)				
Clinical microbiologist, infectious disease specialist or respiratory specia	llist			
RIFABUTIN – Restricted see terms below				•• • •
↓ Cap 150 mg		53.71	30	Mycobutin
➡ Restricted (RS1086)				
Clinical microbiologist, gastroenterologist, infectious disease specialist of	or respira	tory speciali	St	
RIFAMPICIN – Restricted see terms below				
Cap 150 mg - 5% DV Dec-23 to 2026			100	Rifadin
Cap 300 mg - 5% DV Dec-23 to 2026			100	Rifadin
Oral liq 100 mg per 5 ml – 5% DV Dec-23 to 2026			60 ml	Rifadin
Inj 600 mg vial – 5% DV Dec-23 to 2026	1	34.98	1	Rifadin
→ Restricted (RS1087)	otrioion	r nublic boc	lth phys	icion
Clinical microbiologist, dermatologist, internal medicine physician, paed	alliciali		aun priys	
Antiparasitics				
Anthelmintics				
ALBENDAZOLE – Restricted see terms below				
Tab 200 mg				
Tob 400 mg				

Tab 400 mg

98

→ Restricted (RS1088)

Clinical microbiologist or infectious disease specialist

- IVERMECTIN Restricted see terms below
- → Restricted (RS1283) Clinical microbiologist, dermatologist or infectious disease specialist

	Price (ex man. excl \$. GST) Per	Brand or Generic Manufacturer
/EBENDAZOLE			
Tab 100 mg – 5% DV Jan-22 to 2024 Oral liq 100 mg per 5 ml	7.9	97 6	Vermox
PRAZIQUANTEL Tab 600 mg			
Antiprotozoals			
ARTEMETHER WITH LUMEFANTRINE – Restricted see terms be Tab 20 mg with lumefantrine 120 mg Restricted (RS1090) Clinical microbiologist or infectious disease specialist ARTESUNATE – Restricted see terms below Inj 60 mg vial Restricted (RS1091) Clinical microbiologist or infectious disease specialist ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – Restrict Tab 62.5 mg with proguanil hydrochloride 25 mg Tab 250 mg with proguanil hydrochloride 100 mg Restricted (RS1092) Clinical microbiologist or infectious disease specialist CHLOROQUINE PHOSPHATE – Restricted see terms below Tab 250 mg Restricted (RS1093) Clinical microbiologist, dermatologist, infectious disease specialist or MEFLOQUINE – Restricted see terms below Tab 250 mg Restricted (RS1094) Clinical microbiologist, dermatologist, infectious disease specialist or	t ed see terms be 25.0 	00 12	Malarone Junior Malarone
/ETRONIDAZOLE	medinatologist		
Tab 200 mg		5 250	Metrogyl
Tab 400 mg			Metrogyl
Oral liq benzoate 200 mg per 5 ml			Flagyl-S
Inj 5 mg per ml, 100 ml bag - 5% DV Dec-23 to 2026			Baxter
Suppos 500 mg			Flagyl
ITAZOXANIDE - Restricted see terms below Tab 500 mg		00 30	Alinia
 Oral liq 100 mg per 5 ml Restricted (RS1095) Clinical microbiologist or infectious disease specialist ORNIDAZOLE 			
Tab 500 mg - 5% DV Dec-21 to 2024		6 10	Arrow-Ornidazole
PENTAMIDINE ISETHIONATE - Restricted see terms below Inj 300 mg vial	216.0	00 5	Pentacarinat
-			
PRIMAQUINE – Restricted see terms on the next page Tab 15 mg			
Tab 15 mg			

INFECTIONS

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

➡ Restricted (RS1097)

Clinical microbiologist or infectious disease specialist

PYRIMETHAMINE – **Restricted** see terms below

- Tab 25 mg
- ➡ Restricted (RS1098)

Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist

QUININE DIHYDROCHLORIDE - Restricted see terms below

- Inj 60 mg per ml, 10 ml ampoule
- Inj 300 mg per ml, 2 ml vial
- → Restricted (RS1099)

Clinical microbiologist or infectious disease specialist

SODIUM STIBOGLUCONATE - Restricted see terms below

Inj 100 mg per ml, 1 ml vial

→ Restricted (RS1100)

Clinical microbiologist or infectious disease specialist

SPIRAMYCIN - Restricted see terms below

I Tab 500 mg

→ Restricted (RS1101)

Maternal-foetal medicine specialist

Antiretrovirals

Non-Nucleoside Reverse Transcriptase Inhibitors

→ Restricted (RS1898)

Initiation – Confirmed HIV

Patient has confirmed HIV infection.

Initiation - Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following exposure to HIV Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashm.org.au/hiv/hiv-management/pep/).

Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

EF	AVIRENZ – Restricted see terms above		
t	Tab 200 mg	90	Stocrin
t	Tab 600 mg	30	Stocrin
t	Oral liq 30 mg per ml		

INFECTIONS

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
ETRAVIRINE – Restricted see terms on the previous page t Tab 200 mg	770.00	60	Intelence
NEVIRAPINE - Restricted see terms on the previous page t Tab 200 mg - 5% DV Jan-22 to 2024		60	Nevirapine Alphapharm
t Oral suspension 10 mg per ml		240 ml	Nevirapine Viatris Viramune Suspension

Nucleoside Reverse Transcriptase Inhibitors

→ Restricted (RS1899)

Initiation – Confirmed HIV

Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following exposure to HIV Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashm.org.au/hiv/hiv-management/pep/).

Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

ABACAVIR SULPHATE – Restricted see terms above t Tab 300 mgt Oral liq 20 mg per ml	180.00 256.31	60 240 ml	Ziagen Ziagen
ABACAVIR SULPHATE WITH LAMIVUDINE - Restricted see terms above Tab 600 mg with lamivudine 300 mg - 5% DV May-23 to 2025		30	Abacavir/lamivudine Viatris
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL - R	estricted see	terms abov	е
1 Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg			
(300 mg as a maleate)	106.88	30	Mylan Viatris
(Mylan Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 n 2023)	ng (300 mg a	s a maleate)	
EMTRICITABINE – Restricted see terms above			
t Cap 200 mg	307.20	30	Emtriva
LAMIVUDINE - Restricted see terms above			
t Tab 150 mg - 5% DV Feb-24 to 2026	84.50 98.00	60	Lamivudine Alphapharm Lamivudine Viatris
t Oral lig 10 mg per ml			
(Lamivudine Alphapharm Tab 150 mg to be delisted 1 November 2023)			

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
STAVUDINE – Restricted see terms on the previous page t Cap 30 mg t Cap 40 mg t Powder for oral soln 1 mg per ml			
ZIDOVUDINE [AZT] - Restricted see terms on the previous page Cap 100 mg Oral liq 10 mg per ml Inj 10 mg per ml, 20 ml vial		100 200 ml 5	Retrovir Retrovir Retrovir IV
ZIDOVUDINE [AZT] WITH LAMIVUDINE - Restricted see terms on t Tab 300 mg with lamivudine 150 mg		60	Alphapharm

Protease Inhibitors

➡ Restricted (RS1900)

Initiation – Confirmed HIV

Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashm.org.au/hiv/hiv-management/pep/).

Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

t Cap 150 mg - 5% DV May-23 to 2025		60	Atazanavir Mylan
t Cap 200 mg - 5% DV May-23 to 2025	110.00	60	Atazanavir Mylan
DARUNAVIR – Restricted see terms above			
t Tab 400 mg - 5% DV Feb-24 to 2026	132.00	60	Darunavir Mylan
	150.00		Darunavir Viatris
t Tab 600 mg - 5% DV Feb-24 to 2026	225.00	60	Darunavir Viatris
(Demonstring Marian Tab. 400 ments ha delisted 1 January 2004)			

(Darunavir Mylan Tab 400 mg to be delisted 1 January 2024)

INDINAVIR - Restricted see terms above

- 1 Cap 200 mg
- t Cap 400 mg

102

INFECTIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LOPINAVIR WITH RITONAVIR - Restricted see terms on the previou Tab 100 mg with ritonavir 25 mg - 5% DV Feb-22 to 2024		60	Lopinavir/Ritonavir Mvlan
t Tab 200 mg with ritonavir 50 mg - 5% DV Feb-22 to 2024	295.00	120	Lopinavir/Ritonavir Mylan
RITONAVIR - Restricted see terms on the previous page t Tab 100 mg	43.31	30	Norvir
Strand Transfer Inhibitors			

➡ Restricted (RS1901)

Initiation – Confirmed HIV Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following exposure to HIV Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or
 - 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashm.org.au/hiv/hiv-management/pep/).

Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

DOI	UTEGRAVIR – Restricted see terms above				
t	Tab 50 mg	1,090.00	30	Tivicay	
RAL	TEGRAVIR POTASSIUM – Restricted see terms above				
t	Tab 400 mg		60	Isentress	
t	Tab 600 mg	1,090.00	60	Isentress HD	

Antivirals

Hepatitis B

ENTECAVIR Tab 0.5 mg	30	Entecavir Sandoz
LAMIVUDINE Tab 100 mg - 5% DV Feb-24 to 202612.06	28	Zetlam
Oral lig 5 mg per ml	240 ml	Zeffix

Pri (ex man. e \$		ST) Per	Brand or Generic Manufacturer
ENOFOVIR DISOPROXIL Tab 245 mg (300 mg as a maleate) – 5% DV Sep-23 to 20251	5.00	30	Tenofovir Disoproxil Mylan Tenofovir Disoproxil
Tenofovir Disoproxil Mylan Tab 245 mg (300 mg as a maleate) to be delisted 1 Fo	ebruary	(2024)	Viatris
Hepatitis C			
LECAPREVIR WITH PIBRENTASVIR Note: the supply of treatment is via Pharmac's approved direct distribution su Pharmac's website https://www.pharmac.govt.nz/maviret.		Further deta	ils can be found on
Tab 100 mg with pibrentasvir 40 mg24,75 EDIPASVIR WITH SOFOSBUVIR – Restricted see terms below	50.00	84	Maviret
Tab 90 mg with sofosbuvir 400 mg24,36	63.46	28	Harvoni
 Restricted (RS1528) Iote: Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP at its regular meetings and approved subject to eligibility according to the harmaceutical Schedule). 			
Herpesviridae			
CICLOVIR Tab dispersible 200 mg – 5% DV Mar-23 to 2025 Tab dispersible 400 mg – 5% DV Apr-23 to 2025 Tab dispersible 800 mg – 5% DV Apr-23 to 2025 Inj 250 mg vial – 5% DV Jan-22 to 2024	5.81 6.46	25 56 35 5	Lovir Lovir Lovir Aciclovir-Baxter
IIDOFOVIR - Restricted see terms below Inj 75 mg per ml, 5 ml vial * Restricted (RS1108) Ilinical microbiologist, infectious disease specialist, otolaryngologist or oral surged OSCARNET SODIUM - Restricted see terms below		5	
Inj 24 mg per ml, 250 ml bottle • Restricted (RS1109) Hinical microbiologist or infectious disease specialist ANCICLOVIR – Restricted see terms below			
Inj 500 mg vial	80.00	5	Cymevene
Tab 500 mg - 5% DV Jan-22 to 2024		30	Vaclovir
Tab 1,000 mg - 5% DV Jan-22 to 2024	3.76	30	Vaclovir
ALGANCICLOVIR – Restricted see terms below Tab 450 mg – 5% DV Sep-23 to 202413	32.00	60	Valganciclovir Mylan Valganciclovir Viatris
Valganciclovir Mylan Tab 450 mg to be delisted 1 February 2024) ◆ Restricted (RS1799)			raiganoioiorni viatile
nitiation – Transplant cytomegalovirus prophylaxis Re-assessment required after 3 months			
atient has undergone a solid organ transplant and requires valganciclovir for CM	IV propl	nylaxis.	

Price (ex man. excl. GST)	Brand or Generic		
 \$	Per	Manufacturer	

Continuation - Transplant cytomegalovirus prophylaxis

Re-assessment required after 3 months

Either:

1 Both:

- 1.1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
- 1.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin; or

2 Both:

- 2.1 Patient has received pulse methylprednisolone for acute rejection and requires further valganciclovir therapy for CMV prophylaxis; and
- 2.2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following pulse methylprednisolone.

Initiation – Lung transplant cytomegalovirus prophylaxis

Relevant specialist

Limited to 12 months treatment

All of the following:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive; and
- 3 Patient has a high risk of CMV disease.

Initiation – Cytomegalovirus in immunocompromised patients

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL - Restricted see terms below		
5% DV Jun-23 to 2025	30	Tenofovir Disoproxil
		Emtricitabine Mylan

Tenofovir Disoproxil

Emtricitabine Viatr

(Tenofovir Disoproxil Emtricitabine Mylan Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) to be delisted 1 November 2023)

➡ Restricted (RS1902)

Initiation – Confirmed HIV

Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV Both:

 Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

Initiation – Pre-exposure prophylaxis

Re-assessment required after 24 months

Both:

- 1 Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
- 2 The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.
- Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines (https://ashm.org.au/HIV/PrEP/)

Continuation – Pre-exposure prophylaxis

Re-assessment required after 24 months

Both:

- 1 Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
- 2 The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines (https://ashm.org.au/HIV/PrEP/)

Influenza

OSELTAMIVIR - Restricted see terms below

Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

Tab 75 mg

Powder for oral suspension 6 mg per ml

→ Restricted (RS1307)

Initiation

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a Health NZ Hospital approved infections control plan.

ZANAMIVIR

- Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

→ Restricted (RS1369)

Initiation

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a Health NZ Hospital approved infections control plan.

106

INFECTIONS

	Price (ex man. excl. GST)			Brand or Generic		
	(ex man.	exci. \$	usi)	Per	Generic Manufacturer	
COVID-19 Treatments						
MOLNUPIRAVIR - Restricted see terms below ↓ Cap 200 mg → Restricted (RS1893)		0.00		40	Lagevrio	
Initiation Only if patient meets access criteria (as per https://pharmac.govt.nz/co Pharmac's approved distribution process. Refer to the Pharmac webs						
NIRMATRELVIR WITH RITONAVIR – Restricted see terms below ↓ Tab 150 mg with ritonavir 100 mg		0.00		30	Paxlovid	
Only if patient meets access criteria (as per https://pharmac.govt.nz/cc Pharmac's approved distribution process. Refer to the Pharmac webs REMDESIVIR – Restricted see terms below						
Note: Remdesivir to be provided to Health NZ Hospitals at a cost	of \$0.00 a	as stoc	k has	been pı	urchased directly by Pharmac.	
 Inj 100 mg vial → Restricted (RS1912) 		760.57		1	Veklury	
Initiation – Treatment of mild to moderate COVID-19 Only if patient meets access criteria (as per https://pharmac.govt.nz/cc Pharmac's approved distribution process. Refer to the Pharmac webs Initiation – COVID-19 in hospitalised patients Therapy limited to 5 doses All of the following: 1 Patient is hospitalised with confirmed (or probable) symptomat 2 Patient is considered to be at high risk of progression to severe 3 Patient's symptoms started within the last 7 days; and 4 Patient does not require, or is not expected to require, mechan 5 Not to be used in conjunction with other funded COVID-19 anti 6 Treatment not to exceed five days.	site for mo ic COVID- e disease; ical ventila	re info 19; and and ation; a	rmatio d nd			
Immune Modulators INTERFERON ALFA-2B Inj 18 m iu, 1.2 ml multidose pen Inj 30 m iu, 1.2 ml multidose pen Inj 60 m iu, 1.2 ml multidose pen						
INTERFERON GAMMA – Restricted see terms below ↓ Inj 100 mcg in 0.5 ml vial → Restricted (RS1113) Initiation						
Patient has chronic granulomatous disease and requires interferon ga PEGYLATED INTERFERON ALFA-2A – Restricted see terms below Inj 180 mcg prefilled syringe				4 or gen	Pegasys otype 2 or 3 post liver	
				-	-	
					continued	

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

transplant

Limited to 48 weeks treatment

Any of the following:

- 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
- 2 Patient has chronic hepatitis C and is co-infected with HIV; or
- 3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.

Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation - Chronic hepatitis C - genotype 1 infection

Gastroenterologist, infectious disease specialist or general physician

Re-assessment required after 48 weeks

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir.

Initiation - Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior

Gastroenterologist, infectious disease specialist or general physician

Limited to 48 weeks treatment

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir.

Initiation - Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV

Limited to 6 months treatment

Patient has chronic hepatitis C, genotype 2 or 3 infection.

Initiation - Hepatitis B

Gastroenterologist, infectious disease specialist or general physician

Limited to 48 weeks treatment

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 Serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (greater than or equal to Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

continued...

- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon.

Initiation – myeloproliferative disorder or cutaneous T cell lymphoma

Re-assessment required after 12 months

Any of the following:

- 1 Patient has a cutaneous T cell lymphoma*; or
- 2 All of the following:
 - 2.1 Patient has a myeloproliferative disorder*; and
 - 2.2 Patient is intolerant of hydroxyurea; and
 - 2.3 Treatment with anagrelide and busulfan is not clinically appropriate; or
- 3 Both:
 - 3.1 Patient has a myeloproliferative disorder; and
 - 3.2 Patient is pregnant, planning pregnancy or lactating.

Continuation – myeloproliferative disorder or cutaneous T cell lymphoma

Re-assessment required after 12 months

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment; and
- 3 Either:
 - 3.1 Patient has a cutaneous T cell lymphoma*; or
 - 3.2 Both:
 - 3.2.1 Patient has a myeloproliferative disorder*; and
 - 3.2.2 Either:
 - 3.2.2.1 Remains intolerant of hydroxyurea and treatment with anagrelide and busulfan remains clinically inappropriate; or
 - 3.2.2.2 Patient is pregnant, planning pregnancy or lactating.

Note: Indications marked with * are unapproved indications

Initiation – ocular surface squamous neoplasia

Ophthalmologist

Re-assessment required after 12 months

Patient has ocular surface squamous neoplasia*.

Continuation - ocular surface squamous neoplasia

Ophthalmologist

Re-assessment required after 12 months

The treatment remains appropriate and patient is benefitting from treatment.

Note: Indications marked with * are unapproved indications

Initiation - post-allogenic bone marrow transplant

Re-assessment required after 3 months

Patient has received an allogeneic bone marrow transplant* and has evidence of disease relapse.

Continuation - post-allogenic bone marrow transplant

Re-assessment required after 3 months

Patient is responding and ongoing treatment remains appropriate.

Note: Indications marked with * are unapproved indications

		Price . excl. GST) \$	Per	Brand or Generic Manufacturer
Anticholinesterases				
EDROPHONIUM CHLORIDE – Restricted see terms below Inj 10 mg per ml, 15 ml vial Inj 10 mg per ml, 1 ml ampoule → Restricted (RS1015) Initiation				
For the diagnosis of myasthenia gravis. NEOSTIGMINE METILSULFATE Inj 2.5 mg per ml, 1 ml ampoule – 5% DV Mar-22 to 2024		33.81	10	Max Health
NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BRON Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml amp 5% DV Dec-21 to 2024 PYRIDOSTIGMINE BROMIDE	oule -	26.13	10	Max Health
Tab 60 mg		50.28	100	Mestinon
Antirheumatoid Agents				
HYDROXYCHLOROQUINE - Restricted see terms below Tab 200 mg Restricted (RS1776)		8.78	100	Plaquenil
 Any of the following: 1 Rheumatoid arthritis; or 2 Systemic or discoid lupus erythematosus; or 3 Malaria treatment or suppression; or 4 Relevant dermatological conditions (cutaneous forms of lupus ulceration); or 5 Sarcoidosis (pulmonary and non-pulmonary). 	and lichen	i planus, cuta	aneous va	sculitides and mucosal
LEFLUNOMIDE Tab 10 mg – 5% DV Dec-23 to 2026 Tab 20 mg – 5% DV Dec-23 to 2026			30 30	Arava Arava
PENICILLAMINE Tab 125 mg Tab 250 mg SODIUM AUROTHIOMALATE Inj 10 mg in 0.5 ml ampoule Inj 20 mg in 0.5 ml ampoule Inj 50 mg in 0.5 ml ampoule			100 100	D-Penamine D-Penamine
Drugs Affecting Bone Metabolism				
Bisphosphonates				
ALENDRONATE SODIUM				
Tab 70 mg		2.44	4	Fosamax
Tab 70 mg with colecalciferol 5,600 iu		1.51	4	Fosamax Plus

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
PAMIDRONATE DISODIUM			
Inj 3 mg per ml, 10 ml vial		1	Pamisol
Inj 6 mg per ml, 10 ml vial		1	Pamisol
Inj 9 mg per ml, 10 ml vial	94.34	1	Pamisol
RISEDRONATE SODIUM Tab 35 mg - 5% DV Jun-23 to 2025	2.50	4	Risedronate Sandoz
ZOLEDRONIC ACID Inj 5 mg per 100 ml, bag – 5% DV Jun-23 to 2025		100 ml	Zoledronic Acid Viatris

Other Drugs Affecting Bone Metabolism

DENOSUMAB - Restricted see terms below

l	Inj 60 mg prefilled syringe	 1	Prolia
•	Restricted (RS1665)		

Initiation

ſ

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 Either:
 - 2.1 The patient is female and postmenopausal; or
 - 2.2 The patient is male or non-binary; and
- 3 Any of the following:
 - 3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
 - 3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 3.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 3.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and
- 5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and
- 6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

continued...

Price		Brand or
(ex man. excl. GST)	Generic
 \$	Per	Manufacturer

continued...

- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

RALOXIFENE – Restricted see terms below		
	28	Evista
→ Restricted (RS1666)		

Initiation

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score greater than or equal to -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE – **Restricted** see terms below

Initiation

112

Limited to 18 months treatment All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINOL			
Tab 100 mg	11.47	500	DP-Allopurinol
Tab 300 mg		500	DP-Allopurinol
BENZBROMARONE – Restricted: For continuation only → Tab 50 mg			
→ Tab 100 mg	45.00	100	Benzbromaron AL 100
COLCHICINE			
Tab 500 mcg – 5% DV Sep-22 to 2025	6.00	100	Colgout
FEBUXOSTAT – Restricted see terms below			
	20.00	28	Febuxostat multichem
↓ Tab 120 mg	20.00	28	Febuxostat multichem
→ Restricted (RS1844)			

Initiation – Gout

Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); or
 - 2.4 The patient has previously had an initial Special Authority approval for benzbromarone for treatment of gout...

continued...

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Initiation - Tumour lysis syndrome

Haematologist or oncologist

Re-assessment required after 6 weeks

Both:

- 1 Patient is scheduled to receive cancer therapy carrying an intermediate or high risk of tumour lysis syndrome; and
- 2 Patient has a documented history of allopurinol intolerance.

Continuation – Tumour lysis syndrome

Haematologist or oncologist

Re-assessment required after 6 weeks

The treatment remains appropriate and patient is benefitting from treatment.

PROBENECID

Tab 500 mg

RASBURICASE - Restricted see terms below

Inj 1.5 mg vial

→ Restricted (RS1016)

Haematologist

Muscle Relaxants and Related Agents

ATRACURIUM BESYLATE

		_	
Inj 10 mg per ml, 2.5 ml ampoule		5	Tracrium
Inj 10 mg per ml, 5 ml ampoule	12.50	5	Tracrium
BACLOFEN			
Tab 10 mg	4.20	100	Pacifen
Oral lig 1 mg per ml			
Inj 0.05 mg per ml, 1 ml ampoule	11.55	1	Lioresal Intrathecal
Inj 2 mg per ml, 5 ml ampoule - 5% DV Dec-21 to 2024		5	Medsurge
CLOSTRIDIUM BOTULINUM TYPE A TOXIN			·
Inj 100 u vial	467 50	1	Botox
Inj 300 u vial		1	Dysport
Inj 500 u vial		2	Dysport
		2	Бузроп
DANTROLENE			
Cap 25 mg		100	Dantrium
Cap 50 mg		100	Dantrium
Inj 20 mg vial		6	Dantrium IV
MIVACURIUM CHLORIDE			
Inj 2 mg per ml, 10 ml ampoule			
ORPHENADRINE CITRATE			
Tab 100 mg – 5% DV Jan-22 to 2024	20.76	100	Norflex
PANCURONIUM BROMIDE			
Inj 2 mg per ml, 2 ml ampoule			
ROCURONIUM BROMIDE			
Inj 10 mg per ml, 5 ml ampoule – 5% DV Jan-23 to 2025		10	Hameln
SUXAMETHONIUM CHLORIDE			
Inj 50 mg per ml, 2 ml ampoule - 5% DV Feb-24 to 2026		10	Martindale
VECURONIUM BROMIDE			
Inj 10 mg vial			

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Reversers of Neuromuscular Blockade			
SUGAMMADEX – Restricted see terms below Inj 100 mg per ml, 2 ml vial - 5% DV Aug-22 to 2024 Inj 100 mg per ml, 5 ml vial - 5% DV Aug-22 to 2024 → Restricted (RS1370) Initiation		10 10	Sugammadex BNM Sugammadex BNM
 Any of the following: Patient requires reversal of profound neuromuscular blockade f undertaken using rocuronium (i.e. suxamethonium is contraind Severe neuromuscular degenerative disease where the use of it Patient has an unexpectedly difficult airway that cannot be intuk neuromuscular blockade; or The duration of the patient's surgery is unexpectedly short; or Neostigmine or a neostigmine/anticholinergic combination is co disease, morbid obesity or COPD); or Patient has a partial residual block after conventional reversal. 	licated or undesirable neuromuscular block pated and requires a	e); or kade is req rapid reve	uired; or ırsal of anaesthesia and
Non-Steroidal Anti-Inflammatory Drugs			
CELECOXIB Cap 100 mg - 5% DV Nov-22 to 2025 Cap 200 mg - 5% DV Nov-22 to 2025		60 30	Celecoxib Pfizer Celecoxib Pfizer
DICLOFENAC SODIUM Tab EC 25 mg – 5% DV Jan-22 to 2024 Tab 50 mg dispersible Tab EC 50 mg – 5% DV Jan-22 to 2024 Tab long-acting 75 mg Inj 25 mg per ml, 3 ml ampoule Suppos 12.5 mg Suppos 25 mg Suppos 50 mg Suppos 100 mg		50 20 50 100 5 10 10 10 10	Diclofenac Sandoz Voltaren D Diclofenac Sandoz Voltaren SR Voltaren Voltaren Voltaren Voltaren Voltaren Voltaren
 ETORICOXIB - Restricted see terms below ↓ Tab 30 mg ↓ Tab 60 mg ↓ Tab 90 mg ↓ Tab 120 mg → Restricted (RS1592) Initiation For in-vivo investigation of allergy only. IBUPROFEN Tab 200 mg - 1,000 tablet pack - 1% DV Feb-21 to 2024 → Tab 200 mg - 20 tablet pack → Tab 400 mg - Restricted: For continuation only → Tab 600 mg - Restricted: For continuation only → Tab 600 mg - Restricted: For continuation only → Tab 600 mg - Restricted: For continuation only → Tab 100 mg = 7% DV Jan-22 to 2024	1.35	1,000 20 30 200 ml	Relieve Relieve Brufen SR Ethics
Inj 5 mg per ml, 2 ml ampoule Inj 10 mg per ml, 2 ml vial			

Pri (ex man. e \$	excl. GST)	Per	Brand or Generic Manufacturer
INDOMETACIN [INDOMETHACIN]			
Cap 25 mg			
Cap 50 mg			
Cap long-acting 75 mg			
Inj 1 mg vial			
Suppos 100 mg			
KETOPROFEN			
Cap long-acting 200 mg1	2.07	28	Oruvail SR
MEFENAMIC ACID – Restricted: For continuation only Cap 250 mg			
NAPROXEN			
Tab 250 mg – 5% DV Jan-22 to 2024	32.69	500	Noflam 250
Tab 500 mg – 5% DV Jan-22 to 2024 2		250	Noflam 500
Tab long-acting 750 mg - 5% DV Jan-22 to 2024	6.47	28	Naprosyn SR 750
Tab long-acting 1 g - 5% DV Jan-22 to 2024	8.62	28	Naprosyn SR 1000
PARECOXIB			
Inj 40 mg vial10	00.00	10	Dynastat
SULINDAC			
Tab 100 mg			
Tab 200 mg			
TENOXICAM			
Tab 20 mg - 5% DV Jan-23 to 20251	8.50	100	Tilcotil
Inj 20 mg vial	9.95	1	AFT
Topical Products for Joint and Muscular Pain			
CAPSAICIN – Bestricted see terms below			
	9 75	45 g	Zostrix
→ Restricted (RS1309)			
nitiation			

Initiation

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Agents for Parkinsonism and Related Disorders			
Agents for Essential Tremor, Chorea and Related	Disorders		
RILUZOLE - Restricted see terms below ↓ Tab 50 mg - 5% DV Dec-21 to 2024 → Restricted (RS1351) Initiation Neurologist or respiratory specialist	130.00	56	Rilutek
Re-assessment required after 6 months			
 The patient has amyotrophic lateral sclerosis with disease di The patient has at least 60 percent of predicted forced vital of The patient has not undergone a tracheostomy; and The patient has not experienced respiratory failure; and Any of the following: The patient is ambulatory; or The patient is able to use upper limbs; or The patient is able to swallow. 			e initial application; and
Continuation Re-assessment required after 18 months All of the following: 1 The patient has not undergone a tracheostomy; and 2 The patient has not experienced respiratory failure; and 3 Any of the following: 3.1 The patient is ambulatory; or 3.2 The patient is able to use upper limbs; or 3.3 The patient is able to swallow.			
TETRABENAZINE Tab 25 mg – 5% DV Apr-23 to 2025		112	Motetis
Anticholinergics			
BENZATROPINE MESYLATE Tab 2 mg Inj 1 mg per ml, 2 ml ampoule PROCYCLIDINE HYDROCHLORIDE Tab 5 mg	9.59 95.00	60 5	Benztrop Phebra
Dopamine Agonists and Related Agents			
MANTADINE HYDROCHLORIDE Cap 100 mg		60	Symmetrel
APOMORPHINE HYDROCHLORIDE Inj 10 mg per ml, 2 ml ampoule Inj 10 mg per ml, 5 ml ampoule		5 5	Movapo Movapo
BROMOCRIPTINE Cap 5 mg			
ENTACAPONE Tab 200 mg – 5% DV Apr-22 to 2024		100	Comtan

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated. NERVOUS SYSTEM

	Price (ex man. excl. GST)		Brand or Generic
	(ex man. excl. GST) \$	Per	Manufacturer
EVODOPA WITH BENSERAZIDE			
Tab dispersible 50 mg with benserazide 12.5 mg		100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg		100	Madopar 62.5
Cap 100 mg with benserazide 25 mg		100	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg		100	Madopar HBS
Cap 200 mg with benserazide 50 mg		100	Madopar 250
EVODOPA WITH CARBIDOPA			
Tab 100 mg with carbidopa 25 mg	21.11	100	Sinemet
Tab long-acting 100 mg with carbipoda 25 mg			
Tab long-acting 200 mg with carbidopa 50 mg	43.65	100	Sinemet CR
Tab 250 mg with carbidopa 25 mg		100	Sinemet
PRAMIPEXOLE HYDROCHLORIDE			
Tab 0.25 mg – 5% DV Dec-22 to 2025	5 51	100	Ramipex
Tab 1 mg - 5% DV Dec-22 to 2025		100	Ramipex
5		100	nampex
RASAGILINE	E2 E0	30	Azilect
Tab 1mg – 1% DV Jan-22 to 2024		30	Azilect
ROPINIROLE HYDROCHLORIDE			
Tab 0.25 mg - 5% DV Jan-23 to 2025		84	Ropin
Tab 1 mg - 5% DV Jan-23 to 2025		84	Ropin
Tab 2 mg - 5% DV Jan-23 to 2025		84	Ropin
Tab 5 mg - 5% DV Jan-23 to 2025		84	Ropin
SELEGILINE HYDROCHLORIDE – Restricted: For continuation	only		
→ Tab 5 mg			
TOLCAPONE			
Tab 100 mg	152.38	100	Tasmar
Anaesthetics			
General Anaesthetics			
DESFLURANE	1 350 00	6	Suprane
DESFLURANE Soln for inhalation 100%, 240 ml bottle	1,350.00	6	Suprane
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE			
DESFLURANE Soln for inhalation 100%, 240 ml bottle		6 5	
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE			Suprane Dexmedetomidine-Teva
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial			
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule			
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE	97.88		
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle	97.88	5	Dexmedetomidine-Teva
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle	97.88	5	Dexmedetomidine-Teva Aerrane
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle KETAMINE Inj 1 mg per ml, 100 ml bag	97.88 2,730.00 135.00	5 6 5	Dexmedetomidine-Teva Aerrane Biomed
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle KETAMINE Inj 1 mg per ml, 100 ml bag Inj 10 mg per ml, 10 ml syringe		5 6 5 5	Dexmedetomidine-Teva Aerrane Biomed Biomed
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle KETAMINE Inj 1 mg per ml, 100 ml bag Inj 10 mg per ml, 10 ml syringe Inj 100 mg per ml, 2 ml vial		5 6 5	Dexmedetomidine-Teva Aerrane Biomed
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle Soln for inhalation 100%, 250 ml bottle KETAMINE Inj 1 mg per ml, 100 ml bag Inj 10 mg per ml, 10 ml syringe Inj 100 mg per ml, 2 ml vial IJETHOHEXITAL SODIUM		5 6 5 5	Dexmedetomidine-Teva Aerrane Biomed Biomed
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle Soln for inhalation 100%, 250 ml bottle ETAMINE Inj 1 mg per ml, 100 ml bag Inj 10 mg per ml, 10 ml syringe Inj 100 mg per ml, 2 ml vial INETHOHEXITAL SODIUM Inj 10 mg per ml, 50 ml vial		5 6 5 5	Dexmedetomidine-Teva Aerrane Biomed Biomed
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle Soln for inhalation 100%, 250 ml bottle ETAMINE Inj 1 mg per ml, 100 ml bag Inj 10 mg per ml, 10 ml syringe Inj 100 mg per ml, 2 ml vial INETHOHEXITAL SODIUM Inj 10 mg per ml, 50 ml vial		5 6 5 5	Dexmedetomidine-Teva Aerrane Biomed Biomed Ketalar
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle Soln for inhalation 100%, 250 ml bottle Soln for inhalation 100%, 250 ml bottle Soln for inhalation 100%, 250 ml bottle SOFLURANE Inj 1 mg per ml, 100 ml bag Inj 1 mg per ml, 100 ml bag Inj 10 mg per ml, 2 ml vial IETHOHEXITAL SODIUM Inj 10 mg per ml, 50 ml vial PROPOFOL Inj 10 mg per ml, 20 ml ampoule – 5% DV Jan-23 to 2025		5 6 5 5 5 5	Dexmedetomidine-Teva Aerrane Biomed Biomed Ketalar Fresofol 1% MCT/LCT
DESFLURANE Soln for inhalation 100%, 240 ml bottle DEXMEDETOMIDINE Inj 100 mcg per ml, 2 ml vial ETOMIDATE Inj 2 mg per ml, 10 ml ampoule SOFLURANE Soln for inhalation 100%, 250 ml bottle Soln for inhalation 100%, 250 ml bottle KETAMINE Inj 1 mg per ml, 100 ml bag Inj 10 mg per ml, 10 ml syringe Inj 100 mg per ml, 2 ml vial METHOHEXITAL SODIUM Inj 10 mg per ml, 50 ml vial PROPOFOL		5 6 5 5 5	Dexmedetomidine-Teva Aerrane Biomed Biomed

118

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SEVOFLURANE Soln for inhalation 100%, 250 ml bottle THIOPENTAL [THIOPENTONE] SODIUM Inj 500 mg ampoule	930.00	6	Baxter
Local Anaesthetics			
ARTICAINE HYDROCHLORIDE Inj 1% ARTICAINE HYDROCHLORIDE WITH ADRENALINE Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge BENZOCAINE Gel 20% BENZOCAINE WITH TETRACAINE HYDROCHLORIDE Gel 18% with tetracaine hydrochloride 2%			e.g. ZAP Topical Anaesthetic Gel
BUPIVACAINE HYDROCHLORIDE Inj 5 mg per ml, 4 ml ampoule – 5% DV Feb-24 to 2026 Inj 2.5 mg per ml, 20 ml ampoule	62.50	5	Marcain Isobaric
Inj 2.5 mg per ml, 20 ml ampoule sterile pack – 5% DV Feb-24 to 2	026 28.00	5	Marcain
Inj 5 mg per ml, 10 ml ampoule sterile pack Inj 5 mg per ml, 20 ml ampoule sterile pack		5	Marcain
Inj 5 mg per ml, 20 ml ampoule sterile pack Inj 1.25 mg per ml, 100 ml bag Inj 1.25 mg per ml, 200 ml bag	16.56	5	Marcain
Inj 2.5 mg per ml, 100 ml bag Inj 2.5 mg per ml, 200 ml bag Inj 1.25 mg per ml, 500 ml bag BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE Inj 2.5 mg per ml with adrenaline 1:200,000, 10 ml ampoule Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial		5	Marcain Marcain with Adrenaline
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial		5 5	Marcain with Adrenaline
ing 5 mg per mi with autenaline 1.200,000, 20 mi viai		5	

		U U	
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag			
Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag	.160.00	5	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 5% DV Jan-23			
to 2025	. 122.50	5	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – 5% DV Jan-23			
to 2025	. 127.50	5	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe	36.00	5	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe	52.50	5	Biomed
BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE			
Inj 0.5% with glucose 8%, 4 ml ampoule – 5% DV Sep-22 to 2025	26.67	5	Marcain Heavy

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

		Price excl. GST)		Brand or Conorio
	(ex man.	excl. GST) \$	Per	Generic Manufacturer
COCAINE HYDROCHLORIDE				
Paste 5%				
Soln 15%, 2 ml syringe				
Soln 4%, 2 ml syringe		.28.76	1	Biomed
COCAINE HYDROCHLORIDE WITH ADRENALINE				
Paste 15% with adrenaline 0.06%				
Paste 25% with adrenaline 0.06%				
ETHYL CHLORIDE				
Spray 100%				
LIDOCAINE [LIGNOCAINE]			_	
Crm 4%			5 g	LMX4
		27.00	30 g	LMX4
		4.07	00.0	Original
Gel 2% Soln 4%		4.87	20 g	Orion
Spray 10% – 5% DV Jan-23 to 2025		78 95	50 ml	Xylocaine
Oral (gel) soln 2%			200 ml	Mucosoothe
lnj 1%, 20 ml ampoule, sterile pack				
Inj 2%, 20 ml ampoule, sterile pack				
Inj 1%, 5 ml ampoule			25	Lidocaine-Baxter
Inj 1%, 20 ml vial			5	Lidocaine-Baxter
Inj 2%, 5 ml ampoule			25	Lidocaine-Baxter
Inj 2%, 20 ml vial Gel 2%, 11 ml urethral syringe – 5% DV Jan-23 to 2025			5 10	Lidocaine-Baxter Instillagel Lido
		.09.00	10	instinager Liuu
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE Inj 1% with adreanline 1:100,000, 20 ml vial				
Inj 1% with adrenaline 1:100,000, 5 ml ampoule - 5% DV Jan-23				
to 2025		.32.00	10	Xylocaine
Inj 1% with adrenaline 1:200,000, 20 ml vial		.50.00	5	Xylocaine
Inj 2% with adrenaline 1:100,000, 1.7 ml dental cartridge				
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge				
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge				
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge Inj 2% with adrenaline 1:200,000, 20 ml vial		60.00	5	Xylocaine
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE		RACAINE	HYDROC	HLORIDE
Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, syringe		19 75	1	Topicaine
, .		. 10.75	I	Topicalite
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDI Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe		103 32	10	Pfizer
(Pfizer Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe				1 11261
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHR				
Nasal spray 5% with phenylephrine hydrochloride 0.5%				
LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE				
Crm 2.5% with prilocaine 2.5%		45 00	30 g	EMLA
Patch 25 mcg with prilocaine 25 mcg			20	EMLA
Crm 2.5% with prilocaine 2.5%, 5 g			5	EMLA
MEPIVACAINE HYDROCHLORIDE				
Inj 3%, 1.8 ml dental cartridge		.43.60	50	Scandonest 3%
Inj 3%, 2.2 ml dental cartridge			50	Scandonest 3%

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

120

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
MEPIVACAINE HYDROCHLORIDE WITH ADRENALINE Inj 2% with adrenaline 1:100,000, 1.8 ml dental cartridge Inj 2% with adrenaline 1:100,000, 2.2 ml dental cartridge			
PRILOCAINE HYDROCHLORIDE Inj 0.5%, 50 ml vial Inj 2%, 5 ml ampoule		5	Citanest
PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge			
ROPIVACAINE HYDROCHLORIDE			
Inj 2 mg per ml, 10 ml ampoule - 5% DV Feb-24 to 2026	9.80	5	Ropivacaine Kabi
Inj 2 mg per ml, 20 ml ampoule - 5% DV Feb-24 to 2026	10.25	5	Ropivacaine Kabi
Inj 2 mg per ml, 100 ml bag - 5% DV Feb-24 to 2026		5	Ropivacaine Kabi
Inj 2 mg per ml, 200 ml bag - 5% DV Feb-24 to 2026		5	Ropivacaine Kabi
Inj 7.5 mg per ml, 10 ml ampoule - 5% DV Feb-24 to 2026	11.00	5	Ropivacaine Kabi
Inj 7.5 mg per ml, 20 ml ampoule - 5% DV Feb-24 to 2026		5	Ropivacaine Kabi
Inj 10 mg per ml, 10 ml ampoule - 5% DV Feb-24 to 2026	11.75	5	Ropivacaine Kabi
Inj 10 mg per ml, 20 ml ampoule - 5% DV Feb-24 to 2026		5	Ropivacaine Kabi
ROPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag	198 50	5	Naropin
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag		5	Naropin
(Naropin Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag to be delist (Naropin Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag to be delist	ed 1 July 2024)	0	паторит

TETRACAINE [AMETHOCAINE] HYDROCHLORIDE

Gel 4%

Analgesics

Non-Opioid Analgesics

ASPIRIN		
Tab dispersible 300 mg4.50	100	Ethics Aspirin
CAPSAICIN – Restricted see terms below		
↓ Crm 0.075%	45 g	Zostrix HP
→ Restricted (RS1145)	-	

Initiation

For post-herpetic neuralgia or diabetic peripheral neuropathy.

METHOXYFLURANE - Restricted see terms below

Soln for inhalation 99.9%, 3 ml bottle

→ Restricted (RS1292)

Initiation

Both:

1 Patient is undergoing a painful procedure with an expected duration of less than one hour; and

2 Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

NEFOPAM HYDROCHLORIDE

Tab 30 mg

	Price	۲)	Brand or
	(ex man. excl. GS \$	Per	Generic Manufacturer
PARACETAMOL - Some items restricted see terms below			
Tab soluble 500 mg			
Tab 500 mg - blister pack - 1,000 tablet pack - 1% DV Feb-22	2 to 2024 19.75	1,000	Pacimol
Tab 500 mg - blister pack - 12 tablet pack			
Tab 500 mg - blister pack - 20 tablet pack			
Tab 500 mg - bottle pack – 1% DV Feb-22 to 2024		1,000	Noumed Paracetamol
Oral liq 120 mg per 5 ml - 20% DV Jun-23 to 2025		200 ml	Avallon
	3.98		Paracetamol (Ethics)
Oral liq 250 mg per 5 ml - 20% DV Apr-23 to 2025	3.35	200 ml	Pamol
Inj 10 mg per ml, 100 ml vial		10	Paracetamol Kabi
Suppos 25 mg			
Suppos 50 mg			
Suppos 125 mg - 5% DV Feb-24 to 2026	4.29	10	Gacet
Suppos 250 mg - 5% DV Feb-24 to 2026	5.39	10	Gacet
Suppos 500 mg - 5% DV Feb-24 to 2026		50	Gacet
→ Restricted (RS1146)			
Initiation			
Intravenous paracetamol is only to be used where other routes are	unavailable or impracti	cal, or whe	re there is reduced
absorption. The need for IV paracetamol must be re-assessed even	ery 24 hours.		
SUCROSE	•		
Oral lig 25%	13.00	25 ml	Biomed
 Oral lig 66.7% (preservative free) 		20 111	Diomed
→ Restricted (RS1763)			
Initiation			
For use in neonatal patients only.			
i or use in neonatal patients only.			
Opioid Analgesics			
ALFENTANIL			

Inj 0.5 mg per ml, 2 ml ampoule – 5% DV Feb-24 to 2026	24.75 8.99	10 5	Hameln Medsurge
(Hameln Inj 0.5 mg per ml, 2 ml ampoule to be delisted 1 February 2024)			
CODEINE PHOSPHATE			
Tab 15 mg – 5% DV May-23 to 2025	.5.92	100	Noumed
Tab 30 mg - 5% DV Apr-23 to 2025	.6.98	100	Aspen
			Noumed
Tab 60 mg – 5% DV Apr-23 to 2025	13.89	100	Noumed
DIHYDROCODEINE TARTRATE			
Tab long-acting 60 mg – 5% DV Dec-22 to 2025	.8.60	60	DHC Continus

	Price	_	Brand or
	(ex man. excl. GS \$	r) Per	Generic Manufacturer
FENTANYL	÷	1.01	manufacturor
Inj 10 mcg per ml, 10 ml syringe	0.75	10	Boucher and Muir
Inj 50 mcg per ml, 2 ml ampoule - 5% DV Apr-22 to 2024		10	Biomed
Inj 10 mcg per ml, 50 ml bag Inj 10 mcg per ml, 50 ml syringe		10	Biomed
Inj 50 mcg per ml, 10 ml ampoule – 5% DV Apr-22 to 2024		10	Boucher and Muir
Inj 10 mcg per ml, 100 ml bag – 5% DV Feb-24 to 2024		5	Biomed
Inj 20 mcg per ml, 50 ml syringe		1	Biomed
Inj 20 mcg per ml, 100 ml bag	20.50	I	Diomed
Patch 12.5 mcg per hour – 5% DV Jan-22 to 2024	6.00	5	Fentanyl Sandoz
Patch 25 mcg per hour – 5% DV Jan-22 to 2024		5	Fentanyl Sandoz
Patch 50 mcg per hour - 5% DV Jan-22 to 2024		5	Fentanyl Sandoz
Patch 75 mcg per hour - 5% DV Jan-22 to 2024		5	Fentanyl Sandoz
Patch 100 mcg per hour – 5% DV Jan-22 to 2024		5	Fentanyl Sandoz
		5	r chianyr Ganaoz
METHADONE HYDROCHLORIDE	4.45	40	Mathe days DMM
Tab 5 mg - 5% DV Feb-23 to 2025		10	Methadone BNM
Oral liq 2 mg per ml - 5% DV Jan-22 to 2024		200 ml	Biodone
Oral liq 5 mg per ml – 5% DV Jan-22 to 2024		200 ml	Biodone Forte
Oral liq 10 mg per ml – 5% DV Jan-22 to 2024		200 ml	Biodone Extra Forte
Inj 10 mg per ml, 1 ml vial		10	AFT
MORPHINE HYDROCHLORIDE			
Oral liq 1 mg per ml		200 ml	RA-Morph
Oral liq 2 mg per ml		200 ml	RA-Morph
Oral liq 5 mg per ml		200 ml	RA-Morph
Oral liq 10 mg per ml	27.74	200 ml	RA-Morph
MORPHINE SULPHATE			
Tab immediate-release 10 mg	2.80	10	Sevredol
Tab immediate-release 20 mg	5.52	10	Sevredol
Cap long-acting 10 mg - 5% DV Apr-23 to 2025	3.00	10	m-Eslon
Cap long-acting 30 mg - 5% DV Apr-23 to 2025	4.30	10	m-Eslon
Cap long-acting 60 mg - 5% DV Apr-23 to 2025	9.00	10	m-Eslon
Cap long-acting 100 mg - 5% DV Apr-23 to 2025		10	m-Eslon
Inj 1 mg per ml, 100 ml bag - 5% DV Feb-24 to 2026	114.25	5	Biomed
Inj 1 mg per ml, 10 ml syringe - 5% DV Feb-24 to 2026		5	Biomed
Inj 1 mg per ml, 50 ml syringe - 5% DV Feb-24 to 2026	63.75	5	Biomed
Inj 1 mg per ml, 2 ml syringe			
Inj 2 mg per ml, 30 ml syringe		10	Biomed
Inj 5 mg per ml, 1 ml ampoule – 5% DV Mar-23 to 2025		5	Medsurge
Inj 10 mg per ml, 1 ml ampoule - 5% DV Mar-23 to 2025	4.68	5	Medsurge
Inj 10 mg per ml, 100 mg cassette			
Inj 10 mg per ml, 100 ml bag			
Inj 15 mg per ml, 1 ml ampoule - 5% DV Mar-23 to 2025		5	Medsurge
Inj 30 mg per ml, 1 ml ampoule - 5% DV Mar-23 to 2025	6.28	5	Medsurge
Inj 200 mcg in 0.4 ml syringe			
Inj 300 mcg in 0.3 ml syringe			
MORPHINE TARTRATE			

MORPHINE TARTRATE

Inj 80 mg per ml, 1.5 ml ampoule

	Price		Brand or
	(ex man. excl. GS	T)	Generic
	\$	Per	Manufacturer
OXYCODONE HYDROCHLORIDE			
Tab controlled-release 5 mg - 5% DV Jun-22 to 2024		20	Oxycodone Sandoz
Tab controlled-release 10 mg - 5% DV Jun-22 to 2024		20	Oxycodone Sandoz
Tab controlled-release 20 mg - 5% DV Jun-22 to 2024		20	Oxycodone Sandoz
Tab controlled-release 40 mg – 5% DV Jun-22 to 2024		20	Oxycodone Sandoz
Tab controlled-release 80 mg - 5% DV Jun-22 to 2024		20	Oxycodone Sandoz
Cap immediate-release 5 mg - 5% DV Dec-21 to 2024		20	OxyNorm
Cap immediate-release 10 mg - 5% DV Dec-21 to 2024		20	OxyNorm
Cap immediate-release 20 mg - 5% DV Dec-21 to 2024		20	OxyNorm
Oral lig 5 mg per 5 ml - 5% DV Sep-21 to 2024		250 ml	OxyNorm
Inj 1 mg per ml, 100 ml bag		200 111	OxyNorm
Inj 10 mg per ml, 1 ml ampoule – 5% DV Jul-22 to 2024	5 82	5	HameIn
Inj 10 mg per ml, 2 ml ampoule – 5% DV Jul-22 to 2024		5	Hameln
		5	Hameln
Inj 50 mg per ml, 1 ml ampoule - 5% DV Jul-22 to 2024		5	пашеш
PARACETAMOL WITH CODEINE			
Tab paracetamol 500 mg with codeine phosphate 8 mg -5% D	V		
Jan-23 to 2025		1,000	Paracetamol + Codeine
			(Relieve)
PETHIDINE HYDROCHLORIDE			
Tab 50 mg - 5% DV Aug-23 to 2025		10	Noumed Pethidine
Inj 5 mg per ml, 10 ml syringe			
Inj 5 mg per ml, 100 ml bag			
Inj 10 mg per ml, 100 ml bag			
Inj 10 mg per ml, 50 ml syringe			
Inj 50 mg per ml, 1 ml ampoule	29.88	5	DBL Pethidine
	20.00	Ū	Hydrochloride
Inj 50 mg per ml, 2 ml ampoule	30 72	5	DBL Pethidine
		Ū	Hydrochloride
REMIFENTANIL			riyaroomonao
Inj 1 mg vial – 5% DV Feb-24 to 2026	14.05	5	Remifentanil-AFT
		5	Remifentanil-AFT
Inj 2 mg vial – 5% DV Feb-24 to 2026	20.95	5	Rennentanii-AF i
TRAMADOL HYDROCHLORIDE			
Tab sustained-release 100 mg		20	Tramal SR 100
Tab sustained-release 150 mg	2.95	20	Tramal SR 150
Tab sustained-release 200 mg		20	Tramal SR 200
Cap 50 mg – 5% DV Jan-24 to 2026	3.33	100	Arrow-Tramadol
Oral soln 10 mg per ml			
Inj 10 mg per ml, 100 ml bag			
Inj 50 mg per ml, 1 ml ampoule		5	Tramal 50
Inj 50 mg per ml, 2 ml ampoule	9.00	5	Tramal 100
Antidepressants			
Cyclic and Related Agents			
AMITRIPTYLINE			
Tab 10 mg	2 49	100	Arrow-Amitriptyline
Tab 25 mg		100	Arrow-Amitriptyline
Tab 50 mg		100	Arrow-Amitriptyline
		100	Anow-Aminiptymie
CLOMIPRAMINE HYDROCHLORIDE			<u> </u>
CLOMIPRAMINE HYDROCHLORIDE Tab 10 mg – 1% DV Feb-22 to 2024 Tab 25 mg – 1% DV Feb-22 to 2024		30 30	Clomipramine Teva Clomipramine Teva

t Item restricted (see → above); t Item restricted (see → below)

124

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE - Restricted: For ca → Tab 75 mg → Cap 25 mg		30 50	Dosulepin Viatris Dosulepin Mylan Dosulepin Viatris
DOXEPIN HYDROCHLORIDE - Restricted: For continuation only → Cap 10 mg → Cap 25 mg → Cap 50 mg			
IMIPRAMINE HYDROCHLORIDE Tab 10 mg		50	Tofranil
Tab 25 mg	6.58 8.80	60 50	Tofranil Tofranil
MAPROTILINE HYDROCHLORIDE – Restricted: For continuation of → Tab 25 mg → Tab 75 mg	only		
MIANSERIN HYDROCHLORIDE – Restricted: For continuation only Tab 30 mg	1		
NORTRIPTYLINE HYDROCHLORIDE Tab 10 mg – 5% DV May-23 to 2025 Tab 25 mg – 5% DV May-23 to 2025		100 180	Norpress Norpress
Monoamine-Oxidase Inhibitors - Non-Selective			
PHENELZINE SULPHATE Tab 15 mg TRANYLCYPROMINE SULPHATE			
Tab 10 mg			
Monoamine-Oxidase Type A Inhibitors			
MOCLOBEMIDE Tab 150 mg – 5% DV Jan-22 to 2024 Tab 300 mg – 5% DV Jan-22 to 2024		60 60	Aurorix Aurorix
Other Antidepressants			
MIRTAZAPINE Tab 30 mg – 1% DV Jan-22 to 2024 Tab 45 mg – 1% DV Jan-22 to 2024		28 28	Noumed Noumed
VENLAFAXINE Cap 37.5 mg Cap 75 mg Cap 150 mg	10.32	84 84 84	Enlafax XR Enlafax XR Enlafax XR
Selective Serotonin Reuptake Inhibitors			
CITALOPRAM HYDROBROMIDE Tab 20 mg – 5% DV Mar-23 to 2025	0.00	04	Colonrom
Tab 20 mg - 5% DV Mar-23 to 2025	2.80	84	Celapram
Tab 10 mg Tab 20 mg		28 28	Escitalopram (Ethics) Escitalopram (Ethics)

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
	Ψ	1.01	Manufacturer
FLUOXETINE HYDROCHLORIDE	2 50	00	Fluox
Tab dispersible 20 mg, scored – 5% DV Feb-23 to 2025 Cap 20 mg – 5% DV Jun-23 to 2025		28 90	Arrow-Fluoxetine
		30	Allow-Iluoxeulle
		00	Lavamina
Tab 20 mg - 5% DV Jan-23 to 2025	4.11	90	Loxamine
			•
Tab 50 mg - 5% DV Apr-23 to 2025		30	Setrona
Tab 100 mg - 5% DV Apr-23 to 2025	1./4	30	Setrona
Antiepilepsy Drugs			
Agents for the Control of Status Epilepticus			
CLONAZEPAM			
Inj 1 mg per ml, 1 ml ampoule			
DIAZEPAM			
Inj 5 mg per ml, 2 ml ampoule		5	Hospira
Rectal tubes 5 mg - 5% DV Feb-23 to 2025	54.58	5	Stesolid
Rectal tubes 10 mg			
ORAZEPAM			
Inj 2 mg vial			
Inj 4 mg per ml, 1 ml vial			
PARALDEHYDE			
Soln 97%			
Inj 5 ml ampoule			
PHENYTOIN SODIUM	101 50	-	t to an inc
Inj 50 mg per ml, 2 ml ampoule Inj 50 mg per ml, 5 ml ampoule		5 5	Hospira
		5	Hospira
Control of Epilepsy			
CARBAMAZEPINE			
Tab 200 mg		100	Tegretol
Tab long-acting 200 mg		100	Tegretol CR
Tab 400 mg		100	Tegretol
Tab long-acting 400 mg		100 250 ml	Tegretol CR
Oral liq 20 mg per ml	20.37	200 111	Tegretol
Tab 10 mg			
Oral drops 2.5 mg per ml			
ETHOSUXIMIDE	140.00	100	Zarantin
Cap 250 mg Oral liq 50 mg per ml		100 200 ml	Zarontin Zarontin
		200 111	
GABAPENTIN	alia		
Note: Gabapentin not to be given in combination with pregaba Cap 100 mg - 1% DV Feb-22 to 2024		100	Nupentin
Cap 100 mg - 1% DV Feb-22 to 2024 Cap 300 mg - 1% DV Feb-22 to 2024		100	Nupentin
Cap 400 mg - 1% DV Feb-22 to 2024		100	Nupentin
		. •	

t Item restricted (see → above); t Item restricted (see → below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LACOSAMIDE – Restricted see terms below			
Tab 50 mg		14	Vimpat
Tab 100 mg		14	Vimpat
•	200.24	56	Vimpat
Tab 150 mg	75.10	14	Vimpat
•	300.40	56	Vimpat
Tab 200 mg		56	Vimpat

Inj 10 mg per ml, 20 ml vial

→ Restricted (RS1988)

Initiation

Re-assessment required after 15 months Both:

- 1 Patient has focal epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam, and any two of carbamazepine, lamotrigine, and phenytoin sodium (see Note).

Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, or topiramate. Those who can father children are not required to trial sodium valproate.

Continuation

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment.

LAMOTRIGINE

Tab dispersible 2 mg		30	Lamictal
Tab dispersible 5 mg		30	Lamictal
Tab dispersible 25 mg	4.20	56	Logem
Tab dispersible 50 mg	5.11	56	Logem
Tab dispersible 100 mg	6.75	56	Logem
LEVETIRACETAM			
Tab 250 mg	5.84	60	Everet
Tab 500 mg		60	Everet
Tab 750 mg		60	Everet
Tab 1,000 mg	21.82	60	Everet
Oral liq 100 mg per ml		300 ml	Levetiracetam-AFT
Inj 100 mg per ml, 5 ml vial		10	Levetiracetam-AFT
PHENOBARBITONE			
Tab 15 mg		500	PSM
Tab 30 mg - 5% DV Dec-23 to 2025		500	Noumed
	40.00		Phenobarbitone PSM

(PSM Tab 30 mg to be delisted 1 December 2023)

PHENYTOIN

Tab 50 mg PHENYTOIN SODIUM

Cap 30 mg Cap 100 mg Oral lig 6 mg per ml

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PREGABALIN			
Note: Pregabalin not to be given in combination with gabap	entin		
Cap 25 mg		56	Pregabalin Pfizer
Cap 75 mg	2.65	56	Pregabalin Pfizer
Cap 150 mg	4.01	56	Pregabalin Pfizer
Cap 300 mg	7.38	56	Pregabalin Pfizer
PRIMIDONE			
Tab 250 mg			
SODIUM VALPROATE			
Tab 100 mg			
Tab EC 200 mg			
Tab EC 500 mg			
Oral liq 40 mg per ml			
Inj 100 mg per ml, 4 ml vial	9.98	1	Epilim IV
STIRIPENTOL – Restricted see terms below			
Cap 250 mg		60	Diacomit
Powder for oral liq 250 mg sachet	509.29	60	Diacomit
→ Restricted (RS1989)			
Initiation			
Paediatric neurologist			
6			
Paediatric neurologist <i>Re-assessment required after 6 months</i> Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and			
Re-assessment required after 6 months Both:	te courses of sodium valpr dium valproate or topirama	te. Thos	e who can father children a
 Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial som not required to trial sodium valproate. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by redu TOPIRAMATE 	te courses of sodium valpr dium valproate or topirama ced seizure frequency fror	te. Thos n baseline	e who can father children a e.
 Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial some not required to trial sodium valproate. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by redu 	te courses of sodium valpr dium valproate or topirama ced seizure frequency fror 	te. Thos	e who can father children a e. Arrow-Topiramate
 Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial som not required to trial sodium valproate. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by redu TOPIRAMATE 	te courses of sodium valpr dium valproate or topirama ced seizure frequency fror 	te. Thos n baseline	e who can father children a e. Arrow-Topiramate Topamax
 Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soon not required to trial sodium valproate. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 25 mg 	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 	te. Thos n baselin 60	e who can father children a e. Arrow-Topiramate Topamax Topiramate Actavis
 Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial som not required to trial sodium valproate. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by redu TOPIRAMATE 	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 	te. Thos n baseline	e who can father children a e. Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate
 Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soon not required to trial sodium valproate. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 25 mg 	te courses of sodium valpr tium valproate or topirama ced seizure frequency fron 	te. Thos n baselin 60	e who can father children a e. Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax
Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and 2 Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soon trequired to trial sodium valproate. Continuation Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 50 mg	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 	te. Thos n baselin 60 60	e who can father children a e. Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis
 Re-assessment required after 6 months Both: Patient has confirmed diagnosis of Dravet syndrome; and Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial some not required to trial sodium valproate. Continuation Paediatric neurologist Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 25 mg 	te courses of sodium valpr dium valproate or topirama ced seizure frequency from 	te. Thos n baselin 60	e who can father children a Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate
Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and 2 Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soon to required to trial sodium valproate. Continuation Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 50 mg	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 	te. Thos n baselin 60 60	e who can father children a Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax
Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and 2 Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soci not required to trial sodium valproate. Continuation Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 50 mg Tab 100 mg	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 11.07 26.04 11.07 18.81 44.26 18.81 31.99 75.25 31.99	te. Thos n baseline 60 60	e who can father children a Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Topamax Topiramate Actavis
Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and 2 Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soon ot required to trial sodium valproate. Continuation Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 25 mg Tab 50 mg	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 11.07 26.04 11.07 18.81 44.26 18.81 31.99 75.25 31.99	te. Thos n baselin 60 60	e who can father children a Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Actavis Arrow-Topiramate
Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and 2 Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soon to required to trial sodium valproate. Continuation Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 25 mg Tab 50 mg Tab 100 mg	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 11.07 26.04 11.07 18.81 44.26 18.81 31.99 75.25 31.99 55.19	te. Thos n baseline 60 60	e who can father children a Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax
Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and 2 Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soci not required to trial sodium valproate. Continuation Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 50 mg Tab 100 mg	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 	te. Thos n baseline 60 60	e who can father children a Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topiramate Actavis Arrow-Topiramate
Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and 2 Seizures have been inadequately controlled by appropria following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soon or required to trial sodium valproate. Continuation Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 25 mg Tab 50 mg Tab 100 mg Tab 200 mg	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 	te. Thos n baseline 60 60 60	e who can father children a Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis
Re-assessment required after 6 months Both: 1 Patient has confirmed diagnosis of Dravet syndrome; and 2 Seizures have been inadequately controlled by appropriation following: topiramate, levetiracetam, ketogenic diet. Note: Those of childbearing potential are not required to trial soon not required to trial sodium valproate. Continuation Patient continues to benefit from treatment as measured by redu TOPIRAMATE Tab 25 mg Tab 100 mg Tab 200 mg Cap sprinkle 15 mg	te courses of sodium valpr dium valproate or topirama ced seizure frequency fron 	te. Thos n baseline 60 60 60 60	e who can father children a Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Arrow-Topiramate Topamax Topiramate Actavis Topamax

|--|

→ Restricted (RS1865)

Initiation

Re-assessment required after 15 months

Both:

- 1 Any of the following:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; or
 - 1.3 Patient has tuberous sclerosis complex; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Continuation

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Antimigraine Preparations

Acute Migraine Treatment

DIHYDROERGOTAMINE MESYLATE Inj 1 mg per ml, 1 ml ampoule		
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL Tab 5 mg with paracetamol 500 mg		
RIZATRIPTAN		
Tab orodispersible 10 mg - 5% DV Feb-24 to 2026	30	Rizamelt
SUMATRIPTAN		
Tab 50 mg - 1% DV Feb-22 to 2024	90	Sumagran
Tab 100 mg - 1% DV Feb-22 to 2024	90	Sumagran
Inj 12 mg per ml, 0.5 ml prefilled pen34.00	2	Imigran
Prophylaxis of Migraine		
PIZOTIFEN		
Tab 500 mcg23.21	100	Sandomigran
Antinausea and Vertigo Agents		
APREPITANT - Restricted see terms on the next page		
APREPITANT – Restricted see terms on the next page ↓ Cap 2 × 80 mg and 1 × 125 mg – 5% DV Dec-21 to 2024	3	Emend Tri-Pack

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➡ Restricted (RS1154)			
Initiation Patient is undergoing highly emetogenic chemotherapy and/or anthra	cycline-based chemot	herapy fo	or the treatment of
malignancy.			
BETAHISTINE DIHYDROCHLORIDE	0.70	100	Carro
Tab 16 mg - 5% DV Dec-23 to 2026	3.70	100	Serc
CYCLIZINE HYDROCHLORIDE Tab 50 mg - 5% DV Dec-21 to 2024	0.49	10	Nausicalm
CYCLIZINE LACTATE			
Inj 50 mg per ml, 1 ml ampoule – 5% DV Dec-22 to 2025		10	Hameln
DOMPERIDONE			
Tab 10 mg – 5% DV Jun-23 to 2025	4.00	100	Domperidone Viatris
DROPERIDOL			
Inj 2.5 mg per ml, 1 ml ampoule - 5% DV Mar-23 to 2025		10	Droperidol Panpharma
GRANISETRON			
Inj 1 mg per ml, 3 ml ampoule – 5% DV Feb-24 to 2026	1.20	1	Deva
HYOSCINE HYDROBROMIDE			2010
Inj 400 mcg per ml, 1 ml ampoule			
 Patch 1.5 mg 	17 70	2	Scopoderm TTS
→ Restricted (RS1155)		2	
Initiation			
Any of the following:			
 Control of intractable nausea, vomiting, or inability to swallow where the patient cannot tolerate or does not adequately resp. Control of clozapine-induced hypersalivation where trials of at ineffective; or For treatment of post-operative nausea and vomiting where cy ineffective, are not tolerated or are contraindicated. 	ond to oral anti-nause least two other alterna	a agents; ative treat	or ments have proven
METOCLOPRAMIDE HYDROCHLORIDE			
Tab 10 mg	1.30	100	Metoclopramide Actavis 10
Oral liq 5 mg per 5 ml	= 00		_ .
Inj 5 mg per ml, 2 ml ampoule - 5% DV Dec-22 to 2025	7.00	10	Baxter
ONDANSETRON			
Tab 4 mg – 5% DV Aug-23 to 2025		50	Periset
Tab dispersible 4 mg		10	Ondansetron ODT-DRLA
Tab 8 mg – 5% DV Aug-23 to 2025		50 10	Periset Ondansetron ODT-DRLA
Tab dispersible 8 mg Inj 2 mg per ml, 2 ml ampoule – 5% DV Mar-23 to 2025		5	Ondansetron-AFT
Inj 2 mg per ml, 4 ml ampoule – 5% DV Mar-23 to 2025		5	Ondansetron Kabi
ing 2 mg per mi, 4 mi ampodie – 3 % DV mai-25 to 2025	1.89	5	Ondansetron-AFT
PROCHLORPERAZINE	1.00		ondanocaron Ar I
Tab buccal 3 mg			
Tab 5 mg	8.00	250	Nausafix
lnj 12.5 mg per ml, 1 ml ampoule Suppos 25 mg			
TROPISETRON			
lnj 1 mg per ml, 2 ml ampoule			
Inj 1 mg per ml, 5 ml ampoule			

130

			RV005 5151 EM
	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
Antipsychotic Agents			
General			
MISULPRIDE			
Tab 100 mg	7.21	30	Sulprix
Tab 200 mg	20.94	60	Sulprix
Tab 400 mg		60	Sulprix
Oral liq 100 mg per ml			
RIPIPRAZOLE			
Tab 5 mg – 5% DV Oct-22 to 2025		30	Aripiprazole Sandoz
Tab 10 mg - 5% DV Oct-22 to 2025		30	Aripiprazole Sandoz
Tab 15 mg - 5% DV Oct-22 to 2025		30	Aripiprazole Sandoz
Tab 20 mg - 5% DV Oct-22 to 2025		30	Aripiprazole Sandoz
Tab 30 mg – 5% DV Oct-22 to 2025		30	Aripiprazole Sandoz
HLORPROMAZINE HYDROCHLORIDE			
Tab 10 mg	14.83	100	Largactil
Tab 10 mg		100	Largactil
Tab 100 mg		100	Largactil
Oral liq 10 mg per ml		100	Largaoth
Oral liq 20 mg per ml			
Inj 25 mg per ml, 2 ml ampoule	30 79	10	Largactil
argactil Tab 10 mg to be delisted 1 April 2024)		10	Largaoth
	6.60	50	Claning
Tab 25 mg	13.37	50 100	Clopine Clopine
	6.69	50	Clozaril
	13.37	100	Clozaril
Tab 50 mg		50	Clopine
Tab 00 mg	17.33	100	Clopine
Tab 100 mg		50	Clopine
	34.65	100	Clopine
	17.33	50	Clozaril
	34.65	100	Clozaril
Tab 200 mg		50	Clopine
· ~ = = = = = = = = = = = = = = = = = =	69.30	100	Clopine
Oral liq 50 mg per ml		100 ml	Versacloz
ALOPERIDOL			
Tab 500 mcg	6.23	100	Serenace
Tab 500 mcg Tab 1.5 mg		100	Serenace
Tab 5 mg		100	Serenace
Oral liq 2 mg per ml		100 ml	Serenace
Inj 5 mg per ml, 1ml ampoule		10	Serenace
EVOMEPROMAZINE			
	10 10	100	Nozinon
Tab 25 mg		100 100	Nozinan Nozinan
Tab 100 mg		100	NUZIIIAII
EVOMEPROMAZINE HYDROCHLORIDE	- · · -		
Inj 25 mg per ml, 1 ml ampoule - 5% DV Apr-23 to 2025	24.48	10	Wockhardt

	Price (ex man. excl. GST)		Brand or Generic
	(cx man. cxci. ccr) \$	Per	Manufacturer
ITHIUM CARBONATE			
Tab long-acting 400 mg - 5% DV Sep-21 to 2024		100	Priadel
Cap 250 mg		100	Douglas
OLANZAPINE			
Tab 2.5 mg	1 25	28	Zypine
Tab 5 mg		28	
Tab orodispersible 5 mg - 5% DV Feb-24 to 2026	0 / 0	28	Zypine Zypine ODT
Tab 10 mg		28	Zypine
Tab orodispersible 10 mg - 5% DV Feb-24 to 2026		28	Zypine ODT
Inj 10 mg vial		20	Lypine OD I
PERICYAZINE			
Tab 2.5 mg			
Tab 10 mg			
-			
QUETIAPINE	0.00	00	Quatanal
Tab 25 mg – 5% DV Feb-24 to 2026		90	Quetapel
Tab 100 mg - 5% DV Feb-24 to 2026		90	Quetapel
Tab 200 mg - 5% DV Feb-24 to 2026		90	Quetapel
Tab 300 mg – 5% DV Feb-24 to 2026		90	Quetapel
RISPERIDONE			
Tab 0.5 mg		60	Risperidone (Teva)
Tab 1 mg		60	Risperidone (Teva)
Tab 2 mg		60	Risperidone (Teva)
Tab 3 mg		60	Risperidone (Teva)
Tab 4 mg		60	Risperidone (Teva)
Oral liq 1 mg per ml	8.90	30 ml	Risperon
ZIPRASIDONE			
Cap 20 mg	17.90	60	Zusdone
Cap 40 mg	27.41	60	Zusdone
Cap 60 mg		60	Zusdone
Cap 80 mg		60	Zusdone
ZUCLOPENTHIXOL ACETATE			
Inj 50 mg per ml, 1 ml ampoule			
Inj 50 mg per ml, 2 ml ampoule			
ZUCLOPENTHIXOL HYDROCHLORIDE			
Tab 10 mg		100	Clopixol
			- · F · ·
Depot Injections			
FLUPENTHIXOL DECANOATE			
Inj 20 mg per ml, 1 ml ampoule	13.14	5	Fluanxol
Inj 20 mg per ml, 2 ml ampoule		5	Fluanxol
Inj 100 mg per ml, 1 ml ampoule	40.87	5	Fluanxol
HALOPERIDOL DECANOATE			
Inj 50 mg per ml, 1 ml ampoule		5	Haldol
Inj 100 mg per ml, 1 ml ampoule		5	Haldol Concentrate
OLANZAPINE - Restricted see terms on the next page		-	
· · · · · · · · · · · · · · · · · · ·	252.00	1	Zyprexa Relprevv
Inj 210 mg vial Inj 300 mg vial		1	Zyprexa Relprevv Zyprexa Relprevv
 Inj 300 mg vial Inj 405 mg vial 		1	Zyprexa Relprevv Zyprexa Relprevv
▼ IIIj TOJ IIIY VIAI		I	Σγρισκά ιτθιρισνν

➡ Restricted (RS1379)

Initiation

Re-assessment required after 12 months

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE - Restricted see terms below

t	Inj 25 mg syringe	 1	Invega Sustenna
	Inj 50 mg syringe	1	Invega Sustenna
	Inj 75 mg syringe	1	Invega Sustenna
	Inj 100 mg syringe	1	Invega Sustenna
	Inj 150 mg syringe	1	Invega Sustenna
	Restricted (RS1381)		0

➡ Restricted (

Initiation

Re-assessment required after 12 months

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PALIPERIDONE PALMITATE - Restricted see terms below

t	Inj 175 mg syringe	815.85	1	Invega Trinza
t	Inj 263 mg syringe	1,072.26	1	Invega Trinza
t	Inj 350 mg syringe	1,305.36	1	Invega Trinza
	Inj 525 mg syringe		1	Invega Trinza

➡ Restricted (RS1932)

Initiation

Re-assessment required after 12 months

Both:

- 1 The patient has schizophrenia; and
- 2 The patient has had an initial Special Authority approval for paliperidone once-monthly depot injection.

Continuation

Re-assessment required after 12 months

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

	ex man.	Price excl. (\$	GST)	Per	Brand or Generic Manufacturer
IPOTHIAZINE PALMITATE – Restricted: For continuation only → Inj 50 mg per ml, 1 ml ampoule → Inj 50 mg per ml, 2 ml ampoule					
ISPERIDONE – Restricted see terms below					
Inj 25 mg vial	1	35.98		1	Risperdal Consta
Inj 37.5 mg vial	1	78.71		1	Risperdal Consta
Inj 50 mg vial	2	217.56		1	Risperdal Consta
→ Restricted (RS1380)					
nitiation					
Re-assessment required after 12 months					
 The patient has had an initial Special Authority approval for palip All of the following: The patient has schizophrenia or other psychotic disorder The patient has tried but failed to comply with treatment u The patient has been admitted to hospital or treated in restreatment for 30 days or more in the last 12 months. 	; and sing oral	l atypic	cal ant	ipsycho	tic agents; and
Continuation Re-assessment required after 12 months he initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE	antipsyc	chotic o			l.
Continuation Re-assessment required after 12 months he initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule	antipsyc	chotic o			
Continuation Re-assessment required after 12 months the initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule	antipsyc	chotic o		njection	Clopixol
Continuation Re-assessment required after 12 months the initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics	antipsyc	chotic o		njection	Clopixol
Continuation Re-assessment required after 12 months the initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics EUSPIRONE HYDROCHLORIDE	antipsyc	chotic (depot	5	Clopixol e.g. Clopixol Conc
Continuation Re-assessment required after 12 months the initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics USPIRONE HYDROCHLORIDE Tab 5 mg – 5% DV May-22 to 2024	antipsyc	.19.80 .18.50	depot	5 100	Clopixol e.g. Clopixol Conc Buspirone Viatris
Continuation Re-assessment required after 12 months the initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics CUSPIRONE HYDROCHLORIDE Tab 5 mg – 5% DV May-22 to 2024	antipsyc	.19.80 .18.50	depot	5	Clopixol e.g. Clopixol Conc
Continuation Re-assessment required after 12 months the initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics CUSPIRONE HYDROCHLORIDE Tab 5 mg – 5% DV May-22 to 2024 Tab 10 mg – 5% DV May-22 to 2024	antipsyc	.19.80 .18.50 .12.50	depot	5 100 100	Clopixol <i>e.g. Clopixol Conc</i> Buspirone Viatris Buspirone Viatris
Continuation Re-assessment required after 12 months the initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics CUSPIRONE HYDROCHLORIDE Tab 5 mg – 5% DV May-22 to 2024	antipsyc	.19.80 .18.50 .12.50 5.64	depot	5 100	Clopixol e.g. Clopixol Conc Buspirone Viatris
Continuation Re-assessment required after 12 months the initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics CUSPIRONE HYDROCHLORIDE Tab 5 mg - 5% DV May-22 to 2024	antipsyc	.19.80 .18.50 .12.50 5.64	depot	100 100	Clopixol <i>e.g. Clopixol Conc</i> Buspirone Viatris Buspirone Viatris Paxam
Continuation Re-assessment required after 12 months The initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics USPIRONE HYDROCHLORIDE Tab 5 mg - 5% DV May-22 to 2024	antipsyc	.19.80 .18.50 .12.50 5.64 .10.78	depot	100 100	Clopixol <i>e.g. Clopixol Conc</i> Buspirone Viatris Buspirone Viatris Paxam
Continuation Re-assessment required after 12 months the initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics CUSPIRONE HYDROCHLORIDE Tab 5 mg - 5% DV May-22 to 2024	antipsyc	.19.80 .18.50 .12.50 5.64 .10.78 .61.07	depot	5 100 100 100 100	Clopixol <i>e.g. Clopixol Conc</i> Buspirone Viatris Buspirone Viatris Paxam Paxam
Continuation Re-assessment required after 12 months he initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics CUSPIRONE HYDROCHLORIDE Tab 5 mg – 5% DV May-22 to 2024. Tab 10 mg – 5% DV May-22 to 2024. CLONAZEPAM Tab 2 mg	antipsyc	.19.80 .19.80 .12.50 .12.50 .12.50 .12.50 .12.50 .12.50 .12.50 .12.50 .12.50 .12.50 .12.50 .12.50 .12.50 .13.64 .10.78	depot i	100 100 100 100 500	Clopixol e.g. Clopixol Conc Buspirone Viatris Buspirone Viatris Paxam Paxam Arrow-Diazepam
Continuation Re-assessment required after 12 months he initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics CUSPIRONE HYDROCHLORIDE Tab 5 mg – 5% DV May-22 to 2024. Tab 10 mg – 5% DV May-22 to 2024. CLONAZEPAM Tab 500 mcg. Tab 2 mg	antipsyc	18.50 12.50 10.78 61.07 73.60	depot i	100 100 100 100 500	Clopixol e.g. Clopixol Conc Buspirone Viatris Buspirone Viatris Paxam Paxam Arrow-Diazepam
Continuation Re-assessment required after 12 months he initiation of risperidone depot injection has been associated with few uring a corresponding period of time prior to the initiation of an atypical UCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml ampoule Inj 500 mg per ml, 1 ml ampoule Anxiolytics CUSPIRONE HYDROCHLORIDE Tab 5 mg – 5% DV May-22 to 2024. Tab 10 mg – 5% DV May-22 to 2024. CLONAZEPAM Tab 2 mg	antipsyc	18.50 12.50 10.78 61.07 73.60	depot i	100 100 100 100 500 500	Clopixol e.g. Clopixol Conc Buspirone Viatris Buspirone Viatris Paxam Paxam Arrow-Diazepam Arrow-Diazepam

Tab 10 mg

134

Tab 15 mg

Multiple Sclerosis Treatments

→ Restricted (RS1937)

Initiation - Multiple sclerosis

Neurologist or general physician *Re-assessment required after 12 months* All of the following:

continued...

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

con	tin	ue	d.	

- 1 Diagnosis of multiple sclerosis (MS) meets the McDonald 2017 diagnostic criteria for MS and has been confirmed by a neurologist; and
- 2 Patients has an EDSS score between 0 6.0; and
- 3 Patient has had at least one significant attack of MS in the previous 12 months or two significant attacks in the past 24 months; and
- 4 All of the following:
 - 4.1 Each significant attack must be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the attack, but the neurologist/physician must be satisfied that the clinical features were characteristic); and
 - 4.2 Each significant attack is associated with characteristic new symptom(s)/sign(s) or substantially worsening of previously experienced symptoms(s)/sign(s); and
 - 4.3 Each significant attack has lasted at least one week and has started at least one month after the onset of a previous attack (where relevant); and
 - 4.4 Each significant attack can be distinguished from the effects of general fatigue; and is not associated with a fever (T> 37.5°C); and
 - 4.5 Either:
 - 4.5.1 Each significant attack is severe enough to change either the EDSS or at least one of the Kurtze Functional System scores by at least 1 point; or
 - 4.5.2 Each significant attack is a recurrent paroxysmal symptom of multiple sclerosis (tonic seizures/spasms, trigeminal neuralgia, Lhermitte's symptom); and
- 5 Evidence of new inflammatory activity on an MRI scan within the past 24 months; and
- 6 Any of the following:
 - 6.1 A sign of that new inflammatory activity on MRI scanning (in criterion 5 immediately above) is a gadolinium enhancing lesion; or
 - 6.2 A sign of that new inflammatory activity is a lesion showing diffusion restriction; or
 - 6.3 A sign of that new inflammatory is a T2 lesion with associated local swelling; or
 - 6.4 A sign of that new inflammatory activity is a prominent T2 lesion that clearly is responsible for the clinical features of a recent attack that occurred within the last 2 years; or
 - 6.5 A sign of that new inflammatory activity is new T2 lesions compared with a previous MRI scan.

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

Continuation - Multiple sclerosis

Neurologist or general physician

Patient has had an EDSS score of 0 to 6.0 (inclusive) with or without the use unilateral or bilateral aids at any time in the last six months (i.e. the patient has walked 100 metres or more with or without aids in the last six months).

Note: Treatment on two or more funded multiple sclerosis treatments simultaneously is not permitted.

DIMETHYL FUMARATE - Restricted see terms on the previous page

	Note: Treatment on two or more funded multiple sclerosis treatments s	imultaneously is	not permi	tted.
t	Cap 120 mg	520.00	14	Tecfidera
t	Cap 240 mg	2,000.00	56	Tecfidera
FIN	IGOLIMOD – Restricted see terms on the previous page			
	Note: Treatment on two or more funded multiple sclerosis treatments s	imultaneously is	not permi	tted.
t	Cap 0.5 mg	2,200.00	28	Gilenya
GL	ATIRAMER ACETATE – Restricted see terms on the previous page			
	Note: Treatment on two or more funded multiple sclerosis treatments s	imultaneously is	not permi	tted.
t	Inj 40 mg prefilled syringe - 5% DV Oct-22 to 2025	1,137.48	12	Copaxone
INT	ERFERON BETA-1-ALPHA - Restricted see terms on the previous pa	ge		
	Note: Treatment on two or more funded multiple sclerosis treatments s	imultaneously is	not permi	tted.
t	Inj 6 million iu in 0.5 ml pen injector	1,170.00	4	Avonex Pen
t	Inj 6 million iu in 0.5 ml syringe	1,170.00	4	Avonex

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

(e:	Price (man. excl. (\$	GST) Pe	er	Brand or Generic Manufacturer
INTERFERON BETA-1-BETA – Restricted see terms on page 134 Note: Treatment on two or more funded multiple sclerosis treatments Inj 8 million iu per ml, 1 ml vial	simultaneous	sly is not	perm	itted.
NATALIZUMAB - Restricted see terms on page 134				
Note: Treatment on two or more funded multiple sclerosis treatments	simultaneous	sly is not	perm	itted.
1 Inj 20 mg per ml, 15 ml vial	1,750.00		ĺ	Tysabri
OCRELIZUMAB – Restricted see terms on page 134				
Note: Treatment on two or more funded multiple sclerosis treatments		sly is not	perm	itted.
t Inj 30 mg per ml, 10 ml vial	9,346.00		I	Ocrevus
TERIFLUNOMIDE – Restricted see terms on page 134				
Note: Treatment on two or more funded multiple sclerosis treatments	simultaneous	sly is not	perm	itted.
t Tab 14 mg	659.90	2	8	Aubagio
Sedatives and Hypnotics				
CHLORAL HYDRATE				
Oral liq 100 mg per ml				
Oral liq 200 mg per ml				
LORMETAZEPAM – Restricted: For continuation only				
➡ Tab 1 mg				
MELATONIN – Restricted see terms below Tab modified-release 2 mg – 5% DV Apr-22 to 2024 Tab 3 mg	11.50	3	0	Vigisom
Note: Only for use in compounding an oral liquid formulation, for → Restricted (RS1576)	in-hospital us	e only.		
Initiation – insomnia secondary to neurodevelopmental disorder				
Psychiatrist, paediatrician, neurologist or respiratory specialist				
Re-assessment required after 12 months				
All of the following:				
 Patient has been diagnosed with persistent and distressing insomn (including, but not limited to, autism spectrum disorder or attention) 	deficit hypera	ctivity di		
2 Behavioural and environmental approaches have been tried or are				L
3 Funded modified-release melatonin is to be given at doses no great	ter than 10 m	ig per da	y; and	1
4 Patient is aged 18 years or under. Continuation – insomnia secondary to neurodevelopmental disorder				
Psychiatrist, paediatrician, neurologist or respiratory specialist				
Re-assessment required after 12 months				
All of the following:				
1 Patient is aged 18 years or under; and				
2 Patient has demonstrated clinically meaningful benefit from funded	modified-rele	ease mel	atonir	n (clinician determined); and
3 Patient has had a trial of funded modified-release melatonin discon recurrence of persistent and distressing insomnia; and	tinuation with	in the pa	ist 12	months and has had a
4 Funded modified-release melatonin is to be given at doses no great	ter than 10 m	ng per da	y.	
Initiation - insomnia where benzodiazepines and zopiclone are contra			•	
Both:				

- 1 Patient has insomnia and benzodiazepines and zopiclone are contraindicated; and
- 2 For in-hospital use only.

136

	Price		Brand or
	(ex man. excl. GST)	1	Generic
	\$	Per	Manufacturer
MIDAZOLAM			
Tab 7.5 mg			
Oral liq 2 mg per ml			
Inj 1 mg per ml, 5 ml ampoule - 5% DV Jan-22 to 2024		10	Mylan Midazolam
Inj 5 mg per ml, 3 ml ampoule – 5% DV Jan-22 to 2024	3.52	5	Midazolam Viatris
PHENOBARBITONE			Mylan Midazolam
Inj 130 mg per ml, 1 ml vial			
Inj 200 mg per ml, 1 ml ampoule			
TEMAZEPAM			
Tab 10 mg - 5% DV Feb-24 to 2026		25	Normison
TRIAZOLAM – Restricted: For continuation only			
→ Tab 125 mcg			
➡ Tab 250 mcg			
ZOPICLONE			
Tab 7.5 mg			
Spinal Muscular Atrophy			
NUSINERSEN – Restricted see terms below			
Inj 12 mg per 5 ml vial		1	Spinraza
→ Restricted (RS1938)			
Initiation			
Re-assessment required after 12 months All of the following:			
1 Patient has genetic documentation of homozygous SMN1 ge	no dolotion homozugo		point mutation or compound
heterozygous mutation; and	ne deletion, nomozygo		point mutation, or compound
2 Patient is 18 years of age or under; and			
3 Either:			
3.1 Patient has experienced the defined signs and symptotic	oms of SMA type I, II of	r IIIa prior	to three years of age; or
3.2 Both:			
3.2.1 Patient is pre-symptomatic; and			
3.2.2 Patient has three or less copies of SMN2.			
Continuation Re-assessment required after 12 months			
All of the following:			
1 There has been demonstrated maintenance of motor milesto	ne function since treatr	nent initia	tion: and
2 Patient does not require invasive permanent ventilation (at le			
reversible cause while being treated with nusinersen; and			
3 Nusinersen not to be administered in combination other SMA	disease modifying trea	atments o	r gene therapy.
RISDIPLAM – Restricted see terms below			
Note: the supply of risdiplam is via Pharmac's approved direct	distribution supply. Fur	ther deta	ils can be found on
Pharmac's website https://pharmac.govt.nz/risdiplam	44400.00		- "
Powder for oral soln 750 mcg per ml, 60 mg per bottle	14,100.00	80 ml	Evrysdi
→ Restricted (RS1954) Initiation			
Re-assessment required after 12 months			
All of the following:			
-			
			continued
			contailadu

	Price			Brand or
(ex r	man. excl.	GST)	_	Generic
	\$		Per	Manufacturer

continued...

- 1 Patient has genetic documentation of homozygous SMN1 gene deletion, homozygous SMN1 point mutation, or compound heterozygous mutation; and
- 2 Patient is 18 years of age or under; and
- 3 Either:
 - 3.1 Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or 3.2 Both:
 - 3.2.1 Patient is pre-symptomatic; and
 - 3.2.2 Patient has three or less copies of SMN2.

Continuation

Re-assessment required after 12 months

All of the following:

- 1 There has been demonstrated maintenance of motor milestone function since treatment initiation; and
- 2 Patient does not require invasive permanent ventilation (at least 16 hours per day), in the absence of a potentially reversible cause while being treated with risdiplam; and
- 3 Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy.

Stimulants / ADHD Treatments

|--|

AIC	DMOXETINE Cap 10 mg	18.41	28	APO-Atomoxetine
				Generic Partners
	Cap 18 mg	27.06	28	APO-Atomoxetine
				Generic Partners
	Cap 25 mg	29.22	28	APO-Atomoxetine
				Generic Partners
	Cap 40 mg	29.22	28	APO-Atomoxetine
	0 00	40.54	00	Generic Partners
	Cap 60 mg	46.51	28	APO-Atomoxetine Generic Partners
	Cap 90 mg	56 45	28	APO-Atomoxetine
	Cap 80 mg		20	Generic Partners
	Cap 100 mg	58 48	28	APO-Atomoxetine
			20	Generic Partners
CAF	FEINE			
	Tab 100 mg			
	AMFETAMINE SULFATE – Restricted see terms below			
Į.	Tab 5 mg - 5% DV Jan-22 to 2024	28 50	100	Aspen
•	Tab 5 mg 570 DV 041-22 to 2024	21.00	100	PSM
⇒	Restricted (RS1169)	21.00		
Initi	ation – ADHD			
Pae	diatrician or psychiatrist			
Pati	ent has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed a	according to D	SM-IV or I	CD 10 criteria.
Initi	ation – Narcolepsy			
	rologist or respiratory specialist			
	assessment required after 24 months			
	ent suffers from narcolepsy.			
	tinuation – Narcolepsy			
	rologist or respiratory specialist			
	assessment required after 24 months			
Ine	treatment remains appropriate and the patient is benefiting from treatme	ent.		

	Price		Drand ar
	(ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
METHYLPHENIDATE HYDROCHLORIDE - Restr	icted see terms below		
Tab extended-release 18 mg		30	Concerta
· · · · · · · · · · · · · · · · · · ·	7.75		Methylphenidate ER -
			Teva
	65.44	30	Concerta
	11.45		Methylphenidate ER -
Table a deadad a deada a 20 mm	71.00		Teva
Tab extended-release 36 mg		30	Concerta
	15.50		Methylphenidate ER - Teva
	86 24	30	Concerta
	22.25	00	Methylphenidate ER -
	22.20		Teva
Tab immediate-release 5 mg		30	Rubifen
Tab immediate-release 10 mg		30	Ritalin
-			Rubifen
Tab immediate-release 20 mg	7.85	30	Rubifen
Tab sustained-release 20 mg		30	Rubifen SR
Cap modified-release 10 mg		30	Ritalin LA
Cap modified-release 20 mg		30	Ritalin LA
Cap modified-release 30 mg		30	Ritalin LA
Cap modified-release 40 mg		30	Ritalin LA
→ Restricted (RS1294)			
Initiation – ADHD (immediate-release and sustai	ned-release formulations)		
Paediatrician or psychiatrist	in Discussion discussion in DO		
Patient has ADHD (Attention Deficit and Hyperactiv		IVI-IV Or	ICD 10 criteria.
Initiation – Narcolepsy (immediate-release and s Neurologist or respiratory specialist	sustained-release formulations)		
Re-assessment required after 24 months			
Patient suffers from narcolepsy.			
Continuation – Narcolepsy (immediate-release a	nd sustained-release formulations)		
Neurologist or respiratory specialist			
Re-assessment required after 24 months			
The treatment remains appropriate and the patient i	s benefiting from treatment.		
Initiation – Extended-release and modified-relea			
Paediatrician or psychiatrist			
Both:			
1 Patient has ADHD (Attention Deficit and Hyp	eractivity Disorder), diagnosed accordin	g to DSN	M-IV or ICD 10 criteria; and
2 Either:			
2.1 Patient is taking a currently listed forr			
	en effective due to significant administrat		
2.2 There is significant concern regarding	g the fisk of diversion of abuse of infined	late-rele	ase methylphenidate
hydrochloride.			
MODAFINIL – Restricted see terms below	_		
↓ Tab 100 mg - 5% DV Mar-22 to 2024		60	Modavigil
→ Restricted (RS1803)			
Initiation – Narcolepsy			
Neurologist or respiratory specialist			
Re-assessment required after 24 months			
All of the following:			

continued...

	Price		Brand or
(ex ma	n. excl. (GST)	Generic
	\$	Per	Manufacturer

continued...

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
 - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 3 Either:
 - 3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
 - 3.2 Methylphenidate and dexamphetamine are contraindicated.

Continuation – Narcolepsy

Neurologist or respiratory specialist

Re-assessment required after 24 months

The treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

Tab 5 mg Tab 10 mg	90 90	Donepezil-Rex Donepezil-Rex
RIVASTIGMINE - Restricted see terms below Patch 4.6 mg per 24 hour - 5% DV Feb-22 to 2024	 30	Rivastigmine Patch
 Patch 9.5 mg per 24 hour - 5% DV Feb-22 to 2024 Pactriated (DS1426) 	 30	BNM 5 Rivastigmine Patch BNM 10

Restricted (RS1436)

Initiation

Re-assessment required after 6 months Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Continuation

Re-assessment required after 12 months Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

Treatments for Substance Dependence		
BUPRENORPHINE WITH NALOXONE – Restricted see terms below I Tab 2 mg with naloxone 0.5 mg – 5% DV Dec-22 to 2025 11.76	28	Buprenorphine Naloxone BNM
Tab 8 mg with naloxone 2 mg – 5% DV Dec-22 to 2025	28	Buprenorphine Naloxone BNM
➡ Restricted (RS1172)		

Initiation – Detoxific

All of the following:

140

1 Patient is opioid dependent; and

	(ex man.	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
continued					
2 Patient is currently engaged with an opioid treatment service				/ of Hea	lth; and
3 Prescriber works in an opioid treatment service approved by	the Ministry	of Hea	alth.		
nitiation – Maintenance treatment					
All of the following:					
1 Patient is opioid dependent; and					
2 Patient will not be receiving methadone; and					huidhe Ministere of Liesläh.
3 Patient is currently enrolled in an opioid substitution treatmen and	nt program ir	n a ser	vice a	oprovea	by the Ministry of Health;
 4 Prescriber works in an opioid treatment service approved by 	the Ministry	of Ho	alth		
	une ministry	01116	ann.		
BUPROPION HYDROCHLORIDE					_ .
Tab modified-release 150 mg		11.00)	30	Zyban
DISULFIRAM					
Tab 200 mg – 5% DV Nov-21 to 2024		236.40)	100	Antabuse
NALTREXONE HYDROCHLORIDE - Restricted see terms below					
Tab 50 mg – 5% DV Dec-23 to 2026		. 83.33	3	30	Naltraccord
→ Restricted (RS1173)					
nitiation – Alcohol dependence					
Both:					
1 Patient is currently enrolled, or is planned to be enrolled, in a	a recognised	comp	rehens	sive trea	tment programme for alcoh
dependence; and			ا به مادانه		ashal and Durin Consist
 Nattrexone is to be prescribed by, or on the recommendation 	i oi, a priysic	lan wo	JIKING	in an Ai	conor and Drug Service.
Initiation – Constipation For the treatment of opioid-induced constipation.					
NICOTINE – Some items restricted see terms below Patch 7 mg per 24 hours		10.17	1	28	Habitrol
Patch 14 mg per 24 hours				20 28	Habitrol
Patch 21 mg per 24 hours				28	Habitrol
 Oral spray 1 mg per dose 			-	20	e.g. Nicorette QuickMis
					Mouth Spray
Lozenge 1 mg		19.76	6	216	Habitrol
Lozenge 2 mg				216	Habitrol
Soln for inhalation 15 mg cartridge					e.g. Nicorette Inhalator
Gum 2 mg		21.42	2	204	Habitrol (Fruit)
					Habitrol (Mint)
Gum 4 mg		24.17	7	204	Habitrol (Fruit)
- Destricted (DC1072)					Habitrol (Mint)
→ Restricted (RS1873) nitiation					
Any of the following:					
 For perioperative use in patients who have a 'nil by mouth' in 	struction: or				
2 For use within mental health inpatient units; or					
3 Patient would be admitted to a mental health inpatient unit, b	out is unable	to due	to CC)VID-19	self-isolation requirement.
4 For acute use in agitated patients who are unable to leave th					sea lookaton roquiomont,
VARENICLINE – Restricted see terms on the next page					

t	Tab 0.5 mg × 11 and 1 mg × 42 - 5% DV Jan-22 to 2024 1	16.67	53	Varenicline Pfizer
t	Tab 1 mg - 5% DV Jan-22 to 2024 1	17.62	56	Varenicline Pfizer

Price			Brand or
(ex man. excl	GST		Generic
\$		Per	Manufacturer

→ Restricted (RS1702)

Initiation

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and

3 Either:

- 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
- 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BENDAMUSTINE HYDROCHLORIDE - Restricted see ↓ Inj 25 mg vial - 5% DV Sep-21 to 2024 ↓ inj 100 mg vial - 5% DV Sep-21 to 2024 → Restricted (RS1917) Initiation - treatment naive CLL			1 1	Ribomustin Ribomustin
 All of the following: 1 The patient has Binet stage B or C, or progressive 2 The patient is chemotherapy treatment naive; and 3 The patient is unable to tolerate toxicity of full-dose 4 Patient has ECOG performance status 0-2; and 5 Patient has a Cumulative Illness Rating Scale (CIF 6 Bendamustine is to be administered at a maximum 6 cycles. 	PFCR; and S) score of < 6; and dose of 100 mg/m ² or	n days 1 and	d 2 every -	4 weeks for a maximum of
Note: 'Chronic lymphocytic leukaemia (CLL)' includes sm to comprise a known standard therapeutic chemotherapy Initiation – Indolent, Low-grade lymphomas				rapy treatment is considerec
Re-assessment required after 9 months				
All of the following:				
 The patient has indolent low grade NHL requiring t 				
2 Patient has a WHO performance status of 0-2; and				
3 Any of the following:				
3.1 Both:				
3.1.1 Patient is treatment naive; and3.1.2 Bendamustine is to be administered CD20+); or	for a maximum of 6 c	cycles (in co	mbination	with rituximab when
3.2 Both:				
3.2.1 Patient is refractory to or has relaps chemo-immunotherapy regimen; an	d			-
3.2.2 Bendamustine is to be administered	in combination with or	omutuzumat	o ior a ma	ximum of 6 cycles; or
3.3 All of the following:	andomusting thereas u	and		
 3.3.1 The patient has not received prior be 3.3.2 Bendamustine is to be administered rituximab when CD20+); and 0.0.2 Detication bad a difference in the patient bad a structure i	for a maximum of 6 cy	ycles in rela		ents (in combination with
3.3.3 Patient has had a rituximab treatme				imphysication (notion to
3.4 Bendamustine is to be administered as more	iomerapy for a maxim		es in filux	imab refractory patients.
Continuation – Indolent, Low-grade lymphomas Re-assessment required after 9 months				
Either:				
1 Both:				
1.1 Patient is refractory to or has relapsed with	n 12 months of rituxim	ab in combi	nation wit	h bendamustine; and

- 1.2 Bendamustine is to be administered in combination with obinutuzumab for a maximum of 6 cycles; or
- 2 Both:
 - 2.1 Patients have not received a bendamustine regimen within the last 12 months; and
 - 2.2 Either:

continued...

	Price (ex man. excl \$. GST)	Per	Brand or Generic Manufacturer
ontinued				
2.2.1 Both:				
2.2.1.1 Bendamustine is to be administered for a with rituximab when CD20+); and		•	•	
2.2.1.2 Patient has had a rituximab treatment-fre				,
2.2.2 Bendamustine is to be administered as a mono patients.	otherapy for a ma	aximum	of 6 cyc	les in rituximab refractory
lote: 'indolent, low-grade lymphomas' includes follicular, mantle cell nacroglobulinaemia.	l, marginal zone	and lym	nphoplas	smacytic/ Waldenström's
nitiation – Hodgkin's lymphoma*				
Relevant specialist or medical practitioner on the recommendation of	a relevant spec	ialist		
imited to 6 months treatment				
Il of the following:				
1 Patient has Hodgkin's lymphoma requiring treatment; and 2 Patient has a ECOG performance status of 0-2; and				
3 Patient has received one prior line of chemotherapy; and				
4 Patient's disease relapsed or was refractory following prior ch				
5 Bendamustine is to be administered in combination with gend		orelbine	(BeGeV	 at a maximum dose of no
greater than 90 mg/m2 twice per cycle, for a maximum of four	CYCIES.			
lote: Indications marked with * are unapproved indications.				
BUSULFAN			400	Malanan
Tab 2 mg Inj 6 mg per ml, 10 ml ampoule		20	100	Myleran
ARMUSTINE Inj 100 mg vial – 5% DV Sep-22 to 2025	710 (0	1	BICNU
		0	1	DICINU
HLORAMBUCIL Tab 2 mg				
CYCLOPHOSPHAMIDE				
Tab 50 mg - 5% DV Jan-22 to 2024	145 ()()	50	Cyclonex
Inj 1 g vial – 5% DV Dec-21 to 2024			1	Endoxan
Inj 2 g vial – 5% DV Dec-21 to 2024			1	Endoxan
FOSFAMIDE				
Inj 1 g vial)0	1	Holoxan
Inj 2 g vial		00	1	Holoxan
OMUSTINE				
Cap 10 mg		59	20	Ceenu
Cap 40 mg		5	20	Ceenu
/ELPHALAN				
Tab 2 mg				
Inj 50 mg vial – 5% DV Dec-23 to 2026		25	1	Melpha
HIOTEPA				
Inj 15 mg vial				
Inj 100 mg vial				
Anthracyclines and Other Cytotoxic Antibiotics				
BLEOMYCIN SULPHATE				
BLEOMYCIN SULPHATE Inj 15,000 iu vial		6	1	DBL Bleomycin Sulfate
BLEOMYCIN SULPHATE			1	DBL Bleomycin Sulfate

	Price		Brand or
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer
DAUNORUBICIN			
Inj 2 mg per ml, 10 ml vial	171.93	1	Pfizer
Inj 20 mg vial	1 495 00	10	Daunorubicin Zentiva
	1,433.00	10	Daunorubicin Zentiva
DOXORUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial			
Inj 2 mg per ml, 25 ml vial	11.50	1	Doxorubicin Ebewe
Inj 50 mg vial			
Inj 2 mg per ml, 50 ml vial		1	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial - 5% DV Jan-22 to 2024	69.99	1	Doxorubicin Ebewe
EPIRUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial		1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial		1	Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial - 5% DV Jan-22 to 2024		1	Epirubicin Ebewe
		•	
	400 74		7
Inj 5 mg vial		1	Zavedos
Inj 10 mg vial		1	Zavedos
MITOMYCIN C			
Inj 5 mg vial			
Inj 20 mg vial	1,250.00	1	Teva
MITOZANTRONE			
Inj 2 mg per ml, 10 ml vial	97 50	1	Mitozantrone Ebewe
Antimetabolites			
AZACITIDINE – Restricted see terms below			
Inj 100 mg vial - 5% DV Dec-21 to 2024	75.06	1	Azacitidine Dr Reddy's
→ Restricted (RS1904)			-
nitiation			
Haematologist			
Re-assessment required after 12 months			
All of the following:			
1 Any of the following:			
1.1 The patient has International Prognostic Scoring Syst	om (IPSS) intermediate	2 or high	a rick myolodycplactic
syndrome; or			Thisk myelodyspiastic
1.2 The patient has chronic myelomonocytic leukaemia (1	0% 20% marrow blacts	without	muoloproliforativo dicordor):
	0 /0-29 /0 manow biasis	without	inyelopiolilerative disorder),
Or 1.2. The potient has south musicial louksomic with 00.200	blacta and multi linear	a duanta	ain annording to Marid
1.3 The patient has acute myeloid leukaemia with 20-30%	o biasis and multi-inteag	e uyspia	isia, according to world
•			
	nths.		
Haematologist or medical practitioner on the recommendation of a h	aematologist		
Re-assessment required after 12 months			
Both:			
Health Organisation Classification (WHO); and 2 The patient has performance status (WHO/ECOG) grade 0-2 3 The patient has an estimated life expectancy of at least 3 mo Continuation			

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

	Price (ex man. excl. GS		Brand or Generic
	\$	Per	Manufacturer
CAPECITABINE			
Tab 150 mg - 5% DV Jan-24 to 2025	9.80	60	Capecitabine Viatris
	10.00		Capercit
Tab 500 mg - 5% DV Jan-24 to 2025		120	Capecitabine Viatris
	49.00		Capercit
(Capercit Tab 150 mg to be delisted 1 January 2024)			
(Capercit Tab 500 mg to be delisted 1 January 2024)			
CLADRIBINE			
lnj 2 mg per ml, 5 ml vial			
Inj 1 mg per ml, 10 ml vial	749.96	1	Leustatin
CYTARABINE			
Inj 20 mg per ml, 5 ml vial	472.00	5	Pfizer
		1	Pfizer
Inj 100 mg per ml, 20 ml vial	40.00	I	
LUDARABINE PHOSPHATE			
Tab 10 mg		20	Fludara Oral
Inj 50 mg vial – 5% DV Jan-23 to 2025	634.00	5	Fludarabine Ebewe
FLUOROURACIL			
Inj 50 mg per ml, 20 ml vial – 5% DV Feb-22 to 2024		1	Fluorouracil Accord
Inj 50 mg per ml, 100 ml vial - 5% DV Feb-22 to 2024	29.44	1	Fluorouracil Accord
GEMCITABINE			
Inj 10 mg per ml, 100 ml vial	15 89	1	Gemcitabine Ebewe
	05.00	05	Development of
Tab 50 mg - 5% DV Dec-22 to 2025		25	Puri-nethol
Oral suspension 20 mg per ml		100 ml	Allmercap
→ Restricted (RS1635) nitiation			
Paediatric haematologist or paediatric oncologist			
Re-assessment required after 12 months			
The patient requires a total dose of less than one full 50 mg tablet per da Continuation	iy.		
Paediatric haematologist or paediatric oncologist			
Re-assessment required after 12 months			
The patient requires a total dose of less than one full 50 mg tablet per da	iy.		
METHOTREXATE			
Tab 2.5 mg – 5% DV Jan-22 to 2024	9 98	90	Trexate
Tab 10 mg - 5% DV Jan-22 to 2024		90	Trexate
Inj 2.5 mg per ml, 2 ml vial		50	
Inj 7.5 mg prefilled syringe	14.61	1	Methotrexate Sandoz
Inj 10 mg prefilled syringe		1	Methotrexate Sandoz
Inj 15 mg prefilled syringe		1	Methotrexate Sandoz
Inj 20 mg prefilled syringe		1	Methotrexate Sandoz
Inj 25 mg prefilled syringe		1	Methotrexate Sandoz
Inj 30 mg prefilled syringe		1	Methotrexate Sandoz
Inj 25 mg per ml, 2 ml vial		5	Methotrexate DBL
		5	Onco-Vial
Inj 25 mg per ml, 20 ml vial	45.00	1	DBL Methotrexate
		-	Onco-Vial
Inj 100 mg per ml, 10 ml vial		1	Methotrexate Ebewe
Ini 100 mg per ml 50 ml vial - 5% DV Dec-23 to 2026		1	Methotrexate Ebewe

1

Methotrexate Ebewe

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PEMETREXED – Restricted see terms below			
Inj 100 mg vial	60.89	1	Juno Pemetrexed
Inj 500 mg vial		1	Juno Pemetrexed
➡ Restricted (RS1596)			

Initiation – Mesothelioma

Re-assessment required after 8 months

Both:

- 1 Patient has been diagnosed with mesothelioma; and
- 2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

Continuation - Mesothelioma

Re-assessment required after 8 months

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

Initiation - Non small cell lung cancer

Re-assessment required after 8 months

Both:

- 1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient has chemotherapy-naïve disease; and
 - 2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or
 - 2.2 All of the following:
 - 2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
 - 2.2.2 Patient has not received prior funded treatment with pemetrexed; and
 - 2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

Continuation - Non small cell lung cancer

Re-assessment required after 8 months

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

THIOGUANINE

Tab 40 mg

Other Cytotoxic Agents

AMSACRINE Inj 50 mg per ml, 1.5 ml ampoule Inj 75 mg		
ANAGRELIDE HYDROCHLORIDE Cap 0.5 mg		
ARSENIC TRIOXIDE Inj 1 mg per ml, 10 ml vial	10	Phenasen
BORTEZOMIB – Restricted see terms on the next page ↓ Inj 3.5 mg vial – 5% DV May-23 to 2025	1	DBL Bortezomib

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
→ Restricted (RS1725)				
nitiation – multiple myeloma/amyloidosis				
Either:				
 The patient has symptomatic multiple myeloma; or The patient has symptomatic systemic AL amyloidosis. 				
DACARBAZINE				
Inj 200 mg vial		.72.11	1	DBL Dacarbazine
ETOPOSIDE				
Cap 50 mg		340.73	20	Vepesid
Cap 100 mg			10	Vepesid
Inj 20 mg per ml, 5 ml vial		7.90	1	Rex Medical
ETOPOSIDE (AS PHOSPHATE)				
Inj 100 mg vial		.40.00	1	Etopophos
HYDROXYUREA [HYDROXYCARBAMIDE]				
Cap 500 mg - 5% DV Dec-23 to 2026		20 72	100	Devatis
BRUTINIB – Restricted see terms below			100	Borallo
Tab 140 mg	3 /	017.00	30	Imbruvica
Tab 420 mg			30	Imbruvica
→ Restricted (RS1933)		002.00	00	Indiavida
nitiation – chronic lymphocytic leukaemia (CLL)				
Re-assessment required after 6 months				
All of the following:				
1 Patient has chronic lymphocytic leukaemia (CLL) requiring	therapy; and			
2 Patient has not previously received funded ibrutinib; and				
3 Ibrutinib is to be used as monotherapy; and				
4 Any of the following:				
4.1 Both:				
4.1.1 There is documentation confirming that patie				
4.1.2 Patient has experienced intolerable side effe	ects with venet	oclax monot	herapy;	or
4.2 All of the following:				
4.2.1 Patient has received at least one prior immu	inochemothera	py for CLL;	and	
4.2.2 Patient's CLL has relapsed within 36 month				
4.2.3 Patient has experienced intolerable side effe	ects with venet	oclax in corr	bination	with rituximab regimen; o
4.3 Patient's CLL is refractory to or has relapsed within	36 months of	a venetocla	x regime	en.
Continuation – chronic lymphocytic leukaemia (CLL)				
Re-assessment required after 12 months Both:				
1 No evidence of clinical disease progression; and				
2 The treatment remains appropriate and the patient is bene				
Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymp	hocytic lympho	oma (SLL) ar	nd B-cell	l prolymphocytic leukaemia
B-PLL)*. Indications marked with * are Unapproved indications.	-			
RINOTECAN HYDROCHLORIDE				
Int OO man man mil E mil viel _ E0/ DV Man OO to OOO4		F0 F7		

Inj 20 mg per ml, 5 ml vial – 5% DV Mar-22 to 2024	Inj 20 mg per ml, 5 ml vial	- 5% DV Mar-22 to 2024		1	Accord
--	-----------------------------	------------------------	--	---	--------

148

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LENALIDOMIDE – Restricted see terms below			
Cap 5 mg	5,122.76	28	Revlimid
Cap 10 mg		21	Revlimid
	6,207.00	28	Revlimid
Cap 15 mg	5,429.39	21	Revlimid
	7,239.18	28	Revlimid
	7,627.00	21	Revlimid

➡ Restricted (RS1836)

Initiation - Relapsed/refractory disease

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Patient has not previously been treated with lenalidomide; and
- 3 Either:
 - 3.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
 - 3.2 Both:
 - 3.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 3.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 4 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Continuation - Relapsed/refractory disease

Haematologist

Re-assessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Initiation - Maintenance following first-line autologous stem cell transplant (SCT)

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has newly diagnosed symptomatic multiple myeloma and has undergone first-line treatment that included an autologous stem cell transplantation; and
- 2 Patient has at least a stable disease response in the first 100 days after transplantation; and
- 3 Lenalidomide maintenance is to be commenced within 6 months of transplantation; and
- 4 Lenalidomide to be administered at a maximum dose of 15 mg/day.

Continuation - Maintenance following first-line autologous stem cell transplant (SCT)

Haematologist

Re-assessment required after 6 months Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

OL	APARIB – Restricted see terms on the next page		
t	Tab 100 mg	56	Lynparza
t	Tab 150 mg	56	Lynparza

Price			Brand or
(ex man. excl. G	GST)		Generic
\$	Pe	er	Manufacturer

→ Restricted (RS1925)

Initiation – Ovarian cancer

Medical oncologist

Re-assessment required after 12 months

All of the following:

- 1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and
- 2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and
- 3 Either:
 - 3.1 All of the following:
 - 3.1.1 Patient has newly diagnosed, advanced disease; and
 - 3.1.2 Patient has received one line** of previous treatment with platinum-based chemotherapy; and
 - 3.1.3 Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen; or
 - 3.2 All of the following:
 - 3.2.1 Patient has received at least two lines** of previous treatment with platinum-based chemotherapy; and
 - 3.2.2 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy; and
 - 3.2.3 Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen; and
 - 3.2.4 Patient has not previously received funded olaparib treatment; and
- 4 Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen; and
- 5 Treatment to be administered as maintenance treatment; and
- 6 Treatment not to be administered in combination with other chemotherapy.

Continuation - Ovarian cancer

Medical oncologist

Re-assessment required after 12 months

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from treatment; and
- 2 Either:
 - 2.1 No evidence of progressive disease; or
 - 2.2 Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion; and
- 3 Treatment to be administered as maintenance treatment; and
- 4 Treatment not to be administered in combination with other chemotherapy; and
- 5 Either:
 - 5.1 Both:
 - 5.1.1 Patient has received one line** of previous treatment with platinum-based chemotherapy; and
 - 5.1.2 Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years; or
 - 5.2 Patient has received at least two lines** of previous treatment with platinum-based chemotherapy.

Notes: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component. **A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

PEGASPARGASE - Restricted see terms on the next page

Inj 750 iu per ml, 5 ml vial	3,455.00	1	Oncaspar LYO
------------------------------	----------	---	--------------

ONCOLOGY	AGENTS AND II	MMUNC	SUPPRESSANTS
	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
→ Restricted (RS1788)			
Initiation – Newly diagnosed ALL			
Limited to 12 months treatment			
Both:			
1 The patient has newly diagnosed acute lymphoblastic leukaer			
2 Pegaspargase to be used with a contemporary intensive multi	-agent chemotherapy	treatmen	t protocol.
Initiation – Relapsed ALL			
Limited to 12 months treatment Both:			
1 The patient has relapsed acute lymphoblastic leukaemia; and	agent chemotherapy	tractmon	t protocol
 Pegaspargase to be used with a contemporary intensive multi Initiation – Lymphoma 	-agent chemotherapy	liealinei	
Limited to 12 months treatment			
Patient has lymphoma requiring L-asparaginase containing protocol (
PENTOSTATIN [DEOXYCOFORMYCIN]	c.g. OMILL).		
Inj 10 mg vial			
	000 00	50	Natulan
Cap 50 mg		50	Natulali
TEMOZOLOMIDE – Restricted see terms below	0.10	5	Townson
 Cap 5 mg Cap 20 mg 		5 5	Temaccord Temaccord
Cap 100 mg		5	Temaccord
Cap 140 mg		5	Temaccord
↓ Cap 250 mg		5	Temaccord
→ Restricted (RS1645)			
Initiation – High grade gliomas			
Re-assessment required after 12 months			
All of the following:			
1 Either:			
1.1 Patient has newly diagnosed glioblastoma multiforme;1.2 Patient has newly diagnosed anaplastic astrocytoma*;			
 2 Temozolomide is to be (or has been) given concomitantly with 3 Following concomitant treatment temozolomide is to be used dose of 200 mg/m² per day. 	radiotherapy; and	ays treatm	nent per cycle at a maximum
8 1 9			
Continuation – High grade gliomas Re-assessment required after 12 months Either:			
1 Both:			
1.1 Patient has glioblastoma multiforme; and			

- 1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
- 2 All of the following:
 - 2.1 Patient has anaplastic astrocytoma*; and
 - 2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
 - 2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

continued...

Initiation - Neuroendocrine tumours

Re-assessment required after 9 months

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
- 4 Temozolomide to be discontinued at disease progression.

Continuation - Neuroendocrine tumours

Re-assessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Initiation - ewing's sarcoma

Re-assessment required after 9 months

Patient has relapse or refractory Ewing's sarcoma.

Continuation - ewing's sarcoma

Re-assessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not funded for the treatment of relapsed high grade glioma.

THALIDOMIDE - Restricted see terms below

t	Cap 50 mg	28	Thalomid
t	Cap 100 mg756.00	28	Thalomid

➡ Restricted (RS1192)

Initiation

Re-assessment required after 12 months

Any of the following:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*; or
- 3 The patient has erythema nodosum leprosum.

Continuation

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen

Indication marked with * is an unapproved indication

TRETINOIN

Cap 10 mg		100	Vesanoid
VENETOCLAX - Restricted see terms on the next page			
	1,771.86	42	Venclexta
↓ Tab 10 mg		2	Venclexta
,	95.78	14	Venclexta
↓ Tab 50 mg	239.44	7	Venclexta
I Tab 100 mg		120	Venclexta
(Vanalayta Tab 10 mg to be delicted 1 December 2022)			

(Venclexta Tab 10 mg to be delisted 1 December 2023)

	Price		Brand or
(ex	k man. excl.		Generic
	\$	Per	Manufacturer

➡ Restricted (RS1713)

Initiation – relapsed/refractory chronic lymphocytic leukaemia

Haematologist

Re-assessment required after 7 months

All of the following:

- 1 Patient has chronic lymphocytic leukaemia requiring treatment; and
- 2 Patient has received at least one prior therapy for chronic lymphocytic leukaemia; and
- 3 Patient has not previously received funded venetoclax; and
- 4 The patient's disease has relapsed within 36 months of previous treatment; and
- 5 Venetoclax to be used in combination with six 28-day cycles of rituximab commencing after the 5-week dose titration schedule with venetoclax; and
- 6 Patient has an ECOG performance status of 0-2.

Continuation - relapsed/refractory chronic lymphocytic leukaemia

Haematologist

Re-assessment required after 6 months Both:

- 1 Treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment; and
- 2 Venetoclax is to be discontinued after a maximum of 24 months of treatment following the titration schedule unless earlier discontinuation is required due to disease progression or unacceptable toxicity.

Initiation - previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation*

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has previously untreated chronic lymphocytic leukaemia; and
- 2 There is documentation confirming that patient has 17p deletion by FISH testing or TP53 mutation by sequencing; and
- 3 Patient has an ECOG performance status of 0-2.

Continuation – previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation* Haematologist

Re-assessment required after 6 months

The treatment remains clinically appropriate and the patient is benefitting from and tolerating treatment.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma (SLL)* and B-cell prolymphocytic leukaemia (B-PLL)*. Indications marked with * are unapproved indications.

Platinum Compounds

CARBOPLATIN Inj 10 mg per ml, 45 ml vial45.20	1	Carboplatin Ebewe
CISPLATIN Inj 1 mg per ml, 100 ml vial - 5% DV Mar-22 to 2024	1	DBL Cisplatin
OXALIPLATIN Inj 5 mg per ml, 20 ml vial – 5% DV Oct-23 to 2024	1	Alchemy Oxaliplatin
46.32 (Oxaliplatin Accord Inj 5 mg per ml, 20 ml vial to be delisted 1 October 2023)		Oxaliplatin Accord
Protein-Tyrosine Kinase Inhibitors		
ALECTINIB – Restricted see terms on the next page Cap 150 mg7,935.00	224	Alecensa

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

➡ Restricted (RS1712)

Initiation

Re-assessment required after 6 months

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-small cell lung cancer; and
- 2 There is documentation confirming that the patient has an ALK tyrosine kinase gene rearrangement using an appropriate ALK test; and
- 3 Patient has an ECOG performance score of 0-2.

Continuation

Re-assessment required after 6 months Both:

- 1 No evidence of progressive disease according to RECIST criteria; and
- 2 The patient is benefitting from and tolerating treatment.

DASATINIB - Restricted see terms below

t	Tab 20 mg3,774.06	60	Sprycel
	Tab 50 mg	60	Sprycel
t	Tab 70 mg	60	Sprycel

→ Restricted (RS1685)

Initiation

Haematologist or any relevant practitioner on the recommendation of a haematologist *Re-assessment required after 6 months*

Any of the following:

- 1 Both:
 - 1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and
 - 1.2 Maximum dose of 140 mg/day; or
- 2 Both:
 - 2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
 - 2.2 Maximum dose of 140 mg/day; or
- 3 All of the following:
 - 3.1 The patient has a diagnosis of CML in chronic phase; and
 - 3.2 Maximum dose of 100 mg/day; and
 - 3.3 Any of the following:
 - 3.3.1 Patient has documented treatment failure* with imatinib; or
 - 3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
 - 3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
 - 3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

Continuation

154

Haematologist or any relevant practitioner on the recommendation of a haematologist

Re-assessment required after 6 months

All of the following:

- 1 Lack of treatment failure while on dasatinib*; and
- 2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up https://www.cancertrialsnz.ac.nz/kiss/

EF	RLOTINIB – Restricted see terms on the next page		
t	Tab 100 mg	30	Alchemy
t	Tab 150 mg	30	Alchemy

e.g. Brand indicates brand example only. It is not a contracted product.

(6	Price ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
→ Restricted (RS1885)			
Initiation			
Re-assessment required after 4 months All of the following:			
1 Patient has locally advanced or metastatic, unresectable, non-squa	mous Non Small		Canaar (NECLO); and
2 There is documentation confirming that the disease expresses acti 3 Either:			
3.1 Patient is treatment naive; or 3.2 Both:			
3.2.1 The patient has discontinued getitinib due to intolera 3.2.2 The cancer did not progress while on gefitinib; and	ance; and		
4 Erlotinib is to be given for a maximum of 3 months.			
Continuation			
Re-assessment required after 6 months Both:			
 Radiological assessment (preferably including CT scan) indicates Erlotinib is to be given for a maximum of 3 months. 	NSCLC has not pr	ogressed	; and
Continuation – pandemic circumstances			
Re-assessment required after 6 months			
All of the following:			
 The patient is clinically benefiting from treatment and continued tre Erlotinib to be discontinued at progression; and 	eatment remains ap	propriate	; and
3 The regular renewal requirements cannot be met due to COVID-19	e constraints on the	e health s	ector.
GEFITINIB – Restricted see terms below			
↓ Tab 250 mg	918.00	30	Iressa
→ Restricted (RS1887)			
Initiation			
Re-assessment required after 4 months All of the following:			
 Patient has locally advanced, or metastatic, unresectable, non-squ Either: 	amous Non Small	Cell Lung	g Cancer (NSCLC); and
2.1 Patient is treatment naive; or 2.2 Both:			
2.2.1 The patient has discontinued erlotinib due to intolera	ance; and		
2.2.2 The cancer did not progress whilst on erlotinib; and 3 There is documentation confirming that disease expresses activati	na mutations of EC		ing kinase; and
4 Gefitinib is to be given for a maximum of 3 months.		ai ii tyioa	
Continuation			
<i>Re-assessment required after 6 months</i> Both:			
 Radiological assessment (preferably including CT scan) indicates Gefitinib is to be given for a maximum of 3 months. 	NSCLC has not pr	ogressed	; and
Continuation – pandemic circumstances			
Re-assessment required after 6 months			
All of the following: 1 The patient is clinically benefiting from treatment and continued tre	atment remains or	nronriato	and .
2 Gefitinib to be discontinued at progression; and	ממחכות ופווומוווס מן	piopilate	, and
3 The regular renewal requirements cannot be met due to COVID-1	e constraints on the	e health s	ector.

	Price (ex man. excl. GST)		Brand or Generic
	\$	Per	Manufacturer
ATINIB MESILATE			
The Glivec brand of imatinib mesilate (supplied by Novartis)			
unresectable and/or metastatic malignant GIST only, see SA	1460 in Section B of the Pl	narmace	utical Schedule
Tab 100 mg	2,400.00	60	Glivec
Restricted (RS1402)			
itiation			
e-assessment required after 12 months			
oth:			
1 Patient has diagnosis (confirmed by an oncologist) of unr	esectable and/or metastatic	maligna	nt gastrointestinal stromal
tumour (GIST); and			
2 Maximum dose of 400 mg/day.			
ontinuation			
e-assessment required after 12 months dequate clinical response to treatment with imatinib (prescriber	determined)		
ote: The Glivec brand of imatinib mesilate (supplied by Novart		under Sr	pecial Authority for natient
ith unresectable and/or metastatic malignant GIST, see SA146	, ,		, ,
Cap 100 mg - 5% DV Dec-23 to 2026		60	Imatinib-Rex
Cap 400 mg - 5% DV Dec-23 to 2026		30	Imatinib-Rex
Glivec Tab 100 mg to be delisted 1 December 2023)		00	
APATINIB – Restricted see terms below			
Tab 250 mg	1 899 00	70	Tykerb
▶ Restricted (RS1828)		10	Tynoid
itiation			
or continuation use only.			
ontinuation			
e-assessment required after 12 months			
Il of the following:			
1 The patient has metastatic breast cancer expressing HEF	R-2 IHC 3+ or ISH+ (includir	ng FISH	or other current technology
and			
2 The cancer has not progressed at any time point during the		st on lap	atinib; and
3 Lapatinib not to be given in combination with trastuzumat	; and		
4 Lapatinib to be discontinued at disease progression.			
ILOTINIB – Restricted see terms below			
Cap 150 mg		120	Tasigna
Cap 200 mg	6,532.00	120	Tasigna
Restricted (RS1437)			
itiation			
aematologist			
e-assessment required after 6 months			
Il of the following:			
 Patient has a diagnosis of chronic myeloid leukaemia (CN Either: 	/IL) in blast crisis, accelerate	ed phase	e, or in chronic phase; and
2.1 Patient has documented CML treatment failure* w2.2 Patient has experienced treatment limiting toxicity	·	ther trea	ment with imatinib; and
3 Maximum nilotinib dose of 800 mg/day; and			

4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
continued			
Continuation			
Haematologist Re-assessment required after 6 months			
All of the following:			
 Lack of treatment failure while on nilotinib as defined by I Nilotinib treatment remains appropriate and the patient is Maximum nilotinib dose of 800 mg/day; and Subsidised for use as monotherapy only. 			
PALBOCICLIB - Restricted see terms below			
 Tab 75 mg Tab 100 mg 		21	Ibrance
 Tab 100 mg Tab 125 mg 	,	21 21	Ibrance Ibrance
→ Restricted (RS1731)		21	Ibrance
Initiation			
Medical oncologist			
Re-assessment required after 6 months			
All of the following:			
 Patient has unresectable locally advanced or metastatic There is documentation confirming disease is hormone-re- 		nogativo	· and
3 Patient has an ECOG performance score of 0-2; and		-negative	, anu
4 Either:			
second or subsequent line setting			
4.1 Disease has relapsed or progressed during prior e4.2 Both:	endocrine therapy; or		
first line setting			
4.2.1 Patient is amenorrhoeic, either naturally or	r induced, with endocrine le	evels cons	sistent with a postmenopausal
state; and 4.2.2 Either:			
4.2.2.1 Patient has not received prior system	mic treatment for metastati	n disaasa	· or
4.2.2.2 All of the following:		0 0130030	, 0
4.2.2.2.1 Patient commenced treatmen 1 April 2020; and	t with palbociclib in combir	nation with	n an endocrine agent prior to
4.2.2.2.2 Patient has not received prior	systemic endocrine treatn	nent for m	etastatic disease; and
4.2.2.2.3 There is no evidence of progr			
	oconto alcoaco, ana		

Continuation

Medical oncologist

Re-assessment required after 12 months

All of the following:

- 1 Treatment must be used in combination with an endocrine partner; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains appropriate and the patient is benefitting from treatment.

Initiation

Re-assessment required after 3 months All of the following:

continued...

Votrient

Votrient

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

continued...

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 All of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
 - 5.2 Haemoglobin level < lower limit of normal; and
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
 - 5.5 Karnofsky performance score of less than or equal to 70; and
 - 5.6 2 or more sites of organ metastasis.

Continuation

Re-assessment required after 3 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

RUXOLITINIB - Restricted see terms below

t	Tab 5 mg	2,500.00	56	Jakavi
	Tab 10 mg		56	Jakavi
	Tab 15 mg		56	Jakavi
	Tab 20 mg		56	Jakavi

→ Restricted (RS1726)

Initiation

Haematologist

Re-assessment required after 12 months All of the following:

- - 1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
 - 2 Either:
 - 2.1 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; or
 - 2.2 Both:
 - 2.2.1 A classification of risk of intermediate-1 myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
 - 2.2.2 Patient has severe disease-related symptoms that are resistant, refractory or intolerant to available therapy; and
 - 3 A maximum dose of 20 mg twice daily is to be given.

	Price (ex man. excl. GST)	Der	Brand or Generic Monufacturer
	\$	Per	Manufacturer
continued			
Continuation Relevant specialist or medical practitioner on the recommendatio	n of a Relevant specialist		
Re-assessment required after 12 months	n or a molevant specialist		
Both:			
1 The treatment remains appropriate and the patient is bene	fiting from treatment; and		
2 A maximum dose of 20 mg twice daily is to be given.	Ç .		
SUNITINIB – Restricted see terms below			
Cap 12.5 mg - 5% DV Jul-22 to 2024		28	Sunitinib Pfizer
Cap 25 mg - 5% DV Jul-22 to 2024		28	Sunitinib Pfizer
Cap 50 mg - 5% DV Jul-22 to 2024		28	Sunitinib Pfizer
→ Restricted (RS1886)			
Initiation – RCC			
Re-assessment required after 3 months			
All of the following:			
 The patient has metastatic renal cell carcinoma; and Any of the following: 			
2.1 The patient is treatment naive; or			
2.2 The patient has only received prior cytokine treatm	ent: or		
2.3 The patient has only received prior treatment with a		hin the c	confines of a bona fide clinic
trial which has Ethics Committee approval; or	0 0		
2.4 Both:			
2.4.1 The patient has discontinued pazopanib wit	•	atment	due to intolerance; and
2.4.2 The cancer did not progress whilst on pazo			
3 The patient has good performance status (WHO/ECOG gr	ade 0-2); and		
4 The disease is of predominant clear cell histology; and			
5 All of the following:	that many and		
5.1 Lactate dehydrogenase level > 1.5 times upper lim5.2 Haemoglobin level < lower limit of normal; and	it of normal; and		
5.3 Corrected serum calcium level > 10 mg/dL (2.5 mr	nol/L); and		
5.4 Interval of < 1 year from original diagnosis to the st		d	
5.5 Karnofsky performance score of less than or equal		-	
5.6 2 or more sites of organ metastasis; and			
6 Sunitinib to be used for a maximum of 2 cycles.			
Notes: RCC - Sunitinib treatment should be stopped if disease plant	rogresses.		
Poor prognosis patients are defined as having at least 3 of criteria	a 5.1-5.6. Intermediate pro	gnosis p	patients are defined as havir
1 or 2 of criteria 5.1-5.6.			
Continuation – RCC			
Re-assessment required after 3 months Both:			
1 No evidence of disease progression; and			
2 The treatment remains appropriate and the patient is bene	fiting from treatment		
nitiation – GIST	nung nom usalment.		
Re-assessment required after 3 months			
Both:			
 The sector the second stability of the second stability of the sector to second stability of the second stability			

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation - GIST

Re-assessment required after 6 months

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Continuation – GIST pandemic circumstances

Re-assessment required after 6 months

All of the following:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 3 Sunitinib is to be discontinued at progression; and
- 4 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Taxanes

DOCETAXEL Inj 10 mg per ml, 8 ml vial – 5% DV Dec-23 to 2026	24.91	1	DBL Docetaxel
PACLITAXEL			
Inj 6 mg per ml, 5 ml vial4	17.30	5	Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial2	24.00	1	Paclitaxel Ebewe
Inj 6 mg per ml, 25 ml vial2	26.69	1	Paclitaxel Ebewe
Inj 6 mg per ml, 50 ml vial4	14.00	1	Paclitaxel Ebewe

Treatment of Cytotoxic-Induced Side Effects

CALCIUM FOLINATE		
Tab 15 mg	10	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml ampoule		
Inj 10 mg per ml, 5 ml ampoule	5	Calcium Folinate Ebewe
Inj 10 mg per ml, 5 ml vial7.28	1	Calcium Folinate Sandoz
Inj 10 mg per ml, 10 ml vial9.49	1	Calcium Folinate Sandoz
Inj 10 mg per ml, 30 ml vial22.51	1	Calcium Folinate Ebewe
Inj 10 mg per ml, 35 ml vial25.14	1	Calcium Folinate Sandoz
Inj 10 mg per ml, 100 ml vial72.00	1	Calcium Folinate Sandoz
DEXRAZOXANE - Restricted see terms on the next page		
↓ Inj 500 mg		e.g. Cardioxane

t Item restricted (see → above); t Item restricted (see → below) e.g. Brand indicates brand example only. It is not a contracted product.

(ex	Price man. excl. GST) \$	Per	Brand or Generic Manufacturer
→ Restricted (RS1695)			
initiation			
Medical oncologist, paediatric oncologist, haematologist or paediatric haema	atologist		
All of the following:	-		
1 Patient is to receive treatment with high dose anthracycline given wit	h curative inten	t; and	
2 Based on current treatment plan, patient's cumulative lifetime dose of equivalent or greater; and	f anthracycline	will excee	ed 250mg/m2 doxorubicin
3 Dexrazoxane to be administered only whilst on anthracycline treatme	nt and		
4 Either:	in, and		
4.1 Treatment to be used as a cardioprotectant for a child or your	na adult: or		
4.2 Treatment to be used as a cardioprotectant for secondary ma			
	iighanoy.		
MESNA	011.00	50	Line and the second
Tab 400 mg		50	Uromitexan
Tab 600 mg Inj 100 mg per ml, 4 ml ampoule		50 15	Uromitexan Uromitexan
Inj 100 mg per ml, 10 ml ampoule		15	Uromitexan
	407.40	15	UTUTITIEXAIT
Vinca Alkaloids			
/INBLASTINE SULPHATE			
Inj 1 mg per ml, 10 ml vial	270.37	5	Hospira
/INCRISTINE SULPHATE			
Inj 1 mg per ml, 1 ml vial	74 52	5	DBL Vincristine Sulfat
Inj 1 mg per ml, 2 ml vial		5	DBL Vincristine Sulfat
VINORELBINE		•	
Cap 20 mg – 5% DV Oct-23 to 2025	30.00	1	Vinorelbine Te Arai
Cap 30 mg - 5% DV Oct-23 to 2025		1	Vinorelbine Te Arai
Cap 80 mg - 5% DV Oct-23 to 2025		1	Vinorelbine Te Arai
Inj 10 mg per ml, 1 ml vial		1	Navelbine
Inj 10 mg per ml, 5 ml vial		1	Navelbine
Navelbine Inj 10 mg per ml, 1 ml vial to be delisted 1 October 2024)		-	
Navelbine Inj 10 mg per mi, 1 mi vial to be delisted 1 October 2024)			

(Navelbine Inj 10 mg per ml, 5 ml vial to be delisted 1 October 2024)

Endocrine Therapy

ABIRATERONE ACETATE – Restricted see terms below		
I Tab 250 mg4,276.19	120	Zytiga
➡ Restricted (RS1888)		
Initiation		
Medical oncologist, radiation oncologist or urologist		
Re-assessment required after 6 months		
All of the following:		
1 Patient has prostate cancer; and		
2 Patient has metastases; and		
3 Patient's disease is castration resistant; and		
4 Either:		
4.1 All of the following:		

	Pr	rice			Brand or
(ex	x man.	excl.	GST)		Generic
	:	\$		Per	Manufacturer

continued...

- 4.1.1 Patient is symptomatic; and
- 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
- 4.1.3 Patient has ECOG performance score of 0-1; and
- 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
- 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Continuation

Medical oncologist, radiation oncologist or urologist

Re-assessment required after 6 months

All of the following:

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

Continuation – pandemic circumstances

Re-assessment required after 6 months

All of the following:

- 1 The patient is clinically benefiting from treatment and continued treatment remains appropriate; and
- 2 Abiraterone acetate to be discontinued at progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The regular renewal requirements cannot be met due to COVID-19 constraints on the health sector.

BICALUTAMIDE

Tab 50 mg - 5% DV Dec-23 to 20264.18	28	Binarex
FLUTAMIDE		
Tab 250 mg119.50	100	Flutamin
FULVESTRANT – Restricted see terms below		
Inj 50 mg per ml, 5 ml prefilled syringe	2	Faslodex
>> Destricted (D01700)		

→ Restricted (RS1732)

Initiation

Medical oncologist

Re-assessment required after 6 months

All of the following:

1 Patient has oestrogen-receptor positive locally advanced or metastatic breast cancer; and

- 2 Patient has disease progression following prior treatment with an aromatase inhibitor or tamoxifen for their locally advanced or metastatic disease; and
- 3 Treatment to be given at a dose of 500 mg monthly following loading doses; and
- 4 Treatment to be discontinued at disease progression.

Continuation

Medical oncologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment remains appropriate and patient is benefitting from treatment; and
- 2 Treatment to be given at a dose of 500 mg monthly; and
- 3 No evidence of disease progression.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
OCTREOTIDE - Some items restricted see terms below			
Inj 50 mcg per ml, 1 ml ampoule - 5% DV Jun-22 to 2024		5	Max Health
Inj 100 mcg per ml, 1 ml ampoule - 5% DV Jun-22 to 2024		5	Max Health
Inj 500 mcg per ml, 1 ml ampoule - 5% DV Jun-22 to 2024	113.10	5	Max Health
Inj depot 10 mg prefilled syringe − 5% DV Mar-22 to 2024		1	Octreotide Depot Teva
Inj depot 20 mg prefilled syringe - 5% DV Mar-22 to 2024	647.03	1	Octreotide Depot Teva
Inj depot 30 mg prefilled syringe − 5% DV Mar-22 to 2024		1	Octreotide Depot Teva
→ Restricted (RS1889)			•

Initiation - Malignant bowel obstruction

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are unapproved indications

Initiation - acromegaly

Re-assessment required after 3 months

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Continuation - acromegaly

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

Initiation - Other indications

Any of the following:

- 1 VIPomas and glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or

2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or

- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or

5 Both:

- 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
- 5.2 Disabling symptoms not controlled by maximal medical therapy.

F (ex man.	Price	 GST\		Brand or Generic
(ex man.	\$	uo1)	Per	Manufacturer
ontinued				
Note: restriction applies only to the long-acting formulations of octreotide				
nitiation – pre-operative acromegaly				
<i>imited to 12 months</i> treatment				
All of the following:				
1 Patient has acromegaly; and				
2 Patient has a large pituitary tumour, greater than 10 mm at its widest; and 2 Patient is scheduled to undergo pituitary surgery in the part six members.	1 L			
3 Patient is scheduled to undergo pituitary surgery in the next six months. Note: Indications marked with * are unapproved indications				
Continuation – Acromegaly - pandemic circumstances				
Re-assessment required after 6 months				
All of the following:				
1 Patient has acromegaly; and				
 Patient has actionegally, and The patient is clinically benefiting from treatment and continued treatment 	t roma	ine an	nronriato	and
3 The regular renewal requirements cannot be met due to COVID-19 const				
			noulin St	
AMOXIFEN CITRATE	1 - 00		<u> </u>	Tamoxifen Sandoz
Tab 10 mg - 5% DV Dec-23 to 2026			60 60	Tamoxifen Sandoz
Tab 20 mg - 5% DV Dec-23 to 2026	5.32		60	Tamoxilen Sandoz
Aromatase Inhibitors				
NASTROZOLE				
Tab 1 mg - 5% DV Dec-23 to 2026	4.39	1	30	Anatrole
EXEMESTANE				
Tab 25 mg – 5% DV Nov-23 to 2026	9.86		30	Pfizer Exemestane
ETROZOLE				
Tab 2.5 mg – 5% DV Jan-22 to 2024	5.84		30	Letrole
Imaging Agents				
MINOLEVULINIC ACID HYDROCHLORIDE – Restricted see terms below Powder for oral soln, 30 mg per ml, 1.5 g vial4,4	100.00		1	Gliolan
	+00.00 00.00		10	Gliolan
→ Restricted (RS1565)	00.00		10	Gilolan
nitiation – high grade malignant glioma				
All of the following:				
1 Patient has newly diagnosed, untreated, glioblastoma multiforme; and				
2 Treatment to be used as adjuvant to fluorescence-guided resection; and				
3 Patient's tumour is amenable to complete resection.				
Immunosunnrossante				
Immunosuppressants				
Calcineurin Inhibitors				
	44.00		50	Neevel
Cap 25 mg			50	Neoral
	.88.91		50 50	Neoral Neoral
Cap 50 mg	177 04		201	Medial
Cap 100 mg1				
	198.13		50 ml 10	Neoral Sandimmun

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST \$	Per	Brand or Generic Manufacturer
TACROLIMUS – Restricted see terms below			
Cap 0.5 mg		100	Tacrolimus Sandoz
Cap 0.75 mg		100	Tacrolimus Sandoz
↓ Cap 1 mg		100	Tacrolimus Sandoz
Cap 5 mg		50	Tacrolimus Sandoz
Inj 5 mg per ml, 1 ml ampoule			
➡ Restricted (RS1990)			
Initiation — organ transplant reginients			

Initiation – organ transplant recipients

Any specialist

For use in organ transplant recipients.

Initiation - non-transplant indications*

Any specialist

Both:

- 1 Patient requires long-term systemic immunosuppression; and
- 2 Either:
 - 2.1 Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response; or
 - 2.2 Patient is a child with nephrotic syndrome*.

Note: Indications marked with * are unapproved indications

Fusion Proteins

ETANERCEPT – **Restricted** see terms below

t	Inj 25 mg autoinjector - 5% DV Feb-21 to 2024	4	Enbrel
	Inj 25 mg vial – 5% DV Sep-19 to 2024	4	Enbrel
t	Inj 50 mg autoinjector - 5% DV Sep-19 to 2024	4	Enbrel
t	Inj 50 mg syringe - 5% DV Sep-19 to 20241,050.00	4	Enbrel

➡ Restricted (RS1879)

Initiation - polyarticular course juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for polyarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Price		Brand or
(ex man. excl. GS		Generic
\$	Per	Manufacturer

continued...

Continuation - polyarticular course juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - oligoarticular course iuvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for oligoarticular course juvenile idiopathic arthritis (JIA): and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for oligoarticular course JIA: or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance: and
 - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 High disease activity (cJADAS10 score greater than 4) after a 6-month trial of methotrexate.

Continuation - oligoarticular course iuvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Fither:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baselinee: or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - Arthritis - rheumatoid

Rheumatologist Re-assessment required after 6 months Fither:

166

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and
 - 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Continuation - Arthritis - rheumatoid

- Any relevant practitioner
- Re-assessment required after 2 years

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or

2 All of the following:

2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and

¹ Both:

Price	1		Brand or
(ex man. exc	d. GST)		Generic
 \$		Per	Manufacturer

continued...

- 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
- 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
- 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
- 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
- 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

Continuation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab or secukinumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab or secukinumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab or secukinumab to meet the renewal criteria for adalimumab or secukinumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and

168

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
- 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; nr
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application: or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - psoriatic arthritis

Rheumatologist

```
Re-assessment required after 6 months
Both:
```

- 1 Fither:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - severe chronic plaque psoriasis, prior TNF use

Dermatologist

Limited to 4 months treatment

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
- 2 Fither:
 - 2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis: and
- 3 Patient must be reassessed for continuation after 3 doses.

Initiation - severe chronic plague psoriasis, treatment-naive

Dermatologist

Limited to 4 months treatment

All of the followina:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plagues have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin: and

Price		Brand	or	
(ex man. e	excl. G	ST)	Gener	
 \$	5	Pe	r Manuf	acturer

continued...

- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Continuation – severe chronic plaque psoriasis**

Dermatologist

Re-assessment required after 6 months Both:

1 Either:

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Either:
 - 1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
 - 1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.
- Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 8 doses.

continued...

170

Price		Brand or
(ex man. excl. GST)	_	Generic
 \$	Per	Manufacturer

continued...

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a Health NZ Hospital; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD: or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Initiation - undifferentiated spondyloarthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day (or maximum tolerated dose); and
- 4 Patient has tried and not responded to at least three months of leflunomide at a dose of up to 20 mg daily (or maximum tolerated dose); and
- 5 Any of the following:
 - 5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications.

Continuation - undifferentiated spondyloarthritis

Rheumatologist or medical practitioner on the recommendation of a Rheumatologist

Re-assessment required after 6 months

All of the following:

1 Either:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg dose every 7 days.

Monoclonal Antibodies

ABCIXIMAB - Restricted see terms below

Inj 2 mg per ml, 5 ml vial

➡ Restricted (RS1202)

Initiation

Either:

- 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
- 2 For use in patients undergoing intra-cranial intervention.

ADALIMUMAB (AMGEVITA) - Restricted see terms below

t	Inj 20 mg per 0.4 ml prefilled syringe - 5% DV Oct-22 to 31 Jul 2026 190.00	1	Amgevita
t	Inj 40 mg per 0.8 ml prefilled pen - 5% DV Oct-22 to 31 Jul 2026	2	Amgevita
t	Inj 40 mg per 0.8 ml prefilled syringe - 5% DV Oct-22 to 31 Jul 2026375.00	2	Amgevita

→ Restricted (RS1940)

Initiation - Behcet's disease - severe

Any relevant practitioner

Both:

- 1 The patient has severe Behcet's disease* that is significantly impacting the patient's quality of life; and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological, and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s); or
 - 2.2 The patient has severe gastrointestinal, rheumatological and/or mucocutaneous symptoms and has not responded adequately to two or more treatments appropriate for the particular symptom(s).

Note: Indications marked with * are unapproved indications.

Initiation - Hidradenitis suppurativa

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 Patient has 3 or more active lesions; and
- 4 The patient has a DLQI of 10 or more and the assessment is no more than 1 month old at time of application.

Continuation – Hidradenitis suppurativa

Any relevant practitioner *Re-assessment required after 2 years* Both:

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a DLQI improvement of 4 or more from baseline.

Initiation - Plaque psoriasis - severe chronic

Dermatologist

Re-assessment required after 4 months Either:

1 Both:

- 1.1 Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment or (DLQI) assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application.

Continuation - Plaque psoriasis - severe chronic

Any relevant practitioner

- Re-assessment required after 2 years
- Either:

1 Both:

- 1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
- 1.2 Either:
 - 1.2.1 The patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 1.2.2 The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or

2 Both:

- 2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 2.2 Either:
 - 2.2.1 The patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2 The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value.

Initiation – pyoderma gangrenosum

Dermatologist

Both:

1 Patient has pyoderma gangrenosum*; and

	Price			Brand or
(ex ma	n. excl.	GST)		Generic
	\$		Per	Manufacturer

continued...

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response.

Note: Indications marked with * are unapproved indications.

Initiation - Crohn's disease - adults

Any relevant practitioner

Re-assessment required after 6 months

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a CDAI score of greater than or equal to 300 or HBI score of greater than or equal to 10; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Continuation - Crohn's disease - adults

Any relevant practitioner

Re-assessment required after 2 years

Any of the following:

- 1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced 3 points, from when the patient was initiated on adalimumab; or
- 2 CDAI score is 150 or less, or HBI is 4 or less; or
- 3 The patient has demonstrated an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed.

Initiation - Crohn's disease - children

Any relevant practitioner

Re-assessment required after 6 months

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Continuation - Crohn's disease - children

Any relevant practitioner

Re-assessment required after 2 years

Any of the following:

- 1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
- 2 PCDAI score is 15 or less; or
- 3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed.

Initiation – Crohn's disease - fistulising

Any relevant practitioner

Re-assessment required after 6 months

All of the following:

174

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
- 2.2 Patient has one or more rectovaginal fistula(e); or
- 2.3 Patient has complex peri-anal fistula; and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application.

Continuation – Crohn's disease - fistulising

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation - Ocular inflammation - chronic

Any relevant practitioner

Re-assessment required after 4 months Either:

1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; or

2 Both:

- 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation - Ocular inflammation - chronic

Any relevant practitioner

Re-assessment required after 2 years

Any of the following:

- 1 The patient has had a good clinical response following 12 weeks' initial treatment; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initiation - Ocular inflammation - severe

Any relevant practitioner

Re-assessment required after 4 months

Either:

1 Patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; or

2 Both:

- 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or

Price		Brand or	
(ex man. excl.	GST)	Generic	
 \$	Per	Manufacturer	

continued...

- 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
- 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation - Ocular inflammation - severe

Any relevant practitioner

Re-assessment required after 2 years

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 2 year treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 2 year treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months Fither:

1 Both:

- 1.1 Patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit to meet the renewal criteria for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by radiology imaging; and
 - 2.4 Patient has not responded adequately to treatment with two or more NSAIDs, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following BASMI measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender; and
 - 2.6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment and is no more than 1 month old at the time of application.

Continuation - ankylosing spondylitis

Any relevant practitioner

Re-assessment required after 2 years

For applications where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less.

Initiation - Arthritis - oligoarticular course juvenile idiopathic

Named specialist or rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for oligoarticular course juvenile idiopathic

continued...

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

conti	nuea		

arthritis (JIA); and

- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for oligoarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had oligoarticular course JIA for 6 months duration or longer; and
 - 2.3 Either:
 - 2.3.1 At least 2 active joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score greater than 1.5) with poor prognostic features after a 3-month trial of methotrexate (at the maximum tolerated dose).

Continuation - Arthritis - oligoarticular course juvenile idiopathic

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - Arthritis - polyarticular course juvenile idiopathic

Named specialist or rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

- 1.1 Patient has had an initial Special Authority approval for etanercept for polyarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for polyarticular course JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Any of the following:
 - 2.3.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.3.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Continuation – Arthritis - polyarticular course juvenile idiopathic

Any relevant practitioner

Re-assessment required after 2 years Either:

1 Following initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

Pric	Price		Brand or
(ex man. ex	xcl. GS		Generic
\$	6	Per	Manufacturer

continued...

2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - Arthritis - psoriatic

Rheumatologist

Re-assessment required after 6 months Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for etanercept or secukinumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects; or
 - 1.2.2 Patient has received insufficient benefit to meet the renewal criteria for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine or leflunomide at maximum tolerated doses (unless contraindicated); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated ESR greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - Arthritis - psoriatic

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in swollen joint count from baseline and a clinically significant response in the opinion of the physician; or
- 2 Patient demonstrates at least a continuing 30% improvement in swollen joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initiation - Arthritis - rheumatoid

Rheumatologist

Re-assessment required after 6 months Either:

1 Both:

178

- 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or	
(ex man. excl. GST)		Generic	
 \$	Per	Manufacturer	

continued...

- 2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and
- 2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and
- 2.5 Either:
 - 2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with methotrexate; and

2.6 Either:

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
- 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

Continuation - Arthritis - rheumatoid

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Initiation - Still's disease - adult-onset (AOSD)

Rheumatologist

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept and/or tocilizumab for (AOSD); and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 Patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria; and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, NSAIDs and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initiation – ulcerative colitis

Any relevant practitioner

Re-assessment required after 6 months

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Either:
 - 2.1 Patient's SCCAI score is greater than or equal to 4; or
 - 2.2 Patient's PUCAI score is greater than or equal to 20; and

Pri	ice		Brand or
(ex man. e	excl. GST		Generic
\$	\$	Per	Manufacturer

continued...

- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation - ulcerative colitis

Any relevant practitioner

Re-assessment required after 2 years

Either:

- 1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biologic therapy; or
- 2 The PUCAI score has reduced by 10 points or more from the PUCAI score when the patient was initiated on biologic therapy.

Initiation - undifferentiated spondyloarthiritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has undifferentiated peripheral spondyloarthritis* with active peripheral joint arthritis in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2 Patient has tried and not responded to at least three months of each of methotrexate, sulphasalazine and leflunomide, at maximum tolerated doses (unless contraindicated); and
- 3 Any of the following:
 - 3.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 3.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 3.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Note: Indications marked with * are unapproved indications.

Continuation – undifferentiated spondyloarthiritis

Any relevant practitioner

Re-assessment required after 2 years

Either:

180

- 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response in the opinion of the treating physician.

Initiation - inflammatory bowel arthritis - axial

Rheumatologist

Re-assessment required after 6 months All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has axial inflammatory pain for six months or more; and
- 3 Patient is unable to take NSAIDs; and
- 4 Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- 5 Patient has not responded adequately to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 A BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued... Continuation - inflammatory bowel arthritis - axial Any relevant practitioner Re-assessment required after 2 years Where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale. or an improvement in BASDAI of 50%, whichever is less. Initiation - inflammatory bowel arthritis - peripheral Rheumatologist Re-assessment required after 6 months All of the following: 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and 3 Patient has tried and not experienced a response to at least three months of methotrexate, or azathioprine at a maximum tolerated dose (unless contraindicated); and 4 Patient has tried and not experienced a response to at least three months of sulphasalazine at a maximum tolerated dose (unless contraindicated); and 5 Any of the following: 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or 5.2 Patient has an ESR greater than 25 mm per hour; or 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months. Continuation - inflammatory bowel arthritis - peripheral Any relevant practitioner Re-assessment required after 2 years Fither: 1 Following initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or 2 Patient demonstrates at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician. ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND) - Restricted see terms below

t	Inj 20 mg per 0.2 ml prefilled syringe1,599	9.96 2	Humira
	Inj 40 mg per 0.4 ml prefilled syringe1,599		Humira
t	Inj 40 mg per 0.4 ml prefilled pen	9.96 2	HumiraPen
t	Inj 40 mg per 0.8 ml pen	9.96 2	HumiraPen
	Inj 40 mg per 0.8 ml syringe		Humira

(HumiraPen Inj 40 mg per 0.8 ml pen to be delisted 1 March 2024)

(Humira Inj 40 mg per 0.8 ml syringe to be delisted 1 March 2024)

→ Restricted (RS1922)

Initiation - Behcet's disease - severe

Any relevant practitioner

Re-assessment required after 6 months

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and

- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation – Behcet's disease – severe

Any relevant practitioner

Re-assessment required after 6 months

Both:

- 1 The patient has had a good clinical response to treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – Hidradenitis suppurativa

Dermatologist or Practitioner on the recommendation of a dermatologist

Re-assessment required after 6 months

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 7 days. Fortnightly dosing has been considered.

Continuation – Hidradenitis suppurativa

Dermatologist or Practitioner on the recommendation of a dermatologist

Re-assessment required after 6 months

All of the following:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
- 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

Initiation – Psoriasis - severe chronic plaque

Dermatologist or Practitioner on the recommendation of a dermatologist

Re-assessment required after 6 months

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation - Psoriasis - severe chronic plaque

Dermatologist or Practitioner on the recommendation of a dermatologist

Re-assessment required after 6 months

Both:

1 Either:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Either:
 - 1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
- 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – Pyoderma gangrenosum

Dermatologist

Re-assessment required after 6 months

- All of the following:
 - 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
 - 2 Patient has received a maximum of 6 months treatment with Amgevita; and
 - 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
 - 4 A maximum of 8 doses.

Continuation – Pyoderma gangrenosum

Dermatologist

Re-assessment required after 6 months

- Both:
 - 1 The patient has demonstrated clinical improvement and continues to require treatment; and
 - 2 A maximum of 8 doses.

Initiation - Crohn's disease - adult

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or

 Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation - Crohn's disease - adult

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

Re-assessment required after 6 months

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - Crohn's disease - children

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation - Crohn's disease - children

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

Re-assessment required after 6 months

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment, but PCDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - Crohn's disease - fistulising

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1.3 Patient has Crohn's and is considered to be at risk of disease destabilisation if there were to be a change to current treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation - Crohn's disease - fistulising

Gastroenterologist or Practitioner on the recommendation of a gastroenterologist

Re-assessment required after 6 months

Both:

1 Either:

- 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - Ocular inflammation - chronic

Any relevant practitioner

Re-assessment required after 12 months All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease response to a change in treatment regimen; or
 - 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- $3\;$ Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation – Ocular inflammation – chronic

Any relevant practitioner

Re-assessment required after 12 months

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and</p>
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - Ocular inflammation - severe

Any relevant practitioner

Re-assessment required after 12 months

All of the following:

- 1 Any of the following:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment, and a maximum of 6 months treatment with Amgevita; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with Amgevita, and a maximum of 6 months treatment with Amgevita and clinician attributes this loss of disease

Price		Brand or
(ex man. excl. GS		Generic
\$	Per	Manufacturer

response to a change in treatment regimen; or

- 1.3 Patient has uveitis and is considered to be at risk of vision loss if they were to change treatment; and
- 2 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation – Ocular inflammation – severe

Any relevant practitioner

Re-assessment required after 12 months Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 3 initial doses; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and</p>
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - ankylosing spondylitis

Rheumatologist or Practitioner on the recommendation of a rheumatologist *Re-assessment required after 6 months* All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita); and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation - ankylosing spondylitis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Both:

- 1 Treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - Arthritis - oligoarticular course juvenile idiopathic

Named specialist or rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Price		Brand or
(ex man. excl. GS		Generic
 \$	Per	Manufacturer

continued...

Continuation - Arthritis - oligoarticular course juvenile idiopathic

Named specialist or rheumatologist

Re-assessment required after 6 months

For patients that demonstrate at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation – Arthritis - polyarticular course juvenile idiopathic

Named specialist or rheumatologist

Re-assessment required after 6 months

All of the following:

1 Either:

- 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
- 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Continuation - Arthritis - polyarticular course juvenile idiopathic

Named specialist or rheumatologist

Re-assessment required after 6 months

For patients that demonstrate at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - Arthritis - psoriatic

Named specialist or rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
 - 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Continuation – Arthritis - psoriatic

Named specialist or rheumatologist

Re-assessment required after 6 months

Both:

- 1 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – Arthritis – rheumatoid

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Continuation - Arthritis - rheumatoid

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Both:

1 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and

2 Either:

- 2.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
- 2.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Initiation - Still's disease - adult-onset (AOSD)

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

All of the following:

1 Either:

- 1.1 The patient has experienced intolerable side effects from adalimumab (Amgevita) following a minimum of 4 weeks treatment; or
- 1.2 Patient has developed symptoms of loss of disease control following a minimum of 4 weeks treatment with adalimumab (Amgevita) and clinician attributes this loss of disease response to a change in treatment regimen; and
- 2 Patient has received a maximum of 6 months treatment with Amgevita; and
- 3 Patient has previously had a Special Authority approval for the Humira brand of adalimumab for this indication.

Continuation - Still's disease - adult-onset (AOSD)

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

the patient has demonstrated a sustained improvement in inflammatory markers and functional status.

AFLIBERCEPT - Restricted see terms below

➡ Restricted (RS1872)

Initiation - Wet Age Related Macular Degeneration

Ophthalmologist or nurse practitioner

Re-assessment required after 3 months

Either:

1 All of the following:

1.1 Any of the following:

- 1.1.1 Wet age-related macular degeneration (wet AMD); or
- 1.1.2 Polypoidal choroidal vasculopathy; or
- 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and

1.2 Either:

	Price			Brand or
(ex r	man. excl	. GST)		Generic
	\$		Per	Manufacturer

continued...

- 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
- 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
- 1.3 There is no structural damage to the central fovea of the treated eye; and
- 1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or
- 2 Either:
 - 2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
 - 2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Continuation - Wet Age Related Macular Degeneration

Ophthalmologist or nurse practitioner

Re-assessment required after 12 months

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

Initiation - Diabetic Macular Oedema

Ophthalmologist or nurse practitioner

Re-assessment required after 4 months

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Continuation – Diabetic Macular Oedema

Ophthalmologist or nurse practitioner

Re-assessment required after 12 months

All of the following:

- 1 There is stability or two lines of Snellen visual acuity gain; and
- 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
- 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
- 5 After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

BASILIXIMAB - Restricted see terms below

Inj 20 mg vial	2,560.00	1	Simulect
➡ Restricted (RS1203)			
Initiation			
For use in solid organ transplants.			
BENRALIZUMAB – Restricted see terms below			
Inj 30 mg per ml, 1 ml prefilled pen	3,539.00	1	Fasenra
➡ Restricted (RS1920)			
Initiation – Severe eosinophilic asthma			
Respiratory physician or clinical immunologist			
Re-assessment required after 12 months			
All of the following:			

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5 × 10⁹ cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long-acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever therapy plus maintenance regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Treatment is not to be used in combination with subsidised mepolizumab; and
- 8 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and
- 9 Either:
 - 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; or
 - 9.2 Both:
 - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
 - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

Continuation – Severe eosinophilic asthma

Respiratory physician or clinical immunologist

Re-assessment required after 2 years

- Both:
 - 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
 - 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with benralizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

BEVACIZUMAB - Restricted see terms below

- Inj 25 mg per ml, 4 ml vial
- Inj 25 mg per ml, 16 ml vial

→ Restricted (RS1691)

Initiation - Recurrent Respiratory Papillomatosis

Otolaryngologist

Re-assessment required after 12 months

- All of the following:
 - 1 Maximum of 6 doses; and
 - 2 The patient has recurrent respiratory papillomatosis; and
 - 3 The treatment is for intra-lesional administration.

	Price		Brand or Generic
	(ex man. excl. 0 \$	Per	Manufacturer
continued			
Continuation – Recurrent Respiratory Papillomatosis			
Otolaryngologist			
Re-assessment required after 12 months			
All of the following:			
 Maximum of 6 doses; and The treatment is for intra-lesional administration; and There has been a reduction in surgical treatments or disease 	regrowth as a resu	It of treatmen	t.
Initiation – ocular conditions	0		
Either:			
1 Ocular neovascularisation; or			
2 Exudative ocular angiopathy.			
CASIRIVIMAB AND IMDEVIMAB – Restricted see terms below			
Inj 120 mg per ml casirivimab, 11.1 ml vial (1) and inj 120 mg per	ml		
imdevimab, 11.1 ml vial (1)		1	Ronapreve
→ Restricted (RS1874)		•	lionapioro
Initiation - Treatment of profoundly immunocompromised patier	nts		
Limited to 2 weeks treatment			
All of the following:			
 Patient has confirmed (or probable) COVID-19; and 			
2 The patient is in the community (treated as an outpatient) with			
3 Patient is profoundly immunocompromised** and is at risk of r	not having mountee	d an adequate	e response to vaccination
against COVID-19 or is unvaccinated; and			
 4 Patient's symptoms started within the last 10 days; and 5 Patient is not receiving high flow oxygen or assisted/mechanic 	al ventilation: and		
 6 Casirivimab and imdevimab is to be administered at a maximu 		iter than 2.40) աս
Notes: * Mild to moderate disease severity as described on the Minis	0		ug.
** Examples include B-cell depletive illnesses or patients receiving tre			
Initiation - mild to moderate COVID-19-hospitalised patients			
Any relevant practitioner			
Limited to 2 weeks treatment			
All of the following:			
 Patient has confirmed (or probable) COVID-19; and 			
2 Patient is an in-patient in hospital with mild to moderate disease	se severity*; and		
3 Patient's symptoms started within the last 10 days; and			
4 Patient is not receiving high flow oxygen or assisted/mechanic	ai ventilation; and		
5 Any of the following:			
5.1 Age > 50; or 5.2 BMI > 30; or			
5.3 Patient is Māori or Pacific ethnicity; or			
5.4 Patient is at increased risk of severe illness from COVI	D-19. excluding pr	egnancy, as (described on the Ministry of
Health website (see Notes); and	,	- 3	
6 Either:			
6.1 Patient is unvaccinated; or			
6.2 Patient is seronegative where serology testing is readil	y available or stroi	ngly suspecte	d to be seronegative where
serology testing is not available; and			-
7 Casirivimab and imdevimab is to be administered at a maximu	Im dose of no grea	ter than 2,40) mg.
Notes: * Mild to moderate disease severity as described on the Minis			
**(https://www.health.govt.nz/our-work/diseases-and-conditions/covid	-19-novel-coronav	irus/covid-19	information-specific-
audiences/covid-19-advice-higher-risk-people)			

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price		Brand or
	(ex man. excl. GST) \$	Per	Generic Manufacturer
	Ψ	1 61	Manulacturer
CETUXIMAB – Restricted see terms below	004.00		Eshihara
·		1 1	Erbitux
J - 5	1,820.00	I	Erbitux
→ Restricted (RS1613) nitiation			
Aedical oncologist			
All of the following:			
1 Patient has locally advanced, non-metastatic, squamous	coll cancer of the head and	nock: ar	hd
2 Patient is contraindicated to, or is intolerant of, cisplatin; a		neon, ai	
3 Patient has good performance status; and			
4 To be administered in combination with radiation therapy.			
GEMTUZUMAB OZOGAMICIN – Restricted see terms below	10 070 00	4	Mulatora
Inj 5 mg vial → Restricted (RS1923)	12,973.00	1	Mylotarg
nitiation			
All of the following:			
1 Patient has not received prior chemotherapy for this cond	ition: and		
2 Patient has de novo CD33-positive acute myeloid leukaer			
3 Patient does not have acute promyelocytic leukaemia; an			
4 Gemtuzumab ozogamicin will be used in combination with		d cytara	bine (AraC); and
5 Patient is being treated with curative intent; and		a og lara	unio (/ nuo), unu
6 Patient's disease risk has been assessed by cytogenetic	testing to be good or interm	nediate; a	and
7 Patient must be considered eligible for standard intensive			
and cytarabine (AraC); and			
8 Gemtuzumab ozogamicin to be funded for one course on	ly (one dose at 3 mg per m	² body sı	urface area or up to 2 vials o
5 mg as separate doses).			
Note: Acute myeloid leukaemia excludes acute promyelocytic le		l leukaer	nia that is secondary to
another haematological disorder (eg myelodysplasia or myelopro	liferative disorder).		
NFLIXIMAB – Restricted see terms below			
Inj 100 mg - 5% DV Sep-20 to 2025		1	Remicade
→ Restricted (RS1941)			
nitiation – Graft vs host disease			
Patient has steroid-refractory acute graft vs. host disease of the	gut.		
nitiation – rheumatoid arthritis			
Rheumatologist			
Re-assessment required after 4 months All of the following:			
5	en edeline week endlen eten		
 The patient has had an initial Special Authority approval for 2 Either: 	or adalimumab and/or etam	erceptio	r meumatoio annitis; and
	ha fuana a waaaanahia tu'al at		
2.1 The patient has experienced intolerable side effect			
2.2 Following at least a four month trial of adalimumat for adalimumab and/or etanercept; and	anu/or etanercept, the pat		ior meet the renewal chiefla
	rany or monotherany when	0 1100 of	mothatravata is limited by
3 Treatment is to be used as an adjunct to methotrexate the	erapy or monotherapy wher	e use of	memotrexate is limited by
toxicity or intolerance.			
Continuation – rheumatoid arthritis			
Reumatologist Re-assessment required after 6 months			
Re-assessment required after 6 months			

All of the following:

192

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

continued...

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initiation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 3 months Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Continuation – ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 4 months

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis; and

2 Either:

- 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept and/or secukinumab; or
- 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept and/or secukinumab, the patient did not meet the renewal criteria for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Both:

1 Either:

- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

Initiation - severe ocular inflammation

Re-assessment required after 4 months

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or

2 Both:

- 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation - severe ocular inflammation

Re-assessment required after 12 months

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation - chronic ocular inflammation

Re-assessment required after 4 months

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or
- 2 Both:

194

- 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

achieving a therapeutic dose of methotrexate.

Continuation - chronic ocular inflammation

Re-assessment required after 12 months

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation – Pulmonary sarcoidosis

Both:

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initiation - Crohn's disease (adults)

Any relevant practitioner

Re-assessment required after 6 months

All of the following:

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Continuation - Crohn's disease (adults)

Any relevant practitioner

Re-assessment required after 2 years

Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score and/or HBI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - Crohn's disease (children)

Any relevant practitioner *Re-assessment required after 6 months* All of the following:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 Paediatric patient has active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a PCDAI score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids.

Continuation - Crohn's disease (children)

Any relevant practitioner *Re-assessment required after 2 years* Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 6 months Both:

- 1 Patient has confirmed Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); or
 - 2.3 Patient has complete peri-anal fistula.

Continuation - fistulising Crohn's disease

Any relevant practitioner *Re-assessment required after 2 years* Both:

Soun:

- 1 Either:
 - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - acute fulminant ulcerative colitis

Gastroenterologist

Limited to 6 weeks treatment

Both:

- 1 Patient has acute, fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

196

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Continuation - fulminant ulcerative colitis

Any relevant practitioner

Re-assessment required after 2 years

Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – ulcerative colitis

Any relevant practitioner

Re-assessment required after 6 months

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Either:
 - 2.1 Patients SCCAI is greater than or equal to 4; or
 - 2.2 Patients PUCAI score is greater than or equal to 20; and
- 3 Patient has experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids.

Continuation - ulcerative colitis

Any relevant practitioner

Re-assessment required after 2 years

Both:

1 Either:

- 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
- 1.2 The PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - plaque psoriasis

Dermatologist

Re-assessment required after 3 doses Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or secukinumab; or
 - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Continuation – plaque psoriasis**

Dermatologist

Re-assessment required after 3 doses Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation - neurosarcoidosis

Neurologist

Re-assessment required after 18 months All of the following:

- 1 Biopsy consistent with diagnosis of neurosarcoidosis; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:

198

- 4.1 IV cyclophosphamide has been tried; or
- 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Continuation - neurosarcoidosis

Neurologist

Re-assessment required after 18 months

Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
 - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
 - 2.2 There has been a marked reduction in prednisone dose; and
 - 2.3 Either:
 - 2.3.1 There has been an improvement in MRI appearances; or
 - 2.3.2 Marked improvement in other symptomology.

Initiation – severe Behcet's disease

Re-assessment required after 4 months

All of the following:

- 1 The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
 - 2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
- 3 The patient is experiencing significant loss of quality of life.

Notes:

- a) Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.
- b) Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

Continuation - severe Behcet's disease

Re-assessment required after 6 months Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 8 doses.
- Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

3 A maximum of 8 doses.

Initiation - Inflammatory bowel arthritis (axial)

Re-assessment required after 6 months

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has had axial inflammatory pain for six months or more; and
- 3 Patient is unable to take NSAIDs; and
- 4 Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI; and
- 5 Patient has not experienced an adequate response to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist; and
- 6 Patient has a BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment.

Continuation - Inflammatory bowel arthritis (axial)

Re-assessment required after 2 years

Where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10-point scale, or an improvement in BASDAI of 50%, whichever is less.

Initiation – Inflammatory bowel arthritis (peripheral)

Re-assessment required after 6 months

All of the following:

- 1 Patient has a diagnosis of active ulcerative colitis or active Crohn's disease; and
- 2 Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular; and
- 3 Patient has tried and not experienced a response to at least three months of methotrexate or azathioprine at a maximum tolerated dose (unless contraindicated); and
- 4 Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated); and
- 5 Any of the following:
 - 5.1 Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 5.2 Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application; or
 - 5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - Inflammatory bowel arthritis (peripheral)

Re-assessment required after 2 years

Either:

- 1 Following initial treatment, patient has experienced at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician.

MEPOLIZUMAB - Restricted see terms below

t	Inj 100 mg prefilled pen1,638.00	1	Nucala
t	Inj 100 mg vial1,638.00	1	Nucala

→ Restricted (RS1918)

Initiation – Severe eosinophilic asthma

Respiratory physician or clinical immunologist *Re-assessment required after 12 months* All of the following:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1 Patient must be aged 12 years or older; and
- 2 Patient must have a diagnosis of severe eosinophilic asthma documented by a respiratory physician or clinical immunologist; and
- 3 Conditions that mimic asthma eg. vocal cord dysfunction, central airway obstruction, bronchiolitis etc. have been excluded; and
- 4 Patient has a blood eosinophil count of greater than 0.5 × 10⁹ cells/L in the last 12 months; and
- 5 Patient must be adherent to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the single maintenance and reliever therapy regimen, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral corticosteroids; or
 - 6.2 Patient has received continuous oral corticosteroids of at least the equivalent of 10 mg per day over the previous 3 months; and
- 7 Treatment is not to be used in combination with subsidised benralizumab; and
- 8 Patient has an Asthma Control Test (ACT) score of 10 or less. Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 52 weeks after the first dose to assess response to treatment; and
- 9 Either:
 - 9.1 Patient has not previously received an anti-IL5 biological therapy for their severe eosinophilic asthma; or
 - 9.2 Both:
 - 9.2.1 Patient was refractory or intolerant to previous anti-IL5 biological therapy; and
 - 9.2.2 Patient was not eligible to continue treatment with previous anti-IL5 biological therapy and discontinued within 12 months of commencing treatment.

Continuation – Severe eosinophilic asthma

Respiratory physician or clinical immunologist

Re-assessment required after 2 years

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 Either:
 - 2.1 Exacerbations have been reduced from baseline by 50% as a result of treatment with mepolizumab; or
 - 2.2 Reduction in continuous oral corticosteroid use by 50% or by 10 mg/day while maintaining or improving asthma control.

OBINUTUZUMAB - Restricted see terms below

→ Restricted (RS1919)

Initiation

Haematologist

Limited to 6 months treatment All of the following:

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
- 4 Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and

Price		Brand or		
(ex man. excl. GS		Generic		
 \$	Per	Manufacturer		

continued...

- 5 Patient has good performance status; and
- 6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* greater than or equal to 1.5×10^{9} /L and platelets greater than or equal to 75×10^{9} /L

Initiation - follicular / marginal zone lymphoma

Re-assessment required after 9 months

All of the following:

- 1 Either:
 - 1.1 Patient has follicular lymphoma; or
 - 1.2 Patient has marginal zone lymphoma; and
- 2 Patient is refractory to or has relapsed within 12 months of a rituximab containing combined chemo-immunotherapy regimen*; and
- 3 Patient has an ECOG performance status of 0-2; and
- 4 Patient has been previously treated with no more than four chemotherapy regimens; and
- 5 Obinutuzumab to be administered at a maximum dose of 1000 mg for a maximum of 6 cycles in combination with chemotherapy*.

Note: * includes unapproved indications

Continuation - follicular / marginal zone lymphoma

Re-assessment required after 24 months

All of the following:

- 1 Patient has no evidence of disease progression following obinutuzumab induction therapy; and
- 2 Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and
- 3 Obinutuzumab to be discontinued at disease progression.

OMALIZUMAB - Restricted see terms below

t	Inj 150 mg prefilled syringe450.00	1	Xolair
	Inj 150 mg vial		Xolair

→ Restricted (RS1652)

Initiation - severe asthma

Clinical immunologist or respiratory specialist Re-assessment required after 6 months

All of the following:

- 1 Patient must be aged 6 years or older ; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and

6 Either:

- 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
- 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids;

I	Price			Brand or
(ex man.	excl.	GST)		Generic
	\$		Per	Manufacturer

continued...

and

- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Continuation - severe asthma

Respiratory specialist

Re-assessment required after 6 months

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Initiation - severe chronic spontaneous urticaria

Clinical immunologist or dermatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
 - 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; and
- 3 Any of the following:
 - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
 - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
 - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
- 4 Either:
 - 4.1 Treatment to be stopped if inadequate response* following 4 doses; or
 - 4.2 Complete response* to 6 doses of omalizumab.

Continuation – severe chronic spontaneous urticaria

Clinical immunologist or dermatologist

Re-assessment required after 6 months

Either:

1 Patient has previously had a complete response* to 6 doses of omalizumab; or

2 Both:

- 2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
- 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PALIVIZUMAB - Restricted see terms below

➡ Restricted (RS1907)

Initiation – RSV prophylaxis for the 2022/2023 RSV seasons, in the context of COVID-19 Paediatrician

Re-assessment required after 6 months Either:

Price)		Brand or
(ex man. exc	cl. GST)	Generic
\$		Per	Manufacturer

continued...

- 1 Infant was born in the last 2 years and has severe lung, airway, neurological or neuromuscular disease that requires ongoing, life-sustaining community ventilation; or
- 2 Both:
 - 2.1 Infant was born in the last 12 months; and
 - 2.2 Any of the following:
 - 2.2.1 Patient was born at less than 28 weeks gestation; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient was born at less than 32 weeks gestation; and
 - 2.2.2.2 Either:
 - 2.2.2.2.1 Patient has chronic lung disease; or
 - 2.2.2.2.2 Patient is Māori or any Pacific ethnicity; or
 - 2.2.3 Both:
 - 2.2.3.1 Patient has haemodynamically significant heart disease; and
 - 2.2.3.2 Any of the following:
 - 2.2.3.2.1 Patient has unoperated simple congenital heart disease with significant left to right shunt (see note a); or
 - 2.2.3.2.2 Patient has unoperated or surgically palliated complex congenital heart disease; or
 - 2.2.3.2.3 Patient has severe pulmonary hypertension (see note b); or
 - 2.2.3.2.4 Patient has moderate or severe LV failure (see note c).

Notes:

- Patient requires/will require heart failure medication, and/or patient has significant pulmonary hypertension, and/or patient will require surgical palliation/definitive repair within the next 3 months.
- b) Mean pulmonary artery pressure more than 25 mmHg.
- c) LV Ejection Fraction less than 40%.

Continuation - RSV prophylaxis for the 2022/2023 RSV seasons, in the context of COVID-19

Paediatrician

Patient still meets initial criteria.

PERTUZUMAB	 Restricted s 	see terms below
------------	----------------------------------	-----------------

Inj 30 mg per ml, 14 ml vial		Perjeta
------------------------------	--	---------

➡ Restricted (RS1551)

Initiation

Re-assessment required after 12 months

All of the following:

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Fither:
 - 2.1 Patient is chemotherapy treatment naive; or
 - 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months Both:

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

continued...

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RANIBIZUMAB - Restricted see terms below

- Inj 10 mg per ml, 0.23 ml vial
- Inj 10 mg per ml, 0.3 ml vial

➡ Restricted (RS1870)

Initiation – Wet Age Related Macular Degeneration

Ophthalmologist or nurse practitioner

Re-assessment required after 3 months

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Wet age-related macular degeneration (wet AMD); or
 - 1.1.2 Polypoidal choroidal vasculopathy; or
 - 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
 - 1.2 Either:
 - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
 - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
 - 1.3 There is no structural damage to the central fovea of the treated eye; and
 - 1.4 Patient has not previously been treated with aflibercept for longer than 3 months; or
- 2 Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months.

Continuation - Wet Age Related Macular Degeneration

Ophthalmologist or nurse practitioner

Re-assessment required after 12 months

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

RITUXIMAB (MABTHERA) - Restricted see terms below

t	Inj 10 mg per ml, 10 ml vial1,075.50	2	Mabthera
t	Inj 10 mg per ml, 50 ml vial2,688.30	1	Mabthera

➡ Restricted (RS1785)

Initiation - rheumatoid arthritis - prior TNF inhibitor use

Rheumatologist

Limited to 4 months treatment

All of the following:

1 Both:

- 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or

F	rice			Brand or
(ex man.	excl.	GST)		Generic
	\$		Per	Manufacturer

1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and

2 Either:

- 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation - rheumatoid arthritis - TNF inhibitors contraindicated

Rheumatologist

Limited to 4 months treatment

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
 - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
 - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

- 1 Any of the following:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

- 1 Either:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

RITUXIMAB (RIXIMYO) - Restricted see terms below

t	Inj 10 mg per ml, 10 ml vial	275.33	2	Riximyo
t	Inj 10 mg per ml, 50 ml vial	688.20	1	Riximyo
	B - this to d (D01070)			

➡ Restricted (RS1973)

Initiation - haemophilia with inhibitors

Haematologist

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Continuation - haemophilia with inhibitors

Haematologist

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initiation - post-transplant

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Continuation – post-transplant

All of the following:

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.

Initiation - indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 9 months

Either:

1 Both:

- 1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Continuation - indolent, low-grade lymphomas or hairy cell leukaemia*

Re-assessment required after 12 months

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant. Initiation – aggressive CD20 positive NHL

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Continuation - aggressive CD20 positive NHL

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.
- Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Initiation – Chronic lymphocytic leukaemia

Re-assessment required after 12 months

All of the following:

208

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 Any of the following:

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer	
 Ψ	1.01	manalaotaroi	

continued...

- 2.1 The patient is rituximab treatment naive; or
- 2.2 Either:
 - 2.2.1 The patient is chemotherapy treatment naive; or

2.2.2 Both:

- 2.2.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
- 2.2.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; or
- 2.3 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; and
- 3 The patient has good performance status; and

4 Either:

- 4.1 The patient does not have chromosome 17p deletion CLL; or
- 4.2 Rituximab treatment is to be used in combination with funded venetoclax for relapsed/refractory chronic lymphocytic leukaemia; and
- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles; and
- 6 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration), bendamustine or venetoclax.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

Continuation – Chronic lymphocytic leukaemia

Re-assessment required after 12 months

Both:

1 Either:

- 1.1 The patient's disease has relapsed within 36 months of previous treatment and rituximab treatment is to be used in combination with funded venetoclax; or
- 1.2 All of the following:
 - 1.2.1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
 - 1.2.2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
 - 1.2.3 The patient does not have chromosome 17p deletion CLL; and
 - 1.2.4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustin; and
- 2 Rituximab to be administered in combination with fludarabine and cyclophosphamide, bendamustine or venetoclax for a maximum of 6 treatment cycles.
- Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Initiation - severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 8 weeks All of the following:

1 Patient has cold haemagglutinin disease*; and

Price			Brand or
(ex man. exc	. GST)		Generic
\$		Per	Manufacturer

continued...

- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.
- Note: Indications marked with * are unapproved indications.

Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 8 weeks

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation - warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.
- Note: Indications marked with * are unapproved indications.

Continuation - warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 8 weeks

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 8 weeks

All of the following:

1 Either:

210

- 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
- 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and

e.g. Brand indicates brand example only. It is not a contracted product.

Price	Brand or
(ex man. excl. GST)	Generic
 \$	Per Manufacturer

continued...

- 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Continuation - immune thrombocytopenic purpura (ITP)

Haematologist

Re-assessment required after 8 weeks Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 8 weeks

Both:

- 1 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks; and
- 2 Either:
 - 2.1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
 - 2.2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.
- Note: Indications marked with * are unapproved indications.

Continuation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Re-assessment required after 8 weeks

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation – pure red cell aplasia (PRCA)

Haematologist

Re-assessment required after 6 weeks

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

Continuation – pure red cell aplasia (PRCA)

Haematologist

continued...

Re-assessment required after 6 weeks

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initiation – ANCA associated vasculitis

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
 - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
 - 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
 - 3.3 Cyclophosphamide and methotrexate are contraindicated; or
 - 3.4 Patient is a female of child-bearing potential; or
- 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Continuation - ANCA associated vasculitis

Re-assessment required after 8 weeks

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initiation - treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and 4 Maximum of four 1000 mg infusions of rituximab.
- 4 Maximum of four 1000 mg infusions of nuximab.

Note: Indications marked with * are unapproved indications. Continuation – treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initiation – Antibody-mediated organ transplant rejection

Patient has been diagnosed with antibody-mediated organ transplant rejection*.

Note: Indications marked with * are unapproved indications.

212

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued
Initiation – ABO-incompatible organ transplant
Patient is to undergo an ABO-incompatible solid organ transplant*.
Note: Indications marked with * are unapproved indications.
Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS) Nephrologist
Re-assessment required after 8 weeks
All of the following:
1 Patient is a child with SDNS* or FRNS*; and
 Preatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.
Note: Indications marked with a * are unapproved indications.
Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)
Nephrologist
Re-assessment required after 8 weeks All of the following:
 Patient who was previously treated with rituximab for nephrotic syndrome*; and
 Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3 The total rituximab dose used would not exceed the equivalent of 375 mg/m ² of body surface area per week for a total of 4 weeks.
Note: Indications marked with a * are unapproved indications.
Initiation – Steroid resistant nephrotic syndrome (SRNS)
Nephrologist
Re-assessment required after 8 weeks
All of the following:
1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
2 Treatment with tacrolimus for at least 3 months has been ineffective; and
3 Genetic causes of nephrotic syndrome have been excluded; and
4 The total rituximab dose used would not exceed the equivalent of 375 mg/m ² of body surface area per week for a total of 4 weeks.
Note: Indications marked with a * are unapproved indications.
Continuation – Steroid resistant nephrotic syndrome (SRNS)
Nephrologist
Re-assessment required after 8 weeks

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

Pr	ice		Brand or
(ex man.	excl. GST		Generic
	\$	Per	Manufacturer

Initiation - Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 6 months

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Continuation - Neuromyelitis Optica Spectrum Disorder (NMOSD)

Re-assessment required after 2 years

All of the following:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

Initiation - Severe Refractory Myasthenia Gravis

Neurologist

Re-assessment required after 2 years

Both:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
 - 2.2 Both:
 - 2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
 - 2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Continuation - Severe Refractory Myasthenia Gravis

Neurologist

Re-assessment required after 2 years

All of the following:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:

214

- 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
- 3.2 Both:
 - 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Price			Brand or
(ex man.	excl. GS		Generic
	\$	Per	Manufacturer

continued...

Initiation – Severe antisynthetase syndrome

Re-assessment required after 12 months

All of the following:

- 1 Patient has confirmed antisynthetase syndrome; and
- 2 Patient has severe, immediately life or organ threatening disease, including interstitial lung disease; and
- 3 Either:
 - 3.1 Treatment with at least 3 immunosuppressants (oral steroids, cyclophosphamide, methotrexate, mycophenolate, ciclosporin, azathioprine) has not be effective at controlling active disease; or
 - 3.2 Rapid treatment is required due to life threatening complications; and
- 4 Maximum of four 1,000 mg infusions of rituximab.

Continuation - Severe antisynthetase syndrome

Re-assessment required after 12 months

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in inflammatory markers, muscle strength and pulmonary function; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 Maximum of two cycles of 2 × 1,000 mg infusions of rituximab given two weeks apart.

Initiation - graft versus host disease

All of the following:

- 1 Patient has refractory graft versus host disease following transplant; and
- 2 Treatment with at least 3 immunosuppressants (oral steroids, ciclosporin, tacrolimus, mycophenolate, sirolimus) has not be effective at controlling active disease; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Initiation – severe chronic inflammatory demyelinating polyneuropathy

Neurologist

Re-assessment required after 6 months

- All of the following:
 - 1 Patient has severe chronic inflammatory demyelinating polyneuropathy (CIPD); and
 - 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
 - 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Continuation - severe chronic inflammatory demyelinating polyneuropathy

Neurologist or medical practitioner on the recommendation of a Neurologist

Re-assessment required after 6 months

All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological function compared to baseline; and
- 2 The patient has not received rituximab in the previous 6 months; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

Initiation – anti-NMDA receptor autoimmune encephalitis

Neurologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has severe anti-NMDA receptor autoimmune encephalitis; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Treatment with steroids and intravenous immunoglobulin and/or plasma exchange has not been effective at controlling active disease; and
 - 2.1.2 At least one other immunosuppressant (cyclophosphamide, ciclosporin, tacrolimus, mycophenolate) has not been effective at controlling active disease; or
 - 2.2 Rapid treatment is required due to life threatening complications; and
- 3 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Continuation - anti-NMDA receptor autoimmune encephalitis

Neurologist

Re-assessment required after 6 months All of the following:

- 1 Patient's disease has responded to the previous rituximab treatment with demonstrated improvement in neurological
 - function; and
 - 2 The patient has not received rituximab in the previous 6 months; and
 - 3 The patient has experienced a relapse and now requires further treatment; and
 - 4 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart.

Initiation - CD20+ low grade or follicular B-cell NHL

Re-assessment required after 9 months

Either:

- 1 Both:
 - 1.1 The patient has CD20+ low grade or follicular B-cell NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has CD20+ low grade or follicular B-cell NHL requiring first-line systemic chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

Continuation - CD20+ low grade or follicular B-cell NHL

Re-assessment required after 24 months

Both:

- 1 Rituximab is to be used for maintenance in CD20+ low grade or follicular B-cell NHL following induction with first-line systemic chemotherapy; and
- 2 Patient is intended to receive rituximab maintenance therapy for 2 years at a dose of 375 mg/m2 every 8 weeks (maximum of 12 cycles).

Initiation - Membranous nephropathy

Re-assessment required after 6 weeks

All of the following:

- 1 Either:
 - 1.1 Patient has biopsy-proven primary/idiopathic membranous nephropathy*; or
 - 1.2 Patient has PLA2 antibodies with no evidence of secondary cause, and an eGFR of > 60ml/min/1.73m2; and

continued...

216

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

- 2 Patient remains at high risk of progression to end-stage kidney disease despite more than 3 months of treatment with conservative measures (see Note); and
- 3 The total rituximab dose would not exceed the equivalent of 375mg/m2 of body surface area per week for a total of 4 weeks.

Continuation – Membranous nephropathy

Re-assessment required after 6 weeks

All of the following:

- 1 Patient was previously treated with rituximab for membranous nephropathy*; and
- 2 Either:
 - 2.1 Treatment with rituximab was previously successful, but the condition has relapsed, and the patient now requires repeat treatment; or
 - 2.2 Patient achieved partial response to treatment and requires repeat treatment (see Note); and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks.

Notes:

- a) Indications marked with * are unapproved indications.
- b) High risk of progression to end-stage kidney disease defined as > 5g/day proteinuria.
- c) Conservative measures include renin-angiotensin system blockade, blood-pressure management, dietary sodium and protein restriction, treatment of dyslipidaemia, and anticoagulation agents unless contraindicated or the patient has experienced intolerable side effects.
- d) Partial response defined as a reduction of proteinuria of at least 50% from baseline, and between 0.3 grams and 3.5 grams per 24 hours.

Initiation – B-cell acute lymphoblastic leukaemia/lymphoma*

Limited to 2 years treatment

All of the following:

- 1 Patient has newly diagnosed B-cell acute lymphoblastic leukaemia/lymphoma*; and
- 2 Treatment must be in combination with an intensive chemotherapy protocol with curative intent; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m2 per dose for a maximum of 18 doses.
- Note: Indications marked with * are unapproved indications.

Initiation - desensitisation prior to transplant

Limited to 6 weeks treatment

Both:

- 1 Patient requires desensitisation prior to mismatched allogenic stem cell transplant*; and
- 2 Patient would receive no more than two doses at 375 mg/m2 of body-surface area.

Note: Indications marked with * are unapproved indications.

Initiation - pemiphigus*

Dermatologist or relevant specialist Re-assessment required after 6 months

Either:

- 1 All of the following:
 - 1.1 Patient has severe rapidly progressive pemphigus; and
 - 1.2 Is used in combination with systemic corticosteroids (20 mg/day); and
 - 1.3 Any of the following:
 - 1.3.1 Skin involvement is at least 5% body surface area; or
 - 1.3.2 Significant mucosal involvement (10 or more mucosal erosions) or diffuse gingivitis or confluent large erosions; or
 - 1.3.3 Involvement of two or more mucosal sites; or

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

continued...

2 Both:

- 2.1 Patient has pemphigus; and
- 2.2 Patient has not experienced adequate clinical benefit from systemic corticosteroids (20 mg/day) in combination with a steroid sparing agent, unless contraindicated.
- Note: Indications marked with * are unapproved indications.

Continuation - pemiphigus*

Dermatologist or relevant specialist

Re-assessment required after 6 months

Both:

- 1 Patient has experienced adequate clinical benefit from rituximab treatment, with improvement in symptoms and healing of skin ulceration and reduction in corticosteroid requirement; and
- 2 Patient has not received rituximab in the previous 6 months.

Note: Indications marked with * are unapproved indications.

Initiation - immunoglobulin G4-related disease (IgG4-RD*)

Re-assessment required after 6 weeks

All of the following:

- 1 Patient has confirmed diagnosis of IgG4-RD*; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs for at least 3 months has been ineffective in lowering corticosteroid dose below 5 mg per day (prednisone equivalent) without relapse; or
 - 2.2 Treatment with corticosteroids and/or disease modifying anti-rheumatic drugs is contraindicated or associated with evidence of toxicity or intolerance; and
- 3 Total rituximab dose used should not exceed a maximum of two 1000 mg infusions of rituximab given two weeks apart.
- Note: Indications marked with * are unapproved indications.

Continuation - immunoglobulin G4-related disease (IgG4-RD*)

Re-assessment required after 12 months

All of the following:

- 1 Either:
 - 1.1 Treatment with rituximab for IgG4-RD* was previously successful and patient's disease has demonstrated sustained response, but the condition has relapsed; or
 - 1.2 Patient is receiving maintenance treatment for IgG4-RD*; and
- 2 Rituximab re-treatment not to be given within 6 months of previous course of treatment; and
- 3 Maximum of two 1000 mg infusions of rituximab given two weeks apart.

Note: Indications marked with * are unapproved indications.

SECUKINUMAB - Restricted see terms below

t	Inj 150 mg per ml, 1 ml prefilled syringe799.	50 1		Cosentyx
	1,599.	00 2	2	Cosentyx
⇒	Restricted (RS1863)			-

Initiation - severe chronic plaque psoriasis, second-line biologic

Dermatologist

Re-assessment required after 4 months

All of the following:

1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a Health NZ Hospital, for severe chronic plaque psoriasis; and

2 Either:

2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
- 3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Continuation - severe chronic plaque psoriasis, second-line biologic

Dermatologist

Re-assessment required after 6 months Both:

1 Either:

- 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
- 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initiation - severe chronic plaque psoriasis, first-line biologic

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - severe chronic plaque psoriasis, first-line biologic

Dermatologist

Re-assessment required after 6 months

Both:

1 Either:

- 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
- 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

	Price			Brand or
(ex ma	in. excl.	GST)		Generic
	\$		Per	Manufacturer

continued...

Initiation - ankylosing spondylitis, second-line biologic

Rheumatologist

Re-assessment required after 3 months

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and 2 Either:

- 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
- 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Continuation – ankylosing spondylitis, second-line biologic

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks initial treatment of secukinumab treatment, BASDAI has improved by 4 or more points from pre-secukinumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefitted from treatment and that continued treatment is appropriate; and
- 3 Secukinumab to be administered at doses no greater than 150 mg monthly.

Initiation – psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Either:

- 1 Both:
 - 1.1 Patient has had an initial Special Authority approval for adalimumab, etanercept or infliximab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 Patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 1.2.2 Patient has received insufficient benefit from adalimumab, etanercept or infliximab to meet the renewal criteria for adalimumab, etanercept or infliximab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior secukinumab treatment in the opinion of the treating physician; and
- 2 Secukinumab to be administered at doses no greater than 300 mg monthly.

SILTUXIMAB - Restricted see terms below Inj 100 mg vial	1 1	Sylvant Sylvant	
Initiation			
Haematologist or rheumatologist			
Re-assessment required after 6 months			
All of the following:			
 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; a Treatment with an adequate trial of corticosteroids has proven ineffective; and Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks 			
Continuation	•		
Haematologist or rheumatologist			
Re-assessment required after 12 months			
The treatment remains appropriate and the patient has sustained improvement in inflamm	natory mark	ers and functional status	3.
TIXAGEVIMAB WITH CILGAVIMAB – Restricted see terms below			
Inj 100 mg per ml, 1.5 ml vial with cilgavimab 100 mg per ml,1.5 ml vial0.00	1	Evusheld	
→ Restricted (RS1911)			
Initiation			
Only if patient meets access criteria (as per https://pharmac.govt.nz/Evusheld). Note the	supply of tr	reatment is via Pharmac'	's
approved distribution process. Refer to the Pharmac website for more information about	this and sto	ock availability.	
TOCILIZUMAB – Restricted see terms below			
Inj 20 mg per ml, 4 ml vial	1	Actemra	
Inj 20 mg per ml, 10 ml vial	1	Actemra	
Inj 20 mg per ml, 20 ml vial	1	Actemra	
➡ Restricted (RS1924)			
Initiation – cytokine release syndrome			
Therapy limited to 3 doses			
Either:			

- 1 All of the following:
 - 1.1 The patient is enrolled in the Children's Oncology Group AALL1731 trial; and
 - 1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
 - Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or
- 2 All of the following:

Pi	rice			Brand or
(ex man.	excl.	GST)		Generic
	\$	F	Per	Manufacturer

continued...

- 2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
- 2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
- 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initiation - previous use

Any relevant practitioner Limited to 6 months treatment

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 rheumatoid arthritis; or
 - 2.2 systemic juvenile idiopathic arthritis; or
 - 2.3 adult-onset Still's disease; or
 - 2.4 polyarticular juvenile idiopathic arthritis; or
 - 2.5 idiopathic multicentric Castleman's disease.

Initiation - Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Limited to 6 months treatment

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital; and
 - 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initiation - Rheumatoid Arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2 Tocilizumab is to be used as monotherapy; and
- 3 Either:
 - 3.1 Treatment with methotrexate is contraindicated; or
 - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 4 Either:

222

4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
- 5 Either:
 - 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 6 Either:
 - 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initiation - systemic juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initiation - adult-onset Still's disease

Rheumatologist or Practitioner on the recommendation of a rheumatologist Re-assessment required after 6 months

Either:

1 Both:

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a Health NZ Hospital; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initiation - polyarticular juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 4 months

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for polyarticular course juvenile idiopathic arthritis (JIA); and
- 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
- 2 All of the following:

	Price			Brand or
(ex n	nan. excl.	GST)		Generic
	\$		Per	Manufacturer

continued...

- 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
- 2.2 Patient has had polyarticular course JIA for 6 months duration or longer; and
- 2.3 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.4 Any of the following:
 - 2.4.1 At least 5 active joints and at least 3 joints with limited range of motion, pain or tenderness after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.2 Moderate or high disease activity (cJADAS10 score of at least 2.5) after a 3-month trial of methotrexate (at the maximum tolerated dose); or
 - 2.4.3 Low disease activity (cJADAS10 score between 1.1 and 2.5) after a 6-month trial of methotrexate.

Initiation - idiopathic multicentric Castleman's disease

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist *Re-assessment required after 6 months*

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Initiation – moderate to severe COVID-19

Therapy limited to 1 dose

All of the following:

- 1 Patient has confirmed (or probable) COVID-19; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Tocilizumab is to be administered at doses no greater than 8mg/kg IV for a maximum of one dose; and
- 5 Tocilizumab is not to be administered in combination with barcitinib.

Continuation – Rheumatoid Arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Continuation - systemic juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Either:

- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Continuation - adult-onset Still's disease

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

the patient has a sustained improvement in inflammatory markers and functional status.

Continuation - polyarticular juvenile idiopathic arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

Both:

Price		Brand or
(ex man. excl. GST)		Generic
\$	Per	Manufacturer

continued...

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Continuation - idiopathic multicentric Castleman's disease

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist *Re-assessment required after 12 months*

the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB - Restricted see terms below

t	Inj 150 mg vial1,350.00	1	Herceptin
t	Inj 440 mg vial	1	Herceptin

→ Restricted (RS1554)

Initiation – Early breast cancer

Limited to 12 months treatment

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
 - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Initiation - metastatic breast cancer (trastuzumab-naive patients)

Limited to 12 months treatment

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 Both:
 - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

Initiation - metastatic breast cancer (patients previously treated with trastuzumab)

Limited to 12 months treatment

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 Both:
 - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

Continuation - metastatic breast cancer

Re-assessment required after 12 months

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

TRASTUZUMAB EMTANSINE - Restricted see terms below

t	Inj 100 mg vial2,320.00	1	Kadcyla
t	Inj 160 mg vial3,712.00	1	Kadcyla

➡ Restricted (RS1908)

Initiation - early breast cancer

All of the following:

- 1 Patient has early breast cancer expressing HER2 IHC3+ or ISH+; and
- 2 Documentation of pathological invasive residual disease in the breast and/or auxiliary lymph nodes following completion of surgery; and
- 3 Patient has completed systemic neoadjuvant therapy with trastuzumab and chemotherapy prior to surgery; and
- 4 Disease has not progressed during neoadjuvant therapy; and
- 5 Patient has left ventricular ejection fraction of 45% or greater; and
- 6 Adjuvant treatment with trastuzumab emtansine to be commenced within 12 weeks of surgery; and
- 7 Trastuzumab emtansine to be discontinued at disease progression; and
- 8 Total adjuvant treatment duration must not exceed 42 weeks (14 cycles).

Initiation - metastatic breast cancer

Re-assessment required after 6 months All of the following:

Price			Brand or
(ex man. exc	I. GST)		Generic
\$		Per	Manufacturer

- continued...
 - 1 Patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
 - 3 Either:
 - 3.1 The patient has received prior therapy for metastatic disease*; or
 - 3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
 - 4 Patient has a good performance status (ECOG 0-1); and
 - 5 Either:
 - 5.1 Patient does not have symptomatic brain metastases; or
 - 5.2 Patient has brain metastases and has received prior local CNS therapy; and
 - 6 Patient has not received prior funded trastuzumab emtansine treatment; and
 - 7 Treatment to be discontinued at disease progression.

Continuation - metastatic breast cancer

Re-assessment required after 6 months

Both:

- 1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab emtansine; and
- 2 Treatment to be discontinued at disease progression.

Note: *Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

USTEKINUMAE	- Restricted see	e terms below
-------------	------------------	---------------

t	Inj 130 mg vial4,162.00	1	Stelara
t	Inj 90 mg per ml, 1 ml prefilled syringe4,162.00	1	Stelara

➡ Restricted (RS1942)

Initiation - Crohn's disease - adults

Re-assessment required after 6 months

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
 - 2.1 Patient has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy for Crohn's disease and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologics for Crohn's disease are contraindicated.

Continuation - Crohn's disease - adults

Re-assessment required after 12 months Both:

- 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy; or
 - 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and
- 2 Ustekinumab to be administered at a dose no greater than 90 mg every 8 weeks.

Price		Brand or
(ex man. excl. GST))	Generic
\$	Per	Manufacturer

continued...

Initiation - Crohn's disease - children*

Re-assessment required after 6 months

Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
 - 2.1 Patient has active Crohn's disease; and
 - 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for Crohn's disease; and
 - 2.2.2.2 Other biologics for Crohn's disease are contraindicated.

Note: Indication marked with * is an unapproved indication.

Continuation - Crohn's disease - children*

Re-assessment required after 12 months

Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Ustekinumab to administered at a dose no greater than 90 mg every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Initiation - ulcerative colitis

Re-assessment required after 6 months Either:

- 1 Patient is currently on treatment with ustekinumab commenced prior to 1 February 2023 and met all remaining criteria (criterion 2) below at the time of commencing treatment; or
- 2 Both:
 - 2.1 Patient has active ulcerative colitis; and
 - 2.2 Either:
 - 2.2.1 Patient has had an initial approval for prior biologic therapy for ulcerative colitis and has experienced intolerable side effects or insufficient benefit to meet renewal criteria; or
 - 2.2.2 Both:
 - 2.2.2.1 Patient meets the initiation criteria for prior biologic therapies for ulcerative colitis; and
 - 2.2.2.2 Other biologics for ulcerative colitis are contraindicated.

Continuation – ulcerative colitis

Re-assessment required after 12 months Both:

1 Fither:

228

1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or 1.2 PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy*; and

- Ustekinumab will be used at a dose no greater than 90 mg intravenously every 8 weeks.
- Note: Criterion marked with * is for an unapproved indication.

/EDOLIZUMAB - Restricted see terms on the next page	е

t	Inj 300 mg vial3,313.00	1	Entyvic
---	-------------------------	---	---------

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

→ Restricted (RS1943)

Initiation - Crohn's disease - adults

Re-assessment required after 6 months

All of the following:

- 1 Patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10; or
 - 2.3 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.4 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.5 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Any of the following:
 - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
 - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
 - 3.3 Immunomodulators and corticosteroids are contraindicated.

Continuation - Crohn's disease - adults

Re-assessment required after 2 years

Both:

1 Any of the following:

- 1.1 CDAI score has reduced by 100 points, or HBI score has reduced by 3 points, from when the patient was initiated on biologic therapy; or
- 1.2 CDAI score is 150 or less, or HBI is 4 or less; or
- 1.3 The patient has experienced an adequate response to treatment, but CDAI score and/or HBI score cannot be assessed; and
- 2 Vedolizumab to administered at a dose no greater than 300 mg every 8 weeks.

Initiation - Crohn's disease - children*

Re-assessment required after 6 months

All of the following:

- 1 Paediatric patient has active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.3 Patient has extensive small intestine disease; and
- 3 Any of the following:
 - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
 - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
 - 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with * is an unapproved indication.

Continuation - Crohn's disease - children*

Re-assessment required after 2 years

Both:

1 Any of the following:

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 1.1 PCDAI score has reduced by 10 points from when the patient was initiated on biologic therapy; or
- 1.2 PCDAI score is 15 or less; or
- 1.3 The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and
- 2 Vedolizumab to administered at a dose no greater than 300mg every 8 weeks.
- Note: Indication marked with * is an unapproved indication.

Initiation - ulcerative colitis

Re-assessment required after 6 months

All of the following:

- 1 Patient has active ulcerative colitis; and
- 2 Any of the following:
 - 2.1 Patient has had an initial approval for prior biologic therapy and has experienced intolerable side effects or insufficient benefit to meet renewal criteria (unless contraindicated); or
 - 2.2 Patient has a SCCAI score is greater than or equal to 4; or
 - 2.3 Patient's PUCAI score is greater than or equal to 20*; and
- 3 Any of the following:
 - 3.1 Patient has tried but experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or
 - 3.2 Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or
 - 3.3 Immunomodulators and corticosteroids are contraindicated.

Note: Indication marked with * is an unapproved indication.

Continuation - ulcerative colitis

Re-assessment required after 2 years

Both:

- 1 Either:
 - 1.1 The SCCAI score has reduced by 2 points or more from the SCCAI score since initiation on biologic therapy; or
 - 1.2 The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biologic therapy *; and

2 Vedolizumab will be used at a dose no greater than 300 mg intravenously every 8 weeks.

Note: Indication marked with * is an unapproved indication.

Programmed Cell Death-1 (PD-1) Inhibitors

- 1 Patient has locally advanced or metastatic non-small cell lung cancer; and
- 2 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 3 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 4 Patient has an ECOG 0-2; and
- 5 Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy; and
- 6 Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

7 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Continuation - non-small cell lung cancer second line monotherapy

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

Re-assessment required after 4 months

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent); and
- 6 Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

DURVALUMAB - Restricted see terms below

t	Inj 50 mg per ml, 10 ml vial4,	700.00	1	Imfinzi
t	Inj 50 mg per ml, 2.4 ml vial1,	128.00	1	Imfinzi

→ Restricted (RS1926)

Initiation - Non-small cell lung cancer

Medical oncologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC); and
- 2 Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy; and
- 3 Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment; and
- 4 Patient has a ECOG performance status of 0 or 1; and
- 5 Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab; and
- 6 Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition; and
- 7 Either:
 - 7.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
- 7.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 8 Treatment with durvalumab to cease upon signs of disease progression.

Continuation - Non-small cell lung cancer

Medical oncologist

Re-assessment required after 3 months

All of the following:

- 1 The treatment remains clinically appropriate and the patient is benefitting from treatment; and
- 2 Either:
 - 2.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or
 - 2.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and
- 3 Treatment with durvalumab to cease upon signs of disease progression; and
- 4 Total continuous treatment duration must not exceed 12 months.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer	
NIVOLUMAB – Restricted see terms below				
Inj 10 mg per ml, 4 ml vial	1,051.98	1	Opdivo	
Inj 10 mg per ml, 10 ml vial ■ Destricted (PS1801)	2,629.96	1	Opdivo	

\Rightarrow Restricted (RS1891)

Initiation

Medical oncologist

Re-assessment required after 4 months

All of the following:

1 Patient has metastatic or unresectable melanoma (excluding uveal) stage III or IV; and

- 2 Patient has measurable disease as defined by RECIST version 1.1; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded pembrolizumab; or

4.2 Both:

- 4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
- 4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
- 5 Baseline measurement of overall tumour burden is documented (see Note); and
- 6 Documentation confirming that the patient has been informed and acknowledges that funded treatment with nivolumab will not be continued if their disease progresses.

Continuation

Medical oncologist *Re-assessment required after 4 months* Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
 - 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes; and
 - 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
 - 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with nivolumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with nivolumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

• Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

	(ex mar	Price n. excl. \$	GST)	Per	Brand or Generic Manufacturer
continued					
Partial Response: At least a 30% decrease in the sum of	diameters of t	arget l	lesions,	taking a	as reference the baseline su
diameters.Progressive Disease: At least a 20% increase in the sum	of diamotora	oftora	ot Ionia	na takir	a an reference the amellect
 Progressive Disease. At least a 20% increase in the sum sum on study (this includes the baseline sum if that is the 					
the sum must also demonstrate an absolute increase of a					
lesions is also considered progression).					
 Stable Disease: Neither sufficient shrinkage to qualify for disease. 	partial respon	se nor	rsufficie	ent incre	ease to qualify for progressiv
PEMBROLIZUMAB – Restricted see terms below					
Inj 25 mg per ml, 4 ml vial	4	,680.0	0	1	Keytruda
→ Restricted (RS1987)					
nitiation Medical oncologist					
Re-assessment required after 4 months					
All of the following:					
1 Patient has metastatic or unresectable melanoma (exclud			r IV; an	d	
2 Patient has measurable disease as defined by RECIST ve	ersion 1.1; and				
 3 The patient has ECOG performance score of 0-2; and 4 Fither: 					
4.1 Patient has not received funded nivolumab; or					
4.2 Both:					
4.2.1 Patient has received an initial Special Auth			olumab	and has	s discontinued nivolumab
within 12 weeks of starting treatment due to			ام در م		
4.2.2 The cancer did not progress while the patie 5 Baseline measurement of overall tumour burden is docum					
6 Documentation confirming that the patient has been infor	(funded	treatment with
pembrolizumab will not be continued if their disease progr			,		
Continuation					
Medical oncologist					

Re-assessment required after 4 months Fither:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.1.3 Patient has stable disease according to RECIST criteria (see Note); and
 - 1.2 Patient's disease has not progressed clinically and disease response to treatment has been clearly documented in patient notes: and
 - 1.3 No evidence of progressive disease according to RECIST criteria (see Note); and
 - 1.4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; or
- 2 All of the following:
 - 2.1 Patient has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression; and
 - 2.2 Patient has signs of disease progression; and
 - 2.3 Disease has not progressed during previous treatment with pembrolizumab.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Measurable disease includes by CT or MRI imaging or caliper measurement by clinical exam. Target lesion measurements should be assessed using the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target)
 must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Initiation - non-small cell lung cancer first-line monotherapy

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

Re-assessment required after 4 months

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2 Patient has not had chemotherapy for their disease in the palliative setting; and
- 3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 5 Pembrolizumab to be used as monotherapy; and
- 6 Either:
 - 6.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain; or
 - 6.2 Both:
 - 6.2.1 There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain; and
 - 6.2.2 Chemotherapy is determined to be not in the best interest of the patient based on clinician assessment; and
- 7 Patient has an ECOG 0-2; and
- 8 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 9 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Continuation - non-small cell lung cancer first-line monotherapy

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

Re-assessment required after 4 months

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and

e.g. Brand indicates brand example only. It is not a contracted product.

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Initiation - non-small cell lung cancer first-line combination therapy

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

Re-assessment required after 4 months

All of the following:

- 1 Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer; and
- 2 The patient has not had chemotherapy for their disease in the palliative setting; and
- 3 Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC; and
- 4 For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain; and
- 5 Pembrolizumab to be used in combination with platinum-based chemotherapy; and
- 6 Patient has an ECOG 0-2; and
- 7 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks; and
- 8 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Continuation - non-small cell lung cancer first-line combination therapy

Medical oncologist or any relevant practitioner on the recommendation of a medical oncologist

Re-assessment required after 4 months

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment; or
 - 1.2 Patient's disease has had a partial response to treatment; or
 - 1.3 Patient has stable disease; and
- 2 Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period; and
- 3 No evidence of disease progression; and
- 4 The treatment remains clinically appropriate and patient is benefitting from treatment; and
- 5 Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent); and
- 6 Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks).

Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE) Inj 50 mg per ml, 5 ml ampoule2,774.48	5	ATGAM
ANTITHYMOCYTE GLOBULIN (RABBIT) Inj 25 mg vial		
AZATHIOPRINE		
Tab 25 mg – 5% DV Apr-23 to 20257.36	60	Azamun
Tab 50 mg – 5% DV Mar-23 to 20258.10	100	Azamun
Inj 50 mg vial		
Inj 100 mg vial		
BACILLUS CALMETTE-GUERIN (BCG) - Restricted see terms on the next page		
↓ Inj 2-8 × 10°8 CFU vial	1	OncoTICE

	(ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
→ Restricted (RS1206)					
Initiation					
For use in bladder cancer.					
EVEROLIMUS - Restricted see terms below					
T ab 5 mg				30	Afinitor
1 Tab 10 mg	6,	512.29)	30	Afinitor
→ Restricted (RS1811)					
Initiation					
Neurologist or oncologist Re-assessment required after 3 months					
Both:					
1 Patient has tuberous sclerosis; and					
2 Patient has progressively enlarging sub-ependymal giant cell a	etrocutom	20 (98		that roa	uire treatment
Continuation	astrocytom	as (31	LUAS)	inai requ	
Neurologist or oncologist					
Re-assessment required after 12 months					
All of the following:					
1 Documented evidence of SEGA reduction or stabilisation by N	IRI within t	ha lac	t 3 mo	nthe: and	4
2 The treatment remains appropriate and the patient is benefitin				nins, and	4
3 Everolimus to be discontinued at progression of SEGAs.	y nom nee	unon	, and		
MYCOPHENOLATE MOFETIL		05.00		50	0 - 110
Tab 500 mg				50	CellCept
Cap 250 mg				100	CellCept
Powder for oral liq 1 g per 5 ml Inj 500 mg vial				165 ml 4	CellCept CellCept
, ,	•••••	100.00)	4	CellCept
PICIBANIL					
Inj 100 mcg vial					
SIROLIMUS – Restricted see terms below					
I Tab 1 mg	······	749.99)	100	Rapamune
	,			100	Rapamune
Oral liq 1 mg per ml		449.99)	60 ml	Rapamune
→ Restricted (RS1991)					
Initiation					
For rescue therapy for an organ transplant recipient.					and a standard standa
Notes: Rescue therapy defined as unresponsive to calcineurin inhibit	for treatme	nt as o	aetinec	i by refra	ctory rejection; or intolerant
to calcineurin inhibitor treatment due to any of the following:					
 GFR < 30 ml/min; or 					
 Rapidly progressive transplant vasculopathy; or 					
- Danidly prograding abotrivative branchielities or					

- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- · Leukoencepthalopathy; or
- Significant malignant disease

Initiation - severe non-malignant lymphovascular malformations*

Re-assessment required after 6 months

All of the following:

- 1 Patient has severe non-malignant lymphovascular malformation*; and
- 2 Any of the following:

Р	rice		Brand or
(ex man.	excl. GST)		Generic
	\$	Per	Manufacturer

continued...

- 2.1 Malformations are not adequately controlled by sclerotherapy and surgery; or
- 2.2 Malformations are widespread/extensive and sclerotherapy and surgery are not considered clinically appropriate; or 2.3 Sirolimus is to be used to reduce malformation prior to consideration of surgery; and
- 3 Patient is being treated by a specialist lymphovascular malformation multi-disciplinary team; and
- 4 Patient has measurable disease as defined by RECIST version 1.1 (see Note).

Continuation - severe non-malignant lymphovascular malformations*

Re-assessment required after 12 months

All of the following:

- 1 Either:
 - 1.1 Patient's disease has had either a complete response or a partial response to treatment, or patient has stable disease according to RECIST version 1.1 (see Note); or
 - 1.2 Patient's disease has stabilised or responded clinically and disease response to treatment has been clearly documents in patient notes; and
- 2 No evidence of progressive disease; and
- 3 The treatment remains clinically appropriate and the patient is benefitting from the treatment.

Notes: Baseline assessment and disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer et al. Eur J Cancer 2009;45:228-47)

Indications marked with * are unapproved indications

Initiation - renal angiomyolipoma(s) associated with tuberous sclerosis complex*

Nephrologist or urologist

Re-assessment required after 6 months Both:

- 1 Patient has tuberous sclerosis complex*; and
- 2 Evidence of renal angiomyolipoma(s) measuring 3 cm or greater and that have shown interval growth.

Continuation - renal angiomyolipoma(s) associated with tuberous sclerosis complex*

Re-assessment required after 12 months

All of the following:

- 1 Documented evidence of renal angiomyolipoma reduction or stability by magnetic resonance imaging (MRI) or ultrasound; and
- 2 Demonstrated stabilisation or improvement in renal function; and
- 3 The patient has not experienced angiomyolipoma haemorrhage or significant adverse effects to sirolimus treatment; and
- 4 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indications marked with * are unapproved indications

Initiation – refractory seizures associated with tuberous sclerosis complex*

Neurologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has epilepsy with a background of documented tuberous sclerosis complex*; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Vigabatrin has been trialled and has not adequately controlled seizures; and
 - 2.1.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least two of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); or

2.2 Both:

2.2.1 Vigabatrin is contraindicated; and

Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

continued...

- 2.2.2 Seizures are not adequately controlled by, or the patient has experienced unacceptable side effects from, optimal treatment with at least three of the following: sodium valproate, topiramate, levetiracetam, carbamazepine, lamotrigine, phenytoin sodium, and lacosamide (see Note); and
- 3 Seizures have a significant impact on quality of life; and
- 4 Patient has been assessed and surgery is considered inappropriate for this patient, or the patient has been assessed and would benefit from mTOR inhibitor treatment prior to surgery.

Note: Those of childbearing potential are not required to trial phenytoin sodium, sodium valproate, and topiramate. Those who can father children are not required to trial sodium valproate.

Continuation - refractory seizures associated with tuberous sclerosis complex*

Neurologist

Re-assessment required after 12 months

demonstrated significant and sustained improvement in seizure rate (e.g. 50% reduction in seizure frequency) or severity and/or patient quality of life compared with baseline prior to starting sirolimus treatment. Note: Indications marked with * are unapproved indications

JAK inhibitors

BARICITINIB – Restricted see terms below			
↓ Tab 2 mg	0.00	28	Olumiant
I Tab 4 mg		28	Olumiant
→ Restricted (RS1876)			

Initiation - moderate to severe COVID-19*

Limited to 14 days treatment

All of the following:

- 1 Patient has confirmed (or probable) COVID-19*; and
- 2 Oxygen saturation of < 92% on room air, or requiring supplemental oxygen; and
- 3 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and
- 4 Baricitinib is to be administered at doses no greater than 4 mg daily for up to 14 days; and
- 5 Baricitinib is not to be administered in combination with tocilizumab.

Note: Indications marked with * are unapproved indications.

UPADACITINIB – **Restricted** see terms below

➡ Restricted (RS1861)

Initiation - Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)

Rheumatologist

Limited to 6 months treatment

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital; and
 - 3.2.2 Either:

 Price (ex man. excl. GST)		Brand or Generic
 \$	Per	Manufacturer

continued...

3.2.2.1 The patient has experienced intolerable side effects from rituximab; or

3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Continuation – Rheumatoid Arthritis

Rheumatologist

Re-assessment required after 6 months Either:

 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antiallergy Preparations			
Allergic Emergencies			
ADRENALINE – Restricted see terms below Inj 0.15 mg per 0.3 ml auto-injector – 5% DV Jul-23 to 2025 Inj 0.3 mg per 0.3 ml auto-injector – 5% DV Jul-23 to 2025 → Restricted (RS1944) Initiation – anaphylaxis Either:	90.00	1 1	Epipen Jr Epipen
 Patient has experienced a previous anaphylactic reaction whic department; or Patient has been assessed to be at significant risk of anaphyla 			a hospital or emergency
ICATIBANT - Restricted see terms below ↓ Inj 10 mg per ml, 3 ml prefilled syringe	2,668.00	1	Firazyr
 Clinical immunologist or relevant specialist <i>Re-assessment required after 12 months</i> Both: Supply for anticipated emergency treatment of laryngeal/oro-p angioedema (HAE) for patients with confirmed diagnosis of C1 The patient has undergone product training and has agreed up 	I-esterase inhibitor def	iciency; a	nd
Continuation <i>Re-assessment required after 12 months</i> The treatment remains appropriate and the patient is benefiting from	treatment.		
Allergy Desensitisation			
 BEE VENOM - Restricted see terms below Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluer Inj 550 mcg vial with diluent Initiation Kit - 5 vials freeze dried venom with diluent Maintenance Kit - 1 vial freeze dried venom with diluent Restricted (RS1117) Initiation Both: RAST or skin test positive; and Patient has had severe generalised reaction to the sensitising 		1 1	VENOX VENOX
PAPER WASP VENOM – Restricted see terms below ↓ Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent ↓ Inj 550 mcg vial with diluent → Restricted (RS1118) Initiation	agont.		
Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising	agent.		
YELLOW JACKET WASP VENOM - Restricted see terms on the ne	ext page		

- Inj 550 mcg vial with diluent

Brand or Generic Manufacturer
se SteroClear se SteroClear
se Flixonase Hayfever &
Allergy
I Univent
Zista ni Histaclear
Lorafix nl Haylor Syrup
Allersoothe Allersoothe nl Allersoothe Hospira
·
Univent

	Price (ex man. excl. GS \$	ST) Per	Brand or Generic Manufacturer
Anticholinergic Agents with Beta-Adrenoceptor Ag	gonists		
SALBUTAMOL WITH IPRATROPIUM BROMIDE Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per do Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 m ampoule – 5% DV Jan-22 to 2024	nl	20	Duolin
Long-Acting Muscarinic Agents			
GLYCOPYRRONIUM Note: inhaled glycopyrronium treatment must not be used if the or umeclidinium. Powder for inhalation 50 mcg per dose		ving treatmer 30 dose	t with subsidised tiotropium Seebri Breezhaler
TIOTROPIUM BROMIDE Note: tiotropium treatment must not be used if the patient is also or umeclidinium. Soln for inhalation 2.5 mcg per dose	o receiving treatmen	t with subsidi 60 dose	sed inhaled glycopyrronium Spiriva Respimat
Powder for inhalation 18 mcg per dose		30 dose	Spiriva
UMECLIDINIUM Note: Umeclidinium must not be used if the patient is also receiv tiotropium bromide.	ving treatment with s	ubsidised inf	naled glycopyrronium or
Powder for inhalation 62.5 mcg per dose	61.50	30 dose	Incruse Ellipta

Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

→ Restricted (RS1518)

Initiation

Re-assessment required after 2 years Both:

- 1 Patient has been stabilised on a long acting muscarinic antagonist; and
- 2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Continuation

Re-assessment required after 2 years

Both:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

Note: Combination long acting muscarinic antagonist and long acting beta-2 agonist must not be used if the patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

GLYCOPYRRONIUM WITH INDACATEROL - Restricted see terms above

t Powder for Inhalation 50 mcg with indacaterol 110 mcg81.00	30 dose	Ultibro Breezhaler
TIOTROPIUM BROMIDE WITH OLODATEROL - Restricted see terms above		
t Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg	60 dose	Spiolto Respimat
UMECLIDINIUM WITH VILANTEROL – Restricted see terms above		
t Powder for inhalation 62.5 mcg with vilanterol 25 mcg77.00	30 dose	Anoro Ellipta

Antifibrotics

242

NI	NTEDANIB – Restricted see terms on the next page			
t	Cap 100 mg	2,554.00	60	Ofev
-	Cap 150 mg		60	Ofev

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

		Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer	
--	--	------------------------------------	-----	-------------------------------------	--

→ Restricted (RS1813)

Initiation – idiopathic pulmonary fibrosis

Respiratory specialist

Re-assessment required after 12 months

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Nintedanib is to be discontinued at disease progression (See Note); and
- 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with pirfenidone; or
 - 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Continuation - idiopathic pulmonary fibrosis

Respiratory specialist

Re-assessment required after 12 months

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE - Restricted see terms below

t	Tab 267 mg 1,215.00	90	Esbriet
t	Tab 801 mg	90	Esbriet

→ Restricted (RS1814)

Initiation - idiopathic pulmonary fibrosis

Respiratory specialist

Re-assessment required after 12 months

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Notes); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with nintedanib; or
 - 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Continuation - idiopathic pulmonary fibrosis

Respiratory specialist

Re-assessment required after 12 months

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

	Price (ex man. exc	(GST)	Brand or Generic
	(ox main one \$	Per	Manufacturer
Beta-Adrenoceptor Agonists			
SALBUTAMOL			
Oral liq 400 mcg per ml – 5% DV Mar-22 to 2024 Inj 500 mcg per ml, 1 ml ampoule Inj 1 mg per ml, 5 ml ampoule	40.	00 150 ml	Ventolin
Aerosol inhaler, 100 mcg per dose	3.	80 200 dos	e SalAir
	6.		Ventolin
Nebuliser soln 1 mg per ml, 2.5 ml ampoule - 5% DV Jan-22 to 20			Asthalin
Nebuliser soln 2 mg per ml, 2.5 ml ampoule - 5% DV Jan-22 to 20	24 9.4	43 20	Asthalin
TERBUTALINE SULPHATE			
Powder for inhalation 250 mcg per dose			
Inj 0.5 mg per ml, 1 ml ampoule			
Powder for inhalation, 200 mcg per dose (equivalent to 250 mcg metered dose), breath activated	20	20 120 dos	e Bricanyl Turbuhaler
melered dose), bream activated		20 120 005	
Decongestants			
OXYMETAZOLINE HYDROCHLORIDE Aqueous nasal spray 0.25 mg per ml			
Aqueous nasal spray 0.25 mg per ml			
PSEUDOEPHEDRINE HYDROCHLORIDE			
Tab 60 mg			
SODIUM CHLORIDE			
Aqueous nasal spray isotonic			
SODIUM CHLORIDE WITH SODIUM BICARBONATE			
Soln for nasal irrigation			
XYLOMETAZOLINE HYDROCHLORIDE			
Aqueous nasal spray 0.05%			
Aqueous nasal spray 0.1%			
Nasal drops 0.05%			
Nasal drops 0.1%			
Inhaled Corticosteroids			
BECLOMETHASONE DIPROPIONATE			
Aerosol inhaler 50 mcg per dose	R	54 200 dos	e Beclazone 50
Actosol initiator of they ber upserministration and the second se	0.	J- 200 005	

Qvar

Beclazone 100 Qvar 200 dose Beclazone 250

200 dose

Aerosol Illitaler 50 flicg per dose	0.04
	14.01
Aerosol inhaler 100 mcg per dose	
	17.52
Aerosol inhaler 250 mcg per dose	22.67
BUDESONIDE	
Nabuliaar aalo 050 mag nar ml. 0 ml.ampaula	

Nebuliser soln 250 mcg per ml, 2 ml ampoule Nebuliser soln 500 mcg per ml, 2 ml ampoule Powder for inhalation 100 mcg per dose Powder for inhalation 200 mcg per dose Powder for inhalation 400 mcg per dose

1	Price ex man. excl. GS	T)	Brand or Generic
	\$	Per	Manufacturer
FLUTICASONE			
Aerosol inhaler 50 mcg per dose	7.19	120 dose	Flixotide
Powder for inhalation 50 mcg per dose		60 dose	Flixotide Accuhaler
Powder for inhalation 100 mcg per dose	7.81	60 dose	Flixotide Accuhaler
Aerosol inhaler 125 mcg per dose		120 dose	Flixotide
Aerosol inhaler 250 mcg per dose	24.62	120 dose	Flixotide
Powder for inhalation 250 mcg per dose	11.93	60 dose	Flixotide Accuhaler
Leukotriene Receptor Antagonists			
/ONTELUKAST			
Tab 4 mg - 5% DV Sep-23 to 2025	3.10	28	Montelukast Mylan Montelukast Viatris
Tab 5 mg – 5% DV Jul-23 to 2025	3.10	28	Montelukast Mylan
Tab 10 mg – 5% DV Sep-23 to 2025	2 00	28	Montelukast Viatris Montelukast Mylan
Tab To Ting - 3% DV Sep-23 to 2023	2.90	20	Montelukast Viatris
Montelukast Mylan Tab 4 mg to be delisted 1 February 2024)			
Montelukast Mylan Tab 5 mg to be delisted 1 January 2024)			
Montelukast Mylan Tab 10 mg to be delisted 1 February 2024)			
Long-Acting Beta-Adrenoceptor Agonists			
FORMOTEROL FUMARATE Powder for inhalation 12 mcg per dose			
EFORMOTEROL FUMARATE DIHYDRATE			
Powder for inhalation 4.5 mcg per dose, breath activated (equivalent	to		
eformoterol fumarate 6 mcg metered dose)	10		
NDACATEROL			
Powder for inhalation 150 mcg per dose	61.00	30 dose	Onbrez Breezhaler
Powder for inhalation 300 mcg per dose	61.00	30 dose	Onbrez Breezhaler
SALMETEROL			
Aerosol inhaler 25 mcg per dose		120 dose	Serevent
Powder for inhalation 50 mcg per dose		60 dose	Serevent Accuhaler
••			
Inhaled Corticosteroids with Long-Acting Beta-Adren	oceptor Ago	onists	
BUDESONIDE WITH EFORMOTEROL			
Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg			
Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg			
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg			
Powder for inhalation 160 mcg with 4.5 mcg eformoterol fumarate pe	r		
dose (equivalent to 200 mcg budesonide with 6 mcg eformoterol			
fumarate metered dose)	41.50	120 dose	DuoResp Spiromax
Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg		120 dose	Symbicort Turbuhale
Powder for inhalation 320 mcg with 9 mcg eformoterol fumarate per			
dose (equivalent to 400 mcg budesonide with 12 mcg eformoter	bl		
fumarate metered dose)		120 dose	DuoResp Spiromax
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg		60 dose	Symbicort Turbuhaler
LUTICASONE FUROATE WITH VILANTEROL			
Powder for inhalation 100 mcg with vilanterol 25 mcg	<i>44</i> 08	30 dose	Breo Ellipta
Tomasi for initialation foo mog with vilanteror 20 mog		00 0000	Dioo Empla

		Price		Brand or
	(ex man.	excl. \$	GST) Per	Generic Manufacturer
FLUTICASONE WITH SALMETEROL				
Aerosol inhaler 50 mcg with salmeterol 25 mcg		.25.79	9 120 dose	Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg				Seretide Accuhaler
Aerosol inhaler 125 mcg with salmeterol 25 mcg		.32.60) 120 dose	Seretide
Powder for inhalation 250 mcg with salmeterol 50 mcg		.44.08	60 dose	Seretide Accuhaler
Methylxanthines				
AMINOPHYLLINE				
Inj 25 mg per ml, 10 ml ampoule		180.00) 5	DBL Aminophylline
CAFFEINE CITRATE				1.7
Oral lig 20 mg per ml (caffeine 10 mg per ml)		15.10) 25 ml	Biomed
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule				Biomed
THEOPHYLLINE				
Tab long-acting 250 mg		23.94	100	Nuelin-SR
Oral liq 80 mg per 15 ml				Nuelin
Mucolytics and Expectorants				
DORNASE ALFA – Restricted see terms below				
Nebuliser soln 2.5 mg per 2.5 ml ampoule		250.00) 6	Pulmozyme
→ Restricted (RS1787)				
nitiation – cystic fibrosis				
Respiratory physician or paediatrician				
Re-assessment required after 12 months				
All of the following:				
1 Patient has a confirmed diagnosis of cystic fibrosis; and	h	J ! I .		
2 Patient has previously undergone a trial with, or is currently3 Any of the following:	being treated	a witti,	hyperionic sain	ie, anu
, .	oonirotori od	miania	na in tha provia	us 10 month nariadi ar
3.1 Patient has required one or more hospital inpatient re3.2 Patient has had 3 exacerbations due to CF, requiring				
period; or				
3.3 Patient has had 1 exacerbation due to CF, requiring	oral or IV ant	ibiotic	s in the previou	s 12 month period and a
Brasfield score of < 22/25; or			241	
3.4 Patient has a diagnosis of allergic bronchopulmonar	y aspergiliosi	s (ABI	-A).	
Continuation – cystic fibrosis				
Respiratory physician or paediatrician The treatment remains appropriate and the patient continues to be	oofit from trop	otmon		
nitiation – significant mucus production		aunen	ι.	
Limited to 4 weeks treatment				
Both:				
1 Patient is an in-patient; and				
2 The mucus production cannot be cleared by first line chest t	echniques			
Initiation – pleural emphyema				
Limited to 3 days treatment				
Both:				
1 Detient is on in nationt; and				

- 1 Patient is an in-patient; and
- 2 Patient diagnoses with pleural emphyema.

e.g. Brand indicates brand example only. It is not a contracted product.

	Price		Brand or
	(ex man. excl. GST		Generic
	\$	Per	Manufacturer
ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAI	FTOR - Restricted see	terms bel	ow
↓ Tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 m			
ivacaftor 75 mg (28)	• • •	84	Trikafta
		01	initiatia
ivacaftor 150 mg (28)		84	Trikafta
→ Restricted (RS1950)		01	initiatia
Initiation			
All of the following:			
1 Patient has been diagnosed with cystic fibrosis; and			
2 Patient is 6 years of age or older; and			
3 Either:			
3.1 Patient has two cystic fibrosis-causing mutations in	the overtic fibrosis transm	omhrano	regulator (CETB) gene (one
from each parental allele); or		chibrane	regulator (or rri) gene (one
3.2 Patient has a sweat chloride value of at least 60 mm	ol/L by quantitative piloc	arnine ion	tophoresis or by Macroduct
sweat collection system; and	ior - by quantitative prior		tophorodo or by Madroadde
4 Either:			
	I mutation, ar		
4.1 Patient has a heterozygous or homozygous F508de4.2 Patient has a G551D mutation or other mutation res		oftor/tozo	aaftar/iu/aaaftar (aaa pata a);
4.2 Fallent has a GSSTD mutation of other mutation res	ponsive in vitro to elexad	alloi/leza	callor/ivacallor (see hole a),
		ام مد ما	
5 The treatment must be the sole funded CFTR modulator th			rony for this condition
6 Treatment with elexacaftor/tezacaftor/ivacaftor must be give	en concomitantiy with sta	indard the	rapy for this condition.
Note:			
a) Eligible mutations are listed in the Food and Drug Administ		scribing in	formation
https://www.accessdata.fda.gov/drugsatfda_docs/label/202	1/212273s004lbl.pdf.		
IVACAFTOR – Restricted see terms below			
↓ Tab 150 mg		56	Kalydeco
Oral granules 50 mg, sachet		56	Kalydeco
I Oral granules 75 mg, sachet		56	Kalydeco
→ Restricted (RS1818)			
Initiation			
Respiratory specialist or paediatrician			
All of the following:			
 Patient has been diagnosed with cystic fibrosis; and 			
2 Either:			
2.1 Patient must have G551D mutation in the cystic fibre	osis transmembrane con	ductance	regulator (CFTR) gene on at
least 1 allele; or			
2.2 Patient must have other gating (class III) mutation (G1244E, G1349D, G178	R, G551S	, S1251N, S1255P, S549N
and S549R) in the CFTR gene on at least 1 allele; a	Ind		
3 Patients must have a sweat chloride value of at least 60 mr	nol/L by quantitative pilo	carpine io	ntophoresis or by Macroduct
sweat collection system; and			
4 Treatment with ivacaftor must be given concomitantly with s	standard therapy for this	condition;	and
5 Patient must not have an acute upper or lower respiratory i			
(including antibiotics) for pulmonary disease in the last 4 we	eeks prior to commencing	g treatmer	nt with ivacaftor; and
6 The dose of ivacaftor will not exceed one tablet or one sach			
7 Applicant has experience and expertise in the managemen	t of cystic fibrosis.		
SODIUM CHLORIDE			
Nebuliser soln 7%, 90 ml bottle		90 ml	Biomed
	=		

(ex m	Pri an.e \$		GST)	Per	Brand or Generic Manufacturer
Pulmonary Surfactants					
BERACTANT					
Soln 200 mg per 8 ml vial					
PORACTANT ALFA					
Soln 120 mg per 1.5 ml vial	42	25.00)	1	Curosurf
Soln 240 mg per 3 ml vial	69	5.00)	1	Curosurf
Respiratory Stimulants					
DOXAPRAM Inj 20 mg per ml, 5 ml vial					

Sclerosing Agents

TALC

Powder Soln (slurry) 100 mg per ml, 50 ml

SENSORY ORGANS

	Price (ex man. excl. G \$	ST) Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
CHLORAMPHENICOL Eye oint 1% – 5% DV Dec-22 to 2025	1.09	5 g	Devatis
Ear drops 0.5% – 5% DV Sep-23 to 2025 Eye drops 0.5% – 5% DV Sep-23 to 2025 Eye drops 0.5%, single dose		10 ml	Chlorsig
CIPROFLOXACIN		_ .	
Eye drops 0.3% – 5% DV Nov-21 to 2024 FRAMYCETIN SULPHATE Ear/eye drops 0.5%	9.73	5 ml	Ciprofloxacin Teva
GENTAMICIN SULPHATE Eye drops 0.3%			
SODIUM FUSIDATE [FUSIDIC ACID]		_	
Eye drops 1% SULPHACETAMIDE SODIUM Eye drops 10%	5.29	5 g	Fucithalmic
TOBRAMYCIN Eye oint 0.3%	10.45	25 a	Tobrex
Eye drops 0.3%		3.5 g 5 ml	Tobrex
Antifungals			
NATAMYCIN Eye drops 5%			
Antivirals			
ACICLOVIR Eye oint 3% – 5% DV Sep-21 to 2024		4.5 g	ViruPOS
Combination Preparations			
CIPROFLOXACIN WITH HYDROCORTISONE Ear drops ciprofloxacin 0.2% with 1% hydrocortisone		10 ml	Ciproxin HC Otic
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramic 50 mcg per ml	cidin		
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYX			
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b su 6,000 u per g	•	3.5 g	Maxitrol
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml	4.50	5 ml	Maxitrol
DEXAMETHASONE WITH TOBRAMYCIN Eye drops 0.1% with tobramycin 0.3%	12.64	5 ml	Tobradex
FLUMETASONE PIVALATE WITH CLIOQUINOL Ear drops 0.02% with clioquinol 1%		5 111	

	F (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer	
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN						
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 m gramicidin 250 mcg per g	0	5.1	6	7.5 ml	Kenacomb	
Anti-Inflammatory Preparations						
Corticosteroids						
DEXAMETHASONE Eye oint 0.1% Eye drops 0.1% Ocular implant 700 mcg		4.5	0	3.5 g 5 ml 1	Maxidex Maxidex Ozurdex	

→ Restricted (RS1606)

Initiation – Diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months

All of the following:

- 1 Patients have diabetic macular oedema with pseudophakic lens; and
- 2 Patient has reduced visual acuity of between 6/9 6/48 with functional awareness of reduction in vision; and
- 3 Either:
 - 3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or
 - 3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Continuation – Diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months Both:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Initiation - Women of child bearing age with diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months

All of the following:

- 1 Patients have diabetic macular oedema; and
- 2 Patient has reduced visual acuity of between 6/9 6/48 with functional awareness of reduction in vision; and
- 3 Patient is of child bearing potential and has not yet completed a family; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Continuation - Women of child bearing age with diabetic macular oedema

Ophthalmologist

Re-assessment required after 12 months

All of the following:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Patient is of child bearing potential and has not yet completed a family; and
- 3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

SENSORY ORGANS

	Price	Brand or	
	(ex man. excl. GST)		Generic
	\$	Per	Manufacturer
FLUOROMETHOLONE			
Eye drops 0.1%	3.09	5 ml	FML
PREDNISOLONE ACETATE			
Eye drops 0.12%			
Eye drops 1%	7.00	5 ml	Pred Forte
	6.92	10 ml	Prednisolone- AFT
PREDNISOLONE SODIUM PHOSPHATE	(1.00	a a 1	M:
Eye drops 0.5%, single dose (preservative free)		20 dose	Minims Prednisolone
Non-Steroidal Anti-Inflammatory Drugs			
DICLOFENAC SODIUM			
Eye drops 0.1% - 5% DV Nov-21 to 2024	8.80	5 ml	Voltaren Ophtha
KETOROLAC TROMETAMOL			
Eye drops 0.5%			
NEPAFENAC			
Eye drops 0.3%			
Decongestants and Antiallergics			
Antiallergic Preparations			
LEVOCABASTINE			
Eye drops 0.05%			
LODOXAMIDE			
Eye drops 0.1%	8.71	10 ml	Lomide
OLOPATADINE			2011100
Eye drops 0.1% - 5% DV Dec-22 to 2025	2 17	5 ml	Olopatadine Teva
SODIUM CROMOGLICATE		• ····	
Eye drops 2% – 5% DV Mar-23 to 2025	2 62	10 ml	Allerfix
	2.02	10 111	
Decongestants			
NAPHAZOLINE HYDROCHLORIDE			
Eye drops 0.1%	4.15	15 ml	Naphcon Forte
Diagnostic and Surgical Preparations			
Diagnostic Dyes			
FLUORESCEIN SODIUM			
Eye drops 2%, single dose			
lnj 10%, 5 ml vial		12	Fluorescite
Ophthalmic strips 1 mg			
FLUORESCEIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE			
Eye drops 0.25% with lignocaine hydrochloride 4%, single dose			
LISSAMINE GREEN			
Ophthalmic strips 1.5 mg			
ROSE BENGAL SODIUM			
Ophthalmic strips 1%			
· ·			

(ex n	Price nan. excl. GS \$	Г) Per	Brand or Generic Manufacturer
Irrigation Solutions			
MIXED SALT SOLUTION FOR EYE IRRIGATION Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium	9		
chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bottle Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml		15 ml	Balanced Salt Solution
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium	9		Solution
chloride 0.64% and sodium citrate 0.17%, 500 ml bag			e.g. Balanced Salt Solution
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bottle		500 ml	Balanced Salt Solution
Ocular Anaesthetics			
OXYBUPROCAINE HYDROCHLORIDE Eye drops 0.4%, single dose PROXYMETACAINE HYDROCHLORIDE Eye drops 0.5% TETRACAINE [AMETHOCAINE] HYDROCHLORIDE Eye drops 0.5%, single dose Eye drops 1%, single dose			
Viscoelastic Substances			
HYPROMELLOSE Inj 2%, 1 ml syringe Inj 2%, 2 ml syringe			
 SODIUM HYALURONATE [HYALURONIC ACID] Inj 14 mg per ml, 0.85 ml syringe Inj 18 mg per ml, 0.85 ml syringe – 5% DV Dec-22 to 2025 Inj 23 mg per ml, 0.6 ml syringe – 5% DV Dec-22 to 2025 Inj 10 mg per ml, 0.85 ml syringe – 5% DV Dec-22 to 2025 SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SU Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml 	50.00 60.00 28.50 LPHATE	1 1 1	Healon GV Healon GV Pro Healon 5 Healon
syringe Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml		1	Duovisc
syringe Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe		1 1	Duovisc Viscoat
Other			

DISODIUM EDETATE

Inj 150 mg per ml, 20 ml ampoule

Inj 150 mg per ml, 20 ml vial

Inj 150 mg per ml, 100 ml vial

t Item restricted (see \rightarrow above); **f** Item restricted (see \rightarrow below)

e.g. Brand indicates brand example only. It is not a contracted product.

	l (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
RIBOFLAVIN 5-PHOSPHATE Soln trans epithelial riboflavin Inj 0.1% Inj 0.1% plus 20% dextran T500					
Glaucoma Preparations					
Beta Blockers					
BETAXOLOL Eye drops 0.25% Eye drops 0.5% TIMOLOL Eye drops 0.25% Eye drops 0.5% → Eye drops 0.5%, gel forming – Restricted: For continuation or (<i>Timoptol XE Eye drops 0.5%, gel forming to be delisted 1 March 20</i>	ly	7.50 1.81 2.04		5 ml 5 ml 5 ml 5 ml 2.5 ml	Betoptic S Betoptic Arrow-Timolol Arrow-Timolol Timoptol XE
Carbonic Anhydrase Inhibitors					
ACETAZOLAMIDE Tab 250 mg Inj 500 mg BRINZOLAMIDE		. 17.03		100	Diamox
Eye drops 1% – 5% DV Sep-21 to 2024 DORZOLAMIDE – Restricted: For continuation only → Eye drops 2% DORZOLAMIDE WITH TIMOLOL		7.30		5 ml	Azopt
Eye drops 2% with timolol 0.5% - 5% DV Dec-21 to 2024		2.73		5 ml	Dortimopt
Miotics					
ACETYLCHOLINE CHLORIDE Inj 20 mg vial with diluent CARBACHOL Inj 150 mcg vial PILOCARPINE HYDROCHLORIDE Eye drops 1% Eye drops 2% Eye drops 4% PILOCARPINE NITRATE Eye drops 2%, single dose		5.35		15 ml 15 ml 15 ml	Isopto Carpine Isopto Carpine Isopto Carpine
Prostaglandin Analogues					
BIMATOPROST Eye drops 0.03% – 5% DV Apr-22 to 2024 ATANOPROST		5.95		3 ml	Bimatoprost Multichen
Eye drops 0.005% – 5% DV Feb-22 to 2024 ATANOPROST WITH TIMOLOL Eye drops 0.005% with timolol 0.5%				2.5 ml 2.5 ml	Teva Arrow - Lattim

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated. SENSORY ORGANS

SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TRAVOPROST Eye drops 0.004% – 5% DV Dec-21 to 2024	9.75	2.5 ml	Travatan
Sympathomimetics			
APRACLONIDINE Eye drops 0.5% BRIMONIDINE TARTRATE		5 ml	lopidine
Eve drops 0.2% – 5% DV Jan-22 to 2024 BRIMONIDINE TARTRATE WITH TIMOLOL Eye drops 0.2% with timolol 0.5%	4.29	5 ml	Arrow-Brimonidine
Mydriatics and Cycloplegics			
Anticholinergic Agents			
ATROPINE SULPHATE Eye drops 0.5% Eye drops 1%, single dose	10.07		Maria
Eye drops 1% – 5% DV Feb-24 to 2026 CYCLOPENTOLATE HYDROCHLORIDE Eye drops 0.5%, single dose		15 ml	Atropt
Eye drops 1% Eye drops 1%, single dose TROPICAMIDE	8.76	15 ml	Cyclogyl
Eye drops 0.5% Eye drops 0.5%, single dose		15 ml	Mydriacyl
Eye drops 1% Eye drops 1%, single dose	8.66	15 ml	Mydriacyl
Sympathomimetics			
PHENYLEPHRINE HYDROCHLORIDE Eye drops 2.5%, single dose Eye drops 10%, single dose			
Ocular Lubricants			
CARBOMER Ophthalmic gel 0.3%, single dose Ophthalmic gel 0.2%	8.25	30	Poly Gel
CARMELLOSE SODIUM WITH PECTIN AND GELATINE Eye drops 0.5% Eye drops 0.5%, single dose Eye drops 1% Eye drops 1%, single dose			
HYPROMELLOSE Eye drops 0.5%		15 ml	Methopt
HYPROMELLOSE WITH DEXTRAN Eye drops 0.3% with dextran 0.1% Eye drops 0.3% with dextran 0.1%, single dose		15 ml	Poly-Tears

t Item restricted (see → above); t Item restricted (see → below)

e.g. Brand indicates brand example only. It is not a contracted product.

SENSORY ORGANS

(Price ex man. excl. GST \$) Per	Brand or Generic Manufacturer
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN Eye oint 42.5% with soft white paraffin 57.3%			
PARAFFIN LIQUID WITH WOOL FAT Eye oint 3% with wool fat 3%	3.63	3.5 g	Poly-Visc
POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL Eye drops 0.4% with propylene glycol 0.3% preservative free, single	dose10.78	30	Systane Unit Dose
POLYVINYL ALCOHOL WITH POVIDONE Eye drops 1.4% with povidone 0.6%, single dose			
RETINOL PALMITATE Oint 138 mcg per g	3.80	5 g	VitA-POS
SODIUM HYALURONATE [HYALURONIC ACID] Eye drops 1 mg per ml – 5% DV Jan-22 to 2024		10 ml	Hylo-Fresh

Other Otological Preparations

ACETIC ACID WITH PROPYLENE GLYCOL Ear drops 2.3% with propylene glycol 2.8%

DOCUSATE SODIUM Ear drops 0.5%

	Price . excl. GST \$	Per	Brand or Generic Manufacturer
Agents Used in the Treatment of Poisonings			
Antidotes			
ACETYLCYSTEINE Tab eff 200 mg Inj 200 mg per ml, 10 ml ampoule AMYL NITRITE Liq 98% in 3 ml capsule DIGOXIN IMMUNE FAB Inj 38 mg vial Inj 40 mg vial	 52.88	10	Martindale Pharma
ETHANOL Lig 96%			
ETHANOL WITH GLUCOSE Inj 10% with glucose 5%, 500 ml bottle ETHANOL, DEHYDRATED Inj 100%, 5 ml ampoule Inj 96%			
FLUMAZENIL Inj 0.1 mg per ml, 5 ml ampoule – 5% DV Feb-22 to 2024 HYDROXOCOBALAMIN Inj 5 g vial Inj 2.5 g vial	 110.12	10	Hamein
NALOXONE HYDROCHLORIDE Inj 400 mcg per ml, 1 ml ampoule – 5% DV Feb-23 to 2024 PRALIDOXIME IODIDE Inj 25 mg per ml, 20 ml ampoule	 35.26	10	Hameln
SODIUM NITRITE Inj 30 mg per ml, 10 ml ampoule			
SODIUM THIOSULFATE Inj 250 mg per ml, 100 ml vial Inj 250 mg per ml, 10 ml vial Inj 250 mg per ml. 50 ml vial Inj 500 mg per ml, 10 ml vial Inj 500 mg per ml, 20 ml ampoule			
SOYA OIL Inj 20%, 500 ml bag Inj 20%, 500 ml bottle			
Antitoxins			
BOTULISM ANTITOXIN			

BOTULISM ANTITOXIN Inj 250 ml vial DIPHTHERIA ANTITOXIN Inj 10,000 iu vial

Price		Brand or
(ex man. excl. G	GST)	Generic
\$	Per	Manufacturer

Antivenoms

RED BACK SPIDER ANTIVENOM Inj 500 u vial

SNAKE ANTIVENOM

Ini 50 ml vial

Removal and Elimination

CHARCOAL			
Oral liq 200 mg per ml	43.50	250 ml	Carbasorb-X
DEFERASIROX – Restricted see terms below			
Tab 125 mg dispersible		28	Exjade
Tab 250 mg dispersible		28	Exjade
Tab 500 mg dispersible		28	Exjade
- Destricted (DS1////)			•

➡ Restricted (RS1444)

Initiation

Haematologist Re-assessment required after 2 years

All of the following:

1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and

2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and

- 3 Any of the following:
 - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
 - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
 - 3.3 Treatment with deferiprone has resulted in arthritis; or
 - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per µL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per uL).

Continuation

Haematologist

Re-assessment required after 2 years Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE - Restricted see terms below

I Tab 500 mg	533.17	100	Ferriprox
Oral lig 100 mg per ml		250 ml	Ferriprox
➡ Restricted (RS1445)			
Initiation			
Patient has been diagnosed with chronic iron overload due to congenital inh	erited anaemi	a or acquire	d red cell aplasia.

DESFERBIOXAMINE MESILATE

Inj 500 mg vial	 10	DBL Desferrioxamine
		Mesylate for Inj BP

DICOBALT EDETATE

Inj 15 mg per ml, 20 ml ampoule

VARIOUS

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
DIMERCAPROL			
Inj 50 mg per ml, 2 ml ampoule			
DIMERCAPTOSUCCINIC ACID			
Cap 100 mg			e.g. PCNZ, Optimus Healthcare,
Cap 200 mg			Chemet e.g. PCNZ, Optimus Healthcare, Chemet
SODIUM CALCIUM EDETATE Inj 50 mg per ml, 10 ml ampoule Inj 200 mg per ml, 2.5 ml ampoule Inj 200 mg per ml, 5 ml ampoule			
Antiseptics and Disinfectants			
Soin 4% Soin 5%		500 ml	healthE
CHLORHEXIDINE WITH CETRIMIDE Crm 0.1% with cetrimide 0.5% Foaming soln 0.5% with cetrimide 0.5%			
CHLORHEXIDINE WITH ETHANOL Soln 0.5% with ethanol 70% Soln 2% with ethanol 70%			
Soln 2% with ethanol 70% Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml	1.55	1	healthE
ODINE WITH ETHANOL Soln 1% with ethanol 70%			
SOPROPYL ALCOHOL Soin 70%, 500 ml	5.65	1	healthE
POVIDONE-IODINE Vaginal tab 200 mg			
→ Restricted (RS1354)			
nitiation			
Rectal administration pre-prostate biopsy. Oint 10%	7.40	0 5 m	Datadiaa
Soln 10% – 5% DV Mar-22 to 2024		65 g 100 ml	Betadine Riodine
Soln 5%		100 11	linguing
Soln 7.5%			
Soln 10%,		15 ml	Riodine
Pad 10%	5.40	500 ml	Riodine
Swab set 10%			
POVIDONE-IODINE WITH ETHANOL			
Soln 10% with ethanol 30% Soln 10% with ethanol 70%			
SODIUM HYPOCHLORITE			

VARI	ous
------	-----

		Price excl. GST) \$	Per	Brand or Generic Manufacturer
Contrast Media				
Iodinated X-ray Contrast Media				
DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE				
Oral lig 660 mg per ml with sodium amidotrizoate 100 mg per ml,	100 ml			
bottle		.30.00	100 ml	Gastrografin
Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle.		.90.00	1	Urografin
DIATRIZOATE SODIUM				•
Oral liq 370 mg per ml, 10 ml sachet	1	156.12	50	loscan
ODISED OIL				
Inj 38% w/w (480 mg per ml), 10 ml ampoule		110.00	1	Lipiodol Ultra Fluid
	4	10.00	I	
ODIXANOL		0000	10	Vicino que
Inj 270 mg per ml (iodine equivalent), 50 ml bottle			10	Visipaque
Inj 270 mg per ml (iodine equivalent), 100 ml bottle Inj 320 mg per ml (iodine equivalent), 50 ml bottle			10 10	Visipaque Visipaque
Inj 320 mg per ml (iodine equivalent), 30 ml bottle			10	Visipaque
Inj 320 mg per ml (iodine equivalent), 100 ml bottle			10	Visipaque
		.00.00	10	Visipaque
OHEXOL		04.00	10	Omningenue
Inj 240 mg per ml (iodine equivalent), 50 ml bottle Inj 300 mg per ml (iodine equivalent), 20 ml bottle			10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 20 ml bottle			10 10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 30 ml bottle			10	Omnipaque Omnipaque
Inj 350 mg per ml (iodine equivalent), 50 ml bottle			10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 56 ml bottle			10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 100 ml bottle			10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 200 ml bottle			10	Omnipaque
Inj 350 mg per ml, 500 ml bottle			6	Omnipaque
Non-iodinated X-ray Contrast Media				
BARIUM SULPHATE				
Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet	5	507.50	50	E-Z-Cat Dry
Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle			148 g	Varibar - Thin Liquid
Oral liq 600 mg per g (60% w/w), tube			454 g	E-Z-Paste
Oral liq 400 mg per ml (40% w/v), bottle			250 ml	Varibar - Honey
		38.40	240 ml	Varibar - Nectar
			230 ml	Varibar - Pudding
Enema 1,250 mg per ml (125% w/v), 500 ml bag			12	Liquibar
Oral liq 22 mg per g (2.2% w/w), 250 ml bottle			24	CT Plus+
Oral liq 22 mg per g (2.2% w/w), 450 ml bottle			24	CT Plus+
Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle			24	VoLumen
Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle			24	Readi-CAT 2
Powder for oral soln 97.65% w/w, 300 g bottle			24	X-Opaque-HD
Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle			3	Tagitol V
Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle		.91.//	1	Liquibar
BARIUM SULPHATE WITH SODIUM BICARBONATE				
Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g				
sachet	1	102.93	50	E-Z-Gas II

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CITRIC ACID WITH SODIUM BICARBONATE			
Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4	1 g		
sachet	0		e.g. E-Z-GAS II
Paramagnetic Contrast Media			
GADOBENIC ACID			
Inj 334 mg per ml, 10 ml vial		10	Multihance
Inj 334 mg per ml, 20 ml vial		10	Multihance
GADOBUTROL			
Inj 1 mmol per ml, 15 ml vial			
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled			
syringe		5	Gadovist 1.0
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled		•	
syringe		5	Gadovist 1.0
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled			
syringe		10	Gadovist 1.0
GADOTERIC ACID			
Inj 279.30 mg per ml, 10 ml prefilled syringe			e.g. Clariscan
Inj 279.30 mg per ml, 10 ml vial			e.g. Clariscan
Inj 279.30 mg per ml, 15 ml prefilled syringe			e.g. Clariscan
Inj 279.30 mg per ml, 20 ml vial			e.g. Clariscan
Inj 279.30 mg per ml, 5 ml vial			e.g. Clariscan
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe	172.00	10	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle	25.35	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe		10	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe		10	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle	14.30	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle		1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle	9.10	1	Dotarem
GADOXETATE DISODIUM			
Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefil	led		
syringe		1	Primovist
MEGLUMINE GADOPENTETATE			
Inj 469 mg per ml, 10 ml prefilled syringe		5	Magnevist
Inj 469 mg per ml, 10 ml vial		10	Magnevist
			J.
Inj 105 mg per ml, 100 ml bottle	159.00	100 ml	Biliscopin
Ultrasound Contrast Media			
PERFLUTREN			
Inj 1.1 mg per ml, 1.5 ml vial		1	Definity
, , , , , , , , , , , , , , , , , , , 	720.00	4	Definity
			·/

Diagnostic Agents

ARGININE

260

Inj 50 mg per ml, 500 ml bottle Inj 100 mg per ml, 300 ml bottle

ex man	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
HISTAMINE ACID PHOSPHATE Nebuliser soln 0.6%, 10 ml vial Nebuliser soln 2.5%, 10 ml vial Nebuliser soln 5%, 10 ml vial				
MANNITOL Powder for inhalation				e.g. Aridol
METHACHOLINE CHLORIDE Powder 100 mg				0.9. 7 1100
SECRETIN PENTAHYDROCHLORIDE Inj 100 u vial Inj 80 u vial Inj 100 u ampoule				
SINCALIDE Inj 5 mcg per vial				
Diagnostic Dyes				
BONNEY'S BLUE DYE Soin				
INDIGO CARMINE Inj 4 mg per ml, 5 ml ampoule Inj 8 mg per ml, 5 ml ampoule				
INDOCYANINE GREEN Inj 25 mg vial				
METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE] Inj 5 mg per ml, 10 ml ampoule	240.3	5	5	Proveblue
PATENT BLUE V Inj 2.5%, 2 ml ampoule Inj 2.5%, 5 ml prefilled syringe			5 5	Obex Medical InterPharma

CHLORHEXIDINE WITH CETRIMIDE

↓ Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

→ Restricted (RS1683)

Initiation

Re-assessment required after 3 months All of the following:

- 1 Patient has burns that are greater than 30% of total body surface area (BSA); and
- 2 For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
- 3 The use of 30 ml ampoules is impractical due to the size of the area to be covered.

Continuation

Re-assessment required after 3 months

The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

Irrigation soln 0.015% with cetrimide 0.15%, 100 ml bottle	24 30	Baxter Pfizer
GLYCINE Irrigation soln 1.5%, 3,000 ml bag33.50	4	B Braun

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

VARIOUS

VARIOUS

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
SODIUM CHLORIDE			
Irrigation soln 0.9%, 3,000 ml bag		4	B Braun
Irrigation soln 0.9%, 30 ml ampoule		20	Interpharma
Irrigation soln 0.9%, 1,000 ml bottle	16.10	10	Baxter Sodium Chloride 0.9%
Irrigation soln 0.9%, 250 ml bottle	17.64	12	Fresenius Kabi
WATER			
Irrigation soln, 3,000 ml bag		4	B Braun
Irrigation soln, 1,000 ml bottle	18.60	10	Baxter Water for Irrigation
Irrigation soln, 250 ml bottle	17.64	12	Fresenius Kabi

Surgical Preparations

BISMUTH SUBNITRATE AND IODOFORM PARAFFIN Paste DIMETHYL SULFOXIDE Soln 50% Soln 99% PHENOL Inj 6%, 10 ml ampoule PHENOL WITH IOXAGLIC ACID Inj 12%, 10 ml ampoule SODIUM HYDROXIDE Soln 10% TROMETAMOL Inj 36 mg per ml, 500 ml bottle

VARIOUS

	(ex man	Price . excl. \$	GST)	Per	Bran Gene Mani	
Cardioplegia Solutions						
ELECTROLYTES Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 r potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 r tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chlo 1,000 ml bag Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per m acid 11.53 mg per ml, sodium phosphate 0.1725 mg per m	chloride, nmol/l ride, I, glutamic II,				e.g.	Custodiol-HTK
potassium chloride 2.15211 mg per ml, sodium citrate 1.80 per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag)768 mg				e.g.	Cardioplegia Enriched Paed. Soln.
Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, acid 9.375 mg per ml, sodium phosphate 0.6285 mg per m potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg sodium hydroxide 5.133 mg per ml and trometamol 9.097 ml, 527 ml bag	nl, g per ml,				e.g.	Cardioplegia
Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 m potassium chloride 2.181 mg per ml, sodium chloride 1.78 sodium citrate 0.6412 mg per ml and trometamol 5.9 mg p 523 ml baq	8 mg ml,				ea	Enriched Solution
Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calciu 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml b					U	Solution Cardioplegia
Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magne 1.2 mmol/l calcium, 1,000 ml bag	Ū				Ū	Solution AHB7832
IONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bo IONOSODIUM L-ASPARTATE Inj 14 mmol per 10 ml, 10 ml	ottle				5	Electrolyte Solutic

Cold Storage Solutions

SODIUM WITH POTASSIUM Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GS \$	T) Per	Brand or Generic Manufacturer
Extemporaneously Compounded Preparations			
ACETIC ACID			
Liq			
ALUM Powder BP			
ARACHIS OIL [PEANUT OIL]			
Liq			
ASCORBIC ACID			
Powder			
BENZOIN Tincture compound BP			
BISMUTH SUBGALLATE			
Powder			
BORIC ACID			
Powder			
CARBOXYMETHYLCELLULOSE Soln 1.5%			
CETRIMIDE			
Soln 40%			
CHLORHEXIDINE GLUCONATE Soln 20 %			
CHLOROFORM Lig BP			
CITRIC ACID			
Powder BP			
CLOVE OIL			
Liq COAL TAR			
Soln BP		200 ml	Midwest
CODEINE PHOSPHATE Powder			
COLLODION FLEXIBLE			
Liq			
COMPOUND HYDROXYBENZOATE Soln	30.00	100 ml	Midwest
CYSTEAMINE HYDROCHLORIDE		100 111	Midwest
Powder			
DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEI Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule			
DITHRANOL Powder			
GLUCOSE [DEXTROSE]			
Powder			

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price		Brand or
	(ex man. excl. GS	ST)	Generic
	\$	Per	Manufacturer
GLYCERIN WITH SODIUM SACCHARIN			
Suspension		473 ml	Ora-Sweet SF
GLYCERIN WITH SUCROSE			
Suspension		473 ml	Ora-Sweet
GLYCEROL			
Liq	3.23	500 ml	healthE Glycerol BP Liquid
HYDROCORTISONE			
Powder		25 g	ABM
LACTOSE Powder		-	
MAGNESIUM HYDROXIDE Paste			
MENTHOL			
Crystals			
METHADONE HYDROCHLORIDE Powder			
METHYL HYDROXYBENZOATE			
Powder		25 g	Midwest
METHYLCELLULOSE		Ŭ	
Powder		100 g	Midwest
Suspension		473 ml	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN			
Suspension		473 ml	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE			
Suspension		473 ml	Ora-Blend
OLIVE OIL			
Liq			
PARAFFIN			
Liq			
PHENOBARBITONE SODIUM			
Powder			
PHENOL			
Liq			
PILOCARPINE NITRATE Powder			
POLYHEXAMETHYLENE BIGUANIDE			
Liq			
POVIDONE K30 Powder			
SALICYLIC ACID Powder			
SILVER NITRATE			
Crystals			
SODIUM BICARBONATE Powder BP		500 g	Midwest

Products with Hospital Supply Status (HSS) are in **bold** Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	(ex man.	rice excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM CITRATE Powder				
SODIUM METABISULFITE Powder				
STARCH Powder				
SULPHUR Precipitated Sublimed				
SYRUP Liq (pharmaceutical grade)		14.95	500 ml	Midwest
THEOBROMA OIL Oint				
TRI-SODIUM CITRATE Crystals				
TRICHLORACETIC ACID Grans				
UREA Powder BP				
WOOL FAT Oint, anhydrous				
XANTHAN Gum 1%				
ZINC OXIDE Powder				

SPECIAL FOODS

Price (ex man. excl. GST) \$

Per

Brand or Generic Manufacturer

Food Modules

Carbohydrate

→ Restricted (RS1467)

Initiation – Use as an additive

Any of the following:

- 1 Cystic fibrosis; or
- 2 Chronic kidney disease; or
- 3 Cancer in children; or
- 4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 5 Faltering growth in an infant/child; or
- 6 Bronchopulmonary dysplasia; or
- 7 Premature and post premature infant; or
- 8 Inborn errors of metabolism.

Initiation - Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

CARBOHYDRATE SUPPLEMENT - Restricted see terms above

- Powder 95 g carbohydrate per 100 g, 368 g can
- Powder 96 g carbohydrate per 100 g, 400 g can

e.g. Polycal

Fat

➡ Restricted (RS1468)

Initiation – Use as an additive

Any of the following:

- 1 Patient has inborn errors of metabolism; or
- 2 Faltering growth in an infant/child; or
- 3 Bronchopulmonary dysplasia; or
- 4 Fat malabsorption; or
- 5 Lymphangiectasia; or
- 6 Short bowel syndrome; or
- 7 Infants with necrotising enterocolitis; or
- 8 Biliary atresia; or
- 9 For use in a ketogenic diet; or
- 10 Chyle leak; or
- 11 Ascites; or
- 12 Patient has increased energy requirements, and for whom dietary measures have not been successful.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT - Restricted see terms above

- 1 Liquid 50 g fat per 100 ml, 200 ml bottle
- Liquid 50 g fat per 100 ml, 500 ml bottle

		Price excl. G		Brand or Generic
		\$	Per	Manufacturer
 MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT - Restricted Liquid 50 g fat per 100 ml, 250 ml bottle Liquid 95 g fat per 100 ml, 500 ml bottle WALNUT OIL - Restricted see terms on the previous page Liq 	see terms on th	ne previo	ous page	e.g. Liquigen e.g. MCT Oil
Protein				
 Restricted (RS1469) Initiation – Use as an additive Either: Protein losing enteropathy; or High protein needs. Initiation – Use as a module For use as a component in a modular formula made from at leas Section D of the Pharmaceutical Schedule or breast milk Note: Patients are required to meet any Special Authority criteria PROTEIN SUPPLEMENT – Restricted see terms above Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6 can Powder 6 g protein per 7 g, can Powder 89 g protein, < 1.5 g carbohydrate and 2 g fat per 10 can 	a associated wit 6 g, 275 g	h all of t		·
Other Supplements				-
 BREAST MILK FORTIFIER Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sache CARBOHYDRATE AND FAT SUPPLEMENT – Restricted see f Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g 	2 g sachet et erms below			e.g. FM 85 e.g. S26 Human Milk Fortifier e.g. Nutricia Breast Milk Fortifer e.g. Super Soluble
 → Restricted (RS1212) Initiation Both: Infant or child aged four years or under; and Any of the following: Cystic fibrosis; or Cancer in children; or Faltering growth; or Fornchopulmonary dysplasia; or Fremature and post premature infants. 				Duocal

Price (ex man. excl. GST) \$

Per

Brand or Generic Manufacturer

Food/Fluid Thickeners

NOTE:

While pre-thickened drinks and supplements have not been included in Section H, Health NZ Hospitals may continue to use such products for patients with dysphagia, provided that:

- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by Pharmac; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

Pharmac intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN

Powder	e.g.	Feed Thickener Karicare Aptamil
GUAR GUM Powder		Guaraal
MAIZE STARCH	e.y.	Guarcol
Powder	e.g.	Resource Thicken Up; Nutilis
MALTODEXTRIN WITH XANTHAN GUM		Instant Thick
Powder MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID	e.g.	Instant Thick
Powder	e.g.	Easy Thick

Metabolic Products

➡ Restricted (RS1232)

Initiation

Any of the following:

- 1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) - Restricted see terms above

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

- e.g. GA1 Anamix Infant
- e.g. XLYS Low TRY Maxamaid

_	(6	P ex man.	Price excl. \$	GST)	Per	Bran Gene Man	
Η	omocystinuria Products						
	 IINO ACID FORMULA (WITHOUT METHIONINE) - Restricted see te Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre p 100 g, 400 g can Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle 		i the p	oreviou	s page	e.g. e.g.	HCU Anamix Infant XMET Maxamaid XMET Maxamum HCU Anamix Junior LQ
ls	sovaleric Acidaemia Products						
t	 INO ACID FORMULA (WITHOUT LEUCINE) – Restricted see terms Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre p 100 g, 400 g can Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can 		previ	ous pa	ge	e.g.	IVA Anamix Infant XLEU Maxamaid XLEU Maxamum
N	laple Syrup Urine Disease Products						
AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – Restricted see terms on the previous page 1 Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per							e previous page MSUD Anamix
t t	100 g, 400 g can Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle					e.g.	Infant MSUD Maxamum MSUD Anamix Junior LQ

SPECIAL FOODS

	Price (ex man. ex: \$		iST)	Per	Bran Gene Man	
F	Phenylketonuria Products					
Ν	MINO ACID FORMULA (WITHOUT PHENYLALANINE) - Restricted see terms of	on pa	age :	269		
1	Tab 8.33 mg					Phlexy-10
	· · · · · · · · · · · · · · · · · · ·				e.g.	PKU Lophlex Powder (neutral)
	sachet				e.g.	PKU Anamix Juni (van/choc/neutral
	Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per					(van/choc/neutral
	100 g, 400 g can				e.a.	PKU Anamix Infar
	Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can					XP Maxamum
	Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet				e.g.	Phlexy-10
	Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml,				•	
	62.5 ml bottle				e.g.	PKU Lophlex LQ
	Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml,				-	
	125 ml bottle				e.g.	PKU Lophlex LQ
	Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle	.10		125 ml	PKL	J Anamix Junior LC
						(Berry)
					PKL	J Anamix Junior LC
						(Orange)
					PKL	J Anamix Junior LC
						(Unflavoured)
						DKUL anhlas I O
	bottle				e.g.	PKU Lophlex LQ
	Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle				0.0	PKU Lophlex LQ
					e.y.	FRU LUPITIEX LQ
	bottle				٥a	PKU Lophlex LQ
					o.g.	I NO LOPINON LO
	bottle				e.a	PKU Lophlex LQ
	Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml				3	
	carton				e.g.	Easiphen
	Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per				5	
	100 g, 109 g pot				e.g.	PKU Lophlex
						Sensations
						20 (berries)

Propionic Acidaemia and Methylmalonic Acidaemia Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) page 269	- Restricted see terms on
t Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per	o a MMA/DA Anomiv
100 g, 400 g can	e.g. MMA/PA Anamix Infant
Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can	e.g. XMTVI Maxamaid
t Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can	e.g. XMTVI Maxamum
Protein Free Supplements	
PROTEIN FREE SUPPLEMENT – Restricted see terms on page 269	
t Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can	e.g.Energivit
Products with Hospital Supply Status (HSS) are in bold	

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	(ex mar	Price n. excl. \$	GST)	Per	Brand or Generic Manufacturer
Tyrosinaemia Products					
MINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYRC Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g	,	Restric	ted see	e terms	on page 269
sachet					e.g. TYR Anamix Junio
Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fi	ibre per				e.g. TYR Anamix Infant
100 g, 400 g can Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g car	n				e.g. XPHEN, TYR Maxamaid
Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre pe	er				
100 ml, 125 ml bottle					e.g. TYR Anamix Junio LQ
Urea Cycle Disorders Products					
MINO ACID SUPPLEMENT - Restricted see terms on page 269					
Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g car Powder 79 g protein per 100 g, 200 g can	n				e.g. Dialamine e.g. Essential Amino Acid Mix
X-Linked Adrenoleukodystrophy Products					
LYCEROL TRIERUCATE – Restricted see terms on page 269 Liquid, 1,000 ml bottle					
LYCEROL TRIOLEATE - Restricted see terms on page 269					
Specialised Formulas					
Diabetic Products					
Restricted (RS1215)					
nitiation					
ny of the following: 1 For patients with type I or type II diabetes suffering weight los	s and mair	າutritiດາ	n that r	equires	nutritional support: or
2 For patients with pancreatic insufficiency; or					and a support, of
3 For patients who have, or are expected to, eat little or nothing			nd/or ir	oroaca	d nutritional noods from
 4 For patients who have a poor absorptive capacity and/or high causes such as catabolism; or 5 For use pre- and post-surgery; or 	i nutrient 10	sses a	nu/or Ir	icrease	u numuonai neeus irom

- 5 For use pre- and post-surgery; or
- 6 For patients being tube-fed; or
- 7 For tube-feeding as a transition from intravenous nutrition.

LOW-GI ENTERAL FEED 1 KCAL/ML - Restricted see terms above

t	Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 500 ml		
	bottle	500 ml	Glucerna Select
t	Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml,		
	1,000 ml bottle		e.g. Nutrison Advanced Diason

	l (ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
LOW-GI ORAL FEED 1 KCAL/ML – Restricted see terms on the previ Liquid 7 g protein, 10.9 g carbohydrate, 2.7 g fat and 2 g fibre per 100 ml, bottle)	200 ml	Nutren Diabetes (Vanilla)
t Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle					e.g. Diasip
Elemental and Semi-Elemental Products					
 → Restricted (RS1216) Initiation Any of the following: Malabsorption; or Short bowel syndrome; or Enterocutaneous fistulas; or Eosinophilic enteritis (including oesophagitis); or Inflammatory bowel disease; or Acute pancreatitis where standard feeds are not tolerated; or Patients with multiple food allergies requiring enteral feeding. 					
AMINO ACID ORAL FEED – Restricted see terms above t Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet AMINO ACID ORAL FEED 0.8 KCAL/ML – Restricted see terms above t Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 25 carton	e	4.50)	80 g	Vivonex TEN e.g. Elemental 028 Extra
PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – Restricted see term Liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bottle	ns above				e.g. Nutrison Advanced Peptisorb
PEPTIDE-BASED ENTERAL FEED 1.5 KCAL/ML – Restricted see te Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml			6	1,000 ml	, Vital
 PEPTIDE-BASED ORAL FEED - Restricted see terms above Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 400 g can Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 4 					e.g. Peptamen Junior
can PEPTIDE-BASED ORAL FEED 1 KCAL/ML – Restricted see terms at		4.00	-	007 ml	e.g. MCT Pepdite; MCT Pepdite 1+
Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, car	ion	4.95)	237 ml	Peptamen OS 1.0 (Vanilla)
Fat Modified Products					
 FAT-MODIFIED FEED - Restricted see terms below Powder 12.8 g protein, 68.6 g carbohydrate and 12.9 g fat per 100 400 g can → Restricted (RS1470) Initiation Any of the following: 	g,				e.g. Monogen

SPECIAL FOODS

Price		Brand or
(ex man. excl.	GST)	Generic
\$	Per	Manufacturer

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.
- Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Hepatic Products		
 → Restricted (RS1217) Initiation For children (up to 18 years) who require a liver transplant. HEPATIC ORAL FEED - Restricted see terms above Powder 12 g protein, 56 g carbohydrate and 22 g fat per 100 g, can	400 g	Heparon Junior
High Calorie Products		
 → Restricted (RS1317) Initiation Any of the following: Patient is fluid volume or rate restricted; or Patient requires low electrolyte; or Both: 		
 ENTERAL FEED 2 KCAL/ML - Restricted see terms above Liquid 10 g protein, 17.5 g carbohydrate and 10 g fat per 100 ml, bag	500 ml 500 ml 1,000 ml 200 ml 500 ml	Fresubin 2kcal HP Nutrison Concentrated Ensure Two Cal HN RTH Two Cal HN Survimed OPD
High Protein Products		
HIGH PROTEIN ENTERAL FEED 1.2 KCAL/ML - Restricted see terms below ↓ Liquid 10 g protein, 12.9 g carbohydrate and 3.2 g fat and 0.64 g fibre per 100 ml, bag	500 ml	Fresubin Intensive

			SPECIAL FOODS
	Price excl. GST \$	Г) Per	Brand or Generic Manufacturer
continued			
1 The patient has a high protein requirement; and			
 Any of the following: 2.1 Patient has liver disease; or 			
2.2 Patient is obese (BMI > 30) and is undergoing surgery; or			
2.3 Patient is fluid restricted; or			
2.4 Patient's needs cannot be more appropriately met using high calo	•	ct.	
HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – Restricted see terms below Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml,	l		
1,000 ml bottle			e.g. Nutrison Protein
→ Restricted (RS1327)			Plus
Initiation			
Both:			
 The patient has a high protein requirement; and Any of the following: 			
2.1 Patient has liver disease; or			
2.2 Patient is obese (BMI > 30) and is undergoing surgery; or			
2.3 Patient is fluid restricted; or2.4 Patient's needs cannot be more appropriately met using high calo	ria produc	.+	
	•	<i>i</i> l.	
HIGH PROTEIN ENTERAL FEED 1.26 KCAL/ML − Restricted see terms below ↓ Liquid 10 g protein, 10.4 g carbohydrate and 4.9 g fat per 100 ml, bottle		500 ml	Nutrison Protein Intense
→ Restricted (RS1327)			
Initiation Both:			
1 The patient has a high protein requirement; and			
2 Any of the following:			
2.1 Patient has liver disease; or			
2.2 Patient is obese (BMI > 30) and is undergoing surgery; or2.3 Patient is fluid restricted: or			
2.4 Patient's needs cannot be more appropriately met using high calo	rie produc	et.	
HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML - Restricted see terms below	I		
Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per			n a Nation Dest
100 ml, 1,000 ml bottle			e.g. Nutrison Protein Plus Multi Fibre
→ Restricted (RS1327)			
Initiation			

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
 - 2.1 Patient has liver disease; or
 - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
 - 2.3 Patient is fluid restricted; or
 - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

SPECIAL FOODS

	Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
Infant Formulas			
AMINO ACID FORMULA – Restricted see terms below			
Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 1 400 g can	00 ml,		e.g. Neocate
Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100	g, 400 g		-
can			e.g. Neocate SYNEO unflavoured
Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 10	0 g, 400 g		umavoureu
can			e.g. Neocate Junior
Powder 13.3 g protein, 57 g carbohydrate and 24.6 g fat per	100 g, can43.60	400 g	<i>Unflavoured</i> Alfamino
Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per		400 g	Neocate Gold
Dourdow 14.0 a protoin E1.4 a correctively drote and 00 a fat new :	100 g oon E2 00	400 a	(Unflavoured)
 Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 		400 g 400 g	Neocate Junior Vanilla Alfamino Junior
Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 10	U .	400 g	Elecare LCP (Unflavoured)
Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 10	0 ml, can53.00	400 g	Elecare (Unflavoured) Elecare (Vanilla)
Bestricted (BS1867)			Lievale (valilia)

➡ Restricted (RS1867) Initiation

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled for 2-4 weeks and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows' milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis; or
- 4 Ultra-short gut; or
- 5 Severe Immune deficiency.

Continuation

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 Amino acid formula is required for a nutritional deficit.

Initiation - patients who are currently funded under RS1502 or SA1557

Limited to 3 months treatment

All of the following:

- 1 Patient has a valid initiation or renewal approval for extensively hydrolysed formula (RS1502); and
- 2 Patient is unable to source funded Aptamil powder at this time; and
- 3 The approval only applies to funded dispensings of Neocate Gold and Neocate Syneo.

Note: This criteria is short term funding to cover an out-of-stock situation on some extensively hydrolysed formula powder funded under Hospital Restriction RS1502. There is no continuation criteria under this criterion.

ENTERAL LIQUID PEPTIDE FORMULA - Restricted see terms below

↓ Liquid 4.2 g protein, 18.6 g carbohydrate and 6.58 g fat per 100 ml......15.68 500 ml
 Nutrini Peptisorb Energy
 → Restricted (RS1775)

Initiation

All of the following:

 Price		Brand or
(ex man. excl. GST)		Generic
 \$	Per	Manufacturer

- continued...
 - 1 Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable; and
 - 2 Any of the following:
 - 2.1 Severe malabsorption; or
 - 2.2 Short bowel syndrome; or
 - 2.3 Intractable diarrhoea; or
 - 2.4 Biliary atresia; or
 - 2.5 Cholestatic liver diseases causing malabsorption; or
 - 2.6 Cystic fibrosis; or
 - 2.7 Proven fat malabsorption; or
 - 2.8 Severe intestinal motility disorders causing significant malabsorption; or
 - 2.9 Intestinal failure; or
 - 2.10 Both:
 - 2.10.1 The patient is currently receiving funded amino acid formula; and
 - 2.10.2 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula; and
 - 3 Either:
 - 3.1 A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable; or
 - 3.2 For step down from intravenous nutrition.
- Note: A reasonable trial is defined as a 2-4 week trial.

Continuation

Both:

- 1 An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken; and
- 2 The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula.

EXTENSIVELY HYDROLYSED FORMULA - Restricted see terms below

t	Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g			
	can	30.42	900 g	Allerpro Syneo 1
t	Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g		Ū	
	can	30.42	900 g	Allerpro Syneo 2
t	Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g,		•	
	450 g can			e.g. Pepti-Junior
⇒	Restricted (RS1502)			

Initiation

Any of the following:

- 1 Both:
 - 1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or

continued...

	l (ex man.	Price excl. \$	GST)	Per	Bran Gen Man	
continued						
 9 Severe intestinal motility disorders causing significant malabsor 10 Intestinal failure; or 11 For step down from Amino Acid Formula. 	rption; or					
Note: A reasonable trial is defined as a 2-4 week trial, or signs of an in Continuation	nmediate	lgE n	nediat	ed allergi	c reacti	ion.
Both:						
 An assessment as to whether the infant can be transitioned to a undertaken; and The outcome of the assessment is that the infant continues to r 						
FRUCTOSE-BASED FORMULA						
Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 400 g can) g,				e.g.	Galactomin 19
LACTOSE-FREE FORMULA	000					
Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml. can	900 g				e.g.	Karicare Aptamil Gold De-Lact
Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml can	900 g				e.g.	S26 Lactose Free
LOW-CALCIUM FORMULA Powder 14.6 g protein, 55.2 g carbohydrate and 25.8 g fat per 100 400 g can	•				e.g.	Locasol
 PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Restricted see t Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre 100 ml, bottle 	per		5	125 ml	Infa	trini
➡ Restricted (RS1614) Initiation – Fluid restricted or volume intolerance with faltering gr Both:						
1 Either:						
1.1 The patient is fluid restricted or volume intolerant; or1.2 The patient has increased nutritional requirements due to	o faltering	g grow	/th; an	d		
2 Patient is under 18 months old and weighs less than 8kg. Note: 'Volume intolerant' patients are those who are unable to tolerate growth rate. These patients should have first trialled appropriate clinic and adjusting the frequency of feeding.						
PRETERM FORMULA – Restricted see terms below						
 Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, b Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 9 		0.7	5	100 ml	S26	EBW Gold RTF
bottle Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 7	'0 ml				e.g.	Pre Nan Gold RTF
bottle					e.g.	Karicare Aptamil Gold+Preterm
→ Restricted (RS1224) Initiation						
For infants born before 33 weeks' gestation or weighing less than 1.5 H THICKENED FORMULA	kg at birth					
Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml. can	900 g				e.g.	Karicare Aptamil Thickened AR

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Ketogenic Diet Products			
HIGH FAT FORMULA – Restricted see terms below ↓ Powder 14.3 g protein, 2.8 g carbohydrate and 69.2 g fat per 100 g	g, can 35.50	300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)
Powder 15.4 g protein, 7.2 g carbohydrate and 68.6 g fat per 100 g	g, can35.50	300 g	Ketocal
→ Restricted (RS1225)			3:1 (Unflavoured)
Initiation For patients with intractable epilepsy, pyruvate dehydrogenase deficien conditions requiring a ketogenic diet.	ncy or glucose transp	oorted type	-1 deficiency and other
Paediatric Products			
 Restricted (RS1473) Initiation Both: Child is aged one to ten years; and Any of the following: 2.1 The child is being fed via a tube or a tube is to be inserted 2.2 Any condition causing malabsorption; or 2.3 Faltering growth in an infant/child; or 2.4 Increased nutritional requirements; or 2.5 The child is being transitioned from TPN or tube feeding 	to oral feeding; or	of feeding; o	or
2.6 The child has eaten, or is expected to eat, little or nothin PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted see term t Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre 100 ml, bag	per	500 ml	Nutrini Low Energy
 PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted see terms a Liquid 2.5 g protein, 12.5 g carbohydrate and 4.4 g fat per 100 ml. Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, b Liquid 2.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bottle 	6.50 ag2.68	500 ml 500 ml	Multifibre RTH Frebini Original Pediasure RTH <i>e.g. Nutrini RTH</i>
 PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted see terms Liquid 3.8 g protein, 18.7 g carbohydrate and 6.7 g fat per 100 ml. Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre 	6.50	500 ml	Frebini Energy
100 ml, bottle	•	500 ml	Nutrini Energy Multi Fibre
 Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bottle PAEDIATRIC ENTERAL FEED WITH FIBRE 1 KCAL/ML – Restricter 			e.g. Nutrini Energy RTH
Liquid 2.5 g protein, 12.1 g carbohydrate, 4.5g fat and 0.8 g fibre p 100 ml PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5 KCAL/ML – Restrict	7.00	500 ml	Frebini Original Fibre
Liquid 3.8 g protein, 18.1 g carbohydrate, 6.7 g fat and 1.1 g fibre 100 ml.	per	500 ml	Frebini Energy Fibre

Price (ex man. excl. GS` \$	ſ) Per	Brand or Generic Manufacturer
PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms on the previous page Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bottle	200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla)
Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, can1.34	250 ml	Pediasure (Vanilla)
PAEDIATRIC ORAL FEED 1.5 KCAL/ML - Restricted see terms on the previous page		
Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle		e.g. Pediasure Plus
Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle		e.g. Fortini
Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per		e.y. rollill
100 ml, 200 ml bottle		e.g. Fortini Multifibre
Renal Products		
LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted see terms below ↓ Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle	500 ml	Nepro HP RTH
For patients with acute or chronic kidney disease. _OW ELECTROLYTE ORAL FEED - Restricted see terms below ↓ Powder 7.5 g protein, 57.6 g carbohydrate and 25.9 g fat per 100 g, 400 g can → Restricted (RS1227) nitiation		e.g. Kindergen
For children (up to 18 years) with acute or chronic kidney disease.		
LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML		
Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton2.67	220 ml	Nepro HP (Strawberry) Nepro HP (Vanilla)
→ Restricted (RS1228)		
nitiation For patients with acute or chronic kidney disease.		
LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted see terms below Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml		
bottle Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton		e.g. Renilon 7.5
Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, 200 ml		C C
bottle	4	Novasource Renal (Vanilla)
→ Restricted (RS1228) Initiation		

Initiation

For patients with acute or chronic kidney disease.

SPECIAL FOODS

	Price (ex man. excl. GST \$	Per	Brand or Generic Manufacturer
Surgical Products			
 HIGH ARGININE ORAL FEED 1.4 KCAL/ML − Restricted see terms b Liquid 10.4 g protein, 8 g carbohydrate, 4.4 g fat and 0 g fibre per 100 ml, 250 ml carton 		10	Impact Advanced Recovery
→ Restricted (RS1231) Initiation Three packs per day for 5 to 7 days prior to major gastrointestinal, head PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML - Restricted	d see terms below		1.0010.9
 ↓ Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 bottle		4	preOp

Initiation

Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.

Standard Feeds

➡ Restricted (RS1214)

Initiation

Any of the following:

- For patients with malnutrition, defined as any of the following:
- 1 Any of the following:
 - 1.1 BMI < 18.5; or
 - 1.2 Greater than 10% weight loss in the last 3-6 months; or
 - 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
- 2 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 4 For use pre- and post-surgery; or
- 5 For patients being tube-fed; or
- 6 For tube-feeding as a transition from intravenous nutrition; or
- 7 For any other condition that meets the community Special Authority criteria.

ENTERAL FEED 1.5 KCAL/ML - Restricted see terms above

t t	Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bottle7.00 Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per	1,000 ml	Nutrison Energy
	100 ml, 1,000 ml bottle		e.g. Nutrison Energy
t	Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can	250 ml 1,000 ml	<i>Multi Fibre</i> Ensure Plus HN Ensure Plus HN RTH
t	100 ml, bag7.00 Liquid 7.5 g protein, 17 g carbohydrate and 5.8 g fat per 100 ml, bag9.60	1,000 ml 1,000 ml	Jevity HiCal RTH Fresubin HP Energy

	<u> </u>		
	Price (ex man. excl. GS	(T)	Brand or Generic
	(cx man. cxci. cc	Per	Manufacturer
ENTERAL FEED 1 KCAL/ML - Restricted see terms on the previo	us page		
t Liquid 3.8 g protein, 13.8 g carbohydrate and 3.4 g fat per 100 r		1,000 ml	Fresubin Original
t Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre			•
100 ml, 1000 ml bottle			e.g. Nutrison Multi Fibre
Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml		1,000 ml	Osmolite RTH
Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fik	•	4 000 1	
100 ml, bottle Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml		1,000 ml	Jevity RTH
1,000 ml bag	3		e.g. NutrisonStdRTH;
1,000 m bug			NutrisonLowSodium
•			
Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml	,		Al de la contractor
1,000 ml bottle			e.g. Nutrison Low Sodium:
			NutrisonStdRTH
ENTERAL FEED 1.2 KCAL/ML - Restricted see terms on the prev	ious page		numberietarini
Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fik			
100 ml, 1,000 ml bag			e.g. Jevity Plus RTH
ENTERAL FEED WITH FIBRE 0.83 KCAL/ML - Restricted see ter	ms on the previous p	age	
Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre			
100 ml, bottle	5.29	1,000 ml	Nutrison 800 Complete
ENTERAL FEED WITH FIBRE 1 KCAL/ML - Restricted see terms	on the previous page	`	Multi Fibre
 Liquid 3.8 g protein, 13.0 g carbohydrate, 3.4 g fat and 1.5 g fib 		7	
100 ml, bag		1,000 ml	Fresubin Original Fibre
ENTERAL FEED WITH FIBRE 1.5 KCAL/ML - Restricted see term		,	
t Liquid 7.5 g protein, 16.2 g carbohydrate, 5.8 g fat and 1.5 g fib		0.	
100 ml, bag		1,000 ml	Fresubin HP Energy
			Fibre
HIGH PROTEIN ORAL FEED 2.4 KCAL/ML – Restricted see term			
Only to be used for patients currently on or would be using Fort	• •	Ibre	
Liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 125 ml bottle	rnı,		e.g. Fortisip Compact
			Protein
(e.g. Fortisip Compact Protein Liquid 14.6 g protein, 25.3 g carbohy	/drate and 9.6 g fat p	er 100 ml, 12	5 ml bottle to be delisted 1
December 2023)			
ORAL FEED – Restricted see terms on the previous page		050	- (0)
Powder 15.9 g protein, 57.4 g carbohydrate and 14 g fat per 10	0 g, can26.00	850 g	Ensure (Chocolate) Ensure (Vanilla)
t Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g	can 14.00	840 g	Sustagen Hospital
	, our	040 g	Formula
			(Chocolate)
			Sustagen Hospital
			Formula (Vanilla)
ORAL FEED 1 KCAL/ML – Restricted see terms on the previous p	•		
Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 237 ml carton	mi,		e.g. Resource Fruit
			e.g. Resource Fruit Beverage
			Develage

SPECIAL FOODS

Price (ex man. excl. GST \$) Per	Brand or Generic Manufacturer
ORAL FEED 1.5 KCAL/ML - Restricted see terms on page 281		
 Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can	237 ml	Ensure Plus (Vanilla)
carton	200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest)
 Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml 		Ensure Plus (Vanilla) e.g. Fortijuice
bottle Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per		e.g. Fortisip
100 ml, 200 ml bottle		e.g. Fortisip Multi Fibre
Other Supplements for PKU		
AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – Restricted see terms below		
Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet	30	PKU Build 20 Chocolate PKU Build 20 Raspberry
		Lemonade PKU Build 20 Smooth PKU Build 20 Vanilla
Powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet	30	PKU GMPro Ultra Lemonade
Powder 20 g protein, 6.0 g carbohydrate per 35 g sachet	30	PKU sphere20 Lemon
Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet	30	PKU sphere20 Chocolate PKU sphere20 Red Berry PKU sphere20 Vanilla
Powder 20 g protein, 6.7 g carbohydrate per 35 g sachet	30	PKU sphere20 Banana
(PKU Build 20 Chocolate Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet to be d		
PKU Build 20 Raspberry Lemonade Powder 20 g protein, 1.7 g carbohydrate per 32 g sa	chet to be a	delisted 1 January 2024)
(PKU Build 20 Smooth Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet to be deli		
(PKU Build 20 Vanilla Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet to be delis		
(PKU GMPro Ultra Lemonade Powder 20 g protein, 4.9 g carbohydrate per 33.4 g sachet		
(PKU sphere20 Lemon Powder 20 g protein, 6.0 g carbohydrate per 35 g sachet to be dell (PKU sphere20 Chocolate Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet to be		
(PKU sphere20 Red Berry Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet to be		
(PKU sphere20 Vanilla Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet to be		

(PKU sphere20 Banana Powder 20 g protein, 6.7 g carbohydrate per 35 g sachet to be delisted 1 January 2024) → Restricted (RS1972)

Initiation

All of the following:

1 Patient was previously receiving, or would receive PKU Sensation Berries under (RS1232); and

2 PKU Sensation Berries is unable to be sourced at this time; and

3 Patient has trialled the currently funded PKU Lophlex products and these were not tolerated.

Note: These criteria are attached to short term funding to cover an out-of-stock situation on PKU Sensation Berries supplied by Nutricia.

	(ex man	Price . excl. \$	GST)	Per	Brand or Generic Manufacturer
Bacterial and Viral Vaccines					
DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – R	estricted s	ee ter	ms <mark>bel</mark> o	WC	
Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pert	ussis				
toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg]				
pertactin and 80 D-antigen units poliomyelitis virus in 0.5 m					
– 0% DV Oct-20 to 2024		0.0	0	10	Infanrix IPV
Initiation					
Any of the following:					
1 A single dose for children up to the age of 7 who have compl	eted primar	v imm	unisatio	on: or	
2 A course of up to four vaccines is funded for catch up program primary immunisation; or					10 years) to complete full
3 An additional four doses (as appropriate) are funded for (re-) or post splenectomy; pre- or post solid organ transplant, rena or				•	
4 Five doses will be funded for children requiring solid organ tra	ansplantatio	on.			
Note: Please refer to the Immunisation Handbook for appropriate so	chedule for	catch	up prog	grammes	;
DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND	HAEMOPH	HILUS	INFLU	JENZAE	TYPE B VACCINE -
Restricted see terms below					
Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg per					
toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg	,				
pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hep – 0% DV Oct-20 to 2024		0.0	0	10	Infanrix-hexa
→ Restricted (RS1478)		0.0	0	10	iiiidiiiix-iiexa
Initiation					
Any of the following:					
1 Up to four doses for children up to and under the age of 10 for	or primary ir	nmuni	sation;	or	

- 2 An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 3 Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

BACILLUS CALMETTE-GUERIN VACCINE - Restricted see terms below Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent - 0% DV Oct-20 to 2024.....0.00 10 BCG Vaccine → Restricted (RS1233) Initiation All of the following: For infants at increased risk of tuberculosis defined as: 1 Living in a house or family with a person with current or past history of TB; and 2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; and

3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.

Note: A list of countries with high rates of TB are available at http://www.health.govt.nz/tuberculosis (Search for Downloads) or www.bcgatlas.org/index.php

VACCINES

(6	l ex man.	Price excl. \$	GST)	Per	Brand or Generic Manufacturer
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Restricted see	terms	belov	V		
toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg					
pertactin in 0.5 ml syringe - 0% DV Oct-20 to 2024		0.0	0	10	Boostrix
Restricted (RS1790)					
itiation					
ny of the following:					
 A single dose for pregnant women in the second or third trimester A single dose for parents or primary caregivers of infants admitted 					ra Unit or Spacialist Cora
Baby Unit for more than 3 days, who had not been exposed to main					
3 A course of up to four doses is funded for children from age 7 up th immunisation; or					
4 An additional four doses (as appropriate) are funded for (re-)immu	nisatio	n for i	natients	nost ha	ematonoietic stem cell
transplantation or chemotherapy; pre or post splenectomy; pre- or					
severely immunosuppressive regimens; or			J		, ,
5 A single dose for vaccination of patients aged from 65 years old; o	r				
6 A single dose for vaccination of patients aged from 45 years old w			had 4 p	previous	tetanus doses; or
7 For vaccination of previously unimmunised or partially immunised	patient	s; or			
8 For revaccination following immunosuppression; or					
9 For boosting of patients with tetanus-prone wounds.	adula	for oo	tab up i		
ote: Please refer to the Immunisation Handbook for the appropriate sch			ich up j	Jiografi	intes.
AEMOPHILUS INFLUENZAE TYPE B VACCINE - Restricted see term		w			
Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus					
vial 0.5 ml		0.0	n	1	Hiberix
Restricted (RS1520)		0.0	0		THEOTIX
itiation					
herapy limited to 1 dose					
y of the following:					
1 For primary vaccination in children; or					
2 An additional dose (as appropriate) is funded for (re-)immunisation transplantation, or chemotherapy; functional asplenic; pre or post s			•		
post cochlear implants, renal dialysis and other severely immunosi			· •		oliu organ transplant, pre-
3 For use in testing for primary immunodeficiency diseases, on the n			•		nal medicine physician or
paediatrician.					
ENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE - Re	stricte	ed see	e terms	below	
Inj 10 mcg of each meningococcal polysaccharide conjugated to a tot					
of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial .		0.0	0	1	MenQuadfi
Inj 4 mcg of each meningococcal polysaccharide conjugated to a tota					
approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial		0.0	0	1	Menactra
· · · · · · · · · · · · · · · · · · ·				5	Menactra
Aenactra Inj 4 mcg of each meningococcal polysaccharide conjugated to trrier per 0.5 ml vial to be delisted 1 October 2023)	o a tota	i of aj	oproxin	ately 48	3 mcg ot diphtheria toxoid
Restricted (RS1934)					
itiation ther:					
1 Any of the following:					
d d. I have there also and a baseter even five versus for a stick					and a state of the state of the state of the test

1.1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV,

continued...

	Price			Brand or
(ex r	nan. excl.	GST)		Generic
	\$		Per	Manufacturer

complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

- 1.2 One dose for close contacts of meningococcal cases of any group; or
- 1.3 One dose for person who has previously had meningococcal disease of any group; or
- 1.4 A maximum of two doses for bone marrow transplant patients; or
- 1.5 A maximum of two doses for person pre and post-immunosuppression*; or

2 Both:

- 2.1 Person is aged between 13 and 25 years, inclusive; and
- 2.2 One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL B MULTICOMPONENT VACCINE - Restricted see terms below

 Inj 175 mcg per 0.5 ml prefilled syringe......0.00
 1
 Bexsero

⇒ Restricted (RS1947)

Initiation - Primary immunisation for children up to 12 months of age

Therapy limited to 3 doses

Either:

- 1 Three doses for children up to 12 months of age (inclusive) for primary immunisation; or
- 2 Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025.

Initiation - Person is one year of age or over

Any of the following:

- 1 up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
- 2 up to two doses for close contacts of meningococcal cases of any group; or
- 3 up to two doses for person who has previously had meningococcal disease of any group; or
- 4 up to two doses for bone marrow transplant patients; or
- 5 up to two doses for person pre- and post-immunosuppression* .

Initiation - Person is aged between 13 and 25 years (inclusive)

Therapy limited to 2 doses

Both:

- 1 Person is aged between 13 and 25 years (inclusive); and
- 2 Either:
 - 2.1 Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons; or
 - 2.2 Two doses for individuals who are currently living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, from 1 March 2023 to 28 February 2024.

Note: *Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE - Restricted see terms below

Inj 10 mcg in 0.5 ml syringe0.00	1	Neisvac-C
➡ Restricted (RS1935)		
Initiation – Children under 12 months of age		
Any of the following:		

VA	CCINES
----	--------

- 1 Up to three doses for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or
- 2 Two doses for close contacts of meningococcal cases of any group; or
- 3 Two doses for child who has previously had meningococcal disease of any group; or
- 4 A maximum of two doses for bone marrow transplant patients; or
- 5 A maximum of two doses for child pre- and post-immunosuppression*.

Notes: children under 12 months of age require two doses 8 weeks apart. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE - Restricted see terms below

- I inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4,
- 18C and 19F in 0.5 ml prefilled syringe 0% DV Oct-20 to 20240.00 10 Synflorix → Restricted (RS1768)

Initiation

A primary course of three doses for previously unvaccinated individuals up to the age of 59 months inclusive. Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE - Restricted see terms below

Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A,

6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe	1	Prevenar 13
	10	Prevenar 13

➡ Restricted (RS1936)

Initiation - Primary course for previously unvaccinated children aged under 5 years

Therapy limited to 3 doses

A primary course of three doses for previously unvaccinated children up to the age of 59 months inclusive.

Initiation – High risk individuals who have received PCV10

Therapy limited to 2 doses

Two doses are funded for high risk individuals (over the age of 12 months and under 18 years) who have previously received two doses of the primary course of PCV10.

Initiation - High risk children aged under 5 years

Therapy limited to 4 doses

Both:

- 1 Up to an additional four doses (as appropriate) are funded for the (re)immunisation of high-risk children aged under 5 years; and
- 2 Any of the following:
 - 2.1 on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - 2.2 primary immune deficiencies; or
 - 2.3 HIV infection; or
 - 2.4 renal failure, or nephrotic syndrome; or
 - 2.5 are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - 2.6 cochlear implants or intracranial shunts; or
 - 2.7 cerebrospinal fluid leaks; or
 - 2.8 receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - 2.9 chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or

continued...

Price		Brand or
(ex man. excl. GST		Generic
 \$	Per	Manufacturer

- 2.10 pre term infants, born before 28 weeks gestation; or
- 2.11 cardiac disease, with cyanosis or failure; or
- 2.12 diabetes; or
- 2.13 Down syndrome; or
- 2.14 who are pre-or post-splenectomy, or with functional asplenia.

Initiation - High risk individuals 5 years and over

Therapy limited to 4 doses

Up to an additional four doses (as appropriate) are funded for the (re-)immunisation of individuals 5 years and over with HIV, pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, intracranial shunts, cerebrospinal fluid leaks or primary immunodeficiency.

Initiation - Testing for primary immunodeficiency diseases

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE - Restricted see terms below

Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal

serotype) - 0% DV Oct-20 to 2024	0.00	1	Pneumovax 23
➡ Restricted (RS1587)			

Initiation - High risk patients

Therapy limited to 3 doses

For patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.

Initiation - High risk children

Therapy limited to 2 doses

Both:

- 1 Patient is a child under 18 years for (re-)immunisation; and
- 2 Any of the following:
 - 2.1 On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - 2.2 With primary immune deficiencies; or
 - 2.3 With HIV infection; or
 - 2.4 With renal failure, or nephrotic syndrome; or
 - 2.5 Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - 2.6 With cochlear implants or intracranial shunts; or
 - 2.7 With cerebrospinal fluid leaks; or
 - 2.8 Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - 2.9 With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
 - 2.10 Pre term infants, born before 28 weeks gestation; or
 - 2.11 With cardiac disease, with cyanosis or failure; or
 - 2.12 With diabetes; or
 - 2.13 With Down syndrome; or
 - 2.14 Who are pre-or post-splenectomy, or with functional asplenia.

Initiation – Testing for primary immunodeficiency diseases

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

			VACCINES
	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ALMONELLA TYPHI VACCINE - Restricted see terms below I Inj 25 mcg in 0.5 ml syringe Restricted (RS1243) hitiation for use during typhoid fever outbreaks.			
Viral Vaccines			
IEPATITIS A VACCINE - Restricted see terms below Inj 720 ELISA units in 0.5 ml syringe - 0% DV Oct-20 to 2024 Inj 1440 ELISA units in 1 ml syringe - 0% DV Oct-20 to 2024 → Restricted (RS1638) hitiation		1 1	Havrix Junior Havrix
 any of the following: 1 Two vaccinations for use in transplant patients; or 2 Two vaccinations for use in children with chronic liver diseas 3 One dose of vaccine for close contacts of known hepatitis A 	,		
IEPATITIS B RECOMBINANT VACCINE Inj 10 mcg per 0.5 ml prefilled syringe	0.00	1	Engerix-B
 For household or sexual contacts of known acute hepatitis E For children born to mothers who are hepatitis B surface ani For children up to and under the age of 18 years inclusive w and require additional vaccination or require a primary cours For HIV positive patients; or For hepatitis C positive patients; or for patients following non-consensual sexual intercourse; or For solid organ transplant patients; or For post-haematopoietic stem cell transplant (HSCT) patien Following needle stick injury. 	tigen (HBsAg) positive; a tho are considered not to se of vaccination; or	or	
Inj 20 mcg per 1 ml prefilled syringe – 0% DV Oct-20 to 2024. * Restricted (RS1671) itiation	0.00	1	Engerix-B
 Any of the following: For household or sexual contacts of known acute hepatitis E For children born to mothers who are hepatitis B surface and For children up to and under the age of 18 years inclusive we and require additional vaccination or require a primary course For HIV positive patients; or For hepatitis C positive patients; or For patients following non-consensual sexual intercourse; or For solid organ transplant patients; or For post-haematopoietic stem cell transplant (HSCT) patient Following needle stick injury; or For dialysis patients; or For liver or kidney transplant patients. 	tigen (HBsAg) positive; of the are considered not to the of vaccination; or	or	

VACCINES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VAC ↓ Inj 270 mcg in 0.5 ml syringe – 0% DV Oct-20 to 2024 → Restricted (RS1693) Initiation – Children aged 14 years and under Therapy limited to 2 doses		stricted se 10	e terms below Gardasil 9
Children aged 14 years and under. Initiation – other conditions Either:			
1 Up to 3 doses for people aged 15 to 26 years inclusive; or 2 Both:			
 2.1 People aged 9 to 26 years inclusive; and 2.2 Any of the following: 2.2.1 Up to 3 doses for confirmed HIV infection; or 2.2.2 Up to 3 doses for transplant (including stem cell) p 	atients; or		
2.2.3 Up to 4 doses for Post chemotherapy. Initiation – Recurrent Respiratory Papillomatosis All of the following: 1 Either:			
 1.1 Maximum of two doses for children aged 14 years and ur 1.2 Maximum of three doses for people aged 15 years and or 2 The patient has recurrent respiratory papillomatosis; and 3 The patient has not previously had an HPV vaccine. 			
INFLUENZA VACCINE Inj 30 mcg in 0.25 ml syringe (paediatric quadrivalent vaccine)	11.00	1	Afluria Quad Junior (2023 Formulation)
→ Restricted (RS1948) Initiation – children 6 months to 35 months of age Children 6 months to 35 months of age (inclusive) from 1 April 2023 to 3	1 December 2023.		
 Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) Restricted (RS1978) 		5	FluQuadri (2023 Formulation)
Initiation – children 6 months to 35 months of age Children 6 months to 35 months of age (inclusive) from 1 July 2023 to 3	1 December 2023		
 Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) → Restricted (RS1949) 	110.00	10	Afluria Quad (2023 Formulation)
Initiation – People over 65 The patient is 65 years of age or over. Initiation – People of Māori or any Pacific ethnicity People 55 to 64 years of age (inclusive) and is Māori or of any Pacific et Initiation – cardiovascular disease for patients 3 years and over Any of the following:	hnicity, from 1 Apri	l 2023 to 3	1 December 2023.
 Ischaemic heart disease; or Congestive heart failure; or Rheumatic heart disease; or Congenital heart disease; or Cerebro-vascular disease. 			
Note: hypertension and/or dyslipidaemia without evidence of end-organ	disease is exclude	ed from fun	ding.

(ox mail: oxol: dot) \$	Per	Manufacturer
continued Initiation – chronic respiratory disease for patients 3 years and over Either:		
 Asthma, if on a regular preventative therapy; or Other chronic respiratory disease with impaired lung function. Note: asthma not requiring regular preventative therapy is excluded from funding. Initiation – Other conditions for patients 3 years and over 		
Either:		
1 Any of the following:		
1.1 Diabetes; or		
1.2 chronic renal disease; or		
1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or		
 1.4 Autoimmune disease; or 1.5 Immune suppression or immune deficiency; or 		
1.6 HIV; or		
1.7 Transplant recipient; or		
1.8 Neuromuscular and CNS diseases/ disorders; or		
1.9 Haemoglobinopathies; or		
1.10 Is a child on long term aspirin; or		
 1.11 Has a cochlear implant; or 1.12 Errors of metabolism at risk of major metabolic decompensation; or 		
1.13 Pre and post splenectomy; or		
1.14 Down syndrome; or		
1.15 Is pregnant; or		
1.16 Is a child 3 to 4 years of age (inclusive) who has been hospitalised for respirat significant respiratory illness; or	ory illnes	s or has a history of
2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detai a Public Hospital.	ned long	-term in a forensic unit within
Initiation – Serious mental health conditions or addiction Any of the following:		
1 schizophrenia; or		
2 major depressive disorder; or		
3 bipolar disorder; or		
 schizoaffective disorder; or person is currently accessing secondary or tertiary mental health and addiction servic 		
Initiation – children from 3 to 12 years of age (inclusive)	.00.	
Children 3 to 12 years of age (inclusive) from 1 April 2023 to 31 December 2023.		
(FluQuadri (2023 Formulation) Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)	to be del	listed 1 January 2024)
MEASLES, MUMPS AND RUBELLA VACCINE - Restricted see terms below		, ,
Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50, Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent		
0.5 ml – 0% DV Oct-20 to 2024	10	Priorix
→ Restricted (RS1487) Initiation – first dose prior to 12 months		
Therapy limited to 3 doses		
Any of the following:		
1 For primary vaccination in children; or		
2 For revaccination following immunosuppression; or		
		continued

VACCINES

Brand or

Generic

Price (ex man. excl. GST)

(Price excl. GST) \$	Per	Brand or Generic Manufacturer
continued				
3 For any individual susceptible to measles, mumps or rubella.				
Initiation – first dose after 12 months				
Therapy limited to 2 doses				
Any of the following: 1 For primary vaccination in children; or				
 For revaccination following immunosuppression; or For any individual susceptible to measles, mumps or rubella. 				
Note: Please refer to the Immunisation Handbook for appropriate schedu	ule for c	atch up prog	grammes.	
POLIOMYELITIS VACCINE – Restricted see terms below				
 Inj 80 D-antigen units in 0.5 ml syringe – 0% DV Oct-20 to 2024 → Restricted (RS1398) 		0.00	1	IPOL
Initiation				
Therapy limited to 3 doses Either:				
 For partially vaccinated or previously unvaccinated individuals; or For revaccination following immunosuppression. 				
Note: Please refer to the Immunisation Handbook for the appropriate sch	nedule	for catch up	programn	nes.
RABIES VACCINE				
Inj 2.5 IU vial with diluent				
ROTAVIRUS ORAL VACCINE – Restricted see terms below				
I Oral susp live attenuated human rotavirus 1,000,000 CCID50 per do prefilled oral applicator – 0% DV Oct-20 to 2024		0.00	10	Rotarix
Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dos squagzable tube		0.00	10	Rotarix
squeezable tube		0.00	10	Πυίαπλ
Initiation				
Therapy limited to 2 doses Both:				
 First dose to be administered in infants aged under 14 weeks of a No vaccination being administered to children aged 24 weeks or c 	•	1		
VARICELLA VACCINE [CHICKENPOX VACCINE]				
Inj 1350 PFU prefiiled syringe – 0% DV Oct-20 to 2024		0.00	1	Varivax
➡ Restricted (RS1591)			10	Varivax
Initiation – primary vaccinations				
Therapy limited to 1 dose Either:				
 Any infant born on or after 1 April 2016; or For previously unvaccinated children turning 11 years old on or af infection (chickenpox). 	ter 1 Ju	ıly 2017, who	o have no	t previously had a varicella
Initiation – other conditions Therapy limited to 2 doses Any of the following:				
1 Any of the following:				
for non-immune patients:				

Price		Brand or
(ex man. excl. GS	ST)	Generic
\$	Per	Manufacturer

continued...

- 1.1 With chronic liver disease who may in future be candidates for transplantation; or
- 1.2 With deteriorating renal function before transplantation; or
- 1.3 Prior to solid organ transplant; or
- 1.4 Prior to any elective immunosuppression*; or
- 1.5 For post exposure prophylaxis who are immune competent inpatients; or
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
- 4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

Inj 2000 PFU prefilled syringe plus vial

➡ Restricted (RS1777)

Initiation - infants between 9 and 12 months of age

Therapy limited to 2 doses

Any of the following:

- 1 Any of the following:
 - for non-immune patients:
 - 1.1 With chronic liver disease who may in future be candidates for transplantation; or
 - 1.2 With deteriorating renal function before transplantation; or
 - 1.3 Prior to solid organ transplant; or
 - 1.4 Prior to any elective immunosuppression*; or
 - 1.5 For post exposure prophylaxis who are immune competent inpatients; or
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or
- 4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella; or
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] - Restricted see terms on the next page

Inj 50 mcg per 0.5 ml vial plus vial......0.00 1

Shinarix



	Pric (ex man. ex \$		GST)	Per	Brand or Generic Manufacturer
→ Restricted (RS1916)					
Initiation – people aged 65 years (Zostavax)					
Therapy limited to 1 dose					
One dose for all people aged 65 years. Initiation – people aged 65 years (Shingrix)					
Therapy limited to 2 doses					
Two doses for all people aged 65 years.					
Diagnostic Agents					
Diagnostic Agents					
TUBERCULIN PPD [MANTOUX] TEST					
Inj 5 TU per 0.1 ml, 1 ml vial - 0% DV Oct-20 to 2024		0.00		1	Tubersol

PART III: OPTIONAL PHARMACEUTICALS

Price (ex man. ex \$	 Per	Brand or Generic Manufacturer

Optional Pharmaceuticals

NOTE:

In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a range of hospital medical devices are listed in an addendum to Part III which is available at <u>schedule.pharmac.govt.nz</u>. The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

BLOOD GLUCOSE DIAGNOSTIC TEST METER		
1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips 20.00 10.00	1	CareSens N Premier Caresens N Caresens N POP
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP		
Blood glucose test strips10.56	50 test	CareSens N
Test strips 10.56	50 test	CareSens PRO
BLOOD KETONE DIAGNOSTIC TEST STRIP		
Test strips 15.50	10 strip	KetoSens
DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER		
Meter with 50 lancets, a lancing device, and 10 blood glucose diagnostic		
test strips	1	CareSens Dual
MASK FOR SPACER DEVICE		
Small	1	e-chamber Mask
PEAK FLOW METER		
Low Range	1	Mini-Wright AFS Low
ů –		Range
Normal Range9.54	1	Mini-Wright Standard
PREGNANCY TEST - HCG URINE		
Cassette	40 test	Smith BioMed Rapid
		Pregnancy Test
SODIUM NITROPRUSSIDE		
Test strip	50 strip	Ketostix
SPACER DEVICE		
220 ml (single patient)	1	e-chamber Turbo
510 ml (single patient)5.95	1	e-chamber La Grande
800 ml6.50	1	Volumatic

- Symbols -

8-methoxypsoralen
- A -
A-Scabies67
Abacavir sulphate 101
Abacavir sulphate with
lamivudine 101
Abacavir/lamivudine Viatris101
Abciximab172
Abiraterone acetate 161
Acarbose
Accarb
Accuretic 1043
Accuretic 2043
Acetazolamide
Acetec
Acetic acid
Extemporaneously Compounded
Preparations
Genito-Urinary
Acetic acid with hydroxyquinoline,
glycerol and ricinoleic acid
Acetic acid with propylene
glycol
Acetylcholine chloride
Acetylcholine chloride
Acetylcysteine
Infections104
Sensory
Aciclovir-Baxter
Acid Citrate Dextrose A
Acidex
Acipimox
Acitretin
Actemra
Actinomycin D144
Adalimumab (Amgevita)
Adalimumab (Humira - alternative
brand)
Adapalene
Adenocor
Adenosine
Adrenaline
Cardiovascular
Respiratory240
Advantan
Advate
Advnovate
Aerrane
Afinitor
Aflibercept
Afluria Quad
(2023 Formulation)
Afluria Quad Junior

(2023 Formulation) 290
Agents Affecting the
Renin-Angiotensin System
Agents for Parkinsonism and Related
Disorders 117
Agents Used in the Treatment of
Poisonings256
Ajmaline
Albendazole
Alchemy Caspofungin96
Alchemy Oxaliplatin 153
Alchemy Oxybutynin75
Aldurazyme
Alecensa
Alectinib
Alendronate sodium
Alendronate sodium with
colecalciferol
Alfacalcidol
Alfamino
Alfamino Junior
Alfentanil
Alglucosidase alfa
Alinia
Allerfix
Allerpro Syneo 1
Allerpro Syneo 2
Allersoothe
Allmercap
Allopurinol113
Alpha tocopheryl27
Alpha tocopheryl acetate
Alpha-Adrenoceptor Blockers
Alphamox
Alphamox 125
Alphamox 25091
Alprolix
Alprostadil hydrochloride54
Alteplase
Alum
Aluminium chloride 30
Aluminium hydroxide5
Aluminium hydroxide with
magnesium hydroxide and
simeticone5
Amantadine hydrochloride117
AmBisome95
Ambrisentan55
Ambrisentan Mylan55
Ambrisentan Viatris55
Amethocaine
Nervous121
Sensory252
Amgevita

Amikacin87
Amiloride hydrochloride 49
Amiloride hydrochloride with
furosemide 49
Amiloride hydrochloride with
hydrochlorothiazide 49
Aminolevulinic acid
hydrochloride 164
Aminophylline246
Amiodarone hydrochloride45
Amisulpride131
Amitriptyline 124
Amlodipine
Amorolfine
Amoxicillin
Amoxicillin with clavulanic acid91
Amoxiclav multichem
Amphotericin B
Alimentary24
Infections
Amsacrine
Amyl nitrite
Anabolic Agents
Anaesthetics
Anagrelide hydrochloride
Analgesics
Anastrozole164
Anatrole
Andriol Testocaps
Androderm
Androgen Agonists and
Antagonists
Anoro Ellipta
Antabuse
Antacids and Antiflatulents
Anti-Infective Agents
Anti-Infective Agents
Dermatological
Sensory
Anti-Inflammatory Preparations 250
Antiacne Preparations
Antiallergy Preparations
Antianaemics
Antiarrhythmics
Antibacterials
Anticholinergic Agents
Anticholinesterases
Antidepressants
Antidiarrhoeals and Intestinal
Anti-Inflammatory Agents 5
Antiepilepsy Drugs
Antifibrinolytics, Haemostatics and
Local Sclerosants
Antifibrotics

Antifungals95
Antihypotensives46
Antimigraine Preparations 129
Antimycobacterials97
Antinausea and Vertigo Agents 129
Antiparasitics
Antipruritic Preparations67
Antipsychotic Agents 131
Antiretrovirals
Antirheumatoid Agents 110
Antiseptics and Disinfectants
Antispasmodics and Other Agents
Altering Gut Motility
Antithrombotics
Antithymocyte globulin
(equine) 235
(equine)
Antithymocyte globulin (rabbit) 235
Antiulcerants7
Antivirals103
Anxiolytics134
Apidra 10
Apidra Solostar10
APO-Atomoxetine138
APO-Candesartan HCTZ
16/12.5
APO-Candesartan HCTZ
32/12.5
Apomorphine hydrochloride117
Apraclonidine
Aprepitant
Apresoline
Aprotinin
Aqueous cream
Arachis oil [Peanut oil]
Aratac
Arava
Arginine
Alimentary 17
Various260
Argipressin [Vasopressin]86
Aripiprazole131
Aripiprazole Sandoz 131
Aristocort70
Arrotex-Prazosin S2945
Arrow - Clopid
Arrow - Lattim
Arrow-Amitriptyline124
Arrow-Bendrofluazide
Arrow-Brimonidine
Arrow-Diazepam
Arrow-Fluozetine
Arrow-Losartan &
Hydrochlorothiazide
Arrow Norfleveein
Arrow-Norfloxacin
Arrow-Ornidazole
Arrow-Quinapril 1043

Arrow-Quinapril 20	. 43
Arrow-Quinapril 5	. 43
Arrow-Roxithromycin	
Arrow-Timolol	253
Arrow-Topiramate	128
Arrow-Tramadol	124
Arsenic trioxide	147
Artemether with lumefantrine	99
Artesunate	
Articaine hydrochloride	119
Articaine hydrochloride with	
adrenaline	110
Asacol	6
Ascorbic acid	0
Alimentary	06
Extemporaneously Compounded	20
Extemporaneously Compounded	
Preparations	264
Aspen Adrenaline	53
Aspirin	
Blood	
Nervous	
Asthalin	
Atazanavir Mylan	102
Atazanavir sulphate	
Atenolol	. 46
Atenolol Viatris	46
Atenolol-AFT	
Atezolizumab	230
ATGAM	
Ativan	
Atomoxetine	
Atorvastatin	
Atovaquone with proguanil	
hydrochloride	qq
Atracurium besylate	114
Atropine sulphate	
Cardiovascular	15
Sensory	- 40 054
Atrent	204
Atropt	204
Aubagio	
Augmentin	
Aurorix	
Avallon	
Avelox	
Avonex	135
Avonex Pen	135
Azacitidine	145
Azacitidine Dr Reddy's	145
Azactam	. 93
Azamun	235
Azathioprine	235
Azilect	118
Azithromycin	89
Azopt	253
AZT	
Aztreonam	

- B -	
Bacillus calmette-guerin (BCG)	235
Bacillus calmette-guerin	
vaccine	. 284
Baclofen	
Bacterial and Viral Vaccines	
Bacterial Vaccines	
Balanced Salt Solution	252
Baricitinib	
Barium sulphate	
Barium sulphate with sodium	
bicarbonate	259
Barrier Creams and Emollients	
Basiliximab	
BCG Vaccine	
BD PosiFlush	
Beclazone 100	
Beclazone 250	
Beclazone 50	
Beclomethasone dipropionate	244
Bedaquiline	
Bee venom	240
Bendamustine hydrochloride	143
Bendrofluazide	50
Bendroflumethiazide	
[Bendrofluazide]	50
Benralizumab	
Benzathine benzylpenicillin	
Benzatropine mesylate	
Benzbromaron AL 100	113
Benzbromarone	
Benzocaine	119
Benzocaine with tetracaine	
hydrochloride	
Benzoin	264
Benzoyl peroxide	<mark>67</mark>
Benztrop	
Benzydamine hydrochloride	24
Benzydamine hydrochloride with	
cetylpyridinium chloride	24
Benzylpenicillin sodium [Penicillin	
G]	
Beractant	
Beta Cream	
Beta Ointment	
Beta Scalp	/1
Beta-Adrenoceptor Agonists	
Beta-Adrenoceptor Blockers	
Betadine	258
Betahistine dihydrochloride	
Betaine	
Betaloc CR	
Betamethasone	
Betamethasone dipropionate	69
Betamethasone dipropionate with	70
calcipotriol	/ U

Betamethasone sodium phosphate with betamethasone acetate
with betamethasone acetate
Betamethasone valerate69, 71
Betamethasone valerate with
clioquinol70
Betamethasone valerate with sodium
fusidate [Fusidic acid]70
Betaxolol253
Betnovate69
Betoptic253
Betoptic S
Bevacizumab 190
Bexsero
Bezafibrate51
Bezalip51
Bezalip Retard51
Bicalutamide
Bicillin LA
BiCNU
Bile and Liver Therapy
Biliscopin
Bimatoprost
Bimatoprost Multichem
Binarex
Binocrit
Biodone
Biodone Extra Forte
Biodone Forte
Biotin
Bisacodyl
Bisacodyl Viatris15
Bismuth subgallate
Bismuth subnitrate and iodoform
paraffin
Bisoprolol fumarate46
Bisoprolol Mylan46
Bisoprolol Viatris46
Bivalirudin34
Bleomycin sulphate 144
Blood glucose diagnostic test
meter 295
Blood glucose diagnostic test
strip 295
Blood ketone diagnostic test
strip
Bonney's blue dye
Boostrix
Boric acid
Bortezomib147
Bosentan
Bosentan Dr Reddy's57
Bosvate
Botox
Botulism antitoxin
Bplex
Breo Ellipta
2.00 = mpta

Brevinor 1/28
Bricanyl Turbuhaler244
Brimonidine tartrate
Brimonidine tartrate with
timolol
Brinzolamide253
Bromocriptine
Brufen SR115
Budesonide
Alimentary5
Respiratory241, 244
Budesonide with eformoterol
Bumetanide49
Bupafen 119
Bupivacaine hydrochloride 119
Bupivacaine hydrochloride with
adrenaline
Bupivacaine hydrochloride with
fentanyl
glucose
Buprenorphine Naloxone BNM 140
Buprenorphine with naloxone 140
Bupropion hydrochloride141
Burinex
Buscopan7
Buserelin81
Buspirone hydrochloride134
Buspirone Viatris 134
Buspirone Viatris
Buspirone Viatris
Buspirone Viatris
Buspirone Viatris 134 Busulfan 144 - C - Cabergoline Caffeine 138
Buspirone Viatris 134 Busulfan 144 - C - Cabergoline Caffeine 138 Caffeine citrate 246
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calamine-AFT 67
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calamine-AFT 67 Calci-Tab 500 22
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calamine-AFT 67 Calci-Tab 500 22 Calcipotriol 70
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine-AFT 67 Calarine-AFT 67 Calci-Tab 500 22 Calcipotriol 70 Calcitonin 77
Buspirone Viatris 134 Busulfan 144 - C - 60 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 22 Calcipotriol 77 Calcitroin 77 Calcitriol 26
Buspirone Viatris 134 Busulfan 144 - C - 6 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcipotriol 77 Calcitriol 26 Calcitriol-AFT 26
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calamine-AFT 67 Calcipotriol 22 Calcipotriol 70 Calcitriol 26 Calcitriol 26 Calcitriol-AFT 26 Calcium carbonate 5, 22
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calamine-AFT 67 Calcipotriol 22 Calcipotriol 70 Calcitriol 26 Calcitriol 26 Calcitriol-AFT 26 Calcium carbonate 5, 22
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 22 Calcitonin 70 Calcitriol 26 Calcitriol 26 Calcium carbonate 5, 22 Calcium carbonate 54
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calci-Tab 500 22 Calcipotriol 70 Calcitonin 77 Calcitriol-AFT 26 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium Channel Blockers 47
Buspirone Viatris 134 Busulfan 144 - C - 6 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcitonin 77 Calcitriol 26 Calcitriol 26 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium chonate 47 Calcium chloride 39
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcitonin 77 Calcitriol-AFT 26 Calcium carbonate 5, 22 Calcium carbonate PAI 55 Calcium Choride 39 Calcium folinate 160
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcitonin 77 Calcitriol-AFT 26 Calcium carbonate 5, 22 Calcium carbonate PAI 55 Calcium Choride 39 Calcium folinate 160 Calcium Folinate Ebewe 160
Buspirone Viatris 134 Busulfan 144 - C - 6 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine-AFT 67 Calci-Tab 500 22 Calcipotriol 70 Calcitroin 77 Calcitriol 26 Calcitriol 26 Calcium carbonate 5, 22 Calcium carbonate PAI 5 Calcium Channel Blockers 47 Calcium folinate 160 Calcium Folinate Ebewe 160
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine-AFT 67 Calciptriol 70 Calcitrol 70 Calcitriol 70 Calcitriol-AFT 26 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 71 Calcium carbonate 5, 22 Calcium carbonate 71 Calcium carbonate 72 Calcium carbonate 74 Calcium Folinate 160 Calcium Folinate 160 Calcium Folinate 260 Calcium Gluconate 160 Calcium gluconate 160
Buspirone Viatris 134 Busulfan 144 - C - 2 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calciptoriol 70 Calciptriol 70 Calcitrol 70 Calcitrol 70 Calcium carbonate 5, 22 Calcium carbonate 71 Calcium carbonate 74 Calcium folinate 50 Calcium carbonate 74 Calcium carbonate 74 Calcium folinate 160 Calcium folinate 160 Calcium Folinate Sandoz 160 Calcium gluconate 160 Calcium folinate 39
Buspirone Viatris 134 Busulfan 144 - C - 6 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcipotriol 70 Calcitriol-AFT 26 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 71 Calcium carbonate 5, 22 Calcium carbonate 74 Calcium carbonate 5, 22 Calcium carbonate 74 Calcium carbonate 5, 22 Calcium coloride 39 Calcium Folinate 160 Calcium Folinate 160 Calcium Folinate Sandoz 160 Calcium gluconate 39 Dermatological 72
Buspirone Viatris 134 Busulfan 144 - C - 6 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcipotriol 70 Calcitriol 26 Calcitriol-AFT 26 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 71 Calcium carbonate 5, 22 Calcium carbonate 71 Calcium carbonate 71 Calcium carbonate 71 Calcium carbonate 71 Calcium Folinate 160 Calcium Folinate 160 Calcium Folinate 39 Dermatological 72 Calcium Homeostasis 77
Buspirone Viatris 134 Busulfan 144 - C - 6 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcitroil 70 Calcitroil 70 Calcitroil 26 Calcitroil 77 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 71 Calcium carbonate 5, 22 Calcium carbonate 71 Calcium carbonate 5, 22 Calcium carbonate 71 Calcium Folinate 160 Calcium Folinate 160 Calcium Folinate Sandoz 160 Calcium gluconate 39 Dermatological 72 Calcium Homeostasis 77 Calcium polystyrene sulphonate 41
Buspirone Viatris 134 Busulfan 144 - C - 6 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcitriol 26 Calcitriol 26 Calcitriol-AFT 26 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 5 Calcium Folinate Ebewe 160 Calcium Folinate Sandoz 160 Calcium Folinate Sandoz 160 Calcium Homeostasis 77 Calcium Homeostasis 77 Calcium Polystyrene sulphonate 41
Buspirone Viatris 134 Busulfan 144 - C - 6 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcitriol 26 Calcium carbonate 5, 22 Calcium Chonate 5, 22 Calcium Chonate 59 Calcium Folinate Ebewe 160 Calcium Folinate Ebewe 160 Calcium Folinate Sandoz 160 Calcium Homeostasis 77 Calcium Homeostasis 77 Calcium Polystyrene sulphonate 41 Calcium Resonium 41
Buspirone Viatris 134 Busulfan 144 - C - 6 Cabergoline 80 Caffeine 138 Caffeine citrate 246 Calamine 67 Calarine-AFT 67 Calcipotriol 70 Calcitriol 26 Calcitriol 26 Calcitriol-AFT 26 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 5, 22 Calcium carbonate 5 Calcium Folinate Ebewe 160 Calcium Folinate Sandoz 160 Calcium Folinate Sandoz 160 Calcium Homeostasis 77 Calcium Homeostasis 77 Calcium Polystyrene sulphonate 41

hydrochlorothiazide	. 44
Candestar	.44
Capecitabine	
Capecitabine Viatris	146
Capercit	146
Capoten	.43
Capsaicin	
Musculoskeletal	
Nervous	
Captopril	
Carbachol	
Carbamazepine	
Carbasorb-X	
Carbimazole	
Carbomer	
Carboplatin	
Carboplatin Ebewe	
Carboprost trometamol	.74
Carboxymethylcellulose	
Alimentary	.24
Extemporaneously Compounded	
Preparations	264
Cardinol LA	
Cardizem CD	
CareSens Dual	
Caresens N	295
Caresens N POP	295
CareSens N Premier	295
CareSens PRO	295
Carglumic acid	295
Carglumic acid Carmellose sodium with pectin and	295
Carglumic acid Carmellose sodium with pectin and gelatine	295 . 17
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary	295 . 17 . 24
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory	295 .17 .24 254
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine	295 . 17 . 24 254 144
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol	295 .17 .24 254 144 .47
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz	295 .17 .24 254 144 .47 .47
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Casirivimab and imdevimab	295 .17 .24 254 144 .47 .47 191
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Casirivimab and imdevimab Caspofungin	295 .17 .24 254 144 .47 .47 191 .96
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol Carvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres	295 .17 .24 254 144 .47 .47 191 .96 .49
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carwedilol Carvedilol.sandoz Casirivimab and imdevimab Caspofungin Catapres Ceenu	295 .17 .24 254 144 .47 .96 .49 144
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carwedilol Carvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres Ceenu Cefaclor	295 .17 .24 254 144 .47 .96 .49 144 .88
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory. Carmustine Carvedilol. Carvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres. Ceenu Cefaclor Cefalexin.	295 .17 .24 254 144 .47 191 .96 .49 144 .88 .88
Carglumic acid Carmellose sodium with pectin and gelatine AlimentarySensory. Carmustine Carvedilol. Carvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres. Ceenu Cefaclor Cefaclor Cefazolin	295 .17 .24 254 144 .47 .96 .49 144 .88 .88 .88
Carglumic acid Carmellose sodium with pectin and gelatine AlimentarySensory. Carmustine Carvedilol. Carvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres Ceenu Cefaclor. Cefalcor. Cefazolin. Cefepime	295 .17 .24 254 144 .47 191 .96 .49 144 .88 .88 .88 .88
Carglumic acid Carmellose sodium with pectin and gelatine AlimentarySensory. Carmustine Carvedilol. Carvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres. Ceenu. Cefaclor. Cefalexin. Cefazolin. Cefepime Cefepime Kabi	295 .17 .24 254 144 .47 .47 191 .96 .49 144 .88 .88 .88 .88 .88
Carglumic acid Carmellose sodium with pectin and gelatine AlimentarySensory. Carmustine Carvedilol. Carvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres. Ceenu Cefaclor. Cefalexin Cefazolin. Cefapime Kabi Cefotaxime	295 .17 .24 254 144 .47 .47 191 .96 .49 144 .88 .88 .88 .88 .88 .88
Carglumic acid Carmellose sodium with pectin and gelatine AlimentarySensory. Carmustine Carvedilol. Carvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres. Ceenu. Cefaclor. Cefalexin Cefazolin. Cefazolin. Cefepime Cefepime Kabi Cefotaxime Cefotaxime Sandoz	2955 . 17 . 24 254 144 . 47 191 . 96 . 49 144 . 88 . 88 . 88 . 88 . 88 . 88 . 88
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory. Carmustine Carvedilol Sandoz Casiroi/imab and imdevimab Caspofungin Catapres Ceenu Cefaclor	2955 . 17 . 24 254 144 . 47 191 . 96 . 49 144 . 88 . 88 . 88 . 88 . 88 . 88 . 88
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol Sandoz Casirivimab and imdevimab Casirivimab and imdevimab Casirovimab and imdevimab Casafactor Cefaclor Cefaclor Cefaclor Cefalexin Cefazolin Cefepime Kabi Cefotaxime Cefotaxime Sandoz Cefotatin Cefator Cefotaxime Sandoz Cefator Cefator Cefotaxime	2955 . 17 . 24 254 144 . 47 . 47 191 . 96 . 49 144 . 88 . 88 . 88 . 88 . 88 . 88 . 88
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol Sandoz Casvedilol Sandoz Casirivimab and imdevimab Casofungin Catapres Ceenu Cefaclor Cefaclor Cefazolin. Cefazolin. Cefazolin. Cefepime Kabi Cefotaxime Cefotaxime Sandoz Cefotacin. Cefazolin. Cefazolin. Cefotaxime Cefotaxime Cefotaxime Cefotacin. Cefazolin. Cefazolin. Cefotacin. Cefotacin. Cefotacin. Cefotacin. Cefotacin. Cefazolin. Cefotacin.	295 .17 .24 254 144 .47 .47 191 .96 .49 144 .88 .88 .88 .88 .88 .88 .88 .88 .88
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol.Sandoz Casirivimab and imdevimab Caspofungin Catapres Ceenu Cefaclor Cefaclor Cefazolin. Cefazolin. Cefepime Kabi Cefotaxime Sandoz Cefotaxime Sandoz Ceftazidime Ceftazidime Ceftazidime	295 .17 .24 254 .47 .47 191 .96 .49 144 .88 .88 .88 .88 .88 .88 .88 .88 .88
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol.Sandoz Casvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres Ceenu Cefaclor Cefaclor Cefazolin. Cefazolin. Cefepime Kabi Cefotaxime Sandoz Cefotaxime Sandoz Ceftazidime Ceftazidime Ceftazidime Ceftazidime	295 .17 .24 254 144 .47 191 .96 .49 144 .88 .88 .88 .88 .88 .88 .88 .88 .88
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory. Carwedilol. Carvedilol Sandoz Casirivimab and imdevimab Caspofungin Caspofungin Catapres. Ceenu Cefaclor Cefaclor Cefazolin. Cefazolin. Cefazolin. Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Cefotaxime Ceftazidime. Ceftazi	295 .17 .24 254 144 .47 .96 .49 144 .88 .88 .88 .88 .88 .88 .88 .88 .88
Carglumic acid Carmellose sodium with pectin and gelatine Alimentary Sensory Carmustine Carvedilol.Sandoz Casvedilol Sandoz Casirivimab and imdevimab Caspofungin Catapres Ceenu Cefaclor Cefaclor Cefazolin. Cefazolin. Cefepime Kabi Cefotaxime Sandoz Cefotaxime Sandoz Ceftazidime Ceftazidime Ceftazidime Ceftazidime	295 .17 .24 254 144 .47 .96 .49 144 .88 .88 .88 .88 .88 .88 .88 .88 .88

Cefuroxime-AFT
Celapram125
Celecoxib115
Celecoxib Pfizer115
Celiprolol47
CellCept236
Centrally-Acting Agents 48
Cephalexin ABM88
Cetirizine hydrochloride
Cetomacrogol68
Cetomacrogol with glycerol68
Cetomacrogol-AFT
Cetrimide
Cetuximab 192
Charcoal
Chemotherapeutic Agents 143
Chickenpox vaccine
Chloral hydrate 136
Chlorambucil144
Chloramphenicol
Infections93
Sensory249
Chlorhexidine258
Chlorhexidine gluconate
Alimentary24
Extemporaneously Compounded
Preparations
Genito-Urinary73
Genito-Urinary73 Chlorhexidine with
Chlorhexidine with cetrimide
Chlorhexidine with cetrimide

Cipflox	92
Ciprofloxacin	
Infections	92
Sensory2	
Ciprofloxacin Kabi	
Ciprofloxacin Teva2	
Ciprofloxacin with	
hydrocortisone	49
Ciproxin HC Otic	
Cisplatin1	
Citalopram hydrobromide 1	25
Citanest1	21
Citrate sodium	34
Citric acid2	
Citric acid with magnesium oxide and	.04
sodium picosulfate	11
Citric acid with sodium	14
bicarbonate2	00
Cladribine	
Clarithromycin	
Clexane	
Clexane Forte	
Clindamycin	
Clinicians	26
Clinicians Multivit & Mineral	
Boost	
Clinicians Renal Vit	
Clobazam1	
Clobetasol propionate69,	
Clobetasone butyrate	
Clofazimine	97
Clomazol	
Dermatological	66
Genito-Urinary	73
Clomifene citrate	
Clomipramine hydrochloride1	24
Clomipramine Teva1	24
Clonazepam 126, 1	34
Clonidine	48
Clonidine hydrochloride	49
Clonidine Teva	49
Clopidogrel	36
Clopine 1	31
Clopixol	34
Clostridium botulinum type A	
toxin 1	14
Clotrimazole	
Dermatological	66
Genito-Urinary	
Clove oil	
Clozapine1	
Clozaril	
Co-trimoxazole	
Coal tar	
Coal tar with salicylic acid and	+
sulphur	70
Supriui	10

Cocaine hydrochloride1	20
Cocaine hydrochloride with	
adrenaline1	20
Codeine phosphate	
Extemporaneously Compounded	
Preparations2	64
Nervous1	207 202
Coenzyme Q10	
Colchicine	12
Colecalciferol	
Colestimethate	
Colestipol hydrochloride	90
Colestipol Hydrochionide	52
Colestyramine	52
Colestyramine - Mylan	10
Colgout1	13
Colifoam	6
Colistin sulphomethate	
[Colestimethate]	93
Colistin-Link	
Collodion flexible2	64
Colloidal bismuth subcitrate	
Colofac	7
Colony-Stimulating Factors	
Coloxyl	
Compound electrolytes	41
Compound electrolytes with glucose	
[Dextrose]39,	
Compound hydroxybenzoate2	64
Compound sodium lactate	
[Hartmann's solution]	
[Hartmann's solution]1	
	17
Comtan 1 Concerta 1	17 39
Comtan 1 Concerta 1 Condyline	17 39 71
Comtan	17 39 71 73
Comtan	17 39 71 73 59
Comtan	17 39 71 73 59 35
Comtan	17 39 71 73 59 35 22
Comtan	17 39 71 73 59 35 22 22
Comtan	17 39 71 73 59 35 22 22
Comtan 1 Concerta 1 Condyline. Contraceptives. Contrast Media 2 Copaxone 1 Copper	17 39 71 73 59 35 22 22 81 69
Comtan 1 Concerta 1 Condyline. Contraceptives. Contrast Media 2 Copaxone 1 Copper	17 39 71 73 59 35 22 22 81 69
Comtan 1 Concerta 1 Condyline. 1 Contraceptives. 2 Contrast Media 2 Copaxone 1 Copper	17 39 71 73 59 35 22 22 81 69 78
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contrast Media 2 Copaxone 1 Copper 1 Copper chloride 1 Corticorelin (ovine) 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 2 Cosentyx 2	17 39 71 73 59 35 22 22 81 69 78 18
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contrast Media 2 Copaxone 1 Copper 1 Copper chloride 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 2 Cosentyx 2 Cosmegen 1	17 39 71 73 59 35 22 22 81 69 78 18 44
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contrast Media 2 Copaxone 1 Copper 1 Copper 1 Corticorelin (ovine) 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 1 Cosentyx 2 Cosmegen 1 Coversyl 1	17 39 71 73 59 35 22 22 81 69 78 44 43
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contract Media 2 Copaxone 1 Copper 1 Copper chloride 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 1 Cosentyx 2 Cosmegen 1 Coversyl. 1 Creon 10000 10000	17 39 71 73 59 35 22 22 81 69 78 18 44 43 13
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contrast Media 2 Copaxone 1 Copper 1 Copper 1 Corticorelin (ovine) 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 1 Cosentyx 2 Cosmegen 1 Coversyl 1	17 39 71 73 59 35 22 22 81 69 78 44 43 13
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contrast Media 2 Copaxone 1 Copper 1 Copper chloride 1 Corticorelin (ovine) 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 1 Cosentyx 2 Cosmegen 1 Coversyl 1 Creon 10000 1 Creon 25000 1	17 39 71 73 59 35 22 22 81 69 78 44 43 13 13
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contrast Media 2 Copaxone 1 Copper 1 Copper chloride 1 Corticorelin (ovine) 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 2 Cosentyx 2 Cosmegen 1 Coversyl. 1 Creon 10000 1 Creon Micro 1 Crotamiton 1	17 39 71 59 35 22 22 81 69 78 18 44 13 13 67
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contrast Media 2 Copaxone 1 Copper 1 Copper chloride 1 Corticorelin (ovine) 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 1 Cosentyx 2 Cosmegen 1 Coversyl 1 Creon 10000 1 Creon Micro 1 Crotamiton 1	17 39 71 73 59 35 22 22 81 69 78 44 43 13 13 67 66
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contrast Media 2 Copaxone 1 Copper 1 Copper chloride 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 1 Cosentyx 2 Cosmegen 1 Coversyl 1 Creon 10000 1 Creon Micro 1 Crystaderm 2 CT Plus+ 2	17 39 71 73 59 35 22 81 69 78 44 43 13 67 65 9
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contraceptives 2 Copaxone 1 Copper 1 Copper chloride 1 Corticorelin (ovine) 1 Corticosteroids 1 Dermatological 1 Hormone Preparations 2 Cosentyx 2 Cosmegen 1 Coversyl 2 Creon 10000 1 Creon Micro 1 Crystaderm 2 CT Plus+ 2 Cubicin 2	17 39 71 73 59 35 22 22 81 69 78 44 43 13 67 66 59 93
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contraceptives 2 Contrast Media 2 Copper 1 Copper chloride 1 Corticosteroids 0 Dermatological 1 Hormone Preparations 2 Cosmegen 1 Coversyl. 2 Cosmegen 1 Coversyl. 2 Creon 10000 2 Creon Micro 2 Crotamiton 2 Crystaderm 2 Cubicin. 2 Cutram. 2	17 39 71 73 59 35 22 28 1 69 78 44 43 13 13 67 66 93 91
Comtan	17 39 71 73 59 32 22 81 69 78 44 313 67 66 93 91 91
Comtan 1 Concerta 1 Condyline 1 Contraceptives 1 Contraceptives 2 Contrast Media 2 Copper 1 Copper chloride 1 Corticosteroids 0 Dermatological 1 Hormone Preparations 2 Cosmegen 1 Coversyl. 2 Cosmegen 1 Coversyl. 2 Creon 10000 2 Creon Micro 2 Crotamiton 2 Crystaderm 2 Cubicin. 2 Cutram. 2	17 39 71 73 59 35 22 28 69 78 44 43 13 67 66 93 91 48

Cyclizine hydrochloride130
Cyclizine lactate130
Cyclogyl254
Cyclonex144
Cyclopentolate hydrochloride
Cyclophosphamide144
Cycloserine
Cymevene 104
Cyproheptadine hydrochloride241
Cyproterone acetate77
Cyproterone acetate with
ethinyloestradiol73
Cystadane17
Cysteamine hydrochloride
Cytarabine
Cytotec7
- D -
D-Penamine110
Dabigatran34
Dacarbazine148
Dactinomycin [Actinomycin D]144
Daivobet70
Daivonex70
Dalacin C93
Danaparoid35
Dantrium 114
Dantrium IV114
Dantrolene 114
Daonil10
Dapa-Tabs50
Dapsone
Daptomycin
Daptomycin Dr Reddy's93
Darunavir
Darunavir Mylan 102
Darunavir Viatris 102
Dasatinib154
Daunorubicin145
DBL Adrenaline53
DBL Amikacin87
DBL Aminophylline246
DBL Bleomycin Sulfate144
DBL Bortezomib147
DBL Cefotaxime88
DBL Cisplatin153
DBL Dacarbazine148
DBL Desferrioxamine Mesylate for Inj
BP
DBL Docetaxel
DBL Ergometrine
DBL Gentamicin
DBL Leucovorin Calcium
DBL Methotrexate Onco-Vial
DBL Pethidine Hydrochloride
DBL Vincristine Sulfate
Decongestants

Decongestants and
Antiallergics 251
Decozol24
Deferasirox257
Deferiprone257
Defibrotide
Definity260
Demeclocycline hydrochloride93
Denosumab111
Deolate97
Deoxycoformycin151
Depo-Medrol79
Depo-Provera74
Depo-Testosterone77
Deprim
Dermol 69, 71
Desferrioxamine mesilate 257
Desflurane118
Desmopressin86
Desmopressin acetate86
Desmopressin-PH&T86
Dexamethasone
Hormone Preparations78
Sensory250
Dexamethasone phosphate79
Dexamethasone with framycetin and
gramicidin 249
Dexamethasone with neomycin
sulphate and polymyxin B
sulphate 249
Dexamethasone with
tobramycin249
Dexamfetamine sulfate138
Dexmedetomidine118
Dexmedetomidine-Teva118
Dexmethsone78
Dexrazoxane160
Dextrose
Alimentary9
Blood
Extemporaneously Compounded
Preparations
Dextrose with sodium citrate and
citric acid [Acid Citrate Dextrose
A] 35
DHC Continus122
Diabetes9
Diacomit128
Diagnostic Agents
Vaccines294
Various260
Diagnostic and Surgical
Preparations 251
Diamide Relief5
Diamox253
Diatrizoate meglumine with sodium

amidotrizoate	259
Diatrizoate sodium	.259
Diazepam126	134
Diazoxide	
Alimentary	9
Cardiovascular	54
Dichlorobenzyl alcohol with	
amylmetacresol	24
Diclofenac Sandoz	115
Diclofenac sodium	
Musculoskeletal	115
Sensory	
Dicobalt edetate	257
Diflucan	95
Diflucortolone valerate	
Digestives Including Enzymes	
Digoxin	45
Digoxin immune Fab	
Dihydrocodeine tartrate	
Dihydroergotamine mesylate	
Diltiazem CD Clinect	
Diltiazem hydrochloride	48
Dimercaprol	
Dimercaptosuccinic acid	258
Dimethicone	
Dimethyl fumarate	135
Dimethyl sulfoxide	.262
Dinoprostone	
Dipentum	7
Dipentum	7
Dipentum Diphemanil metilsulfate	7
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with	7 71
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate	7 71 5
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin	7 71 5
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis	7 71 5 .256
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and	7 5 .256 .285
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and	7 5 .256 .285
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine	7 5 .256 .285 .284
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio,	7 5 .256 .285 .284
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	7 71 5 .256 .285 .284
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone	7
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Dipyridamole	7
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone	7
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diporsone Dipyridamole Disodium edetate Disodium hydrogen phosphate with	7
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Disodium edetate Disodium hydrogen phosphate with sodium dihydrogen	71 5 .256 .285 .284 .284 36 .252
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diporsone Disodium edetate Disodium hydrogen phosphate with sodium dihydrogen phosphate	71 5 .256 .285 .284 .284 69 36 .252
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Disodium edetate Disodium hydrogen phosphate with sodium dihydrogen	71 5 .256 .285 .284 .284 69 36 .252
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Diporsone Disodium edetate Disodium hydrogen phosphate with sodium dihydrogen phosphate Disopyramide phosphate Disoulfiram	71 71 5 .256 .285 .284 .284
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Diporsone Disodium edetate Disodium hydrogen phosphate with sodium dihydrogen phosphate Disopyramide phosphate Disulfiram Disulfiram	71 5 .256 .285 .284 .284 69 36 .252 .264 45 .141 .264
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis, and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Diprosone Dipyridamole Disodium edetate Disodium dihydrogen phosphate Disopyramide phosphate Disulfiram Disulfiram	71 5 . 2566 . 2855 . 2884 . 2884 . 2884 . 2884 . 2522 . 264 45 . 141 . 264 49
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Dipyridamole Disodium edetate Disodium detate Disodium dihydrogen phosphate with sodium dihydrogen phosphate Disopyramide phosphate Disulfiram Dithranol Diuretics Dobutamine	71 5 . 2556 . 2855 . 2884 . 2884 . 2884 . 2884 . 2522 . 264 45 . 141 . 264 49 53
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Dipyridamole Disodium edetate. Disodium dihydrogen phosphate with sodium dihydrogen phosphate Disopyramide phosphate Disulfiram Dithranol Diuretics. Dobutamine	7 71 5 .256 .285 .284 .284 .284 .284 .284 .252 .264 36 .252 .141 .264 49 53 53
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Dipyridamole Disodium edetate. Disodium dihydrogen phosphate with sodium dihydrogen phosphate Disopyramide phosphate Disulfiram Dithranol Diuretics. Dobutamine Dobutamine	7 71 5 .256 .285 .284 .284 .284 .284 .284 .252 .264 36 .252 .141 .264 49 53 53
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Diprosone Disodium edetate Disodium edetate Disodium hydrogen phosphate with sodium dihydrogen phosphate Disulfiram Disulfiram Dithranol Divuretics Dobutamine Dobutamine Docetaxel Docusate sodium	7 71 5 .256 .285 .284 .284 .284 .284 .284 .252 .252 .252 .252 .252 .141 .264 45 .141 .264 49 53 .160
Dipentum Diphemanil metilsulfate Diphenoxylate hydrochloride with atropine sulphate Diphtheria antitoxin Diphtheria, tetanus and pertussis vaccine Diphtheria, tetanus, pertussis and polio vaccine Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Diprosone Dipyridamole Disodium edetate. Disodium dihydrogen phosphate with sodium dihydrogen phosphate Disopyramide phosphate Disulfiram Dithranol Diuretics. Dobutamine Dobutamine	7 71 5 . 256 . 285 . 284 . 284 . 284 . 284 . 284 . 284 . 252 . 264

Docusate sodium with
sennosides 15
Dolutegravir 103
Domperidone 130
Domperidone Viatris130
Donepezil hydrochloride
Donepezil-Rex
Dopamine hydrochloride
Dornase alfa
Dortimopt
Dorzolamide
Dorzolamide with timolol
Dostinex
Dosulepin [Dothiepin]
hydrochloride 125
Nulorin Mular 105
Dosulepin Mylan
Dosulepin Viatris
Dotarem
Dothiepin
Doxapram
Doxazosin
Doxazosin Clinect45
Doxepin hydrochloride125
Doxine
Doxorubicin Ebewe145
Doxorubicin hydrochloride145
Doxycycline93
DP Lotn HC69
DP-Allopurinol113
Dr Reddy's Omeprazole8
Drofate
Droperidol130
Droperidol Panpharma130
Drugs Affecting Bone
Metabolism 110
Dual blood glucose and blood ketone
diagnostic test meter 295
Dulaglutide11
Dulcolax SP Drop16
Duolin
DuoResp Spiromax245
Duovisc
Duride53
Durvalumab231
Dynastat
Dysport 114
-E-
e-chamber La Grande295
e-chamber Mask295
e-chamber Turbo
E-Mycin
E-Z-Cat Dry
E-Z-Gas II
E-Z-Paste
Econazole nitrate
Edrophonium chloride

Efavirenz	.100
Efavirenz with emtricitabine and	
tenofovir disoproxil	
Eformoterol fumarate	
Eformoterol fumarate dihydrate	245
Eftrenonacog alfa [Recombinant	
factor IX]	
Efudix	71
eg Clinicians selenium oral	
drops	
Elaprase	18
Elecare (Unflavoured)	276
Elecare (Vanilla)	.276
Elecare LCP (Unflavoured)	
Electral	41
Electrolytes	
Elelyso	
Elexacaftor with tezacaftor, ivacaftor	
and ivacaftor	
Elidel	
Elocon	69
Elocon Alcohol Free	69
Eltrombopag	30
Emend Tri-Pack	.129
Emicizumab	
EMLA	120
Empagliflozin	13
Empagliflozin with metformin	
hydrochloride	13
Emtricitabine	.101
Emtricitabine with tenofovir	
disoproxil	105
Emtriva	. 101
Emulsifying ointment	68
Emulsifying Ointment ADE	
Enalapril maleate	43
Enbrel	165
Endocrine Therapy	.161
Endoxan	
Engerix-B Enlafax XR	.289
	125
Enoxaparin sodium	
Enstilar	
Ensure (Chocolate)	.202
Ensure (Vanilla) Ensure Plus (Banana)	.202
Ensure Plus (Chocolate)	200
Ensure Plus (Fruit of the	200
	283
Forest) Ensure Plus (Vanilla)	200
Ensure Plus (Vanina)	
Ensure Plus HN RTH	201
Ensure Two Cal HN RTH	
Entacapone	
Entecavir	
Entecavir Sandoz	

Entresto 24/26	44
Entresto 49/51	44
Entresto 97/103	
Entyvio	228
Enzymes	113
Ephedrine	54
Epilim IV	
Epipen	240
Epipen Jr	240
Epirubicin Ebewe	
Epirubicin hydrochloride	. 145
Eplerenone	49
Epoetin alfa	28
Epoetin beta	29
Epoprostenol	61
Eptacog alfa [Recombinant factor	
VIIa]	33
Eptifibatide	36
Eptifibatide Viatris	
Erbitux	. 192
Ergometrine maleate	74
Erlotinib	.154
Ertapenem	87
Erythrocin IV	90
Erythromycin (as	
ethylsuccinate)	90
Erythromycin (as lactobionate)	90
Erythromycin (as stearate)	00
Esbriet	2/13
Escitalopram	105
Escitalopram (Ethics)	105
Escilalopiani (Elnics)	. 120
Esmolol hydrochloride	47
Essential Prednisolone	
Estradot	
Etanercept	. 165
Ethambutol hydrochloride	97
Ethanol	.256
Ethanol with glucose	
Ethanol, dehydrated	.256
Ethics Aspirin	
Ethics Aspirin EC	
Ethics Lisinopril	43
Ethinyloestradiol with	
desogestrel	73
Ethinyloestradiol with	
levonorgestrel	73
Ethinyloestradiol with	
norethisterone	73
Ethosuximide	
Ethyl chloride	
Etomidate	118
Etopophos	
Etoposide	148
Etoposide (as phosphate)	
Etoricoxib	115
Etravirine	. 101

Evara68
Everet
Everolimus
Evista
Evrysdi
Evusheld
Exemestane
Exjade
Extemporaneously Compounded
Preparations
Eylea
Ezetimibe
Ezetimibe Sandoz52
Ezetimibe with simvastatin52
-F-
Factor eight inhibitor bypassing
fraction33
Famotidine8
Fasenra 189
Faslodex162
Fatty Cream AFT68
Febuxostat113
Febuxostat multichem 113
FEIBA NF
Felo 10 ER
Felo 5 ER
Felodipine
Fentanyl123
Fentanyl Sandoz
Ferinject
Ferodan
Ferric subsulfate
Ferriprox
Ferro-F-Tabs
Ferro-tab
Ferrograd
Ferrosig
Ferrous fumarate
Ferrous fumarate with folic acid22
Ferrous gluconate with ascorbic
acid
Ferrous sulfate
Ferrous sulfate with ascorbic
acid22
Fexofenadine hydrochloride241
Filgrastim
Finasteride75
Fingolimod135
Firazyr240
Flagyl
FlagyI-S
Flamazine
Flecainide acetate46
Flecainide BNM46
Flecainide Controlled Release
Teva

Fleet Phosphate Enema	15
Flixonase Hayfever & Allergy	241
Flixotide	245
Flixotide Accuhaler	245
Florinef	
Fluanxol	
Flucil	91
Flucloxacillin	91
Flucloxacillin-AFT	91
Flucloxin	91
Fluconazole	
Fluconazole-Baxter	95
Flucytosine	
Fludara Oral	
Fludarabine Ebewe	146
Fludarabine phosphate	
Fludrocortisone acetate	
Fluids and Electrolytes	
Flumazenil	
Flumetasone pivalate with	
clioquinol	. 249
Fluocortolone caproate with	
fluocortolone pivalate and	
cinchocaine	7
Fluorescein sodium	
Fluorescein sodium with lignocaine	
hydrochloride	. 251
Fluorescite	
Fluorometholone	
Fluorouracil	
Fluorouracil Accord	. 146
Fluorouracil sodium	71
Fluox	
Fluoxetine hydrochloride	126
Flupenthixol decanoate	
FluQuadri (2023 Formulation)	290
Flutamide	
Flutamin	162
Fluticasone	245
Fluticasone furoate with	
vilanterol	. 245
Fluticasone propionate	241
Fluticasone with salmeterol	246
Flynn	<mark>88</mark>
FML	251
Foban	<mark>66</mark>
Folic acid	
Folic Acid multichem	29
Folic Acid Mylan	
Folic Acid Viatris	29
Fondaparinux sodium	35
Food Modules	
Food/Fluid Thickeners	
Forteo	112
Fosamax	
Fosamax Plus	110

Foscarnet sodium	. 104
Fosfomycin	93
Framycetin sulphate	.249
Frebini Energy	.279
Frebini Energy Fibre	.279
Frebini Original	.279
Frebini Original Fibre	
Fresofol 1% MCT/LCT	.118
Fresubin 2kcal HP	.274
Fresubin HP Energy	.281
Fresubin HP Energy Fibre	
Fresubin Intensive	
Fresubin Original	
Fresubin Original Fibre	282
Frusemide	102
Fucidin	
Fucithalmic	240
Fulvestrant	
Fungilin	24
Furosemide [Frusemide]	
Furosemide-Baxter	49
Fusidic acid	
Dermatological	6, 70
Infections	94
Sensory	.249
- 6 -	
Gabapentin	126
Gacet	122
Gadobenic acid	260
Gadobutrol	260
Gadoteric acid	200
Gadovist 1.0	.200
	.200
Gadoxetate disodium	.260
Galsulfase	18
Galvumet	
Galvus	
Ganciclovir	
Gardasil 9	.290
Gastrodenol	<mark>8</mark>
Gastrografin	.259
Gazyva	.201
Gefitinib	. 155
Gelatine, succinylated	42
Gelofusine	42
GEM Aqueous Cream	68
Gemcitabine	4 4 0
Gemcitabine Ebewe	14h
	.146 146
Gentuzumah ozogamicin	.146
Gemtuzumab ozogamicin	.146
Gemtuzumab ozogamicin Gentamicin sulphate	. 146 . 192
Gemtuzumab ozogamicin Gentamicin sulphate Infections	. 146 . 192 87
Gemtuzumab ozogamicin Gentamicin sulphate Infections Sensory	.146 .192 87 .249
Gemtuzumab ozogamicin Gentamicin sulphate Infections Sensory Gestrinone	. 146 . 192 87 . 249 80
Gemtuzumab ozogamicin Gentamicin sulphate Infections Sensory Gestrinone Gilenya	. 146 . 192 87 . 249 80 . 135
Gemtuzumab ozogamicin Gentamicin sulphate Infections Sensory Gestrinone Gilenya Ginet	. 146 . 192 87 . 249 80 . 135 73
Gemtuzumab ozogamicin Gentamicin sulphate Infections Sensory Gestrinone Gilenya	. 146 . 192 87 . 249 80 . 135 73 . 135

Glecaprevir with pibrentasvir 10	4
Glibenclamide1	0
Gliclazide1	
Gliolan	
Glipizide1	
Glivec15	
Glizide1	
Glucagen Hypokit	9
Glucagon hydrochloride	9
Glucerna Select	
Glucose [Dextrose]	
Alimentary	9
Blood	
Extemporaneously Compounded	Č
Preparations	4
Glucose with potassium chloride	à
Glucose with potassium chloride and	9
sodium chloride	^
Glucose with sodium chloride	
Glucose with sucrose and	U
	^
fructose	9
Glycerin with sucrose	5
	-
Alimentary1 Extemporaneously Compounded	Э
Extemporaneously Compounded	_
Preparations	о 0
Glyceryl trinitrate	o
	-
Alimentary	
Cardiovascular	
Glycoprep-O1	1
Glycopyrronium	
Glycopyrronium bromide	'
Glycopyrronium with indacaterol	~
Glypressin	
Gonadorelin	
Goserelin	
Granisetron13	י ר
- H -	0
Habitrol	4
Habitrol (Fruit)14	
Habitrol (Mint)14	÷
Haem arginate	
Haemophilus influenzae type B	0
vaccine	_
Haldol	
Haldol Concentrate	
Haloperidol	
Haloperidol decanoate	1
Hardmann's solution	2
Harunann's solution	
Harvoni	
Havrix Junior	
1 Iaviix Julii0128	J

Haylor Syrup241
Healon
Healon 5 252
Healon GV252
Healon GV Pro252
healthE Dimethicone 10%67
healthE Dimethicone 4% Lotion 66
healthE Dimethicone 5%67
healthE Fatty Cream68
healthE Glycerol BP Liquid 265
healthE Urea Cream69
Hemlibra31
Heparin sodium35
Heparin Sodium Panpharma
Heparinised saline35
Heparon Junior274
Hepatitis A vaccine289
Hepatitis B recombinant
vaccine 289
Herceptin 225
Hiberix
Hiprex94
Histaclear241
Histamine acid phosphate261
Holoxan
Hormone Replacement Therapy79
HPV
Humalog Mix 2510
Humalog Mix 50 10
Human papillomavirus (6, 11, 16, 18,
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]290
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV]
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen. 181
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid 181
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid 24
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid 24 Sensory 252, 255
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid Alimentary Alimentary 24 Sensory 252, 255 Hyaluronic acid with lidocaine
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid Alimentary Sensory 252, 255 Hyaluronic acid with lidocaine 24
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid Alimentary Sensory 252, 255 Hyaluronic acid with lidocaine 24 Iignocaine] 24 Hyaluronic acid with lidocaine 113
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid Alimentary Sensory 252, 255 Hyaluronic acid with lidocaine 24 Iignocaine] 24 Hyaluronic acid with lidocaine 113 Hyaluronidase 113
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid 24 Sensory 252, 255 Hyaluronic acid with lidocaine 24 Iignocaine] 24 Hyaluronic acid with lidocaine 113 Hydralazine hydrochloride 54
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid 181 Hyaluronic acid 24 Sensory 252, 255 Hyaluronic acid with lidocaine 24 Iignocaine] 24 Hyaluronidase 113 Hydralazine hydrochloride 54 Hydrocortisone 0 Dermatological 69
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid 181 Hyaluronic acid with lidocaine 252, 255 Hyaluronic acid with lidocaine 113 Hydralazine hydrochloride 54 Hydrocortisone 69 Extemporaneously Compounded
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid Alimentary Alimentary 24 Sensory 252, 255 Hyaluronic acid with lidocaine 113 Hyaluronidase 113 Hydralazine hydrochloride 54 Hydrocortisone 69 Extemporaneously Compounded Preparations
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid Alimentary Alimentary 24 Sensory 252, 255 Hyaluronic acid with lidocaine 113 Hyaluronidase 113 Hydralazine hydrochloride 54 Hydrocortisone 69 Extemporaneously Compounded Preparations Preparations 265 Hormone Preparations 79
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid 181 Hyaluronic acid 252, 255 Hyaluronic acid with lidocaine 113 Hyaluronidase 113 Hydralzine hydrochloride 54 Hydrocortisone 69 Extemporaneously Compounded Preparations Preparations 265 Hormone Preparations 79 Hydrocortisone acetate 6
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid 181 Hyaluronic acid 252, 255 Hyaluronic acid with lidocaine 113 Hyaluronidase 113 Hydralzine hydrochloride 54 Hydrocortisone 69 Extemporaneously Compounded Preparations Preparations 265 Hormone Preparations 79 Hydrocortisone acetate 64
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 Humira Pen 181 Hyaluronic acid 181 Alimentary 24 Sensory 252, 255 Hyaluronic acid with lidocaine [lignocaine] [lignocaine] 24 Hyaluronidase 113 Hydralazine hydrochloride 54 Hydrocortisone 0 Dermatological 69 Extemporaneously Compounded 79 Hydrocortisone acetate 61 Hydrocortisone hydrochloride 61
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 Humira 181 Hyaluronic acid 24 Sensory. 252, 255 Hyaluronic acid with lidocaine 113 Hyaluronic acid with lidocaine 113 Hydralazine hydrochloride 54 Hydrocortisone 0 Dermatological 69 Extemporaneously Compounded 79 Hydrocortisone acetate 61 Hydrocortisone acetate with 61 Hydrocortisone acetate with 61 Hydrocortisone acetate mith 61 Hydrocortisone and paraffin liquid 61
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid 24 Sensory 252, 255 Hyaluronic acid with lidocaine 113 Hyaluronic acid with lidocaine 113 Hydralazine hydrochloride 54 Hydrocortisone 0 Dermatological 69 Extemporaneously Compounded 9 Preparations 265 Hydrocortisone acetate 64 Hydrocortisone and paraffin liquid and lanolin 69
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid Alimentary Alimentary 24 Sensory 252, 255 Hyaluronic acid with lidocaine 113 Hydralazine hydrochloride 54 Hydrocortisone Dermatological Dermatological 69 Extemporaneously Compounded Preparations Preparations 265 Hydrocortisone acetate 64 Hydrocortisone butyrate 69 Hydrocortisone acetate 64
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid Alimentary Alimentary 24 Sensory 252, 255 Hyaluronic acid with lidocaine [lignocaine] Lignocaine] 24 Hydralazine hydrochloride 54 Hydrocortisone Dermatological Dermatological 69 Extemporaneously Compounded Preparations Preparations 265 Hydrocortisone acetate 64 Hydrocortisone acetate 64 Hydrocortisone acetate 64 Hydrocortisone hydrochloride 64 Hydrocortisone butyrate 69, 71 Hydrocortisone butyrate 69, 71 Hydrocortisone with miconazole 70
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] 290 Humatin 87 Humira 181 HumiraPen 181 Hyaluronic acid Alimentary Alimentary 24 Sensory 252, 255 Hyaluronic acid with lidocaine 113 Hydralazine hydrochloride 54 Hydrocortisone Dermatological Dermatological 69 Extemporaneously Compounded Preparations Preparations 265 Hydrocortisone acetate 64 Hydrocortisone butyrate 69 Hydrocortisone acetate 64

Hydrogen peroxide66
Hydroxocobalamin
Alimentary26
Various256
Hydroxocobalamin Panpharma26
hydroxycarbamide148
Hydroxychloroquine110
Hydroxyurea
[hydroxycarbamide] 148
Hygroton
Hylo-Fresh
Hyoscine butylbromide7
Hyoscine hydrobromide130
Hyperuricaemia and Antigout
HypoPak Glucose
Hypromellose
Hypromellose with dextran
-] -
lbiamox
Ibrance
Ibrutinib148
Ibuprofen
Icatibant
Idarubicin hydrochloride
Idarucizumab
Idursulfase
Ifosfamide144
lkorel
Ilomedin63
lloprost63
Imaging Agents164
Imatinib mesilate
Imatinib-Rex156
Imbruvica
Imfinzi
Imigran129
Imipenem with cilastatin87
Imipenem+Cilastatin RBX87
Imipramine hydrochloride 125
Imiquimod
Immune Modulators 107
Immunosuppressants 164
Impact Advanced Recovery
Incruse Ellipta
Indacaterol245
Indapamide50
Indigo carmine
Indinavir102
Indocyanine green
Indometacin [Indomethacin]116
Indomethacin 116
Infanrix IPV
Infanrix-hexa
Infatrini
Infliximab 192
Influenza vaccine290

Inhaled Corticosteroids244
Inspra49
Instillagel Lido 120
Insulin aspart10
Insulin aspart with insulin aspart
protamine9
Insulin glargine10
Insulin glulisine 10
Insulin isophane9
Insulin lispro10
Insulin lispro with insulin lispro
protamine10
Insulin neutral10
Insulin neutral with insulin
isophane 10
Intelence
Interferon alfa-2b 107
Interferon beta-1-alpha
Interferon beta-1-beta
Interferon gamma
Intra-uterine device
Invanz
Invega Sustenna
Invega Trinza
lodine
lodine with ethanol258
lodised oil
lodixanol
lohexol
lopidine
loscan
IPCA-Frusemide
IPCA-Metoprolol
IPCA-Propranolol
IPOL
Ipratropium bromide
Iressa155
Irinotecan hydrochloride 148
Iron (as ferric carboxymaltose)23
Iron (as sucrose)23
Iron polymaltose
Irrigation Solutions
Isentress 103
Isentress HD 103
Ismo 2053
Ismo 40 Retard53
Isoflurane118
Isoniazid
Isoniazid with rifampicin98
Isoprenaline [Isoproterenol]54
Isopropyl alcohol
Isoproterenol54
Isoptin48
Isoptin SR48
Isopto Carpine253
Isosorbide mononitrate53

Isotretinoin67
Ispaghula (psyllium) husk 14
Isradipine
Itch-Soothe
Itraconazole95
Itrazole95
Ivabradine46
Ivacaftor
Ivermectin
- J -
Jadelle74
Jakavi
Jardiamet13
Jardiance 13
Jaydess74
Jevity HiCal RTH
Jevity RTH
Jinarc50
Juno Pemetrexed 147
- K -
Kadcyla226
Kalydeco
Kalydeco247
Kenacomb
Kenacort-A 1079
Kenacort-A 4079
Kenalog in Orabase24
Kehalog III Olabase
Ketalar118
Ketamine118
Ketocal 3:1 (Unflavoured)279
Ketocal 4:1 (Unflavoured)279
Ketocal 4:1 (Vanilla)279
Ketoconazole
Dermatological 66
Infections95
Ketoprofen116
Ketorolac trometamol
KetoSens
Ketostix295
Keytruda233
Klacid90
Klean Prep14
Kogenate FS
Konstrant MM
Konakion MM34
Konsyl-D14
Kuvan19
•L•
L-ornithine L-aspartate9
Labetalol47
Lacosamide 127
Lactose
Lactulose15
Laevolac15
Lagevrio
Lamictal
Lamivudine 101, 103
Lamivudine Alphapharm101

	_
Lamivudine Viatris	
Lamotrigine	
Lanoxin	
Lanoxin PG	
Lansoprazole	
Lantus	.10
Lantus SoloStar	
Lanzol Relief	8
Lapatinib	
Largactil	131
Laronidase	.18
Lasix	.49
Latanoprost	
Latanoprost with timolol	253
Lax-Suppositories	.15
Lax-suppositories Glycerol	.15
Laxatives	.14
Laxsol	
Ledipasvir with sofosbuvir	
Leflunomide	
Lenalidomide	
Letrole	
Letrozole	
Leukotriene Receptor	
Antagonists	245
Leuprorelin acetate	.81
Leustatin	146
Levetiracetam	
Levetiracetam-AFT	127
Levocabastine	
Levocarnitine	
Levodopa with benserazide	
Levodopa with carbidopa	118
Levomepromazine	
Levomepromazine	
hydrochloride	131
Levonorgestrel	74
Levonorgestrel BNM	
Levosimendan	
Levothyroxine	
Lidocaine [Lignocaine]	120
Lidocaine [Lignocaine]	0
Lidocaine [Lignocaine] hydrochloride	120
Lidocaine [Lignocaine] hydrochloride	.20
with adrenaline	120
Lidocaine [Lignocaine] hydrochloride	
with adrenaline and tetracaine	
	120
Lidocaine [Lignocaine] hydrochloride	120
with chlorhexidine	120
Lidocaine [Lignocaine] hydrochloride	120
with phenylephrine	
hydrochloride	120
Lidocaine [Lignocaine] with	120
prilocaine	120
Lidocaine-Baxter	
	120

lignocaine
Alimentary24
Nervous
Lincomycin94
Linezolid
Linezolid Kabi94
Lioresal Intrathecal 114
Liothyronine sodium86
Lipid-Modifying Agents51
Lipiodol Ultra Fluid259
Liquibar259
Liraglutide 11
Lisinopril43
Lissamine green251
Lithium carbonate 132
LMX4 120
Lo-Oralcon 20 ED73
Local Preparations for Anal and
Rectal Disorders 7
Locoid
Locoid Crelo 69
Locoid Lipocream
Lodoxamide
Logem
Lomide
Lomustine
Long-Acting Beta-Adrenoceptor
Agonists
Loniten
Lopinavir with ritonavir
Lopinavir/Ritonavir Mylan 103
Lorafix
Loratadine
Lorazepam
Lormetazepam
Lorstat
Losartan Actavis
Losartan potassium
Losartan potassium with
hydrochlorothiazide 44
Lovir
Loxamine
Lucrin Depot 1-month81
Lucrin Depot 3-month81
Lyderm
Lynparza149
Lysine acetylsalicylate [Lysine
asprin]
Lysine asprin36
- M -
m-Eslon
Mabthera
Macrobid
Macrogol 3350 with ascorbic acid,

potassium chloride and sodium

chloride	14
Macrogol 3350 with ascorbic acid,	
potassium chloride, sodium	
chloride and citric acid with	
magnesium oxide and sodium	
picosulfate	11
	14
Macrogol 3350 with potassium	
chloride and sodium chloride with/	
without sodium sulfate, sodium	
ascorbate, ascorbic acid	14
Macrogol 3350 with potassium	
chloride, sodium bicarbonate and	
sodium chloride	15
Macrogol 3350 with potassium	
chloride, sodium bicarbonate,	
sodium chloride and sodium	
sulphate	
Madopar 125 1	18
Madopar 250 1	
Madopar 62.5 1	18
Madopar HBS 1	
Madopar Rapid1	18
Mafenide acetate	66
Magnesium amino acid chelate	23
Magnesium chloride	
Magnesium hydroxide	
Alimentary	23
Extemporaneously Compounded	
Preparations2	65
Magnesium oxide	
Magnesium oxide with magnesium	
aspartate, magnesium amino acid	
chelate and magnesium	
citrate	23
Magnesium sulphate	23
Magnevist2	60
Malarone	
Malarone Junior	
Malathion [Maldison]	67
Maldison	
	67
Mannitol	67
Mannitol	67
Cardiovascular	67 49
Cardiovascular2 Various2	67 49 61
Cardiovascular2 Various2 Mantoux	67 49 61 94
Cardiovascular	67 49 61 94 25
Cardiovascular	67 49 61 94 25 19
Cardiovascular	67 49 61 94 25 19 19
Cardiovascular	67 49 61 94 25 19 19 19
Cardiovascular	67 49 61 94 25 19 19 19 19
Cardiovascular	67 49 61 94 25 19 19 19 19 36
Cardiovascular	67 49 61 94 25 19 19 19 36 71
Cardiovascular	67 49 61 25 19 19 19 19 36 71 56
Cardiovascular	67 49 61 94 25 19 19 19 36 71 56 95
Cardiovascular	67 49 61 94 25 19 19 19 19 36 71 56 95 04
Cardiovascular	67 49 61 94 25 19 19 19 36 71 56 95 04 50

Measles, mumps and rubella
vaccine
Mebendazole99
Mebeverine hydrochloride7
Medrol
Medroxyprogesterone80
Medroxyprogesterone acetate
Genito-Urinary74
Hormone Preparations80
Mefenamic acid 116
Mefloquine
Meglumine gadopentetate 260
Meglumine iotroxate260
Melatonin 136
Melpha144
Melphalan144
Menactra
Meningococcal (A, C, Y and W-135)
conjugate vaccine 285
Meningococcal B multicomponent
vaccine 286
Meningococcal C conjugate
vaccine 286
MenQuadfi285
Menthol
Mepivacaine hydrochloride 120
Mepivacaine hydrochloride with
adrenaline121
Mepolizumab
Mercaptopurine146
Meropenem
Meropenem-AFT
Mesalazine6
Mesna
Mestinon
Metabolic Disorder Agents
Metabolic Products
Metaraminol
Metformin hydrochloride 11 Metformin Mylan 11
Metformin Viatris11
Methacholine chloride
Methadone BNM
Methadone hydrochloride
Extemporaneously Compounded
Preparations
Nervous
Methenamine (Hexamine)
hippurate
Methohexital sodium
WEILIGHT 254
Methopt
Methotrexate146
Methotrexate
Methotrexate146

[8-methoxypsoralen]70
Methoxyflurane 121
Methyl aminolevulinate
hydrochloride71
Methyl hydroxybenzoate
Methylcellulose
Methylcellulose with glycerin and
sodium saccharin 265
Methylcellulose with glycerin and
sucrose
Methyldopa
Methyldopa Mylan
Methylene blue
Methylnaltrexone bromide15
Methylphenidate ER - Teva
Methylphenidate hydrochloride 139
Methylprednisolone (as sodium
succinate) 79
Methylprednisolone aceponate
Methylprednisolone acetate
Methylthioninium chloride [Methylene
blue]
Methylxanthines
Metoclopramide Actavis 10 130
Metoclopramide hydrochloride 130
Metoclopramide hydrochloride with
paracetamol
Metolazone
Metoprolol IV Mylan
Metoprolol IV Viatris
Metoprolol succinate
Metoprolol tartrate47
Metrogyl
Metronidazole
Dermatological
Infections
Metyrapone80
Mexiletine hydrochloride
Miacalcic
Mianserin hydrochloride 125
Micolette
Miconazole24
Miconazole nitrate
Dermatological
Genito-Urinary
Micreme73
Micreme H70
Microlut74
Midazolam 137
Midazolam Viatris 137
Midodrine46
Mifepristone
Milrinone54
Milrinone-Baxter54
Minerals22
Mini-Wright AFS Low Range 295

Mini-Wright Standard	295
Minidiab	10
Minims Prednisolone	
Minirin	<mark>86</mark>
Minirin Melt	
Minocycline	
Minoxidil	
Mirena	74
Mirtazapine	
Misoprostol	
Mitomycin C	
Mitozantrone	
Mitozantrone Ebewe	
Mivacurium chloride	114
Mixed salt solution for eye	
irrigation	
Moclobemide	
Modafinil	
Modavigil	139
Molaxole	
Molnupiravir	
Mometasone furoate	
Monosodium glutamate with sodiur	
aspartate	
Monosodium I-aspartate	
Montelukast	245
Montelukast Mylan Montelukast Viatris	245
vionteiukast viatris	
Moroctocog alfa [Recombinant fact	or
Moroctocog alfa [Recombinant fact VIII]	or <mark>33</mark>
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride	or 33 123
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate	or 33 123 123
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate	or 33 123 123 123
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis	or 33 123 123 123 117
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat	or 33 123 123 123 117 24
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movapo	or 33 123 123 123 117 24 117
Moroctocog alfa [Recombinant fact VIII] Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movapo Moxifloxacin	or 33 123 123 123 117 24 117 92
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movapo Moxifloxacin Moxifloxacin Kabi	or 33 123 123 123 123 123 123 24 24 92 92
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motelis Mouth and Throat Movapo Moxifloxacin Moxifloxacin Kabi Mozobil	or 33 123 123 123 117 24 117 92 92 38
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis	or 33 123 123 123 117 24 92 92 38 246
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Movapo Movapo Moxifloxacin Mozobil Mucolytics and Expectorants Mucosoothe	or 33 123 123 123 123 24 92 92 92 92 92 38 246 120
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movafloxacin Moxifloxacin Kabi Mozobil Mucolytics and Expectorants Mucosoothe Multihance	or 33 123 123 123 117 24 92 92 92 38 246 120 260
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movifloxacin Moxifloxacin Kabi Mozobil Mucolytics and Expectorants Mucosoothe Multipiance Multipia Sclerosis Treatments Multivitamin and mineral	or 33 123 123 123 117 24 117 92 92 38 246 120 260 134
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movifloxacin Moxifloxacin Kabi Mozobil Mucolytics and Expectorants Mucosoothe Multipiance Multipia Sclerosis Treatments Multivitamin and mineral	or 33 123 123 123 117 24 117 92 92 38 246 120 260 134
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movapo Moxifloxacin Moxifloxacin Kabi Mucosoothe Mucosoothe Multihance Multiple Sclerosis Treatments Multivitamin and mineral supplement	or 33 123 123 123 123 123 123 123 124 120 246 120 260 134 246 120 260 134
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movapo Moxifloxacin Kabi Mozobil Mucosoothe Multipics and Expectorants Multipic Sclerosis Treatments Multivitamin and mineral supplement Multivitamin renal	or 33 123 123 123 123 123 123 123 124 120 246 120 260 124 260 134 224 25
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movifloxacin Movifloxacin Kabi Moxifloxacin Kabi Mozobil Mucolytics and Expectorants Multiple Sclerosis Treatments Multipic Sclerosis Treatments Multivitamin and mineral supplement Multivitamin renal	or
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Mouth and Throat Movapo Moxifloxacin Moxifloxacin Mozobil Mucolytics and Expectorants Mucosoothe Multiplance Multiplance Multiplance Multivitamin and mineral supplement Multivitamin renal Multivitamins Multivitamins	or 33 123 123 123 123 123 123 123 124 120 246 120 260 124 260 134 224 25
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis	or
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis	or
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis	or
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis	or
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis	or
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis Motaloxacin Movapo Moxifloxacin Moxifloxacin Kabi Mozobil Mucolytics and Expectorants Mucosoothe Multiple Sclerosis Treatments Multiple Sclerosis Treatments Multivitamin and mineral supplement Multivitamins Multivitamins Multivitamins Muscle Relaxants and Related Agents Mvite Myroobutin	or
Moroctocog alfa [Recombinant fact VIII] Morphine hydrochloride Morphine sulphate Morphine tartrate Motetis	or

Mudvistics and Qualantasian 054
Mydriatics and Cycloplegics
Mylan (24 hr release)
Mylan Atenolol
Mylan Clomiphen
Mylan Italy (24 hr release)
Mylan Midazolam
Myleran
Mylotarg
Myozyme 16 - N -
- N - Nadolol
Nadolol BNM
Naglazyme 18 Naloxone hydrochloride 256
Naloxone nyurochionue
Naltraccord
Naphazoline hydrochloride
Naphcon Forte251 Naprosyn SR 1000116
Naprosyn SR 750 116
Naproxen
Natalizumab136
Natamycin249 Natulan
Nausafix
Nausicalm
Nefopam hydrochloride
Neisvac-C286
Neo-Mercazole
Neocate Gold (Unflavoured)
Neocate Junior Vanilla
Neoral
Neostigmine metilsulfate
Neostigmine metilsulfate with
glycopyrronium bromide 110
Neosynephrine HCL
Nepafenac
Nepro HP (Strawberry)
Nepro HP (Vanilla)
Nepro HP RTH
Neupogen
NeuroTabs22
Nevirapine101
Nevirapine Alphapharm 101
Nevirapine Viatris 101
Nicardipine hydrochloride48
Nicorandil
Nicotine141
Nifedipine
Nifuran
Nilotinib156
Nilstat
Alimentary24

Genito-Urinary73
Infections95
Nimodipine48
Nimotop
Nintedanib
Nirmatrelvir with ritonavir 107
Nitazoxanide99
Nitrates53
Nitroderm TTS 1053
Nitroderm TTS 553
Nitrofurantoin
Nitrolingual Pump Spray53
Nivestim
Nivolumab232
Nodia
Noflam 250 116
Noflam 500 116
Non-Steroidal Anti-Inflammatory
Drugs
Nonacog gamma, [Recombinant
factor IX] 33
Noradrenaline
Noradrenaline BNM
Norethisterone
Genito-Urinary74
Hormone Preparations
Norflex
Norfloxacin
Noriday 28
Normison
Norpress
Nortriptyline hydrochloride125
Norvir
Noumed Paracetamol122
Noumed Pethidine
Noumed Phenobarbitone
Novasource Renal (Vanilla)280
Novatretin
NovoMix 30 FlexPen9
NovoRapid FlexPen10
NovoSeven RT
Nozinan 131
Nucala200
Nuelin246
Nuelin-SR246
Nupentin 126
Nusinersen137
Nutren Diabetes (Vanilla)273
Nutrini Energy Multi Fibre 279
Nutrini Low Energy Multifibre
RTH 279
Nutrini Peptisorb Energy276
Nutrison 800 Complete Multi
Fibre 282
Nutrison Concentrated274

Nutrison Energy2	31
Nutrison Protein Intense	75
Nyefax Retard	48
Nystatin	
Alimentary	
Dermatological	
Genito-Urinary	73
Infections	95
- 0 -	
Obinutuzumab20)1
Obstetric Preparations	74
Ocrelizumab 13	
Ocrevus1	36
Octocog alfa [Recombinant factor	
VIII] (Advate)	33
Octocog alfa [Recombinant factor	
VIII] (Kogenate FS)	
Octreotide10	33
Octreotide Depot Teva 10	
Ocular Lubricants2	
Oestradiol	
Oestradiol valerate	79
Oestradiol with norethisterone	
acetate	30
Oestriol	
Genito-Urinary	75
Hormone Preparations	30
Oestrogens	
Oestrogens (conjugated equine)	79
Oestrogens with	
medroxyprogesterone	
acetate	
Ofev24	
Oil in water emulsion	
Oily phenol [Phenol oily]	.7
Olanzapine1	
Olaparib14	
Olive oil	
Olopatadine2	51
Olopatadine Teva2	
Olsalazine	
Olumiant	
Omalizumab20	
Omeprazole	
Omeprazole actavis 10	. 8
Omeprazole actavis 20	
Omeprazole actavis 40	
Omezol IV	Q
Omnipaque2	59
Omnitrope	59 81
Omnitrope	59 81 45
Omnitrope	59 81 45 50
Omnitrope Onbrez Breezhaler	59 81 45 50 35
Omnitrope	59 81 45 50 35 30
Omnitrope Onbrez Breezhaler	59 81 45 50 35 30 30

Ondansetron-AFT	130
One-Alpha	26
Opdivo	232
Optional Pharmaceuticals	295
Ora-Blend	
Ora-Blend SF	
Ora-Plus	265
Ora-Sweet	265
Ora-Sweet SF	265
Oralcon 30 ED	73
Oratane	67
Ornidazole	99
Orphenadrine citrate	114
Oruvail SR	116
Oseltamivir	
Osmolite RTH	282
Other Cardiac Agents	53
Other Endocrine Agents	80
Other Oestrogen Preparations	80
Other Otological Preparations	255
Other Progestogen	
Preparations	80
Other Skin Preparations	71
Other Supplements for PKU	283
Ovestin	
Genito-Urinary	75
Hormone Preparations	80
Oxaliplatin	
Oxaliplatin Accord	
Oxandrolone	77
Oxazepam	134
Oxpentifylline	55
Oxybuprocaine hydrochloride	252
Oxybutynin	75
Oxycodone hydrochloride	
Oxycodone Sandoz	124
Oxymetazoline hydrochloride	244
OxyNorm	124
Oxytocin	74
Oxytocin BNM	74
Oxytocin with ergometrine	
maleate	
Ozurdex	250
Pacifen	114
Pacimol	
Paclitaxel	
Paclitaxel Ebewe	
Palbociclib	
Paliperidone	
Paliperidone palmitate	
Palivizumab	
Pamidronate disodium	
Pamisol	
Pamol	
Pancreatic enzyme	I 3

Pancuronium bromide114
Pantoprazole8
Panzop Relief8
Papaverine hydrochloride55
Paper wasp venom240
Para-aminosalicylic Acid98
Paracetamol
Paracetamol (Ethics) 122
Paracetamol Kabi
Paracetamol with codeine 124
Paraffin
Alimentary 15
Dermatological
Extemporaneously Compounded
Preparations
Paraffin liquid with soft white
paraffin
Paraffin liquid with wool fat
Paraffin with wool fat
Paraldehyde
Parecoxib116
Paromomycin
Paroxetine
Paser
Patent blue V261
Paxam
Paxlovid 107
Pazopanib157
Peak flow meter
Peanut oil
Pedialyte - Bubblegum41
Pediasure (Chocolate)280
Pediasure (Strawberry)280
Pediasure (Vanilla)
Pediasure RTH
Pegaspargase150
Pegasys107
Pegfilgrastim
Pegylated interferon alfa-2a 107
Pembrolizumab233
Pemetrexed147
Penicillamine110
Penicillin G91
Penicillin V91
Pentacarinat99
Pentagastrin80
Pentamidine isethionate
Pentasa6
Pentostatin [Deoxycoformycin]151
Pentoxifylline [Oxpentifylline]55
Peptamen OS 1.0 (Vanilla)273
Perflutren
Perhexiline maleate48
Pericyazine 132
Perindopril43
Periset 130

Perjeta204
Permethrin
Perrigo71
Pertuzumab204
Peteha
Pethidine hydrochloride 124
Pexsig48
Pfizer Exemestane
Pheburane
Phenasen147
Phenelzine sulphate 125
Phenindione
Phenobarbitone 127, 137
Phenobarbitone sodium
Phenol
Extemporaneously Compounded
Preparations
Various
Phenol oily
Phenol with ioxaglic acid
Phenothrin
Phenoxybenzamine
hydrochloride
Phenoxymethylpenicillin [Penicillin
V]91
Phentolamine mesylate
Phenylephrine hydrochloride
Cardiovascular
Sensory
Phenytoin
Phenytoin sodium
Phosphorus
Phytomenadione
Picibanil
Pilocarpine hydrochloride
Pilocarpine nitrate Extemporaneously Compounded
Preparations
Sensory
Pimafucort
Pimecrolimus
and fluorescein
Pinetarsol
Pioglitazone
Piperacillin with tazobactam
Pipothiazine palmitate
PipTaz-AFT
Pirfenidone
Pituitary and Hypothalamic
Hormones and Analogues
Pivmecillinam
Pizotifen
PKU Anamix Junior LQ (Berry)271
PKU Anamix Junior LQ
(Orange) 271

PKU Anamix Junior LQ	
(Unflavoured)	. 271
PKU Build 20 Chocolate	283
PKU Build 20 Raspberry	
Lemonade	. 283
PKU Build 20 Smooth	
PKU Build 20 Vanilla	
PKU GMPro Ultra Lemonade	
PKU sphere20 Banana	283
PKU sphere20 Chocolate	283
PKU sphere20 Lemon	283
PKU sphere20 Red Berry	283
PKU sphere20 Vanilla	283
Plaquenil	
Plasma-Lyte 148	39
Plasma-Lyte 148 & 5% Glucose	
Plendil ER	47
Plenvu	
Plerixafor	38
Pneumococcal (PCV10) conjugate	
vaccine	. 287
Pneumococcal (PCV13) conjugate	
vaccine	. 287
Pneumococcal (PPV23)	
polysaccharide vaccine	. 288
Pneumovax 23	
Podophyllotoxin	71
Polidocanol	
Poliomyelitis vaccine	
Poloxamer	15
Poly Gel	
Poly-Tears	
Poly-Visc	255
Polyethylene glycol 400 and	
propylene glycol	. 255
Polyhexamethylene biguanide	265
Polyvinyl alcohol with povidone	
Poractant alfa	248
Posaconazole	
Posaconazole Juno	
Potassium chloride4	0-41
Potassium chloride with sodium	
chloride	
Potassium citrate	75
Potassium dihydrogen	
phosphate	40
Potassium iodate	
Alimentary	
Hormone Preparations	<mark>86</mark>
Potassium iodate with iodine	
Potassium perchlorate	
Potassium permanganate	
Povidone K30	265
Povidone-iodine	
Povidone-iodine with ethanol	
Pradaxa	34

Pralidoxime iodide
Pralidoxime lodide256
Pramipexole hydrochloride118
Pravastatin51
Pravastatin Mylan51
Pravastatin Viatris
Praxbind
Praziquantel99
Prazosin45
Pred Forte251
Prednisolone79
Prednisolone acetate251
Prednisolone sodium
Prednisolone sodium
phosphate
Prednisolone- AFT251
Prednisone79
Prednisone Clinect
Pregabalin
Pregabalin Pfizer
Preyaballit Filzer
Pregnancy test - hCG urine
preOp281
Prevenar 13287
Priadel
Prilocaine hydrochloride121
Prilocaine hydrochloride with
felypressin 121
Dimensional International Inte
Primaquine
Primidone128
Primolut N81
Primovist
Priorix
Probenecid114
Procaine penicillin
Procarbazine hydrochloride151
Prochlorperazine 130
Proctosedyl7
Procyclidine hydrochloride117
Progesterone74
Proglicem
Proglycem
Progynova
Prolia
Promethazine hydrochloride241
Propafenone hydrochloride46
Propofol118
Propranolol
Propylthiouracil
Prostin E2
Prostin VR
Protamine sulphate35
Protionamide98
Protirelin
Proveblue
Provera
Provera HD80
Proxymetacaine hydrochloride252

Pseudoephedrine
hydrochloride 244
Psoriasis and Eczema
Preparations 70
PTU
Pulmonary Surfactants248
Pulmozyme246
Puri-nethol 146
Puria
Pyrazinamide98
Pyridostigmine bromide 110
Pyridoxal-5-phosphate19
Pyridoxine hydrochloride
Pyridoxine multichem26
Pyrimethamine100
Pytazen SR
- Q -
Quetapel132
Quetiapine 132
Quinapril
Quinapril with
hydrochlorothiazide 43
Quinine dihydrochloride100
Qvar
- R -
RA-Morph 123
Rabies vaccine
Raloxifene112
Raltegravir potassium103
Ramipex
Ramipril
Ranbaxy-Cefaclor
Ranibizumab205
Ranitidine8
Rapamune236
Rasagiline118
Rasburicase114
Readi-CAT 2259
Reandron 100077
Recombinant factor IX 32-33
Recombinant factor VIIa
Recombinant factor VIII
Rectogesic7
Red back spider antivenom 257
Redipred
Relenza Rotadisk 106
Relistor
Remdesivir
Remicade192
Remifentanil124
Remifentanil-AFT124
Resonium A42
Resource Beneprotein
Respiratory Stimulants248
Retinol
Retinol Palmitate

ReTrieve	. 67
Retrovir	102
Retrovir IV	102
Revlimid	149
Revolade	30
Riboflavin	. 19
Riboflavin 5-phosphate	253
Ribomustin	143
Ricit	75
Rifabutin	. 98
Rifadin	
Rifampicin	
Rifaximin	
Rifinah	
Rilutek	117
Riluzole	117
Ringer's solution	. 40
RINVOQ	
Riodine	
Risdiplam	
Risedronate Sandoz	111
Risedronate sodium	111
Risperdal Consta	134
Risperidone	134
Risperidone (Teva)	132
Risperon	
Ritalin	
Ritalin LA	
Ritonavir	
Rituximab (mabthera)	
Rituximab (riximyo)	200
Rivaroxaban	201
Rivastigmine Rivastigmine Patch BNM 10	
Rivastigmine Patch BNM 5	
Riximyo	
RIXUBIS	33 100
Rizamelt	129
Rizatriptan	129
Robinul	
Rocuronium bromide	
Ronapreve	
Ropin	118
Ropinirole hydrochloride	118
Ropivacaine hydrochloride	121
Ropivacaine hydrochloride with	
fentanyl	121
Ropivacaine Kabi	
Rose bengal sodium	
Rosuvastatin	
Rosuvastatin Viatris	
Rotarix	
Rotavirus oral vaccine	
Roxithromycin	
Rubifen	
Rubifen SR	139

Rurioctocog alfa pegol [Recombinant
factor VIII]
Ruxolitinib
- S -
S26 LBW Gold RTF278
Sabril
Sacubitril with valsartan
SalAir
Salazopyrin7 Salazopyrin EN7
Salbutamol
Salbutamol with ipratropium
bromide242
Salicylic acid265
Salmeterol245
Salmonella typhi vaccine 289
Sandimmun 164
Sandomigran 129
Sapropterin Dihydrochloride19
Scalp Preparations71
Scandonest 3% 120
Sclerosing Agents248
Scopoderm TTS 130
Sebizole 66
Sebizole
Secukinumab
Sedatives and Hypnotics
Seebri Breezhaler242
Selegiline hydrochloride
Selenium
Sennosides
Serc
Serenace
Seretide
Seretide Accuhaler246
Serevent245
Serevent Accuhaler245
Sertraline 126
Setrona 126
Sevoflurane 119
Sevredol123
Shingles vaccine293
Shingrix
Sildenafil60
Siltuximab221
Silver nitrate
Dermatological71
Extemporaneously Compounded
Preparations
Simeticone
Simulect
Simvastatin
Simvastatin Mylan
Simvastatin Viatris
Sincalide
Sinemet118

Sinemet CR 118
Sirolimus236
Sirturo97
Siterone77
Slow-Lopresor 47
Slow-Lopresor47 Smith BioMed Rapid Pregnancy
Test
Snake antivenom257
Sodibic42
Sodium acetate40
Sodium acid phosphate41
Sodium alginate with magnesium
alginate 5
Sodium alginate with sodium
bicarbonate and calcium
carbonate
Sodium aurothiomalate
Sodium benzoate20
Sodium bicarbonate
Blood40, 42
Extemporaneously Compounded
Preparations265
Sodium calcium edetate258
Sodium chloride
Blood
Respiratory244, 247
Various
Sodium chloride with sodium
bicarbonate244
Sodium citrate
Alimentary5
Extemporaneously Compounded
Preparations266
Sodium citrate with sodium chloride
and potassium chloride
Sodium citrate with sodium lauryl
sulphoacetate
Sodium citro-tartrate
Sodium cromoglicate
Alimentary7
Respiratory241
Sensory251
Sodium dihydrogen phosphate
[Sodium acid phosphate] 41
Sodium fluoride22
Sodium fusidate [Fusidic acid]
Dermatological
Infections
Sensory
Sodium hyaluronate [Hyaluronic acid]
Alimentary24
Sensory
Sodium hyaluronate [Hyaluronic acid]
with chondroitin sulphate 252
Sodium hydroxide262
Sodium hypochlorite 258
••

Sodium metabisulfite	266
Sodium nitrite	256
Sodium nitroprusside	
Cardiovascular	55
Optional Pharmaceuticals	295
Sodium phenylbutyrate	
Sodium phosphate with phosphoric	
acid	15
Sodium picosulfate	10 10
Sodium polystyrene sulphonate	10
Sodium polystyrene suprioriale	42
Sodium stibogluconate	100
Sodium tetradecyl sulphate	
Sodium thiosulfate	
Sodium valproate	128
Sodium with potassium	263
Solifenacin Mylan	76
Solifenacin succinate	
Solifenacin Viatris	
Solu-Cortef	79
Solu-Medrol	79
Solu-Medrol Act-O-Vial	. 79
Somatropin	81
Sotalol	. 47
Soya oil	256
Spacer device	295
Span-K	41
Spazmol	
Specialised Formulas	272
Spinal Muscular Atrophy	137
Spinraza	137
Spiolto Respimat	040
Spiolio Respinal	242
Spiractin	
Spiramycin	100
Spiriva	242
Spiriva Respimat	242
Spironolactone	50
Sprycel	154
Standard Feeds	
Starch	
Stavudine	102
Stelara	227
Sterculia with frangula	14
SteroClear	241
Stesolid Stimulants / ADHD Treatments	126
Stimulants / ADHD Treatments	138
Stiripentol	128
Stocrin	
Streptomycin sulphate	87
Stromectol	. 98
Sucralfate	
Sucrose	
Sugammadex	
Sugammadex BNM	115
Sulfadiazine silver	89
Sulfasalazine	
Sulindac	
oum was	. 110

Sulphacetamide sodium 249
Sulphadiazine
Sulphur
Sulprix
Sumagran129
Sumatriptan 129
Sunitinib159
Sunitinib Pfizer159
Sunscreen, proprietary71
Suprane
Surgical Preparations
Survimed OPD274
Sustagen Hospital Formula
(Chocolate) 282
Sustagen Hospital Formula
(Vanilla) 282
Suxamethonium chloride 114
Sylvant221
Symbicort Turbuhaler245
Symmetrel 117
Sympathomimetics53
Synacthen81
Synacthen Depot81
Svnagis
Synflorix
Syntometrine74
Syrup
Systane Unit Dose255
Systane Unit Dose
- T - Tacrolimus
- T - Tacrolimus Dermatological71
- T - Tacrolimus Dermatological
- T - Tacrolimus Dermatological
- T - Tacrolimus Dermatological
- T - Tacrolimus Dermatological
-T- Tacrolimus Dermatological
-T- Tacrolimus Dermatological
-T- Tacrolimus Dermatological
- T - Tacrolimus Dermatological

	105
Tenofovir Disoproxil Emtricitabine	
Viatr	105
Tenofovir Disoproxil Mylan	104
Tenofovir Disoproxil Viatris	104
Tenoxicam	
Tensipine MR10	۰۱۱۵. ۸۵
Terazosin	40
Terbinafine	
Terbutaline	
Terbutaline sulphate	.244
Teriflunomide	.136
Teriparatide	
Terlipressin	<mark>86</mark>
Testosterone	77
Testosterone cipionate	77
Testosterone esters	
Testosterone undecanoate	
Tetrabenazine	
Tetracaine [Amethocaine] hydrochlo	ride
Nervous	
Sensory	
Tetracosactide [Tetracosactrin]	
Tetracosactrin	
Tetracycline	01
Teva Lisinopril	
Thalidomide	
Thalomid	
Theobroma oil	
Theophylline	.246
Theophylline Thiamine hydrochloride	.246
Theophylline	.246
Theophylline Thiamine hydrochloride Thiamine multichem Thioguanine	.246 26 26
Theophylline Thiamine hydrochloride Thiamine multichem Thioguanine Thiopental [Thiopentone]	.246 26 26 .147
Theophylline Thiamine hydrochloride Thiamine multichem Thioguanine Thiopental [Thiopentone]	.246 26 26 .147
Theophylline Thiamine hydrochloride Thiamine multichem Thioguanine Thiopental [Thiopentone] sodium	.246 26 26 .147 .119
Theophylline Thiamine hydrochloride Thiamine multichem Thioguanine Thiopental [Thiopentone] sodium Thiopentone	.246 26 26 .147 .147 .119
Theophylline Thiamine hydrochloride Thiamine multichem Thioguanine Thiopental [Thiopentone] sodium Thiopentone Thiotepa	.246 26 .147 .147 .119 .119 .144
Theophylline Thiamine hydrochloride Thiamine multichem Thioguanine Thiopental [Thiopentone] sodium Thiopentone Thiotepa Thrombin	.246 26 .147 .147 .119 .119 .144
Theophylline Thiamine hydrochloride Thiamine multichem Thioguanine Thiopental [Thiopentone] sodium Thiopentone Thiotepa Thrombin Thyroid and Antithyroid	.246 26 .147 .147 .119 .119 .144 32
Theophylline Thiamine hydrochloride Thiamine multichem Thioguanine Thiopental [Thiopentone] sodium Thiopentone Thiotepa Thrombin Thyroid and Antithyroid Preparations	.246 26 .147 .147 .119 .119 .144 32
Theophylline Thiamine hydrochloride Thiamine multichem Thiogental [Thiopentone] sodium Thiopentone Thiotepa Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa.	.246 26 .147 .147 .119 .119 .144 32 85 81
Theophylline Thiamine hydrochloride Thiamine multichem Thiopental [Thiopentone] sodium Thiopentone Thiotepa Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor	.246 26 .147 .119 .119 .144 32 85 81 36
Theophylline Thiamine hydrochloride Thiamine multichem Thiopental [Thiopentone] sodium . Thiopentone Thiotepa. Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa. Ticagrelor. Ticagrelor Sandoz	.246 26 26 .147 .119 .119 .144 32 81 81 36 36
Theophylline Thiamine hydrochloride Thiamine multichem Thiogental [Thiopentone] sodium Thiopentone Thiotepa Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Ticagrelor Sandoz Ticacrillin with clavulanic acid	.246 26 26 .147 .119 .119 .144 32 85 81 36 36 91
Theophylline Thiamine hydrochloride Thiamine multichem Thiogental [Thiopentone] sodium . Thiopentone Thiopentone Thiotepa Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Ticagrelor Sandoz Ticarcillin with clavulanic acid Ticlopidine	.246 26 26 .147 .119 .144 32 85 81 36 36 91 37
Theophylline Thiamine hydrochloride Thiamine multichem Thiopental [Thiopentone] sodium . Thiopentone. Thiotepa. Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Sandoz Ticagrelor Sandoz Ticarcillin with clavulanic acid Ticlopidine Tigecycline	.246 26 26 .147 .119 .144 32 85 81 36 91 37 93
Theophylline Thiamine hydrochloride Thiamine multichem Thiopental [Thiopentone] sodium Thiopentone. Thiotepa. Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Ticagrelor Sandoz Ticarcillin with clavulanic acid Ticlopidine Tigecycline Tilcotil	.246 26 26 .147 .119 .144 32 85 81 36 91 37 93 .116
Theophylline Thiamine hydrochloride Thiamine multichem Thiogental [Thiopentone] sodium Thiopentone Thiotepa Thorobin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticaprelor Sandoz Ticlopidine Tigecycline Tilcotil Timolol	.246 26 26 .147 .119 .144 32 85 81 36 36 37 93 .116 .253
Theophylline Thiamine hydrochloride Thiamine multichem Thiogental [Thiopentone] sodium Thiopentone Thiotepa Thorobin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticlopidine Tigecycline Tilcotil Timolol	.246 26 .147 .119 .144 32 85 81 36 36 91 37 93 .116 .253 .253
Theophylline Thiamine hydrochloride Thiamine multichem Thiogental [Thiopentone] sodium Thiopentone Thiotepa Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticlopidine Ticopidine Tigecycline Tilcotil Timotol XE Tiotropium bromide	.246 26 .147 .119 .144 32 85 81 36 36 91 37 93 .116 .253 .253
Theophylline Thiamine hydrochloride Thiamine multichem Thiogental [Thiopentone] sodium Thiopentone Thiotepa Thormbin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Ticagrelor Sandoz Ticarcillin with clavulanic acid Ticlopidine Tigecycline Tilcotil Timoptol XE Tiotropium bromide Tiotropium bromide with	.246 26 26 .147 .119 .144 32 85 81 36 91 37 93 .116 .253 .253 .242
Theophylline Thiamine hydrochloride Thiamine multichem Thiopental [Thiopentone] sodium Thiopentone Thiopentone Thiotepa Thorobin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Ticagrelor Sandoz Ticagrelor Sandoz Ticarcillin with clavulanic acid Ticlopidine Tigecycline Tiloctil Timotol XE Tiotropium bromide Tiotropium bromide with olodaterol	.246 26 26 .147 .119 .144 32 85 81 36 91 93 .116 .253 .253 .242 .242
Theophylline Thiamine hydrochloride Thiamine multichem Thiopental [Thiopentone] sodium Thiopentone Thiotepa Thrombin Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticopidine Ticopidine Ticopidine Ticopidine Timoptol XE Tiotropium bromide Tiotropium bromide with olodaterol	.246 26 26 26 26 26 26
Theophylline Thiamine hydrochloride Thiamine multichem Thiopental [Thiopentone] sodium Thiopentone Thiotepa Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticapelor Sandoz Ticapelor Sandoz Ticolpidine Ticolpidine Ticolpidine Ticolpidine Timoptol XE Tiotropium bromide Tiotropium bromide with olodaterol Tivicay Tixagevimab with cilgavimab	.246 26 26 26 26 26 26
Theophylline Thiamine hydrochloride Thiamine multichem Thiopental [Thiopentone] sodium Thiopentone Thiotepa Thrombin Thrombin Thyroid and Antithyroid Preparations Thyrotropin alfa Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticagrelor Sandoz Ticopidine Ticopidine Ticopidine Ticopidine Timoptol XE Tiotropium bromide Tiotropium bromide with olodaterol	.246 26 26 .147 .119 .144 32 85 81 36 91 37 93 .116 .253 .253 .242 .242 .103 .221 94

Tobramycin	
Infections	
Sensory24	
Tobramycin BNM	87
Tobramycin Mylan	
Tobrex24	
Tocilizumab2	
Tofranil1	
Tolcapone1	18
Tolvaptan	50
Topamax1	28
Topicaine 12	20
Topical Products for Joint and	
Muscular Pain1	16
Topiramate12	
Topiramate Actavis12	
Torbay	
Tracrium1	14
Tramadol hydrochloride1	24
Tramal 100 12	24
Tramal 50 12	24
Tramal SR 100 12	24
Tramal SR 150 12	24
Tramal SR 200 12	
Trandate	
Tranexamic acid	
Tranexamic-AFT	
Tranylcypromine sulphate 12	
Trastuzumab2	25
Trastuzumab emtansine2	
Travatan2	54
Travoprost2	
Treatments for Dementia14	40
Treatments for Substance	
Dependence 14	40
Tretinoin	
Dermatological	
Oncology1	52
Trexate	
Tri-sodium citrate2	66
Triamcinolone acetonide	
Alimentary	24
Dermatological	70
Hormone Preparations	79
Triamcinolone acetonide with	
gramicidin, neomycin and	
nystatin 2	50
Triamcinolone acetonide with	
neomycin sulphate, gramicidin	
and nystatin	/0
Triamcinolone hexacetonide	
Triazolam	
Trichloracetic acid	66
Trientine dihydrochloride	
Trikafta	47
Trimethoprim	94

Trimethoprim with
sulphamethoxazole
[Co-trimoxazole] 94
Trisul94
Trometamol
Tropicamide254
Tropisetron 130
Trulicity11
Trvzan
Tuberculin PPD [Mantoux] test294
Tubersol
Two Cal HN
Tykerb156
Tysabri136
- U -
Ultibro Breezhaler242
Ultraproct7
Umeclidinium
Umeclidinium with vilanterol
Univent
Upadacitinib238
Ural
Urea
Dermatological
Extemporaneously Compounded
Preparations
Urex Forte
Urografin259
Urokinase
Urologicals
Uromitexan 161
Ursodeoxycholic acid13
Ursosan
Ustekinumab227
Utrogestan
- V -
Vaclovir104
Valaciclovir104
Valganciclovir 104
Valganciclovir Mylan 104
Valganciclovir Viatris 104
Vancomycin
Varenicline141
Varenicline Pfizer141
Varibar - Honey
Varibar - Nectar
Varibar - Pudding259
Varibar - Thin Liquid259
Varicella vaccine [Chickenpox
vaccine] 292
Varicella zoster vaccine [Shingles
vaccine]
Varivax
Vasodilators
Vasopressin
Vasopressin Agents

Vasorex	47
Vebulis	63
Vecuronium bromide	.114
Vedafil	60
Vedolizumab	228
Veklury	107
Veletri	
Venclexta	152
Venetoclax	152
Venlafaxine	125
Venofer	
VENOX	
Ventolin	
Vepesid	
Verapamil hydrochloride	48
Vermox	4 0 00
Versacloz	121
Vesanoid	
Vexazone	
Vfend Victoza	
Vigabatrin	
Vigisom	
Vildagliptin	11
Vildagliptin with metformin	
hydrochloride	11
Vimpat	.127
Vinblastine sulphate	161
Vincristine sulphate	
Vinorelbine	161
Vinorelbine Te Arai	
Viral Vaccines	289
Viramune Suspension	
ViruPOS	
Viscoat	252
Visipaque	
Vit.D3	26
VitA-POS	255
Vital	273
Vitamin B complex	26
Vitamin B6 25	
Vitamins	24
Vivonex TEN	273
Voltaren	115
Voltaren D	115
Voltaren Ophtha	251
Voltaren SR	115
Volumatic	295
VoLumen	259
Voriconazole	_96
Votrient	
Vttack	
- W -	
Warfarin sodium	36
Wart Preparations	

Water
Blood4
Various262
White Soft Liquid Paraffin AFT
Wool fat
Dermatological
Extemporaneously Compounded
Preparations
- X -
X-Opaque-HD259
Xanthan
Xarelto
Xifaxan
Xolair
Xylocaine
Xylometazoline hydrochloride
Xyntha
- Y -
Yellow jacket wasp venom
- Z -
Zanamivir
Zapril43
Zarontin
Zavedos145
Zeffix
Zematop
Zetlam
Zelidiii
Ziagen
Zidovudine [AZT] 102
Zidovudine [AZT] with lamivudine
Ziextenzo
Zimybe
Zinc
Alimentary
Dermatological
Zinc and castor oil
Zinc chloride
Zinc oxide
Zinc sulphate
Zinc with wool fat
Zincaps
Zinforo
Ziprasidone132
Zista
Zithromax
Zoledronic acid
Hormone Preparations78
Musculoskeletal 11
Zoledronic acid Mylan78
Zoledronic acid Viatris
Hormone Preparations78
Musculoskeletal 11
Zopiclone 137
Zostrix116

Zostrix HP	121
Zuclopenthixol acetate	132
Zuclopenthixol decanoate	134
Zuclopenthixol hydrochloride	132
Zusdone	132
Zyban	141
Zypine	132
Zypine ODT	132
Zyprexa Relprevv	132
Zytiga	161
Zyvox	94







